---
created: 2024-09-04T00:04:57 (UTC -09:00)
tags: []
source: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
author: McEvoy, John William, McCarthy, Cian P, Bruno, Rosa Maria, Brouwers, Sofie, Canavan, Michelle D, Ceconi, Claudio, Christodorescu, Ruxandra Maria, Daskalopoulou, Stella S, Ferro, Charles J, Gerdts, Eva, Hanssen, Henner, Harris, Julie, Lauder, Lucas, McManus, Richard J, Molloy, Gerard J, Rahimi, Kazem, Regitz-Zagrosek, Vera, Rossi, Gian Paolo, Sandset, Else Charlotte, Scheenaerts, Bart, Staessen, Jan A, Uchmanowicz, Izabella, Volterrani, Maurizio, Touyz, Rhian M, ,
---

# 2024 ESC Guidelines for the management of elevated blood pressure and hypertension | European Heart Journal | Oxford Academic

> ## Excerpt
> Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approac

---
# 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and _endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO)_

John William McEvoy, Cian P McCarthy, Rosa Maria Bruno, Sofie Brouwers, Michelle D Canavan, Claudio Ceconi, Ruxandra Maria Christodorescu, Stella S Daskalopoulou, Charles J Ferro, Eva Gerdts [... Show more](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#)

[Author Notes](javascript:;)

_European Heart Journal_, ehae178, [https://doi.org/10.1093/eurheartj/ehae178](https://doi.org/10.1093/eurheartj/ehae178)

Published:

30 August 2024

$(document).ready(function () { $('.article-top-widget').on('click', '.ati-toggle-trigger', function () { $(this).find('.icon-general-add, .icon-minus').toggleClass('icon-minus icon-general-add'); $(this).siblings('.ati-toggle-content').toggleClass('hide'); }); // In Chrome, an anchor tag with target="\_blank" and a "mailto:" href opens a new tab/window as well as the email client // I suspect this behavior will be corrected in the future // Remove the target="\_blank" $('ul.wi-affiliationList').find('a\[href^="mailto:"\]').each(function () { $(this).removeAttr('target'); }); });

-   [![pdf](https://academic.oup.com//oup.silverchair-cdn.com/UI/app/svg/pdf.svg)PDF](https://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehae178/58916755/ehae178.pdf)
-   [Split View](javascript:;)
-   [Cite](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#)
    
-   [_Permissions Icon_ Permissions](https://s100.copyright.com/AppDispatchServlet?publisherName=OUP&publication=1522-9645&title=2024%20ESC%20Guidelines%20for%20the%20management%20of%20elevated%20blood%20pressure%20and%20hypertension%3A%20Developed%20by%20the%20task%20force%20on%20the%20management%20of%20elevated%20blood%20pressure%20and%20hypertension%20of%20the%20European%20Society%20of%20Cardiology%20%28ESC%29%20and%20endorsed%20by%20the%20European%20Society%20of%20Endocrinology%20%28ESE%29%20and%20the%20European%20Stroke%20Organisation%20%28ESO%29&publicationDate=2024-08-30&volumeNum=&issueNum=&author=McEvoy%2C%20John%20William%3B%20McCarthy%2C%20Cian%20P&startPage=1&endPage=107&contentId=10.1093%2Feurheartj%2Fehae178&oa=&copyright=%C2%A9%20The%20European%20Society%20of%20Cardiology%202024.%20All%20rights%20reserved.%20For%20permissions%2C%20please%20email%3A%20journals.permissions%40oup.com&orderBeanReset=True)
    
-   [_Share Icon_ Share](javascript:;)

[Guidelines](javascript:;), [Blood pressure](javascript:;), [Hypertension](javascript:;), [Hypertension-mediated organ damage](javascript:;), [Blood pressure measurement](javascript:;), [Ambulatory blood pressure monitoring](javascript:;), [Home blood pressure monitoring](javascript:;), [Antihypertensive medication](javascript:;), [Hypertension treatment](javascript:;), [Hypertension targets](javascript:;), [Secondary hypertension](javascript:;), [Cardiovascular disease risk estimation](javascript:;), [Cardiovascular disease prevention](javascript:;), [Resistant hypertension](javascript:;), [Hypertension screening](javascript:;)

Topic:

-   [hypertension](javascript:;)
-   [cardiovascular diseases](javascript:;)
-   [heart disease risk factors](javascript:;)
-   [blood pressure](javascript:;)
-   [blood pressure determination](javascript:;)
-   [guidelines](javascript:;)

## Table of contents

-   1\. Preamble 7
    
-   2\. Introduction 8
    
-    2.1. What is new 9
    
-   3\. Pathophysiology of elevated blood pressure and hypertension 17
    
-   4\. Clinical consequences of elevated blood pressure and hypertension 17
    
-   5\. Measuring blood pressure 18
    
-    5.1. Introduction and pertinent definitions 18
    
-    5.2. Practical recommendations for measuring blood pressure 19
    
-     5.2.1. Clinical validation of equipment for measuring blood pressure 19
    
-     5.2.2. Office blood pressure measurement 19
    
-     5.2.3. Home blood pressure measurement 20
    
-     5.2.4. Ambulatory blood pressure measurement 22
    
-     5.2.5. Comparison of home and ambulatory blood pressure monitoring 23
    
-    5.3. What is the best method for measuring blood pressure to diagnose hypertension? 23
    
-     5.3.1. Blood pressure measurement for hypertension screening  23
    
-     5.3.2. Blood pressure measurement for diagnosing hypertension  23
    
-    5.4. What is the best method for measuring blood pressure for long-term management of hypertension? 23
    
-     5.4.1. Home monitoring 23
    
-     5.4.2. Ambulatory monitoring 23
    
-    5.5. Measuring blood pressure in selected groups 24
    
-     5.5.1. Pregnancy 24
    
-     5.5.2. Atrial fibrillation 24
    
-     5.5.3. Orthostatic hypotension 24
    
-    5.6. Novel methods of measuring blood pressure 24
    
-   6\. Definition and classification of elevated blood pressure and hypertension, and cardiovascular disease risk assessment 25
    
-    6.1. Definition and classification of elevated blood pressure and hypertension 25
    
-    6.2. Principles of a risk-based approach for managing blood pressure and preventing cardiovascular disease 25
    
-     6.2.1. Role of cardiovascular disease risk assessment 25
    
-    6.3. Predicting cardiovascular disease risk 26
    
-     6.3.1. 10-year cardiovascular disease risk-prediction models 27
    
-    6.4. Refining cardiovascular disease risk estimation beyond risk models 28
    
-     6.4.1. Sex-specific non-traditional cardiovascular disease risk modifiers 28
    
-     6.4.2. Non-traditional cardiovascular disease risk modifiers shared by men and women 29
    
-     6.4.3. Additional risk decision tests 30
    
-    6.5. Summary of the cardiovascular disease risk stratification approach for allocating blood pressure treatment 30
    
-   7\. Diagnosing hypertension and investigating underlying causes 32
    
-    7.1. Screening for hypertension 32
    
-    7.2. Confirming the diagnosis of hypertension 32
    
-    7.3. Communicating the diagnosis 33
    
-    7.4. Baseline assessment and diagnostic approach 33
    
-     7.4.1. Medical history, medication history, and physical examination 33
    
-     7.4.2. Drug adherence and persistence with treatment 34
    
-     7.4.3. Routine and optional tests 34
    
-      7.4.3.1. The kidneys 36
    
-      7.4.3.2. The heart 36
    
-      7.4.3.3. The arteries 37
    
-     7.4.4. Genetic testing 37
    
-    7.5. Resistant hypertension: definition and diagnosis 37
    
-    7.6. Secondary hypertension: when to screen/further investigations  39
    
-     7.6.1. General considerations 39
    
-     7.6.2. Primary aldosteronism 39
    
-     7.6.3. Renovascular hypertension 40
    
-     7.6.4. Obstructive sleep apnoea syndrome 40
    
-     7.6.5. Phaeochromocytoma/paraganglioma 43
    
-   8\. Preventing and treating elevated blood pressure and hypertension  43
    
-    8.1. Prevention strategies in early life 43
    
-    8.2. Non-pharmacological interventions 43
    
-     8.2.1. Dietary sodium and potassium intake 43
    
-      8.2.1.1. Sodium 43
    
-      8.2.1.2. Potassium 44
    
-     8.2.2. Physical activity and exercise 45
    
-     8.2.3. Weight reduction and diet 46
    
-     8.2.4. Alcohol, coffee, and soft drinks 46
    
-     8.2.5. Smoking 46
    
-    8.3. Pharmacological interventions 47
    
-     8.3.1. Treatment strategy to reduce adverse cardiovascular disease outcomes 47
    
-     8.3.2. Drug classes with evidence on clinical outcomes in the target population 47
    
-     8.3.3. New therapies with blood pressure-lowering properties that await supportive evidence from cardiovascular outcomes trials prior to guideline endorsement and routine use in hypertension 48
    
-     8.3.4. Drug combinations and up-titrating strategies 48
    
-     8.3.5. A practical algorithm for intensive, effective, and tolerable blood pressure lowering with drug therapy, including considerations around single-pill combinations 48
    
-     8.3.6. Timing of blood pressure-lowering drug treatment 51
    
-    8.4. Selecting patients for pharmacological blood pressurelowering treatment 51
    
-    8.5. Intensity of blood pressure-lowering therapy and ideal treatment targets 53
    
-     8.5.1. Expected degree of blood pressure reduction with approved drugs 53
    
-     8.5.2. The ideal target of blood pressure-lowering treatment 53
    
-     8.5.3. Personalizing treatment strategies 54
    
-     8.5.4. Duration and monitoring of drug therapy 55
    
-    8.6. Device-based blood pressure lowering 55
    
-     8.6.1. Catheter-based renal denervation 55
    
-     8.6.2. Other devices 57
    
-    8.7. Unintended and potentially harmful consequences of blood pressure lowering and implications for treatment targets 57
    
-     8.7.1. Adverse effects of blood pressure-lowering medications 57
    
-      8.7.1.1. Symptomatic adverse effects 57
    
-      8.7.1.2. Renal effects 57
    
-      8.7.1.3. Erectile dysfunction 57
    
-     8.7.2. Pill burden and non-adherence 57
    
-     8.7.3. Potentially harmful consequences of blood pressure lowering for frail older people 57
    
-     8.7.4. Clinical inertia in blood pressure lowering 57
    
-   9\. Managing specific patient groups or circumstances 58
    
-    9.1. Young adulthood (18–40 years) 58
    
-     9.1.1. Definition and epidemiology 58
    
-     9.1.2. Secondary hypertension in young adulthood 58
    
-     9.1.3. Measurement and management of blood pressure in young adults 58
    
-    9.2. Pregnancy 58
    
-     9.2.1. Definition and epidemiology 58
    
-     9.2.2. Classifying hypertension in pregnancy 58
    
-     9.2.3. Measuring blood pressure in pregnancy 59
    
-     9.2.4. Investigating hypertension in pregnancy 59
    
-     9.2.5. Preventing hypertension and pre-eclampsia 59
    
-     9.2.6. Treatment initiation and blood pressure targets 59
    
-     9.2.7. Managing mild hypertension in pregnancy (office blood pressure 140–159/90–109 mmHg) 59
    
-     9.2.8. Managing severe hypertension in pregnancy (>160/110 mmHg) 60
    
-     9.2.9. Managing blood pressure post-partum 60
    
-     9.2.10. Risk of recurrence of hypertensive disorders in a subsequent pregnancy 60
    
-    9.3. Very old age (≥85 years), frailty, multimorbidity, and polypharmacy 60
    
-     9.3.1. Definition of frailty 60
    
-     9.3.2. Randomized controlled trials of blood pressure lowering in frail older patients 61
    
-     9.3.3. Starting blood pressure-lowering treatment in very old or frail patients 62
    
-     9.3.4. Maintaining blood pressure lowering in very old or frail patients 62
    
-    9.4. Isolated systolic and diastolic hypertension 62
    
-     9.4.1. Definition of isolated systolic hypertension 62
    
-     9.4.2. Isolated systolic hypertension, risk factors, and ageing 62
    
-     9.4.3. Isolated systolic hypertension in young adults 63
    
-     9.4.4. Isolated diastolic hypertension 63
    
-    9.5. Orthostatic hypotension with supine hypertension 63
    
-    9.6. Diabetes 64
    
-     9.6.1. Diabetes and elevated blood pressure/hypertension 64
    
-     9.6.2. J-shaped curve of blood pressure and risk of cardiovascular disease in patients with diabetes 64
    
-     9.6.3. Managing blood pressure in diabetes 64
    
-    9.7. Chronic kidney disease 64
    
-     9.7.1. Relationship between hypertension and chronic kidney disease 64
    
-     9.7.2. Blood pressure lowering in chronic kidney disease 65
    
-     9.7.3. Managing blood pressure in chronic kidney disease 65
    
-     9.7.4. Blood pressure targets in chronic kidney disease 65
    
-    9.8. Cardiac disease 65
    
-     9.8.1. Blood pressure thresholds and targets in patients with cardiac disease 65
    
-     9.8.2. Coronary artery disease with particular reference to the blood pressure J-curve 66
    
-     9.8.3. Valvular heart disease 66
    
-     9.8.4. Heart failure 66
    
-     9.8.5. Heart rhythm disease (including AF) 67
    
-    9.9. Chronic cerebrovascular disease and/or cognitive impairment 67
    
-     9.9.1. Role of hypertension in chronic cerebrovascular disease 67
    
-     9.9.2. Treatment in patients with history of prior stroke or transient ischaemic attack 67
    
-     9.9.3. Treatment in patients with chronic cerebrovascular disease and cognitive impairment 67
    
-    9.10. Aortopathy 68
    
-     9.10.1. Coarctation of the aorta 68
    
-     9.10.2. Bicuspid aortic valve-related aortopathy 68
    
-     9.10.3. Preventing aortic dilation and dissection in high-risk patients 68
    
-    9.11. Different ethnic groups 68
    
-    9.12. Nocturnal hypertension 68
    
-     9.12.1. Definition 68
    
-     9.12.2. Epidemiology 69
    
-     9.12.3. Night-time blood pressure as a cardiovascular disease risk factor 69
    
-     9.12.4. Treatment of nocturnal hypertension 69
    
-    9.13. Resistant hypertension 69
    
-     9.13.1. Definition of resistant hypertension 69
    
-     9.13.2. Non-pharmacological interventions 69
    
-     9.13.3. Pharmacological interventions 69
    
-     9.13.4. Devices for blood pressure lowering 70
    
-    9.14. Management of specific causes of secondary hypertension 71
    
-     9.14.1. General considerations 71
    
-     9.14.2. Primary aldosteronism 71
    
-     9.14.3. Renovascular hypertension 71
    
-     9.14.4. Phaeochromocytoma/paraganglioma 72
    
-     9.14.5. Obstructive sleep apnoea syndrome 72
    
-     9.14.6. Drug-induced hypertension 72
    
-      9.14.6.1. Anticancer drug-induced hypertension 72
    
-     9.14.7. Other forms of secondary hypertension 72
    
-   10\. Acute and short-term lowering of blood pressure 72
    
-    10.1. Acute blood pressure management in hypertensive emergencies 72
    
-     10.1.1. Definition and characteristics of hypertensive emergencies 72
    
-     10.1.2. Acute management of hypertensive emergencies 73
    
-     10.1.3. Prognosis and follow-up 73
    
-    10.2. Acute blood pressure management in acute intracerebral haemorrhage 73
    
-    10.3. Acute blood pressure management in acute ischaemic stroke  73
    
-    10.4. Acute blood pressure management in pre-eclampsia and severe hypertension in pregnancy 74
    
-     10.4.1. Pre-eclampsia 74
    
-     10.4.2. Severe acute hypertension in pregnancy 74
    
-    10.5. Peri-operative acute management of elevated blood pressure  74
    
-     10.5.1. Blood pressure-lowering drugs in the peri-operative phase 74
    
-   11\. Patient-centred care in hypertension 75
    
-    11.1. Definition 75
    
-    11.2. Communicating consequences of treatment 75
    
-    11.3. Self-measuring and monitoring 76
    
-    11.4. Facilitating medication adherence and persistence 76
    
-    11.5. Multidisciplinary management 76
    
-   12\. Key messages 77
    
-   13\. Gaps in the evidence 78
    
-   14\. ‘What to do’ and ‘what not to do’ messages from the guidelines  78
    
-   15\. Evidence tables 82
    
-   16\. Data availability statement 82
    
-   17\. Author information 82
    
-   18\. Appendix 82
    
-   19\. References 83
    

## Tables of Recommendations

-   Recommendation Table 1 — Recommendations for measuring blood pressure (see Evidence Tables 1–8) 24
    
-   Recommendation Table 2 — Recommendations for categorizing blood pressure (see Evidence Table 9) 25
    
-   Recommendation Table 3 — Recommendations for assessing cardiovascular disease risk among individuals with elevated blood pressure (office systolic blood pressure 120–139 mmHg or diastolic blood pressure 70–89 mmHg) (see Evidence Tables 10 and 11) 28
    
-   Recommendation Table 4 — Recommendations for refining cardiovascular disease risk (see Evidence Tables 12–14) 30
    
-   Recommendation Table 5 — Recommendations for blood pressure screening (see Evidence Table 15) 32
    
-   Recommendation Table 6 — Recommendations for confirming hypertension diagnosis 32
    
-   Recommendation Table 7 — Recommendations for assessing adherence and persistence with treatment (see Evidence Table 16) 34
    
-   Recommendation Table 8 — Recommendations for assessing renal hypertension-mediated organ damage 36
    
-   Recommendation Table 9 — Recommendations for assessing cardiac hypertension-mediated organ damage 36
    
-   Recommendation Table 10 — Recommendations for assessing vascular hypertension-mediated organ damage (see Evidence Table 17) 37
    
-   Recommendation Table 11 — Recommendations for genetic testing in hypertension management 37
    
-   Recommendation Table 12 — Recommendations for resistant hypertension work-up (see Evidence Table 18) 39
    
-   Recommendation Table 13 — Recommendations for screening for secondary hypertension (see Evidence Tables 19 and 20) 43
    
-   Recommendation Table 14 — Recommendations for screening for hypertension in children and adolescents (see Evidence Table 21) 43
    
-   Recommendation Table 15 — Recommendations for non-pharmacological treatment of blood pressure and cardiovascular risk reduction (see Evidence Tables 22–26) 47
    
-   Recommendation Table 16 — Recommendations for pharmacological treatment of hypertension (see Evidence Tables 27, 28, and 29) 51
    
-   Recommendation Table 17 — Recommendations for initiating blood pressure-lowering treatment (see Evidence Tables 30–32) 52
    
-   Recommendation Table 18 — Recommendations for blood pressure targets with treatment (see Evidence Table 34) 55
    
-   Recommendation Table 19 — Recommendations for follow-up in patients with treated hypertension (see Evidence Table 33) 55
    
-   Recommendation Table 20 — Recommendations for device-based treatment of hypertension (see Evidence Table 35) 56
    
-   Recommendation Table 21 — Recommendations for managing hypertension in young adults (see Evidence Tables 36 and 37) 58
    
-   Recommendation Table 22 — Recommendations for managing hypertension in pregnancy (see Evidence Tables 38–40) 60
    
-   Recommendation Table 23 — Recommendations for managing hypertension in patients who are very old or frail (see Evidence Table 41) 62
    
-   Recommendation Table 24 — Recommendations for managing hypertension in patients with orthostatic hypotension 64
    
-   Recommendation Table 25 — Recommendations for managing hypertension in patients with diabetes 64
    
-   Recommendation Table 26 — Recommendations for managing hypertension in patients with chronic kidney disease 65
    
-   Recommendation Table 27 — Recommendations for managing hypertension in patients with cardiac disease 67
    
-   Recommendation Table 28 — Recommendations for managing hypertension in patients with chronic cerebrovascular disease and cognitive impairment 68
    
-   Recommendation Table 29 — Recommendations for managing hypertension in different ethnic groups 68
    
-   Recommendation Table 30 — Recommendations for treating resistant hypertension (see Evidence Tables 42 and 43) 70
    
-   Recommendation Table 31 — Recommendations for managing hypertension in patients with renovascular hypertension (see Evidence Tables 44 and 45) 71
    
-   Recommendation Table 32 — Recommendations for acutely managing blood pressure in patients with intracerebral haemorrhage or acute ischaemic stroke 73
    
-   Recommendation Table 33 — Recommendations for acutely managing blood pressure in patients with severe hypertension in pregnancy and pre-eclampsia (see Evidence Table 46) 74
    
-   Recommendation Table 34 — Recommendations for communicating consequences of treatment (see Evidence Table 47) 76
    
-   Recommendation Table 35 — Recommendations for self-measuring and monitoring blood pressure (see Evidence Table 48) 76
    
-   Recommendation Table 36 — Recommendations for multi/interdisciplinary blood pressure management (see Evidence Table 49) 76
    

## List of tables

-   Table 1 Classes of recommendations 7
    
-   Table 2 Levels of evidence 8
    
-   Table 3 New recommendations 9
    
-   Table 4 Revised recommendations 12
    
-   Table 5 Comparison of office, home, and ambulatory blood pressure measurement thresholds for elevated blood pressure and hypertension 22
    
-   Table 6 Comparison of ambulatory and home blood pressure monitoring 23
    
-   Table 7 Key illness representations and treatment beliefs: how these apply to communicating a hypertension diagnosis to the patient (note that gender influences these representations) 34
    
-   Table 8 Routine tests recommended in the initial work-up of a patient with elevated blood pressure or hypertension 35
    
-   Table 9 Optional tests that may be used as clinically indicated in the initial work-up of a patient with elevated blood pressure or hypertension to assess hypertension-mediated organ damage or established cardiovascular disease 36
    
-   Table 10 Current definition of resistant hypertension 39
    
-   Table 11 Conditions found to cause pseudo-resistance or resistance to blood pressure-lowering treatment 39
    
-   Table 12 Drugs and conditions that affect aldosterone, renin, and aldosterone-to-renin ratio 40
    
-   Table 13 Optional tests that should be used to screen for secondary hypertension in the presence of suggestive signs, symptoms, or medical history 41
    
-   Table 14 Initiation of blood pressure-lowering treatment based on confirmed blood pressure category and cardiovascular disease risk 52
    
-   Table 15 What to do and what not to do 78
    

## List of figures

-   Figure 1 Pathophysiology of elevated blood pressure and hypertension 17
    
-   Figure 2 Persistently elevated blood pressure and hypertension lead to hypertension-mediated organ damage and cardiovascular disease 18
    
-   Figure 3 Summary of office blood pressure measurement 20
    
-   Figure 4 Summary of home blood pressure measurement 21
    
-   Figure 5 Summary of ambulatory blood pressure measurement 22
    
-   Figure 6 Blood pressure categories 26
    
-   Figure 7 Sufficiently high cardiovascular risk conditions that warrant blood pressure-lowering treatment among adults with elevated blood pressure 27
    
-   Figure 8 Cardiovascular disease risk modifiers to consider for up-classification of risk 29
    
-   Figure 9 Summary of cardiovascular disease risk-stratification approach for blood pressure treatment in adults with elevated blood pressure 31
    
-   Figure 10 Protocol for confirming hypertension diagnosis 33
    
-   Figure 11 Definitions, assessments, and potential interventions for the three phases of adherence to BP-lowering medications 35
    
-   Figure 12 Tests and criteria for defining hypertension-mediated organ damage and considerations for their use in clinical practice 38
    
-   Figure 13 Summary of primary aldosteronism as a common form of secondary hypertension 41
    
-   Figure 14 Summary of renovascular disease as a common form of secondary hypertension 42
    
-   Figure 15 Summary of obstructive sleep apnoea as a common form of secondary hypertension 42
    
-   Figure 16 Physical activity according to different types of exercise and reduction of blood pressure and overall cardiovascular disease risk 44
    
-   Figure 17 Effects of main lifestyle factors on blood pressure and cardiovascular risk reduction 45
    
-   Figure 18 Practical algorithm for pharmacological blood pressure lowering 49
    
-   Figure 19 Central Illustration 50
    
-   Figure 20 Systolic blood pressure categories and treatment target range 54
    
-   Figure 21 Frailty assessment in the management of blood pressure 61
    
-   Figure 22 Management of resistant hypertension 70
    
-   Figure 23 Patient-centred care 75
    
-   Figure 24 The five dimensions of adherence (WHO, 2003) applied to hypertension 77
    

## Abbreviations and acronyms

 -   ABI
    
    Ankle–brachial index
    
 -   ABPM
    
    Ambulatory blood pressure monitoring
    
 -   ACCORD
    
    Action to Control Cardiovascular Risk in Diabetes
    
 -   ACE
    
    Angiotensin-converting enzyme
    
 -   ACR
    
    Albumin:creatinine ratio
    
 -   AF
    
    Atrial fibrillation
    
 -   AHI
    
    Apnoea–hypopnoea index
    
 -   ALARA
    
    As low as reasonably achievable
    
 -   ALLHAT
    
    Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack
    
 -   AOBP
    
    Automated office blood pressure (measurement)
    
 -   ARB
    
    Angiotensin receptor blocker
    
 -   ARNi
    
    Angiotensin receptor-neprilysin inhibitor
    
 -   ARR
    
    Aldosterone-to-renin ratio
    
 -   ASCVD
    
    Atherosclerotic cardiovascular disease
    
 -   BMI
    
    Body mass index
    
 -   BP
    
    Blood pressure
    
 -   BSA
    
    Body surface area
    
 -   CAC
    
    Coronary artery calcium
    
 -   CAD
    
    Coronary artery disease
    
 -   CCB
    
    Calcium channel blocker
    
 -   CHAP
    
    Chronic Hypertension and Pregnancy
    
 -   CI
    
    Confidence interval
    
 -   CKD
    
    Chronic kidney disease
    
 -   CKD-EPI
    
    Chronic Kidney Disease Epidemiology Collaboration
    
 -   COVID-19
    
    Coronavirus disease 2019
    
 -   CPAP
    
    Continuous positive airway pressure
    
 -   CPG
    
    Clinical Practice Guidelines
    
 -   CT
    
    Computed tomography
    
 -   CVD
    
    Cardiovascular disease
    
 -   DASH
    
    Dietary Approaches to Stop Hypertension
    
 -   DBP
    
    Diastolic blood pressure
    
 -   DECIDE-Salt
    
    Diet, ExerCIse and carDiovascular hEalth–Salt
    
 -   EACTS
    
    European Association for Cardio-Thoracic Surgery
    
 -   ECG
    
    Electrocardiogram
    
 -   eGFR
    
    Estimated glomerular filtration rate
    
 -   EPIC
    
    European Prospective Investigation into Cancer and Nutrition
    
 -   ESC
    
    European Society of Cardiology
    
 -   ESH
    
    European Society of Hypertension
    
 -   ESPRIT
    
    Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs
    
 -   FMD-RVH
    
    Fibromuscular dysplasia-induced renovascular hypertension
    
 -   GFR
    
    Glomerular filtration rate
    
 -   GLP-1
    
    Glucagon-like peptide-1
    
 -   GP
    
    General practitioner
    
 -   HbA1c
    
    Glycated haemoglobin
    
 -   HBPM
    
    Home blood pressure monitoring
    
 -   HDL
    
    High-density lipoprotein
    
 -   HFpEF
    
    Heart failure with preserved ejection fraction
    
 -   HF(m)rEF
    
    Heart failure with (mildly) reduced ejection fraction
    
 -   HIV
    
    Human immunodeficiency virus
    
 -   HMOD
    
    Hypertension-mediated organ damage
    
 -   i.m.
    
    Intramuscular
    
 -   i.v.
    
    Intravenous
    
 -   KDIGO
    
    Kidney Disease: Improving Global Outcomes
    
 -   LA
    
    Left atrial
    
 -   LDL
    
    Low-density lipoprotein
    
 -   LV
    
    Left ventricular
    
 -   LVH
    
    Left ventricular hypertrophy
    
 -   MRA
    
    Mineralocorticoid receptor antagonist
    
 -   MRI
    
    Magnetic resonance imaging
    
 -   NNT
    
    Number needed to treat
    
 -   NT-proBNP
    
    N-terminal pro-brain natriuretic peptide
    
 -   OSAS
    
    Obstructive sleep apnoea syndrome
    
 -   PPGL
    
    Phaeochromocytoma/paraganglioma
    
 -   PREOP-ACEI
    
    Prospective Randomized Evaluation of Preoperative Angiotensin-Converting Enzyme Inhibition
    
 -   PREMs
    
    Patient-Reported Experience Measures
    
 -   PROMS
    
    Patient-Reported Outcome Measures
    
 -   PTRA
    
    Percutaneous transluminal renal angioplasty
    
 -   PWV
    
    Pulse wave velocity
    
 -   RAAS
    
    Renin-angiotensin-aldosterone system
    
 -   RADIANCE-HTN
    
    A Study of the Recor Medical Paradise System in Clinical Hypertension
    
 -   RAS
    
    Renin–angiotensin system
    
 -   RCT
    
    Randomized controlled trial
    
 -   RVH
    
    Renovascular hypertension
    
 -   RWT
    
    Relative wall thickness
    
 -   SBP
    
    Systolic blood pressure
    
 -   SCORE2
    
    Systematic COronary Risk Evaluation 2
    
 -   SCORE2-OP
    
    Systematic COronary Risk Evaluation 2–Older Persons
    
 -   SGLT2
    
    Sodium–glucose co-transporter 2
    
 -   SNP
    
    Single-nucleotide polymorphism
    
 -   SNS
    
    Sympathetic nervous system
    
 -   SPC
    
    Single-pill combination
    
 -   SPRINT
    
    Systolic Blood Pressure Intervention Trial
    
 -   SSaSS
    
    Salt Substitute and Stroke Study
    
 -   STEP
    
    Strategy of Blood Pressure Intervention in Elderly Hypertensive Patients
    
 -   STEP-1
    
    Semaglutide Treatment Effect in People with Obesity
    
 -   TIA
    
    Transient ischaemic attack
    
 -   TRIUMPH
    
    Treating Resistant Hypertension Using Lifestyle Modification to Promote Health
    
 -   TSH
    
    Thyroid-stimulating hormone
    
 -   WHO
    
    World Health Organization
    
 -   WML
    
    White matter lesion
    

## 1\. Preamble

Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approach for an individual patient with a given condition. Guidelines are intended for use by health professionals and the European Society of Cardiology (ESC) makes its guidelines freely available.

ESC Guidelines do not override the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription and to respect the ethical rules of their profession.

ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated when warranted by new evidence. ESC Policies and Procedures for formulating and issuing ESC Guidelines can be found on the ESC website ([https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines](https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines)). This guideline version updates and replaces the previous version from 2018.

The Members of this task force were selected by the ESC to include professionals involved in the medical care of patients with this pathology, as well as patient representatives and methodologists. The selection procedure included an open call for authors and aimed to include members from across the whole of the ESC region and from relevant ESC Subspecialty Communities. Consideration was given to diversity and inclusion, notably with respect to gender and country of origin. The task force performed a critical review and evaluation of the published literature on diagnostic and therapeutic approaches including assessment of the risk-benefit ratio. The strength of every recommendation and the level of evidence supporting them were weighed and scored according to predefined scales as outlined in _[Tables 1](javascript:;)_ and _[2](javascript:;)_ below. Patient-Reported Outcome Measures (PROMs) and Patient-Reported Experience Measures (PREMs) were also evaluated as the basis for recommendations and/or discussion in these guidelines. The task force followed ESC voting procedures and all approved recommendations were subject to a vote and achieved at least 75% agreement among voting members. Members of the task force with declared interests on specific topics were asked to abstain from voting on related recommendations.

Table 1

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375722)

Classes of recommendations

![Classes of recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178il1.jpeg?Expires=1728462844&Signature=Y0NNSv60jeHOwJxH4v9cd81tPUbbMIkmgAjiOs0o4lmgYuTGYTh2Fg~jOuWDDShtFV3ZY8hQelpORhHOgbLRbSAGdnFXqU5Za3byuEkVFXR8PbgkhJmJh12jznM-DUDiE1C4pGWF1kYwP4h9KkobOCqSqFjkRfyVIKebWerFAjAGJKYZ2eeQzsd1O1i-vDPJpEDcEhrPUNRoRwx~cl1rTgIqlWV3kwdBooZMEGnUeATPaDoJUx9dQli9ZB9~oWRv7kDkNNIDeINz-sob72qBRNiyejOgp9vcc7xbCoUzQrrB1bVj80cFQkcJ6Kazn8dfCjmiYpWgxHVsYzPF20SAeQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 2

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375723)

Levels of evidence

![Levels of evidence](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178il2.jpeg?Expires=1728462844&Signature=FNy2Dfjps8T6LBo75RlmW2WjbImnkSoGp6Z3JzyR-GwnpXL93ER2Ru0QgpNxUjR2PsbQi1HXMrC3NYk~Bd5gJ1iTbqpTx3EkxgMjXv63nPrNIYrr~UuPJv3uuFu1tvgUYylvpNJbaQmMKj5jHw0yPsy57PmEdFml2XsRUVphd48yckivo5WUe0yRLZOXqaZ3Wv2DFgrrmcgrmvwgD8Sh8ng8i-1eMPaCeCTwSsa88Ma~mI5cSTVM4D6RNc~MtCyBMVdfWS7JPGwSWE58YVePXgghniYmjt73qYX2dK5KFv5ncNHDPIS~P6qLg3p2sw4q8zu2EvW2j1a-o5Nz0IhHnw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules, which can be found on the ESC website ([http://www.escardio.org/guidelines](http://www.escardio.org/guidelines)) and have been compiled in a report published in a supplementary document with the guidelines. Funding for the development of ESC Guidelines is derived entirely from the ESC with no involvement of the healthcare industry.

The ESC Clinical Practice Guidelines (CPG) Committee supervises and co-ordinates the preparation of new guidelines and is responsible for the approval process. In addition to review by the CPG Committee, ESC Guidelines undergo multiple rounds of double-blind peer review by external experts, including members from across the whole of the ESC region, all National Cardiac Societies of the ESC and from relevant ESC Subspecialty Communities. After appropriate revisions, the guidelines are signed off by all the experts in the task force. The finalized document is signed off by the CPG Committee for publication in the _European Heart Journal_.

ESC Guidelines are based on analyses of published evidence, chiefly on clinical trials and meta-analyses of trials, but potentially including other types of studies. Evidence tables summarizing key information from relevant studies are generated early in the guideline development process to facilitate the formulation of recommendations, to enhance comprehension of recommendations after publication, and reinforce transparency in the guidelines development process. The tables are published in their own section of ESC Guidelines and reference specific recommendation tables.

Off-label use of medication may be presented in these guidelines if a sufficient level of evidence shows that it can be considered medically appropriate for a given condition. However, the final decisions concerning an individual patient must be made by the responsible health professional giving special consideration to:

-   The specific situation of the patient. Unless otherwise provided for by national regulations, off-label use of medication should be limited to situations where it is in the patient’s interest with regard to the quality, safety, and efficacy of care, and only after the patient has been informed and has provided consent;
    
-   Country-specific health regulations, indications by governmental drug regulatory agencies, and the ethical rules to which health professionals are subject, where applicable.
    

## 2\. Introduction

This 2024 document updates the 2018 ESC/European Society of Hypertension (ESH) Guidelines on the management of arterial hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B1" data-open="ehae178-B1" class="link link-ref link-reveal xref-bibr">1</a></sup> While the current document builds on prior guidelines, it also incorporates important updates and new recommendations based on current evidence. For example:

1.  The title has changed from ‘Guidelines on the management of arterial hypertension’ to ‘Guidelines on the management of elevated blood pressure and hypertension’. This is based on evidence that the risk for cardiovascular disease (CVD) attributable to blood pressure (BP) is on a continuous exposure scale, not a binary scale of normotension vs. hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B2" data-open="ehae178-B2" class="link link-ref link-reveal xref-bibr">2</a>,<a href="javascript:;" reveal-id="ehae178-B3" data-open="ehae178-B3" class="link link-ref link-reveal xref-bibr">3</a></sup> Updated evidence also increasingly demonstrates the benefit on CVD outcomes of BP-lowering medications among persons with high CVD risk and BP levels that are elevated but that do not meet traditional thresholds used to define hypertension. The term ‘arterial’ is removed from the title of the 2024 Guidelines, as arterial hypertension can also occur in the pulmonary arteries, which is not a focus here.
    
2.  The 2024 Guidelines continue to define hypertension as office systolic BP of ≥140 mmHg or diastolic BP of ≥90 mmHg. However, a new BP category called ‘Elevated BP’ is introduced. Elevated BP is defined as an office systolic BP of 120–139 mmHg or diastolic BP of 70–89 mmHg.
    
3.  A major, evidence-based change in the 2024 Guidelines is the recommendation to pursue a target systolic BP of 120–129 mmHg among adults receiving BP-lowering medications. There are several important caveats to this recommendation, including: (i) the requirement that treatment to this BP target is well tolerated by the patient, (ii) the fact that more lenient BP targets can be considered in persons with symptomatic orthostatic hypotension, those aged 85 years or over, or those with moderate-to-severe frailty or limited life expectancy, and (iii) a strong emphasis on out-of-office BP measurement to confirm the systolic BP target of 120–129 mmHg is achieved. For those selected individual cases where a target systolic BP of 120–129 mmHg is not pursued, either due to intolerance or the existence of conditions that favour a more lenient BP target, we recommend targeting a BP that is as low as reasonably achievable. Personalized clinical decision-making and shared decisions with the patient are also emphasized.
    
4.  Another important change in the 2024 Guidelines compared with earlier versions is the increased focus on evidence related to fatal and non-fatal CVD outcomes rather than surrogate outcomes such as BP lowering alone. Except for lifestyle interventions and low-risk non-pharmacological interventions aimed at implementation or care delivery, the current guidelines require that, for a Class I recommendation to be made for a drug or procedural intervention, the evidence must show benefit on CVD outcomes and not only BP lowering.
    
5.  The task force comprised of a balanced representation of males and females.
    
6.  The present guidelines consider sex and gender as an integral component throughout the document, rather than in a separate section at the end. In this document, sex is the biological condition of being female or male from conception, based on genes, and gender is the socio-cultural dimension of being a woman or a man in a given society, based on gender roles, gender norms, gender identity, and gender relations valid in the respective society at a given timepoint.<sup><a href="javascript:;" reveal-id="ehae178-B4" data-open="ehae178-B4" class="link link-ref link-reveal xref-bibr">4</a>,<a href="javascript:;" reveal-id="ehae178-B5" data-open="ehae178-B5" class="link link-ref link-reveal xref-bibr">5</a></sup>
    
7.  The 2024 Guidelines are written to make them more ‘user friendly’. Input from general practitioners (GPs) was obtained in this regard, and one task force member is a GP. Given the ageing population in Europe, there was also a focus on tailoring treatment with respect to frailty and into older age, which is addressed in multiple sections. Moreover, patient input and their lived experiences are considered throughout. We also now include evidence tables in the Supplementary section to provide improved transparency regarding our recommendations. As appropriate, readers who wish to seek additional details and information are referred to the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) and to the ![graphic](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178il4.jpeg?Expires=1728462844&Signature=Uok7hDvPxFT3d~1RJy9LSmybAUAgvvgord~KlDRiQKZ88AMXHz9o4X15d1PsK2yVQ0VxGXPeoUCFNqKQ-Qb-n4RpImN5fVooV5060kD6jtBqmFJVY-ZDEuVR6uBgYDYlVoGTJnsEU7EdNFNAyjztFXZlbYXKO3vocogQ4UXRI51gv1ouSmwujlS63F0twr0MqIFkn8F~yiZUrnwpvtXC0~bCDuwdmFDsFcQyOv4IGiZ71BkKWNrchFwE~-B64ue1J3mdlmyYUT09Glfb38ZNvBbcOTYpW24ld6q4AMjc4dM-k4oD~pIXGwjwnY0S7EXzaeVTMcr1HH5AbgsJE-hVSQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)  [ESC CardioMed](https://doi.org/10.1093/med/9780198784906.001.0001).<sup><a href="javascript:;" reveal-id="ehae178-B6" data-open="ehae178-B6" class="link link-ref link-reveal xref-bibr">6</a></sup>
    
8.  The task force recognized that a major challenge in guideline usage is poor implementation. This likely contributes to suboptimal control of hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B7 ehae178-B8 ehae178-B9" data-open="ehae178-B7 ehae178-B8 ehae178-B9" class="link link-ref link-reveal xref-bibr">7–9</a></sup> To address this, a dedicated section on implementation is included in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA). Moreover, through a new initiative, we include information from national societies following a survey on guideline implementation completed during the national society peer review of the guidelines document. It is hoped this information may help inform national societies about potential barriers to implementation.
    

### 2.1. What is new

These 2024 Guidelines contain a number of new and revised recommendations, which are summarized in _[Tables 3](javascript:;)_ and _[4](javascript:;)_, respectively.

Table 3

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375734)

New recommendations

![New recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178t3.jpeg?Expires=1728462844&Signature=LvInzHkasbylidSNQ-4bnslhs3cSntjWrmo7xnhqAjsDVA58fXXWE~ZMYaDryY4z-8C5oH6igWPQzZghIxy4YTr606u1vCtSYpMl0VeeGpj4WjifimCv4kjes~v85UuibxLnmHTIxxIWHac--WmHg-gi-STttdwCEpqUMkYLjyEASxCDCbvBs2ULcAsYy2mkbzL~HqZIQ-ObDG8iEkI7ahdedUn0e85T74a-hSS~-McFTMpNHXCtOLvlFjwEeUIM4LTmg4CWEGQYX1jFsKQvvmD7HU8HKtx2I03i1wEVxgG-iv-kKEHNACWRvMqWT5gp3basn0vhGyYUzeqZtBHDnA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 4

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375735)

Revised recommendations

![Revised recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178t4.jpeg?Expires=1728462844&Signature=PSmRnw58w9els3~aAKAQEB49k1vZpkRp8ROT73K7WZCwyi3TB98Go5PehuDB~M~fXmoYV6tb7r6Yfm8jiAq6t~7j-KqwfNYCK0wtqmfpzr8Fay3BNHkRn1Zf8I6765ZWPELQ61BGVBa~xknTsZfyEVXBV8nBPC~lK-oE4gz9FCrtOZgdFy9hXHbmXIGMoDyvCZaOrrUiKYtxUDXeK15CiUjql6pgReThvsQIe1J5SZB3hHM3xDfwBZM0XUFJoDiyuv-3gCa3tbbisx76ahdy~hIkkdNnlQihQzoqH~Vs2~7Pb-zAGt5tSdI8fubVl5HuHt5z5we6MYXN~q5xMjgttA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 3\. Pathophysiology of elevated blood pressure and hypertension

Persistently high BP in systemic arteries is the hallmark of hypertension, which is the most important modifiable risk factor for all-cause and CVD morbidity and mortality globally.<sup><a href="javascript:;" reveal-id="ehae178-B2" data-open="ehae178-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> Most patients with hypertension have essential or primary hypertension, where the exact cause remains unknown, while an estimated 10% have secondary hypertension, with an identifiable cause (notably some studies indicate that the prevalence of secondary hypertension may be substantially higher, with modern systematic screening).<sup><a href="javascript:;" reveal-id="ehae178-B10" data-open="ehae178-B10" class="link link-ref link-reveal xref-bibr">10</a></sup>

The pathophysiology of hypertension involves complex interactions between environmental and behavioural factors, genes, hormonal networks, and multiple organ systems (renal, cardiovascular, and central nervous system<sup><a href="javascript:;" reveal-id="ehae178-B11" data-open="ehae178-B11" class="link link-ref link-reveal xref-bibr">11</a></sup>) (_[Figure 1](javascript:;)_). In addition, vascular and immune mechanisms are involved.<sup><a href="javascript:;" reveal-id="ehae178-B12" data-open="ehae178-B12" class="link link-ref link-reveal xref-bibr">12</a></sup> Dysregulation of these processes leads to hypertension, which if uncontrolled, can lead to hypertension-mediated organ damage (HMOD) and adverse CVD outcomes.

![Pathophysiology of elevated blood pressure and hypertension.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f1.jpeg?Expires=1728462844&Signature=mYBuPuhVcIN0y7IZVhdhDhoLYn4SmlBqZlEf7W2oO5nIOptYXxC4FvryPHraXX4GlLu7tSx3FWgFnBlb8Gr2lxexrO-biGLIixvkWbp42qkEuDn9~PGgeX~4V8y3~2YeV9QIZuKZS7fM68Zmz9zo5Sy4JWlH~VtDNmro2uwTzz5Wtlob7Z5hBLanqk9bS0QKnFTAywSPXPxQIGZyRut-HCGBaYn6qu-Lss~Gg630HcBaUwPbz6s-98MKkSeK~2FMDIb4m2R8jEq2wT~95QUT4dfMGbdWcOzST0eBH9icyHb4RLG-DpUuojahGdpT8E3ykcincrLrs~i6llpQMp4V6g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 1

Pathophysiology of elevated blood pressure and hypertension.

BP, blood pressure; PNS, parasympathetic nervous system; RAAS, renin-angiotensin-aldosterone system; SNP, single-nucleotide polymorphism; SNS, sympathetic nervous system. Complex interplay between genes, environmental, and behavioural factors, organs, physiological systems, and neurohumoral processes contribute to BP regulation. Dysfunction of these processes leads to hypertension. The contribution of these factors to elevated BP and hypertension may differ among males and females.

[Open in new tab](https://academic.oup.com/view-large/figure/479375739/ehae178f1.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f1.jpeg?Expires=1728462844&Signature=nH1uYHoixGbyJIuWsFsWIV4qipo8gDRAN1uMmMXBMj-h2RgjrOWKhYxjWXU67PgHKGWWXbhggF~NDaFup8mseHzD1NIdGmLHWeegdSTbZLLsZc3GTUzo7B3qfUd5QO-Rw5xl~IA05cxqBSRFo9LtLmhEI9T1uKLJ7fvpe7T~HtntVsZQgfi-9RFwRMhtlnuLTSx9ge6WXgNORGsfkdC7dY9pM0CofNWjDfv58IEXTQSuXszcFhbZX1sTutaLIQXlqTyb0fnobrAVmcQu4vVnCA8~O6Xv4BciRrol8GjyjvPf991JqjO~cuJuaKKb6aszZG64M-C-r92W4oAbGaCZBQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375739&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Details on the pathophysiological processes, molecular mechanisms, and environmental and psychosocial elements that underlie hypertension are provided in the [Supplementary text](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) ([Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).

## 4\. Clinical consequences of elevated blood pressure and hypertension

Longstanding hypertension causes organ damage and ultimately leads to cardiovascular, cerebrovascular, and clinical renal disease, which are all major contributors to the global burden of chronic disease (_[Figure 2](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae178-B2" data-open="ehae178-B2" class="link link-ref link-reveal xref-bibr">2</a>,<a href="javascript:;" reveal-id="ehae178-B13 ehae178-B14 ehae178-B15 ehae178-B16 ehae178-B17 ehae178-B18 ehae178-B19 ehae178-B20 ehae178-B21 ehae178-B22" data-open="ehae178-B13 ehae178-B14 ehae178-B15 ehae178-B16 ehae178-B17 ehae178-B18 ehae178-B19 ehae178-B20 ehae178-B21 ehae178-B22" class="link link-ref link-reveal xref-bibr">13–22</a></sup> Organs adversely affected by elevated BP and hypertension include the heart, brain, kidneys, eyes, and vessels (macrocirculation and microcirculation in organs with low resistance, such as the brain or kidney<sup><a href="javascript:;" reveal-id="ehae178-B23" data-open="ehae178-B23" class="link link-ref link-reveal xref-bibr">23</a></sup>), which undergo structural and functional changes. Although factors besides BP can contribute to these changes (i.e. dyslipidaemia, hyperglycaemia), we use the term ‘hypertension-mediated organ damage’ to indicate the presence of subclinical complications of hypertension that indicate high risk for subsequent clinical events. HMOD may have different profiles in men and women; for instance, left ventricular hypertrophy (LVH) and left atrial dilatation are more frequent in women.<sup><a href="javascript:;" reveal-id="ehae178-B24 ehae178-B25 ehae178-B26 ehae178-B27 ehae178-B28" data-open="ehae178-B24 ehae178-B25 ehae178-B26 ehae178-B27 ehae178-B28" class="link link-ref link-reveal xref-bibr">24–28</a></sup>

![Persistently elevated blood pressure and hypertension lead to hypertension-mediated organ damage and cardiovascular disease.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f2.jpeg?Expires=1728462844&Signature=ByruCCljoRJXcx2XtJZ7DYMcICChPUQu2s4qn7w1oGY7ImyW5ekGlzeFAA4l55~dUo8-ktD7CY3X8eM-mlNyiJ~WMZ78TKrVjp-lmRMKh4JquWhmrvmQEla5153C9hfdgftBj-lyvg9UIL3L3b4ROamCv4Wigxogepza0UTYfxXWsv5ngutYgGbCDznP3n5DZ2qNAC5iBY~-AD0LuWyfErybP3UxQjjCNH-tDuCj9aFsv8j6aupFh-1X1s82lXST8Q5vjcE8Nz3NiBo7Rqr5kDKyRCCBIIfztbMfBqyT4Frrx3cKAokVs6lRP6f3c-YWLvh8xLAILLzKsitLkEJOlQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 2

Persistently elevated blood pressure and hypertension lead to hypertension-mediated organ damage and cardiovascular disease.

AF, atrial fibrillation; CAD, coronary artery disease; GFR, glomerular filtration rate; LA, left atrial; LV, left ventricular; LVH, left ventricular hypertrophy. See the [supplementary data](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) online for detailed information on sex differences.

[Open in new tab](https://academic.oup.com/view-large/figure/479375743/ehae178f2.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f2.jpeg?Expires=1728462844&Signature=sP04~8WY-ilxhvFvNyfx6mCbe1uUpaXwQ7g3-0~qpT6G~8NL0dZY9SrGWIz4v-a4HL-v2qpIlJCzl47NJq4ttVvXx~LqC7ASMAxqQcStCvzVt1OlVXvNvc-HWb2AWkN~VPqq4TpL1RNwNizI83Xv9KPGQxIOkcTlSJYhqJJGKeNZpOSMc08pRNsX9XxRIRzmtitSEVpm3it3ws3soQW3~k8yJLBHoLmBiOUIRTgmxLy5KT8pDPTVEqUl5ZSWigk0~Lpj-dEpvEPo8LonqcAoh9hn-htkLW9WVSdrFqa27UmvFu5iuGCaH88ZiPFiTvymIuGyFQB2ue-aLwmkF7n25w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375743&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Evidence of HMOD usually indicates long-standing elevated BP and/or hypertension and confers incremental prognostic information regarding CVD risk in all BP categories.<sup><a href="javascript:;" reveal-id="ehae178-B29 ehae178-B30 ehae178-B31" data-open="ehae178-B29 ehae178-B30 ehae178-B31" class="link link-ref link-reveal xref-bibr">29–31</a></sup> Unless treated, HMOD can progress from asymptomatic to symptomatic, ultimately resulting in overt CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B31" data-open="ehae178-B31" class="link link-ref link-reveal xref-bibr">31</a></sup>

The pathophysiological mechanisms underlying HMOD in the heart, brain, kidneys, vessels, and eyes are detailed in the [Supplementary text](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) ([Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)). The clinical consequences of HMOD, especially cerebrovascular disease (stroke and cognitive decline), kidney disease (acute and chronic), and heart disease \[heart failure, atrial fibrillation (AF), ischaemic heart disease, and valvular disease\] are also discussed in the [Supplementary text](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) ([Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)). In addition, the Supplement highlights the impact of different measures of BP on CVD risk, including systolic BP, diastolic BP, pulse pressure, and BP variability.<sup><a href="javascript:;" reveal-id="ehae178-B22" data-open="ehae178-B22" class="link link-ref link-reveal xref-bibr">22</a>,<a href="javascript:;" reveal-id="ehae178-B32 ehae178-B33 ehae178-B34 ehae178-B35 ehae178-B36" data-open="ehae178-B32 ehae178-B33 ehae178-B34 ehae178-B35 ehae178-B36" class="link link-ref link-reveal xref-bibr">32–36</a></sup>

## 5\. Measuring blood pressure

### 5.1. Introduction and pertinent definitions

This section reviews practical aspects of BP measurement, including technique and clinical validation of devices. It also reviews the evidence for the most appropriate BP measurement methods when screening populations for hypertension, diagnosing hypertension, and managing patients receiving BP-lowering interventions. The current guidelines promote use of out-of-office measurement for diagnosis and ongoing management of hypertension, reflecting increasing evidence for the stronger relationship of home and ambulatory monitoring with outcomes, the ability to detect white-coat and masked hypertension, new BP treatment targets as low as 120–129 mmHg systolic (_[Table 5](javascript:;)_), and evidence supporting enabling patient involvement and shared decision-making.

Table 5

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375749)

Comparison of office, home, and ambulatory blood pressure measurement thresholds for elevated blood pressure and hypertension

|  | Office BP (mmHg)<sup><a href="javascript:;" reveal-id="tblfn116" data-open="tblfn116" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> | Home BP (mmHg) | Daytime ABPM (mmHg) | 24 h ABPM (mmHg) | Night-time ABPM (mmHg) |
| --- | --- | --- | --- | --- | --- |
| **Reference** |  |  |  |  |  |
| Non-elevated BP | <120/70 | <120/70 | <120/70 | <115/65 | <110/60 |
| Elevated BP | 120/70–<140/90 | 120/70–<135/85 | 120/70–<135/85 | 115/65–<130/80 | 110/60–<120/70 |
| Hypertension | ≥140/90 | ≥135/85 | ≥135/85 | ≥130/80 | ≥120/70 |

ABPM, ambulatory blood pressure monitoring; BP, blood pressure.

<sup>a</sup>The BP thresholds provided assume that a standardized approach to office BP measurement is performed (_[Figure 3](javascript:;)_). However, evidence indicates that office BP measurement in routine clinical settings is often not done using a standardized approach and, in this case, the routine office BP value may be 5–10 mmHg higher than it would have been if measured using the recommended standardized approach.<sup><a href="javascript:;" reveal-id="ehae178-B65" data-open="ehae178-B65" class="link link-ref link-reveal xref-bibr">65</a>,<a href="javascript:;" reveal-id="ehae178-B66" data-open="ehae178-B66" class="link link-ref link-reveal xref-bibr">66</a></sup>

© ESC 2024

**Definitions:**

**Systolic BP:** arterial BP during systole (maximum arterial pulsatile pressure). This is measured using an auscultatory device at the onset of the first Korotkoff sound. Oscillometric devices estimate systole using an algorithm that imputes from mean arterial pressure.<sup><a href="javascript:;" reveal-id="ehae178-B37" data-open="ehae178-B37" class="link link-ref link-reveal xref-bibr">37</a></sup>

**Diastolic BP:** arterial BP during diastole (minimum arterial pulsatile pressure). This is measured using an auscultatory device at the time of complete disappearance of the Korotkoff sounds (fifth sound). If there is no disappearance of sounds (no fifth sound) then the fourth Korotkoff sound (muffling) is used to estimate diastolic BP. Oscillometric devices estimate diastole using an algorithm that imputes from mean arterial pressure.<sup><a href="javascript:;" reveal-id="ehae178-B37" data-open="ehae178-B37" class="link link-ref link-reveal xref-bibr">37</a></sup>

**Inter-arm difference:** systolic BP difference of >10 mmHg when BP is measured sequentially in each arm.<sup><a href="javascript:;" reveal-id="ehae178-B38" data-open="ehae178-B38" class="link link-ref link-reveal xref-bibr">38</a></sup>

**Postural/orthostatic hypotension:** decrement of ≥20 mmHg in systolic BP and/or ≥10 mmHg in diastolic BP when BP is measured in the standing position at 1 and/or 3 min after standing following a 5-min period in the sitting or lying position.

**White-coat hypertension:** BP that is above the threshold for diagnosing hypertension in the office but below the threshold in home/ambulatory settings, e.g. ≥140/90 mmHg in office but <135/85 mmHg at home/ambulatory daytime (or 24-h BP < 130/80 mmHg).

**Masked hypertension:** BP that is below the hypertension diagnostic threshold in the office but above the hypertension diagnostic threshold in home/ambulatory settings, e.g. <140/90 mmHg in clinic but ≥135/85 mmHg at home/ambulatory daytime (or 24-h BP ≥130/80 mmHg).

**Office BP:** also known as clinic BP. The two terms are interchangeable. This guidelines document uses ‘office BP’ preferentially. Of note, office BP can be measured manually or using an automated device. In addition, automated office BP (AOBP) can be conducted in a setting attended by a healthcare professional or in an unattended fashion. Finally, not all office BP measurements are equal, with some facilities using a standardized method (which is recommended and outlined below) and others unfortunately using suboptimal approaches to office BP measurement.

**Home BP measurement (HBPM):** an out-of-office approach to measuring BP when the patient measures their own BP at home using a validated monitor (usually an upper-arm oscillometric cuff device).

**Ambulatory BP measurement (ABPM):** an out-of-office BP measurement that uses a fully automated oscillometric device, usually for a 24-h period, and measures BP at set intervals.

### 5.2. Practical recommendations for measuring blood pressure

#### 5.2.1. Clinical validation of equipment for measuring blood pressure

A prerequisite of BP measurement is that it must be undertaken using a device that has been clinically validated and confirmed to be accurate. Of the commercially available oscillometric BP measurement devices, as few as 6% have been adequately tested.<sup><a href="javascript:;" reveal-id="ehae178-B39 ehae178-B40 ehae178-B41" data-open="ehae178-B39 ehae178-B40 ehae178-B41" class="link link-ref link-reveal xref-bibr">39–41</a></sup> National and international organizations provide lists of validated monitors (e.g. [www.stridebp.org](https://www.stridebp.org), [www.validatebp.org](https://www.validatebp.org)).

Since the 2018 ESC/ESH Guidelines on the management of arterial hypertension, three arbiters of device accuracy (the Association for the Advancement of Medical Instrumentation, the ESH, and the International Organization for Standardization) have published a universal standard for validating devices for measuring BP.<sup><a href="javascript:;" reveal-id="ehae178-B42" data-open="ehae178-B42" class="link link-ref link-reveal xref-bibr">42</a></sup> This standard will likely become widely adopted. Validation standards and methodology need to be developed and implemented for novel BP measurement devices that are non-occlusive and ‘cuffless’.<sup><a href="javascript:;" reveal-id="ehae178-B43" data-open="ehae178-B43" class="link link-ref link-reveal xref-bibr">43</a>,<a href="javascript:;" reveal-id="ehae178-B44" data-open="ehae178-B44" class="link link-ref link-reveal xref-bibr">44</a></sup>

#### 5.2.2. Office blood pressure measurement

All BP measurements can be influenced by circumstances of measurement, including position, ambient temperature, the technique of measurement, accuracy of equipment, and physical condition of the patient.<sup><a href="javascript:;" reveal-id="ehae178-B45" data-open="ehae178-B45" class="link link-ref link-reveal xref-bibr">45</a></sup> For BP measurements in the office, we recommend following a standardized method (_[Figure 3](javascript:;)_).

![Summary of office blood pressure measurement.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f3.jpeg?Expires=1728462844&Signature=K8WtezBkKT~XJSWx4DYuELTbqNvvDlccvLsV9daea8gH9SlhAVolPn~l3mTcUNykE2pJ3Qxtz-Z0NorzdP47tOI0HAlHiHiFhxLn7MK62xi2cH3Zerj0cVQ-6gwEpZddLI~HwOKpD3Ian86Vq84mllk5It-r1Ij5Xz7VDqrY9CNrb-yOxFljVjyMLqYqRoVsk9yjUYkubb7Xfs0XQk-NPKMeztNn9cwf2xzhIBCggRPIheDYLCXjOSENOLjY5by4oheFTTL8dB2nR9tTzgS9qTEwrX9ttOzwk0ZCocMmDGPQrSUYLehQwS-CCEiZYCMDqyIrwWECnvHCMytvxVNuEQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 3

Summary of office blood pressure measurement.

BP, blood pressure.

[Open in new tab](https://academic.oup.com/view-large/figure/479375766/ehae178f3.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f3.jpeg?Expires=1728462844&Signature=Na6W3bNYknLppBYBXjy3QeP6H3BBZYixsYfggXvSTwV~NejpjoHLZhrT0JwCfg5gwpM6qWrjGEfdA8dfxOTLldOn92RU1IFi0dI114eEQR0wk5QV73ioq9HUbWvE5Rs-o7X4G~Q513gkEothHdlVkhpJ3an3UKpNjaArSiT7tsr8pFuwHx2km3-~2ejrrDz6qYmixAtdUwTHNxxHwLINMxaYjiaFoyE-Vm0fh8OVDi-yDbvgjbaxyFlUMozcvK24GHelzvh4VZeGW9j9mdvRCEfT8TjASAHRxxl40Yo5QMlo654GKiFeJXgdkYgej6b7cgriqMMD3j8SEvf6TT4nhQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375766&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

**Patient preparation:** BP should be measured with the patient seated comfortably after 5 min of rest. Patients should avoid exercising and stimulants (caffeine, tobacco) for at least 30 min before measurement. The patient’s bladder should be emptied if needed.<sup><a href="javascript:;" reveal-id="ehae178-B46" data-open="ehae178-B46" class="link link-ref link-reveal xref-bibr">46</a></sup> Patients should be seated with their legs unfolded and their back supported at the time of measurement. The arm should be supported (to avoid isometric exercise-induced increases in BP). Clothing at the location of the cuff placement should be removed; rolling up of shirt sleeves should be avoided as this can result in a tourniquet effect.

**BP measurement technique:** auscultatory or oscillometric techniques can be used to measure BP non-invasively. The manual auscultatory approach is the traditional method of measuring systolic and diastolic BP at the brachial artery site using a stethoscope. In contrast, oscillometric devices compute mean arterial BP using the oscillation amplitude with cuff deflation (or inflation) and then estimate systolic and diastolic BP. Oscillometric devices can be semi-automated (taking one reading per activation) or fully automated (obtaining multiple readings before averaging them). Oscillometric devices are not typically validated for use in AF, and the manual auscultatory method is preferred in these circumstances when feasible.<sup><a href="javascript:;" reveal-id="ehae178-B47 ehae178-B48 ehae178-B49" data-open="ehae178-B47 ehae178-B48 ehae178-B49" class="link link-ref link-reveal xref-bibr">47–49</a></sup>

**BP cuff selection and positioning:** an appropriately sized cuff should be used, as an under-sized or over-sized cuff will artificially elevate or reduce BP, respectively.<sup><a href="javascript:;" reveal-id="ehae178-B50" data-open="ehae178-B50" class="link link-ref link-reveal xref-bibr">50</a></sup> The bladder length should be 75%–100% and the width 35%–50% of the arm circumference. The arm circumference can be measured at the mid-point of the olecranon and the acromion but many cuffs include sizing indicators. The cuff should be positioned on the patient’s upper arm at the level of the heart with the lower edge of the cuff a few centimetres above the antecubital fossa. The stethoscope should not be placed under the cuff. In those with significant obesity where a correctly fitting upper arm cuff is not available, measurement at the lower arm or wrist can be considered as an alternative.<sup><a href="javascript:;" reveal-id="ehae178-B51" data-open="ehae178-B51" class="link link-ref link-reveal xref-bibr">51</a></sup>

**BP measurement by manual auscultation:** three BP measurements should be taken, each 1–2 min apart, and additional measurements only if the readings differ by >10 mmHg (e.g. this may occur with arrhythmias or white-coat effects). The BP recorded should be the average of the last two BP readings.

**BP measurement using AOBP measurement:** as noted above, AOBP using oscillometric devices may be obtained with (attended) or without (unattended) clinicians or staff present. Clear evidence regarding superiority of unattended vs. attended AOBP in managing BP to reduce rates of CVD is lacking; however, because BP readings may differ for unattended vs. attended measurements,<sup><a href="javascript:;" reveal-id="ehae178-B52" data-open="ehae178-B52" class="link link-ref link-reveal xref-bibr">52</a></sup> we advise that a consistent approach be used depending on local resource and preference. AOBP monitors typically make three or six readings at 1-min intervals and provide an average. AOBP correlates more closely with mean ABPM than with the manual auscultatory technique and may reduce measurement error and white-coat effects.<sup><a href="javascript:;" reveal-id="ehae178-B53" data-open="ehae178-B53" class="link link-ref link-reveal xref-bibr">53</a></sup>

**Inter-arm BP difference:** at the initial visit, BP should be measured in both arms to detect an inter-arm difference. Though devices allowing simultaneous measurement in both arms exist, sequential arm measurement is considered sufficiently reliable.<sup><a href="javascript:;" reveal-id="ehae178-B54" data-open="ehae178-B54" class="link link-ref link-reveal xref-bibr">54</a>,<a href="javascript:;" reveal-id="ehae178-B55" data-open="ehae178-B55" class="link link-ref link-reveal xref-bibr">55</a></sup> Measurement in the contralateral arm should be undertaken once the three measurements in the index arm have been taken, and if a difference is detected, further measurement in the original arm is indicated to ensure the difference is consistent. If systolic BP differs by >10 mmHg between arms, subsequent measurements are obtained using the arm with the higher BP value. Significant inter-arm BP differences may reflect arterial stenosis or coarctation of the aorta, which may require investigation. Also, of note, in some patients one arm is preferred to the other for routine BP measurement (e.g. to avoid measurement of BP in an arm with an arteriovenous fistula or an arm where axillary lymph node dissection has occurred).

**Postural/orthostatic hypotension:** patients should be assessed for orthostatic hypotension at the initial visit and if concerning symptoms arise. After 5 min of rest in the sitting or lying position, BP should be measured at 1 min and/or 3 min after standing, with a threshold for orthostatic hypotension of ≥20/10 mmHg (systolic BP/diastolic BP) drop. Measurement after lying may be more sensitive for detecting orthostatic hypotension and may better predict falls but may be less feasible than measurement after sitting in clinical practice.<sup><a href="javascript:;" reveal-id="ehae178-B56" data-open="ehae178-B56" class="link link-ref link-reveal xref-bibr">56</a></sup>

**Pulse assessment:** heart rate should be recorded at the initial visit and arrhythmia excluded.

#### 5.2.3. Home blood pressure measurement

HBPM is an out-of-office approach to measuring BP when the patient measures their own BP at home using a validated monitor (usually an upper-arm oscillometric cuff device).<sup><a href="javascript:;" reveal-id="ehae178-B57" data-open="ehae178-B57" class="link link-ref link-reveal xref-bibr">57</a>,<a href="javascript:;" reveal-id="ehae178-B58" data-open="ehae178-B58" class="link link-ref link-reveal xref-bibr">58</a></sup> A consistent approach to HBPM should be used (_[Figure 4](javascript:;)_). Patients should be counselled to follow the same preparation steps as used in clinics, which are outlined in _Section [5.2.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4.2.2)_. Two measurements should be taken at each measurement session, performed 1–2 min apart. Measurements should be made twice a day (morning and evening) at the same time for a minimum of 3 days and up to 7 days.<sup><a href="javascript:;" reveal-id="ehae178-B59" data-open="ehae178-B59" class="link link-ref link-reveal xref-bibr">59</a></sup> At the end of the measurement period, all readings are averaged. If the average after 3 days is close to the treatment threshold, then measurement should continue for the full 7 days. Patients should be informed to keep a record of their home BP values and to ask their healthcare provider that the device accuracy be intermittently checked. Devices older than 4 years may be inaccurate and, if inaccurate, should be replaced.<sup><a href="javascript:;" reveal-id="ehae178-B60" data-open="ehae178-B60" class="link link-ref link-reveal xref-bibr">60</a></sup>

![Summary of home blood pressure measurement.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f4.jpeg?Expires=1728462844&Signature=FwYXdFteHT2YFdhjU3J1wjCb5tpFtHWQlw3KUJ6T0J~1zTUc1Ka9Y2S~h0TRcAClrPp0Y0HsyAy~zQVdMN2k7YC3zI72DLdf3BYygs7Wxv1iiDJl0jDA670hnQyfAURzSNNqvFeAV1tsY6VuGS~xAjVVShYT5oEbk4dTwQB8~XBefkZBeqJRxY7ntN2nTjbiJ11Jht19mxZvjOF86vBnUlM2sJMNdHvHjpEbk0YT6euEKtCKiL1Q8rcQ7DhE5YNH8kNHFk5AMYWPhWBK37HjPYGAflC-5UDjbW8tCW3ljE80vP6mRuqmIe~3zYfc24Ec2ELW~mtkfj7gTjdoWfn8vg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 4

Summary of home blood pressure measurement.

BP, blood pressure; HBPM, home blood pressure measurement. <sup>a</sup>Morning HBPM readings should be obtained before breakfast and before intake of medication but not immediately after awakening.

[Open in new tab](https://academic.oup.com/view-large/figure/479375777/ehae178f4.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f4.jpeg?Expires=1728462844&Signature=EDoLVnByLZXdZ-bMUYJ1QJr8KnDx4KCEWw4w9JSGEmseTuq8Kr83ceLBE34Hn7b2MoIFzTF-j-C~xvpEf-5-1RgGhCwfHesbFvA4zANaM6nTwb0sCj7e2pDbZ4v4c1KbV~f36tiAqbeRYQxFxRoStpB8xGL2NP9ryqIJSZPmyICDvxi0xmJCrDbk74ZSnpXyqisqU8YCXYwMDW9a7YXNbhhJN1I6R3qzeBRTt0o3EiZbOEfnVeNhcVQngOr~fe02qHxhQFrG1gdAR2p6-7XRK6G5UtzUPFirlH1RJS8tIVUt1Rp2HZcdUfPwKaaNVpBPmntWLoTZ7OF-Ih4mRlkltg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375777&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

An average HBPM of ≥135/85 mmHg (equivalent to an office BP of ≥140/90 mmHg) should be used to diagnose hypertension and an average systolic BP of 120–134 mmHg or diastolic BP of 70–84 mmHg should be used to diagnose elevated BP. Of note, we use the same lower BP threshold (120/70 mmHg) for both office and HBPM in defining elevated BP.<sup><a href="javascript:;" reveal-id="ehae178-B61" data-open="ehae178-B61" class="link link-ref link-reveal xref-bibr">61</a></sup>

#### 5.2.4. Ambulatory blood pressure measurement

ABPM (summarized in _[Figure 5](javascript:;)_) is an out-of-office BP measurement that uses a fully automated device, usually for a 24-h period. The devices measure BP by the oscillometric method and are programmed to measure BP at set intervals. Readings are usually obtained at 15–30 min intervals during the day (typically 7 a.m. to 11 p.m.) and 30–60 min intervals at night (typically 11 p.m. to 7 a.m.). The software usually provides average BP measurements for daytime, night-time, and 24 h. A minimum of 70% useable BP recordings is required for a valid measurement session, typically numbering ≥27 measurements over 24 h. Preferably, seven nocturnal readings should also be obtained.<sup><a href="javascript:;" reveal-id="ehae178-B62" data-open="ehae178-B62" class="link link-ref link-reveal xref-bibr">62</a></sup> However, emerging data indicate that ≥8/≥4 wake/sleep readings may be adequate if more cannot be obtained.<sup><a href="javascript:;" reveal-id="ehae178-B63" data-open="ehae178-B63" class="link link-ref link-reveal xref-bibr">63</a></sup> Prior to using mean ABPM values (either 24 h, daytime, or night-time) the raw BP values at each measurement should be reviewed for possible outlier or erroneous values. A diary should record activities (e.g. meals and exercise) and sleep time to assist interpretation. The diagnostic thresholds for elevated BP and hypertension using ABPM, and comparison with office BP and HBPM, are provided in _[Table 5](javascript:;)_.<sup><a href="javascript:;" reveal-id="ehae178-B61" data-open="ehae178-B61" class="link link-ref link-reveal xref-bibr">61</a>,<a href="javascript:;" reveal-id="ehae178-B64" data-open="ehae178-B64" class="link link-ref link-reveal xref-bibr">64</a></sup>

![Summary of ambulatory blood pressure measurement.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f5.jpeg?Expires=1728462844&Signature=qlzR4QkvGYA4ZTRGMjaefBzrbTxZBy8boJ1pB3VW3BjdXs3c0VXYK9moU31A5IArNjucH~4-nZkAfSxrRjg-jfdl-d3Cu6iQDcFfcwVxCeQ-SFSI51uh4hCz8Klz7iPUyM1e8E9JZekEbNre3lNOAKcZOIeM3sdLLcCdtFgkF-QzwBNfH8pVwR4cDSqqq6H9fjwF98pMyzrX0UdheCz-A9Q1CuOGzC9m0pCiIJ5z~vmSRqAmIySGW5b~433SquEAdUoahNJrLgq1GXSKphvWdXdXLW3xVgunMlil~Fs05fDNpuE7j5v2IQNLZg9ORrOM8-CICWF7w1Dj7CjY5I6rZg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 5

Summary of ambulatory blood pressure measurement.

ABPM, ambulatory blood pressure measurement; BP, blood pressure.

[Open in new tab](https://academic.oup.com/view-large/figure/479375781/ehae178f5.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f5.jpeg?Expires=1728462844&Signature=eUpTk4VA65c1yskj0uTcTEe942q3wGDTAR5qtp8RhuypMpqKBCd0drDXKCZ5Oqjfv0oHR~0TS8gV6mRyOPY3zmdbvk2FTDNKCLlojGDx4TG7ke6gTXSlhRrbzjCDuo-yjpL6sqNHjunnPFaK-QPaC3gmV~A5Itc67E1E6jZuY0cO4f6LsGUHmpttlT3K1WX1dGHYWnIO7j1n6yqUSxR2TkBmc3vDMP3cpq05q0MEX~heApEbhs8DVVgQIq9FtKFyLMy6AytIF9LZsmNAxW6zu20JdJ5~S9rqJTNSj2xiJq~O22vyvHGN4BoQbrKMn3gcRyH~gTi1PL3n3ZjrfVDVAg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375781&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

#### 5.2.5. Comparison of home and ambulatory blood pressure monitoring

There is overlap between home and ambulatory monitoring in terms of differentiating between hypertensive phenotypes. However, around 15% of people will have diagnostic disagreement, of whom approximately 50% will represent clinically significant differences of >5 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B67" data-open="ehae178-B67" class="link link-ref link-reveal xref-bibr">67</a></sup> The advantages and disadvantages of home and ambulatory monitoring are outlined in _[Table 6](javascript:;)_.

Table 6

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375784)

Comparison of ambulatory and home blood pressure monitoring

<table role="presentation" aria-labelledby="
                        label-63593" aria-describedby="
                        caption-63593"><tbody><tr><td><strong>Ambulatory monitoring</strong><br><em>Advantages</em><ul class="bullet"><li><p class="chapter-para">Can identify white-coat and masked hypertension</p></li><li><p class="chapter-para">Measurement in real-life settings and during usual activities</p></li><li><p class="chapter-para">Stronger prognostic evidence</p></li><li><p class="chapter-para">Night-time readings</p></li><li><p class="chapter-para">Abundant information from a single investigation, including short-term diurnal BP variability</p></li><li><p class="chapter-para">Additional BP phenotyping (e.g. nocturnal dipping status)</p></li></ul><em>Disadvantages</em><ul class="bullet"><li><p class="chapter-para">Relatively expensive and sometimes limited availability</p></li><li><p class="chapter-para">Can be uncomfortable and affect sleep</p></li></ul></td></tr><tr><td><strong>Home monitoring</strong><br><em>Advantages</em><ul class="bullet"><li><p class="chapter-para">Identify white-coat and masked hypertension</p></li><li><p class="chapter-para">Cheap and widely available</p></li><li><p class="chapter-para">Measurement at home, which may be more relaxed than at doctor’s office</p></li><li><p class="chapter-para">Patient engagement in BP measurement and telemedicine potential</p></li><li><p class="chapter-para">Easily repeated and used over longer periods to assess day-to-day BP variability</p></li></ul><em>Disadvantages</em><ul class="bullet"><li><p class="chapter-para">Only static BP at rest is typically available</p></li><li><p class="chapter-para">Potential for measurement error due to improper measurement technique or unvalidated or poorly calibrated device</p></li><li><p class="chapter-para">Nocturnal readings not usually possible</p></li></ul></td></tr></tbody></table>

BP, blood pressure.

© ESC 2024

### 5.3. What is the best method for measuring blood pressure to diagnose hypertension?

#### 5.3.1. Blood pressure measurement for hypertension screening

Opportunistic screening is typically performed using office BP measurement and is key in detecting possible hypertension. However, a single screening office BP alone does not typically have sufficient diagnostic test performance to establish a diagnosis, especially for BP values close to diagnostic thresholds. Therefore, a single screening office BP requires some form of repeat BP assessment to confirm a diagnosis (preferably out-of-office or repeat office if out-of-office is not available). Relatedly, the BP threshold for acting on a screening office BP by conducting repeat BP assessments should also be lower than the office BP threshold used for diagnosing hypertension. This latter consideration is particularly relevant in the presence of increased CVD risk or markers of HMOD. Also of note, populations where masked hypertension is more prevalent include men, those who smoke, those with excessive alcohol intake, or those with diabetes or obesity.<sup><a href="javascript:;" reveal-id="ehae178-B68" data-open="ehae178-B68" class="link link-ref link-reveal xref-bibr">68</a>,<a href="javascript:;" reveal-id="ehae178-B69" data-open="ehae178-B69" class="link link-ref link-reveal xref-bibr">69</a></sup> While a screening office BP of >160/100 mmHg is almost always consistent with a diagnosis of hypertension, a small proportion of patients will have extreme white-coat effects that motivate prompt repeat BP assessment.<sup><a href="javascript:;" reveal-id="ehae178-B68" data-open="ehae178-B68" class="link link-ref link-reveal xref-bibr">68</a></sup> Hypertension screening approaches are discussed further in _Section [7.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6.1)_.

#### 5.3.2. Blood pressure measurement for diagnosing hypertension

After detecting high BP in the office, subsequent BP measurement for diagnosing hypertension depends on the clinical circumstances. Office BP has lower specificity than ABPM for detecting hypertension, so diagnosis based on office BP alone is less desirable unless resources do not allow out-of-office measurements.<sup><a href="javascript:;" reveal-id="ehae178-B70" data-open="ehae178-B70" class="link link-ref link-reveal xref-bibr">70</a></sup> For screening BP of 160–179 mmHg systolic or 100–109 mmHg diastolic, prompt confirmation (within 1 month) using either office or out-of-office methods is recommended, as delays in treatment are associated with increased CVD event rates.<sup><a href="javascript:;" reveal-id="ehae178-B71" data-open="ehae178-B71" class="link link-ref link-reveal xref-bibr">71</a></sup> For BP of ≥180/110 mmHg, assessment for hypertensive emergency is recommended. In the setting of hypertensive emergency, immediately commencing BP-lowering treatment is recommended, otherwise, prompt confirmation (preferably within a week) can be considered prior to commencing treatment (_Sections [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6) and [10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s9)_).

For screening BP of 140–159/90–99 mmHg, out-of-office BP should be measured to confirm the diagnosis.<sup><a href="javascript:;" reveal-id="ehae178-B72" data-open="ehae178-B72" class="link link-ref link-reveal xref-bibr">72</a></sup> When treatment of elevated BP is being considered (e.g. 120–139/70–89 mmHg) for individuals with high risk CVD conditions or sufficiently high 10-year predicted CVD risk, out-of-office BP measurement is recommended, both to confirm BP and to assess for masked hypertension. Out-of-office measurements may also be helpful for individuals with office BP of 130–139/85–89 mmHg to diagnose masked hypertension. Further details on the diagnostic evaluation of hypertension are provided in _Section [7.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6.2)_.

### 5.4. What is the best method for measuring blood pressure for long-term management of hypertension?

While repeat office measurement of BP remains the commonest approach to long-term management of hypertension, several lines of investigation support augmenting office BP measurements with out-of-office assessment.

#### 5.4.1. Home monitoring

There are over 50 trials of different self-monitoring-based interventions.<sup><a href="javascript:;" reveal-id="ehae178-B73" data-open="ehae178-B73" class="link link-ref link-reveal xref-bibr">73</a></sup> Self-monitoring is associated with lower mean systolic BP at 12 months \[−3.2 mmHg; 95% confidence interval (CI) −4.9 to −1.6 mmHg\].<sup><a href="javascript:;" reveal-id="ehae178-B74" data-open="ehae178-B74" class="link link-ref link-reveal xref-bibr">74</a></sup> Furthermore, there are known benefits of telemonitoring, digital interventions, and mobile health in managing BP.<sup><a href="javascript:;" reveal-id="ehae178-B75 ehae178-B76 ehae178-B77 ehae178-B78" data-open="ehae178-B75 ehae178-B76 ehae178-B77 ehae178-B78" class="link link-ref link-reveal xref-bibr">75–78</a></sup> Self-monitoring is also likely to be cost-effective.<sup><a href="javascript:;" reveal-id="ehae178-B79" data-open="ehae178-B79" class="link link-ref link-reveal xref-bibr">79</a></sup> Unfortunately, in clinical practice, some patients may not provide reliable information on their home BP, and both their device and measurement technique need to be checked.

#### 5.4.2. Ambulatory monitoring

ABPM provides a reference BP measurement but repeat ABPM testing is sometimes not practical due to resource constraints and, uncommonly, low patient acceptability.<sup><a href="javascript:;" reveal-id="ehae178-B80" data-open="ehae178-B80" class="link link-ref link-reveal xref-bibr">80</a></sup> There is a paucity of data on treatment guided by ABPM vs. that of office or HBPM measurements. A trial of treatment guided by HBPM vs. clinic and ambulatory monitoring found equivalence in BP control and HMOD.<sup><a href="javascript:;" reveal-id="ehae178-B81" data-open="ehae178-B81" class="link link-ref link-reveal xref-bibr">81</a></sup> Other studies reported a non-significant trend to worse BP control with ambulatory vs. office BP monitoring, though the ambulatory group also received fewer medications.<sup><a href="javascript:;" reveal-id="ehae178-B82" data-open="ehae178-B82" class="link link-ref link-reveal xref-bibr">82</a></sup> Potential advantages of ABPM over HBPM include diagnosing nocturnal hypertension or symptomatic transient hypotension or hypertension with exertion. As such, ABPM and HBPM should be considered complementary and additive, rather than competing approaches to long-term BP management.<sup><a href="javascript:;" reveal-id="ehae178-B83" data-open="ehae178-B83" class="link link-ref link-reveal xref-bibr">83</a></sup>

### 5.5. Measuring blood pressure in selected groups

#### 5.5.1. Pregnancy

Monitoring BP during pregnancy is typically done at antenatal visits, which vary dependent on trimester (with increasing frequency towards term). BP tends to reach a nadir at 20–30 weeks of pregnancy before increasing towards term at 40 weeks.<sup><a href="javascript:;" reveal-id="ehae178-B84" data-open="ehae178-B84" class="link link-ref link-reveal xref-bibr">84</a></sup> Only a small number of automated oscillometric BP monitors have been adequately validated in pregnancy and several have failed, usually due to providing BP values that are erroneously high.<sup><a href="javascript:;" reveal-id="ehae178-B85" data-open="ehae178-B85" class="link link-ref link-reveal xref-bibr">85</a></sup> Auscultatory measurement with sphygmomanometry is consequently the clinical standard in pregnancy.<sup><a href="javascript:;" reveal-id="ehae178-B85" data-open="ehae178-B85" class="link link-ref link-reveal xref-bibr">85</a></sup> Self-monitoring at home is not yet proven to be effective in gestational hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B86" data-open="ehae178-B86" class="link link-ref link-reveal xref-bibr">86</a>,<a href="javascript:;" reveal-id="ehae178-B87" data-open="ehae178-B87" class="link link-ref link-reveal xref-bibr">87</a></sup> While norms for BP during pregnancy remain unclear, the 2022 Chronic Hypertension and Pregnancy (CHAP) trial indicated benefit of targeting clinic BP below 140/90 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B88" data-open="ehae178-B88" class="link link-ref link-reveal xref-bibr">88</a></sup> Consideration of secondary causes of hypertension is important in young women with gestational hypertension. Further details are provided in _Section [9.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8.2)_ and the 2018 ESC Guideline for the management of cardiovascular disease during pregnancy.<sup><a href="javascript:;" reveal-id="ehae178-B89" data-open="ehae178-B89" class="link link-ref link-reveal xref-bibr">89</a></sup>

#### 5.5.2. Atrial fibrillation

Hypertension is a risk factor for AF.<sup><a href="javascript:;" reveal-id="ehae178-B90" data-open="ehae178-B90" class="link link-ref link-reveal xref-bibr">90</a>,<a href="javascript:;" reveal-id="ehae178-B91" data-open="ehae178-B91" class="link link-ref link-reveal xref-bibr">91</a></sup> Oscillometric BP monitors are not always accurate in the presence of AF, due to the greater variability of BP beat to beat, so multiple auscultatory measurements are recommended.<sup><a href="javascript:;" reveal-id="ehae178-B48" data-open="ehae178-B48" class="link link-ref link-reveal xref-bibr">48</a>,<a href="javascript:;" reveal-id="ehae178-B92" data-open="ehae178-B92" class="link link-ref link-reveal xref-bibr">92</a>,<a href="javascript:;" reveal-id="ehae178-B93" data-open="ehae178-B93" class="link link-ref link-reveal xref-bibr">93</a></sup> Some oscillometric BP monitors include an algorithm for detecting AF, but an electrocardiogram (ECG) is still required to confirm the diagnosis.<sup><a href="javascript:;" reveal-id="ehae178-B49" data-open="ehae178-B49" class="link link-ref link-reveal xref-bibr">49</a>,<a href="javascript:;" reveal-id="ehae178-B94" data-open="ehae178-B94" class="link link-ref link-reveal xref-bibr">94</a></sup>

#### 5.5.3. Orthostatic hypotension

Postural or orthostatic hypotension is common,<sup><a href="javascript:;" reveal-id="ehae178-B95" data-open="ehae178-B95" class="link link-ref link-reveal xref-bibr">95</a>,<a href="javascript:;" reveal-id="ehae178-B96" data-open="ehae178-B96" class="link link-ref link-reveal xref-bibr">96</a></sup> present in approximately 10% of all hypertensive adults and up to 50% of older institutionalized adults.<sup><a href="javascript:;" reveal-id="ehae178-B97" data-open="ehae178-B97" class="link link-ref link-reveal xref-bibr">97</a>,<a href="javascript:;" reveal-id="ehae178-B98" data-open="ehae178-B98" class="link link-ref link-reveal xref-bibr">98</a></sup> Orthostatic hypotension is defined as a BP drop of ≥20/10 mmHg 1 and/or 3 min after standing following a 5-min period in the seated or lying position.<sup><a href="javascript:;" reveal-id="ehae178-B99 ehae178-B100 ehae178-B101" data-open="ehae178-B99 ehae178-B100 ehae178-B101" class="link link-ref link-reveal xref-bibr">99–101</a></sup> Diagnosis is made in the office. Routine ABPM is not currently suitable for formally assessing orthostatic hypotension,<sup><a href="javascript:;" reveal-id="ehae178-B102" data-open="ehae178-B102" class="link link-ref link-reveal xref-bibr">102</a></sup> though it may help in some cases, particularly when accompanied by a patient symptom diary.<sup><a href="javascript:;" reveal-id="ehae178-B103" data-open="ehae178-B103" class="link link-ref link-reveal xref-bibr">103</a></sup>

### 5.6. Novel methods of measuring blood pressure

New methods to measure BP are under development. Continuous office and out-of-office BP recordings and ABPM and HBPM have been developed that derive beat-to-beat, reading-to-reading, and day-to-day BP variability. However, there is no agreement on the optimum approach to measuring variability, and there is no trial evidence that reducing BP variability specifically can reduce CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B104" data-open="ehae178-B104" class="link link-ref link-reveal xref-bibr">104</a></sup> Other emerging technologies include wearable, wrist-based BP measurement devices, devices evaluating central BP, and cuffless devices implementing plethysmographic or other technologies.<sup><a href="javascript:;" reveal-id="ehae178-B105" data-open="ehae178-B105" class="link link-ref link-reveal xref-bibr">105</a>,<a href="javascript:;" reveal-id="ehae178-B106" data-open="ehae178-B106" class="link link-ref link-reveal xref-bibr">106</a></sup> However, there is at present insufficient scientific consensus on the accuracy standards and validation procedures that these cuffless devices must comply with prior to commercialization.<sup><a href="javascript:;" reveal-id="ehae178-B43" data-open="ehae178-B43" class="link link-ref link-reveal xref-bibr">43</a>,<a href="javascript:;" reveal-id="ehae178-B44" data-open="ehae178-B44" class="link link-ref link-reveal xref-bibr">44</a>,<a href="javascript:;" reveal-id="ehae178-B107 ehae178-B108 ehae178-B109" data-open="ehae178-B107 ehae178-B108 ehae178-B109" class="link link-ref link-reveal xref-bibr">107–109</a></sup>

In view of these issues, none of these cuffless measurement modalities are currently recommended for routine clinical use.

Recommendation Table 1

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375807)

Recommendations for measuring blood pressure (see Evidence Tables 1–8)

![Recommendations for measuring blood pressure (see Evidence Tables 1–8)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt1.jpeg?Expires=1728462844&Signature=2WVr0-HB2QLbbMn4zqssKyWfLyOzUw27lnFBbeSycUfB1bhb-BWsKgA6mKcXV5COE4ZRTZ3uLP9tFhLeuMKMfwjRrrKLZAQtOscc0A0Duus-4fRq1rSKm5R2p7j0pduoYfkQ~w-V4rBXG-b5wdCqcPXorhdSFUAqZwonERzLc~elmaYx-tM3gKO6kZhORKWkyNGfQg0gl6ww2ZsT3BMngGc3Ma-20LdL3MWyg2MPvcLYtBh1iNVOdbUlKb9Mh6ghunZHwsLWQHQ56RxIWEudwHwEmRKLnbKMvf37~avCAWtnfaoiaRPFPXue-TC3aK65gz57gV9XMqc8I0fSMnpSxA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 6\. Definition and classification of elevated blood pressure and hypertension, and cardiovascular disease risk assessment

### 6.1. Definition and classification of elevated blood pressure and hypertension

Epidemiological studies demonstrate a continuous and log-linear association between BP and adverse CVD outcomes.<sup><a href="javascript:;" reveal-id="ehae178-B22" data-open="ehae178-B22" class="link link-ref link-reveal xref-bibr">22</a>,<a href="javascript:;" reveal-id="ehae178-B32" data-open="ehae178-B32" class="link link-ref link-reveal xref-bibr">32</a>,<a href="javascript:;" reveal-id="ehae178-B33" data-open="ehae178-B33" class="link link-ref link-reveal xref-bibr">33</a>,<a href="javascript:;" reveal-id="ehae178-B114" data-open="ehae178-B114" class="link link-ref link-reveal xref-bibr">114</a>,<a href="javascript:;" reveal-id="ehae178-B115" data-open="ehae178-B115" class="link link-ref link-reveal xref-bibr">115</a></sup> Starting at levels as low as 90 mmHg systolic, the higher the BP the higher the relative risk of CVD including atherosclerosis.<sup><a href="javascript:;" reveal-id="ehae178-B32" data-open="ehae178-B32" class="link link-ref link-reveal xref-bibr">32</a>,<a href="javascript:;" reveal-id="ehae178-B114" data-open="ehae178-B114" class="link link-ref link-reveal xref-bibr">114</a></sup> These observational data are complemented by randomized clinical trials (RCTs),<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a></sup> which have provided experimental evidence regarding the BP range for which BP lowering with treatment is proven to reduce CVD events. Of note, some studies suggest a stronger relative risk for CVD for a given BP among females compared with males.<sup><a href="javascript:;" reveal-id="ehae178-B117" data-open="ehae178-B117" class="link link-ref link-reveal xref-bibr">117</a>,<a href="javascript:;" reveal-id="ehae178-B118" data-open="ehae178-B118" class="link link-ref link-reveal xref-bibr">118</a></sup>

A healthy lifestyle should be encouraged for all adults to prevent an increase in BP and development of hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B119" data-open="ehae178-B119" class="link link-ref link-reveal xref-bibr">119</a>,<a href="javascript:;" reveal-id="ehae178-B120" data-open="ehae178-B120" class="link link-ref link-reveal xref-bibr">120</a></sup> To aid pharmacological treatment decisions, the 2024 ESC Guidelines recommend a simplified categorization of adults according to their BP (_[Figure 6](javascript:;)_). In compiling this categorization, priority was given to evidence from randomized trials over observational data. However, it is important to reiterate that the risk of CVD attributable to BP is continuous and that interpreting randomized trial data is an iterative process involving an element of subjectivity. As such, no categorization of BP can be considered immutable or flawless.

![Blood pressure categories.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f6.jpeg?Expires=1728462844&Signature=QEu3RcLVpoEpx811aKThAKsEdP5sTCXEguaLx9uhbjJDPgdC18swZXOXEI10KnWSb1tR7SaGDB9kKT1RHR7ptLu4ZoVQGqJJe8qnHkG9Oi8Yb1XwkBq0iPMLGQ6KmESI~WEMuTy6gC1Vute~A1ehEtnD7p8C92WOq~xwesBe7QFEN5mETOgS5t07T-YKSTyyNIsJ239jwOmr12Qysfb1IzUK6cQvDdhyIdiw-dQnQiQ872FgoM6mlbLwxr2aRyWcvERR-9wAmcqGAPrY~v~WAoS51I2ZkeKiE2NF076r8jDbZyzJrIDg6VMlbgBOdhlVXr5aJYlnRfpuYgOQxl6~-A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 6

Blood pressure categories.

ABPM, ambulatory blood pressure monitoring; BP, blood pressure; DBP, diastolic blood pressure; HBPM, home blood pressure monitoring; SBP, systolic blood pressure. We note that the respective non-daytime ABPM thresholds for elevated BP and hypertension diagnosis are listed in _Section [5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4)_ (_[Table 5](javascript:;)_).

[Open in new tab](https://academic.oup.com/view-large/figure/479375812/ehae178f6.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f6.jpeg?Expires=1728462844&Signature=f54ROSdlfc0QbDjXISigER7GhnJk3tq645GaxXL1yYE6k1HiMxPru-LGrUDTenmp-IgYT4mMm1fdokzYoSdmfYjLBMIJ-gQlV-O5Yiy87crAAl4Bhj0WQlRg25dHLm3KGFOSLDb~hL-y2nAEelp7SAvscKyhU6ofnslQPHagmmmc6YtQFB3d3ReKrobbjZIAjn0~Wc33D1KA83yIJwrfGhuBIlMkI2jk23S5Zz0dMxrAxSAxkm-ZIcWLwCKflyZEoP~R7GcrqB36l9jt8g~GRTEoImc4UWoOGg19sn9PbyiKqQuum81Gk286dAqkIOhtT4LdePHgFzgK6UFC9O4~sQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375812&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

The 2024 Guidelines define hypertension as a confirmed office systolic BP of ≥140 mmHg or diastolic BP of ≥90 mmHg. For this diagnosis to be made, confirmation is recommended with out-of-office measurements (HBPM or ABPM) or at least one repeat office measurement at a subsequent visit, as detailed in _Section [5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4)_ and _Section [7.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6.2)_. This definition is based on several factors. First, meta-analyses of randomized trials provide evidence among all adults and across various settings for the benefit of BP-lowering therapy among patients with BP above this threshold.<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a>,<a href="javascript:;" reveal-id="ehae178-B121" data-open="ehae178-B121" class="link link-ref link-reveal xref-bibr">121</a>,<a href="javascript:;" reveal-id="ehae178-B122" data-open="ehae178-B122" class="link link-ref link-reveal xref-bibr">122</a></sup> Second, most adults with BP above this threshold are at increased CVD risk, typically with 10-year risk estimates of ≥10% for fatal and non-fatal CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B123 ehae178-B124 ehae178-B125" data-open="ehae178-B123 ehae178-B124 ehae178-B125" class="link link-ref link-reveal xref-bibr">123–125</a></sup> The higher the patient’s baseline absolute risk for CVD, the greater the net benefit from BP-lowering treatment and, at the population level, the lower the estimated number needed to treat (NNT).<sup><a href="javascript:;" reveal-id="ehae178-B126 ehae178-B127 ehae178-B128" data-open="ehae178-B126 ehae178-B127 ehae178-B128" class="link link-ref link-reveal xref-bibr">126–128</a></sup> Third, this more traditional BP threshold for hypertension is already widely used by policymakers to define a disease state, and maintaining this BP threshold to define hypertension (vs. lowering it) does not require most adults to be labelled with what is widely considered a disease.<sup><a href="javascript:;" reveal-id="ehae178-B129" data-open="ehae178-B129" class="link link-ref link-reveal xref-bibr">129</a></sup>

Here, we introduce a new BP category called ‘elevated BP’, which is defined as an office systolic BP of 120–139 mmHg or diastolic BP of 70–89 mmHg. Within this BP range, the efficacy of BP-lowering therapy has been established in meta-analyses of RCTs,<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a></sup> but average CVD risk in the elevated BP group is not sufficiently high to merit drug treatment in all patients.<sup><a href="javascript:;" reveal-id="ehae178-B123" data-open="ehae178-B123" class="link link-ref link-reveal xref-bibr">123</a>,<a href="javascript:;" reveal-id="ehae178-B124" data-open="ehae178-B124" class="link link-ref link-reveal xref-bibr">124</a>,<a href="javascript:;" reveal-id="ehae178-B130" data-open="ehae178-B130" class="link link-ref link-reveal xref-bibr">130</a></sup> Pharmacological treatment initiation is, however, suggested for a subgroup of patients within this BP range who are at increased global risk of CVD as identified by the risk stratification approach outlined in _Sections [6.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5.3)_, _[6.4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5.4)_, and [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7).

Non-elevated BP is defined as a systolic BP of <120 mmHg and a diastolic BP of <70 mmHg. Fewer individuals within this BP range are at increased risk of CVD,<sup><a href="javascript:;" reveal-id="ehae178-B124" data-open="ehae178-B124" class="link link-ref link-reveal xref-bibr">124</a></sup> and evidence for CVD benefit with BP-lowering pharmacological treatment is lacking due to an absence of trials. We use the term ‘non-elevated BP’ to define this BP category in recognition that these are treatment categories and not prognostic categories. Because the relative risk for CVD starts to increase at BP below this threshold (even as low as 90 mmHg systolic BP), particularly among women,<sup><a href="javascript:;" reveal-id="ehae178-B117" data-open="ehae178-B117" class="link link-ref link-reveal xref-bibr">117</a>,<a href="javascript:;" reveal-id="ehae178-B118" data-open="ehae178-B118" class="link link-ref link-reveal xref-bibr">118</a></sup> we avoid terms like ‘normal BP’, ‘optimal BP’, or ‘normotension’ in defining this category.

Recommendation Table 2

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375816)

Recommendations for categorizing blood pressure (see Evidence Table 9)

![Recommendations for categorizing blood pressure (see Evidence Table 9)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt2.jpeg?Expires=1728462844&Signature=RxCiKLR3NzlU3OPF9hQr47IL9YyGkmkLC0o1DIMY8XOk9m0iiXXtQM0I6ZTOK4OTSoIqC0tJdM~hyACNIHP6PS2zar8PHptCepLyInxuLq1d6C~7-kW~o6juGwRLRBVGS4YxA7pr3pulO6o7R1wOoyrWWQvQoLbFqH2hOS5ttMJOxPbaV1E7jUtehOgUsd4JKWb-FMp-CW8zo1CChlMjKd3b3omKVJ47HfBKm4CPTvXqRv3lpffefILD2ilypxHk0oNyjJUtJZOAVSILun4nx1BLIVkMAAAkeqDmhll9kHKiMM~5VGeFEh0QJiaLLi5CIBDX5uCeaWJlpg-R5HbEXg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 6.2. Principles of a risk-based approach for managing blood pressure and preventing cardiovascular disease

In the context of BP-lowering interventions, randomized trials demonstrate a consistent relative risk reduction in adverse CVD outcomes per unit reduction in BP.<sup><a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a>,<a href="javascript:;" reveal-id="ehae178-B139" data-open="ehae178-B139" class="link link-ref link-reveal xref-bibr">139</a></sup> However, many medical interventions incur costs and have side effects. Therefore, guidance is needed on selecting patients most likely to benefit from BP-lowering treatment. This is especially true among adults with elevated BP (office systolic BP of 120–139 mmHg and/or diastolic BP of 70–89 mmHg). Practical aspects for implementing a risk-based approach are further discussed in _Section [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)._

#### 6.2.1. Role of cardiovascular disease risk assessment

The risk of adverse CVD outcomes increases log-linearly with constant increments in systolic BP and diastolic BP.<sup><a href="javascript:;" reveal-id="ehae178-B22" data-open="ehae178-B22" class="link link-ref link-reveal xref-bibr">22</a>,<a href="javascript:;" reveal-id="ehae178-B32" data-open="ehae178-B32" class="link link-ref link-reveal xref-bibr">32</a>,<a href="javascript:;" reveal-id="ehae178-B33" data-open="ehae178-B33" class="link link-ref link-reveal xref-bibr">33</a>,<a href="javascript:;" reveal-id="ehae178-B114" data-open="ehae178-B114" class="link link-ref link-reveal xref-bibr">114</a>,<a href="javascript:;" reveal-id="ehae178-B140" data-open="ehae178-B140" class="link link-ref link-reveal xref-bibr">140</a></sup> Concurrently, at higher BP, there is clustering of additional CVD risk factors.<sup><a href="javascript:;" reveal-id="ehae178-B141" data-open="ehae178-B141" class="link link-ref link-reveal xref-bibr">141</a>,<a href="javascript:;" reveal-id="ehae178-B142" data-open="ehae178-B142" class="link link-ref link-reveal xref-bibr">142</a></sup> Consequently, many patients with hypertension will have an estimated 10-year risk for CVD events of ≥10%,<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a>,<a href="javascript:;" reveal-id="ehae178-B121" data-open="ehae178-B121" class="link link-ref link-reveal xref-bibr">121</a>,<a href="javascript:;" reveal-id="ehae178-B122" data-open="ehae178-B122" class="link link-ref link-reveal xref-bibr">122</a></sup> which, for the purposes of these guidelines, is considered sufficiently high risk to merit consideration of BP-lowering treatment in the setting of elevated BP.<sup><a href="javascript:;" reveal-id="ehae178-B143" data-open="ehae178-B143" class="link link-ref link-reveal xref-bibr">143</a></sup>

Using BP thresholds for hypertension alone for allocating treatment would lead to under-treatment of many high-risk patients.<sup><a href="javascript:;" reveal-id="ehae178-B144" data-open="ehae178-B144" class="link link-ref link-reveal xref-bibr">144</a>,<a href="javascript:;" reveal-id="ehae178-B145" data-open="ehae178-B145" class="link link-ref link-reveal xref-bibr">145</a>,<a href="javascript:;" reveal-id="ehae178-B115" data-open="ehae178-B115" class="link link-ref link-reveal xref-bibr">115</a></sup> A substantial proportion of excess CVD events attributable to BP occur in patients with BP levels below the traditional threshold for hypertension diagnosis. As the efficacy of BP lowering on preventing CVD events extends down to a systolic BP of 120 mmHg and a diastolic BP of 70 mmHg,<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a>,<a href="javascript:;" reveal-id="ehae178-B135" data-open="ehae178-B135" class="link link-ref link-reveal xref-bibr">135</a>,<a href="javascript:;" reveal-id="ehae178-B136" data-open="ehae178-B136" class="link link-ref link-reveal xref-bibr">136</a>,<a href="javascript:;" reveal-id="ehae178-B146" data-open="ehae178-B146" class="link link-ref link-reveal xref-bibr">146</a></sup> patients with elevated BP and increased CVD risk can also derive benefit from BP-lowering treatment.<sup><a href="javascript:;" reveal-id="ehae178-B124" data-open="ehae178-B124" class="link link-ref link-reveal xref-bibr">124</a>,<a href="javascript:;" reveal-id="ehae178-B145" data-open="ehae178-B145" class="link link-ref link-reveal xref-bibr">145</a></sup>

The heterogeneity in CVD risk among adults with elevated BP is larger than in those with hypertension, as such patients tend to be younger, and their absolute CVD risk depends more on the prevalence of concomitant CVD risk factors.<sup><a href="javascript:;" reveal-id="ehae178-B123" data-open="ehae178-B123" class="link link-ref link-reveal xref-bibr">123</a>,<a href="javascript:;" reveal-id="ehae178-B147" data-open="ehae178-B147" class="link link-ref link-reveal xref-bibr">147</a></sup> Consequently, formally estimating the patient’s CVD risk, encapsulating demographics and other CVD risk factors, is recommended to guide BP-lowering treatment decisions among patients with elevated BP.<sup><a href="javascript:;" reveal-id="ehae178-B148 ehae178-B149 ehae178-B150 ehae178-B151" data-open="ehae178-B148 ehae178-B149 ehae178-B150 ehae178-B151" class="link link-ref link-reveal xref-bibr">148–151</a></sup>

### 6.3. Predicting cardiovascular disease risk

Certain conditions on their own are associated with sufficient CVD risk such that patients with elevated BP alongside these conditions can be considered for BP-lowering therapy (_[Figure 7](javascript:;)_). These include moderate or severe chronic kidney disease (CKD),<sup><a href="javascript:;" reveal-id="ehae178-B152" data-open="ehae178-B152" class="link link-ref link-reveal xref-bibr">152</a></sup> established clinical CVD (coronary heart disease, cerebrovascular disease, peripheral arterial disease, or heart failure)<sup><a href="javascript:;" reveal-id="ehae178-B153 ehae178-B154 ehae178-B155 ehae178-B156 ehae178-B157 ehae178-B158" data-open="ehae178-B153 ehae178-B154 ehae178-B155 ehae178-B156 ehae178-B157 ehae178-B158" class="link link-ref link-reveal xref-bibr">153–158</a></sup> concomitant HMOD (see _[Figure 7](javascript:;)_; _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6)_; [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_),<sup><a href="javascript:;" reveal-id="ehae178-B31" data-open="ehae178-B31" class="link link-ref link-reveal xref-bibr">31</a>,<a href="javascript:;" reveal-id="ehae178-B159" data-open="ehae178-B159" class="link link-ref link-reveal xref-bibr">159</a></sup> diabetes mellitus, and familial hypercholesterolaemia (probable or definite).<sup><a href="javascript:;" reveal-id="ehae178-B160 ehae178-B161 ehae178-B162 ehae178-B163" data-open="ehae178-B160 ehae178-B161 ehae178-B162 ehae178-B163" class="link link-ref link-reveal xref-bibr">160–163</a></sup> Regarding diabetes, some adults aged <60 years with type 2 diabetes and elevated BP have 10-year CVD risk of <10%. Accordingly, the diabetes-specific Systematic COronary Risk Evaluation 2 (SCORE2)-Diabetes risk-prediction model should be considered to confirm CVD risk is sufficiently high (≥10%) among individuals with type 2 diabetes mellitus who are aged <60 years.<sup><a href="javascript:;" reveal-id="ehae178-B164" data-open="ehae178-B164" class="link link-ref link-reveal xref-bibr">164</a></sup>

![Sufficiently high cardiovascular risk conditions that warrant blood pressure-lowering treatment among adults with elevated blood pressure.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f7.jpeg?Expires=1728462844&Signature=jUkmMK5Augjst5-F3t497CryQ5-etvqjHfpk43gNpn~S5IRtduTMOFjB85DjstCgnxrheI4Ce5iKPnBL-uQ17LEEbUF3Eoee2uRO5jxK5Q6HBWalc7iFJR33ZcHwfdmPv2z51dTrkd6JQpFfGA6NfUDvZilyjkvBn19Aug~b22JKteyBHAkYf~yrcIIwdD3GSdK20ICgKazE3nAUnz4pZhS~f2ZHXcy9M3gz2qxz9-cTwTygqvBgRShMGQsfwUuPpTh777DcxdTpm-ZpdhH2A~K~rs1SX~jmKPbkrI0zEz6NKieqVsdU6bzFgZLM5kLRLsxTwEUlvLUNoMFLBb84VQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 7

Sufficiently high cardiovascular risk conditions that warrant blood pressure-lowering treatment among adults with elevated blood pressure.

CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate. <sup>a</sup>Coronary heart disease, cerebrovascular disease, peripheral arterial disease. <sup>b</sup>See _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6)_. <sup>c</sup>SCORE2-Diabetes should be considered to identify lower-risk individuals (<10% 10-year CVD risk), who may not require BP-lowering medication, particularly in individuals <60 years.

[Open in new tab](https://academic.oup.com/view-large/figure/479375825/ehae178f7.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f7.jpeg?Expires=1728462844&Signature=Elbick~hzxfvgSzluRMhnfOd4fsfNEPbG2CpRWSbVtWGf8CqJIgZJSo6ZAvyx5NzK3UO~tFoBW0AkApT66g3Q75hDVsNMDPLxv~-5-cFVZ-NFRJdn84ye7wIoxGMajE3WEnWQ9s8eQhbmXb8kqc8pFFZjcTepi9P8CM0rXJgo1y0mEaq~0O0bY5xfL5DR5kINh093km2KWyL-n8sz1AcbyjSED7ajD9J4~gBVFjhybcB8hB~nxHOJEkbwdRq8vDW-CQMibw8HexcUV4AKLvJiZ8vDiOrh3-narFvuxHjUWaJK1xaBhPblooISVgEEYXC2z980d1b4LXW0mQ9tzWo0Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375825&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

In the absence of these sufficiently high-risk conditions, risk-prediction models (SCORE2 and SCORE-OP) have been developed in the general population to predict 10-year risk of CVD.<sup><a href="javascript:;" reveal-id="ehae178-B165" data-open="ehae178-B165" class="link link-ref link-reveal xref-bibr">165</a>,<a href="javascript:;" reveal-id="ehae178-B166" data-open="ehae178-B166" class="link link-ref link-reveal xref-bibr">166</a></sup> In adults with elevated BP without the above sufficiently high-risk conditions, risk-prediction models are recommended to inform BP-lowering treatment decisions. Risk-prediction models are more accurate than clinical judgment or tallying of individual risk factors.<sup><a href="javascript:;" reveal-id="ehae178-B167 ehae178-B168 ehae178-B169" data-open="ehae178-B167 ehae178-B168 ehae178-B169" class="link link-ref link-reveal xref-bibr">167–169</a></sup>

#### 6.3.1. 10-year cardiovascular disease risk-prediction models

Prediction models differ in their input variables, predicted endpoints (outputs), and populations in which they were derived and validated. We endorse the use of SCORE2 for individuals aged 40–69 years and SCORE2–Older Persons (SCORE2-OP) for individuals aged ≥70 years for predicting 10-year global risk of fatal and non-fatal CVD events (stroke or myocardial infarction).<sup><a href="javascript:;" reveal-id="ehae178-B165" data-open="ehae178-B165" class="link link-ref link-reveal xref-bibr">165</a>,<a href="javascript:;" reveal-id="ehae178-B166" data-open="ehae178-B166" class="link link-ref link-reveal xref-bibr">166</a></sup> The management of adults aged <40 years is discussed in _Section [9.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8.1)_. The SCORE2 and SCORE2-OP models are preferred over other 10-year risk-prediction models, as they predict both fatal and non-fatal CVD events, have been validated and recalibrated to European populations, and because SCORE2-OP is adjusted for the competing risk of non-cardiovascular mortality. Calculating SCORE2 or SCORE2-OP is recommended for individuals with elevated BP who are not already at sufficiently high CVD risk due to established CVD, moderate or severe CKD, probable or definite familial hypercholesterolaemia, diabetes mellitus, or HMOD.<sup><a href="javascript:;" reveal-id="ehae178-B165" data-open="ehae178-B165" class="link link-ref link-reveal xref-bibr">165</a>,<a href="javascript:;" reveal-id="ehae178-B166" data-open="ehae178-B166" class="link link-ref link-reveal xref-bibr">166</a>,<a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup>

For the purpose of BP-lowering treatment decisions, individuals with elevated BP and a predicted 10-year CVD risk of ≥10% by SCORE2 or SCORE2-OP are considered in these guidelines to be sufficiently high risk, with details on the choice of lifestyle or drugs to facilitate BP-lowering treatment in this setting provided in _Section [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)._<sup><a href="javascript:;" reveal-id="ehae178-B171" data-open="ehae178-B171" class="link link-ref link-reveal xref-bibr">171</a>,<a href="javascript:;" reveal-id="ehae178-B172" data-open="ehae178-B172" class="link link-ref link-reveal xref-bibr">172</a></sup> A number of considerations influenced our choice to recommend a single risk threshold of ≥10%, vs. the alternative option of using age-specific risk thresholds, such as those provided in the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.<sup><a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup> For example, contemporary data indicate the heightened importance of BP control in older adults due to their higher absolute CVD risk (resulting in a lower NNT) and concomitantly to reduce age-dependent adverse outcomes attributable to increased BP, such as dementia. Recent treat-to-target trials (testing systolic BP targets of approximately 120 mmHg) used a single CVD risk inclusion threshold and were also enriched with older adults.<sup><a href="javascript:;" reveal-id="ehae178-B135" data-open="ehae178-B135" class="link link-ref link-reveal xref-bibr">135</a>,<a href="javascript:;" reveal-id="ehae178-B136" data-open="ehae178-B136" class="link link-ref link-reveal xref-bibr">136</a>,<a href="javascript:;" reveal-id="ehae178-B146" data-open="ehae178-B146" class="link link-ref link-reveal xref-bibr">146</a></sup> In addition, the average CVD event rate in the control arm of a landmark meta-analysis showing the benefits of more intensive BP-lowering treatment was approximately equivalent to a 10% 10-year risk.<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a></sup> Finally, the task force, which included patient members, felt that age-specific risk thresholds could result in BP treatment decisions being made solely based on age, which is difficult to support scientifically or otherwise. To try to avoid any confusion with the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice, we use the terms ‘sufficiently high risk’ or ‘increased risk’ to describe a person with 10-year CVD risk of ≥10% (rather than the terms ‘high risk’ or ‘very high risk’).

Recommendation Table 3

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375830)

Recommendations for assessing cardiovascular disease risk among individuals with elevated blood pressure (office systolic blood pressure 120–139 mmHg or diastolic blood pressure 70–89 mmHg) (see Evidence Tables 10 and 11)

![Recommendations for assessing cardiovascular disease risk among individuals with elevated blood pressure (office systolic blood pressure 120–139 mmHg or diastolic blood pressure 70–89 mmHg) (see Evidence Tables 10 and 11)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt3.jpeg?Expires=1728462844&Signature=XB6d2MwjxGCHyvxbNfRUjsPQg6gMTqMDkeS3PIjaBVJl9nCHzx7M-C8KlBDe6dbv8fcl1mfeDUWp9xQcBsHYq2nvZhG3EuogTnbPyv4MNNvroHHc8Zxr20pe9GNxwxZ43DMhhz8bIgzc2bCZT6WLVXtKjazoY307qrdctykV8vwhgu0m8sgZ99XGbPR-nKPeRJc7mZLCcAubLK~ElpBLVk-2Z5GWrTG3DIoVoSNaBX6qHcAidfW8JzjvftiP4OGHjLF5aOTa6bZ5bGgi43YGcYjXTldpG9fddgDsKwS8cooXCfmHbR4DWae~lA5cr5cDO2evEPBl9sanO2~miGdbFg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 6.4. Refining cardiovascular disease risk estimation beyond risk models

The SCORE2 and SCORE2-OP risk-prediction models incorporate traditional risk factors such as age, sex, systolic BP, cholesterol values, and smoking status to predict 10-year risk of CVD.<sup><a href="javascript:;" reveal-id="ehae178-B165" data-open="ehae178-B165" class="link link-ref link-reveal xref-bibr">165</a>,<a href="javascript:;" reveal-id="ehae178-B166" data-open="ehae178-B166" class="link link-ref link-reveal xref-bibr">166</a></sup> However, they do not include ‘non-traditional’ CVD risk factors (detailed below and hereafter termed 'risk modifiers’). Non-traditional CVD risk modifiers can improve the predictive performance (i.e. discrimination) of other CVD risk-prediction models, and may also apply to SCORE2 or SCORE2-OP.<sup><a href="javascript:;" reveal-id="ehae178-B173" data-open="ehae178-B173" class="link link-ref link-reveal xref-bibr">173</a></sup> For example, among individuals with elevated BP and borderline increased 10-year predicted CVD risk by SCORE2 or SCORE2-OP (estimates of 5% to <10%), these non-traditional CVD risk modifiers may help up-classify the patient's risk and thereby prompt BP-lowering treatment (_[Figure 8](javascript:;)_).

![Cardiovascular disease risk modifiers to consider for up-classification of risk.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f8.jpeg?Expires=1728462844&Signature=H~SkuF6eDh1bGFfOsI1rUzoUeERKdvbGOfsWbnp9bkYB0PRITApdX-5VgItbwcy5BkqdSI2OL-~oeQQDpsL5mWQ8vIwISq9Nal-HgcFL50tNtclqKeyPQNO4BPGb3jXlhvEXqDkB-foHYGPaVY5a8ixuphLgb3VSaeCT~Cu3O1bjwX900sjQ6Xfu3Jou~T31cFPDWERstGXNtUyRfNr1Ovynmct952bJUTUimAScBzcaOcnZYULVScWzZxwCtVvFGAH1sH4xC2wQZdH54nll25IqC-YaIhCu~LHT14CGmDBisbRgLYj6lLbVGc8zJqb7xLRtlNlKD31qptHpSK2t9g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 8

Cardiovascular disease risk modifiers to consider for up-classification of risk.

ASCVD, atherosclerotic cardiovascular disease; HIV, human immunodeficiency virus.

[Open in new tab](https://academic.oup.com/view-large/figure/479375833/ehae178f8.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f8.jpeg?Expires=1728462844&Signature=C5B3yVsyglRFDYrtgE9AVbdxe-Y7CkumzqbNJwglssF6PdUwyKjm9Ny3ZuJRUea7sqG1pbUFql1LTt3Ofro2rN-SrIeENagY0SOMHSUX9Xsp8CspxvBCt9Lq55XEsHVU-gmoUU7Cx34o8w-K6-jnZYrU~3NqfFhZHa792tOAEMAOejJNRPF03YCs5WY3QUupAlMdTXzbNdpxqDAfDp~xA7HFgIkq8zxEqi7rgqT8fBQZWF78xuUbrmxrBjPCg5A7sdMxNfM4eNR87MK2WldKMr55WtWEe07cfpuPvw8bbpxv2-qIR1MFxDXDLxYeMD~-5DM1hSUGB~s9kw3FSNIizw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375833&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

#### 6.4.1. Sex-specific non-traditional cardiovascular disease risk modifiers

Sex differences in the distribution of traditional and non-traditional CVD risk factors have been documented among patients with hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B174" data-open="ehae178-B174" class="link link-ref link-reveal xref-bibr">174</a></sup> Although sex itself is included as an input variable in the SCORE2 and SCORE2-OP, and though these models were derived separately in men and women, some sex-specific, non-traditional risk modifiers were not included, and their associated impact on CVD risk may not be fully captured by SCORE2, SCORE2-OP, or SCORE2-Diabetes.

The relationship between BP and overall CVD risk is similar in both sexes, though some studies even suggest a stronger relative risk for CVD for a given BP level among females compared with males.<sup><a href="javascript:;" reveal-id="ehae178-B117" data-open="ehae178-B117" class="link link-ref link-reveal xref-bibr">117</a></sup> Female-specific, non-traditional CVD risk modifiers often arise at specific times throughout the life course, especially during pregnancy and the peri-partum period. Women with a history of hypertensive disorders of pregnancy, including gestational hypertension and pre-eclampsia, have a two-fold higher long-term risk of CVD vs. women without these pregnancy conditions.<sup><a href="javascript:;" reveal-id="ehae178-B175 ehae178-B176 ehae178-B177" data-open="ehae178-B175 ehae178-B176 ehae178-B177" class="link link-ref link-reveal xref-bibr">175–177</a></sup> The relative long-term CVD risk associated with hypertensive disorders of pregnancy may also be higher in younger vs. older pregnant women.<sup><a href="javascript:;" reveal-id="ehae178-B178" data-open="ehae178-B178" class="link link-ref link-reveal xref-bibr">178</a>,<a href="javascript:;" reveal-id="ehae178-B179" data-open="ehae178-B179" class="link link-ref link-reveal xref-bibr">179</a></sup> Most, but not all, of the excess CVD risk associated with hypertensive disorders of pregnancy is captured by conventional CVD risk factors.<sup><a href="javascript:;" reveal-id="ehae178-B176" data-open="ehae178-B176" class="link link-ref link-reveal xref-bibr">176</a>,<a href="javascript:;" reveal-id="ehae178-B178" data-open="ehae178-B178" class="link link-ref link-reveal xref-bibr">178</a></sup> Gestational diabetes is independently associated with an approximately two-fold increase in the long-term relative risk of CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B180" data-open="ehae178-B180" class="link link-ref link-reveal xref-bibr">180</a></sup> Other complications such as pre-term delivery, recurrent miscarriage, and one or more stillbirths are associated with a 40% relative increase in long-term CVD risk.<sup><a href="javascript:;" reveal-id="ehae178-B181 ehae178-B182 ehae178-B183 ehae178-B184 ehae178-B185" data-open="ehae178-B181 ehae178-B182 ehae178-B183 ehae178-B184 ehae178-B185" class="link link-ref link-reveal xref-bibr">181–185</a></sup> Accordingly, a history of specific pregnancy complications, including gestational hypertension, pre-eclampsia, gestational diabetes, pre-term delivery, one or more stillbirths, and recurrent miscarriage, can be considered as non-traditional CVD risk modifiers to up-classify women with elevated BP and borderline increased 10-year predicted CVD risk (5% to <10%) to sufficiently high risk, thereby influencing the risk-based management of their elevated BP.

Evidence whether other female-specific conditions (infertility, polycystic ovary syndrome, and premature menopause) and male-specific conditions (androgenic alopecia and erectile dysfunction) improve prediction of CVD sufficiently to inform risk-based BP-lowering treatment decisions is inconclusive at present.

#### 6.4.2. Non-traditional cardiovascular disease risk modifiers shared by men and women

In addition to sex-specific risk modifiers, several other non-traditional risk factors are associated with an increased risk of CVD, but few have been shown to improve risk prediction or discrimination beyond traditional CVD risk factors.

We advise considering high-CVD-risk race/ethnicity (e.g. South Asian),<sup><a href="javascript:;" reveal-id="ehae178-B186 ehae178-B187 ehae178-B188" data-open="ehae178-B186 ehae178-B187 ehae178-B188" class="link link-ref link-reveal xref-bibr">186–188</a></sup> family history of premature onset atherosclerotic CVD (CVD event in males aged <55 years and/or females <65 years),<sup><a href="javascript:;" reveal-id="ehae178-B189" data-open="ehae178-B189" class="link link-ref link-reveal xref-bibr">189</a>,<a href="javascript:;" reveal-id="ehae178-B190" data-open="ehae178-B190" class="link link-ref link-reveal xref-bibr">190</a></sup> socio-economic deprivation,<sup><a href="javascript:;" reveal-id="ehae178-B191" data-open="ehae178-B191" class="link link-ref link-reveal xref-bibr">191</a></sup> inflammatory conditions (e.g. systemic lupus erythematosus, rheumatoid arthritis, and psoriasis affecting 10% or more of body surface area or requiring systemic therapy),<sup><a href="javascript:;" reveal-id="ehae178-B192 ehae178-B193 ehae178-B194 ehae178-B195 ehae178-B196 ehae178-B197 ehae178-B198 ehae178-B199 ehae178-B200 ehae178-B201 ehae178-B202" data-open="ehae178-B192 ehae178-B193 ehae178-B194 ehae178-B195 ehae178-B196 ehae178-B197 ehae178-B198 ehae178-B199 ehae178-B200 ehae178-B201 ehae178-B202" class="link link-ref link-reveal xref-bibr">192–202</a></sup> HIV,<sup><a href="javascript:;" reveal-id="ehae178-B203 ehae178-B204 ehae178-B205" data-open="ehae178-B203 ehae178-B204 ehae178-B205" class="link link-ref link-reveal xref-bibr">203–205</a></sup> and severe mental illness (major depressive disorder, bipolar disorder, and schizophrenia)<sup><a href="javascript:;" reveal-id="ehae178-B206 ehae178-B207 ehae178-B208" data-open="ehae178-B206 ehae178-B207 ehae178-B208" class="link link-ref link-reveal xref-bibr">206–208</a></sup> as shared non-traditional risk modifiers to up-classify the risk of individuals with a borderline increased 10-year predicted risk using SCORE2/SCORE2-OP (5% to <10%) to sufficiently high CVD risk.

#### 6.4.3. Additional risk decision tests

Coronary artery calcium (CAC) scoring improves CVD risk prediction and reclassifies risk when added to conventional CVD risk factor-based estimation models.<sup><a href="javascript:;" reveal-id="ehae178-B209" data-open="ehae178-B209" class="link link-ref link-reveal xref-bibr">209</a>,<a href="javascript:;" reveal-id="ehae178-B210" data-open="ehae178-B210" class="link link-ref link-reveal xref-bibr">210</a></sup> A CAC score of >100 Agatston units or ≥75th percentile for age, sex, and ethnicity favours up-classification of CVD risk.<sup><a href="javascript:;" reveal-id="ehae178-B127" data-open="ehae178-B127" class="link link-ref link-reveal xref-bibr">127</a></sup> Internal or external carotid plaque may also improve CVD risk prediction.<sup><a href="javascript:;" reveal-id="ehae178-B211" data-open="ehae178-B211" class="link link-ref link-reveal xref-bibr">211</a></sup> Similarly, femoral artery plaque detection may improve CVD risk prediction.<sup><a href="javascript:;" reveal-id="ehae178-B212 ehae178-B213 ehae178-B214" data-open="ehae178-B212 ehae178-B213 ehae178-B214" class="link link-ref link-reveal xref-bibr">212–214</a></sup> Arterial stiffness, as assessed by pulse wave velocity (PWV), is associated with increased risk of CVD events and improves CVD risk stratification.<sup><a href="javascript:;" reveal-id="ehae178-B215 ehae178-B216 ehae178-B217 ehae178-B218" data-open="ehae178-B215 ehae178-B216 ehae178-B217 ehae178-B218" class="link link-ref link-reveal xref-bibr">215–218</a></sup> Common arterial stiffness thresholds for increased risk include carotid–femoral PWV of >10 m/s and brachial–ankle PWV of >14 m/s. After assessing 10-year predicted CVD risk and non-traditional risk factors, if a risk-based treatment decision remains uncertain for patients with elevated BP, it is reasonable to measure a CAC score or, alternatively, carotid or femoral plaque, or arterial stiffness; most especially after shared decision-making with the patient and after considering cost (see _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6)_ for more details on these tests). There is also evidence that elevated cardiac biomarker levels (specifically high-sensitivity cardiac troponin and B-type natriuretic peptide/N-terminus B-type natriuretic peptide) are significant and effective risk modifiers,<sup><a href="javascript:;" reveal-id="ehae178-B219" data-open="ehae178-B219" class="link link-ref link-reveal xref-bibr">219</a>,<a href="javascript:;" reveal-id="ehae178-B220" data-open="ehae178-B220" class="link link-ref link-reveal xref-bibr">220</a></sup> with further supportive data from hypertensive participants.<sup><a href="javascript:;" reveal-id="ehae178-B159" data-open="ehae178-B159" class="link link-ref link-reveal xref-bibr">159</a>,<a href="javascript:;" reveal-id="ehae178-B221" data-open="ehae178-B221" class="link link-ref link-reveal xref-bibr">221</a>,<a href="javascript:;" reveal-id="ehae178-B222" data-open="ehae178-B222" class="link link-ref link-reveal xref-bibr">222</a></sup> Of note, these cardiac biomarkers can be considered markers of HMOD (_Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6)_); however, we focus on them in this risk modifier section because they may be elevated due to other reasons besides high BP (such as atherosclerosis or heart rhythm disease).

Recommendation Table 4

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375843)

Recommendations for refining cardiovascular disease risk (see Evidence Tables 12–14)

![Recommendations for refining cardiovascular disease risk (see Evidence Tables 12–14)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt4.jpeg?Expires=1728462844&Signature=PlbVdJGTjJxwhzSHh0gAPDnVOb4ZGNWlEsltDKpfsImSkv7cEycnoxFcsnGsYj~5xbMqmieX4HGhPx8wZm8-OoCHHTAnd7VjBiAwdBh5h-8FlUb4GT47M3jybZYdl8zHN1FKd~BwvJCNfU1u0oJE4DaT5ShUR6DMvvF7IWmbUg5D8EjlLsTuCcwrg7JYXBmYZOeK9WvUXhyH4j4o6J8kbUy38EiktrbasIc5U4u35UIeJf5MLCJdUexUNgqiwN8d6dwILp25vczYEWF7iEZ3xoZKU0Tjfq0lAhP~03LDK1ERUoB3~vIHLEXZO1hf-w4ww1as6Y9~2vWTBYJfo~tgBQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 6.5. Summary of the cardiovascular disease risk stratification approach for allocating blood pressure treatment

Measured BP combined with 10-year CVD risk-prediction models and non-traditional risk modifiers should be used for stratifying risk when allocating BP-lowering treatment for persons with elevated BP (_[Figure 9](javascript:;)_). It is important to stress here that patients with confirmed hypertension are recommended to receive BP-lowering treatment and no further risk stratification is needed.

![Summary of cardiovascular disease risk-stratification approach for blood pressure treatment in adults with elevated blood pressure.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f9.jpeg?Expires=1728462844&Signature=KpMaGupz2ya-wDITBmsRAA0BrB5p35jmQPWt2DLgya79lPUlrYimInemd3Qv95ssux0jMYlSpH0aQfssGWqhpY0R-DzpCOd27-19nRcnBzDoQdenILgw4xeqrtujZ~Km~sZpL6JqDIwykNWDsX1RcaispzW5Xg~6Ung89FNO~wF1-LhkN8ygCGDvWqLyIfvTLM3ThCga-ycM6buxPGFQ0TrxLo1FSZs1PqsIo73ELIr~iVqRVpQLQzZBNwF-5SeZ3vlI0Y7rMnWpzy1B40j4dYS1c0BBzcCYpUD86FzKoMykuUAFRF5qsy4jC52YWBFbu~E~fQXfILqSoyotjxPjZA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 9

Summary of cardiovascular disease risk-stratification approach for blood pressure treatment in adults with elevated blood pressure.

ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CAC, coronary artery calcium; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; DM, diabetes mellitus; FH, familial hypercholesterolaemia; HMOD, hypertension-mediated organ damage; NT-proBNP, N-terminal pro-brain natriuretic peptide; SBP, systolic blood pressure; SCORE2, Systematic COronary Risk Evaluation 2; SCORE2-OP, Systematic COronary Risk Evaluation 2–Older Persons.

[Open in new tab](https://academic.oup.com/view-large/figure/479375846/ehae178f9.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f9.jpeg?Expires=1728462844&Signature=3vWi5~-pEbbUpXZDlx1aBtC7ALFr6DzwYVd96O~qzX5Ak8PspOBF~txKVb2T3dSAeNj81eaAnfpxL6okPIGHDz47J3J8fXm1V~z2plz48y5HqdJ3v~XRk0tVKo6tVkNNAeHe~8c0X9AuQWMHr-8V6Xu0MEtpnJjQa9I1DHO2X1nAseFRNsokf-y9t72dfa7G1gfzUVdgkLxzio0xN2-pzyPOZPQDa4gOVInOVhQLNLOXEic~mbCoKgzmBRD-LlTcYA9TGVknsC-IZT0DVpkz~9WBIKw24ECo0Q9oWsYKLnT1GvIaDKIAZNPnePZDloYRgap63f1IqMnbFwbJ-tAxSw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375846&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

For patients with elevated BP, the presence of diabetes, familial hypercholesterolaemia, established CVD (defined as prior acute or chronic coronary syndrome, cerebrovascular disease, symptomatic peripheral arterial disease, or heart failure), moderate or severe CKD, or HMOD confers increased CVD risk. One caveat is that, specifically for individuals with elevated BP and type 2 diabetes mellitus only aged <60 years, SCORE2-Diabetes should be considered to identify lower CVD risk individuals (<10% over 10 years).

Otherwise, for patients without these high-risk conditions, 10-year risk of CVD should be calculated using SCORE2 (if aged 40–69 years) and SCORE2-OP (if aged ≥70 years). Patients with elevated BP and a 10-year predicted risk of CVD events ≥10% are considered sufficiently high risk to warrant BP-lowering treatment (either by lifestyle or drug treatment, see _Section [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_). For patients with elevated BP and borderline increased predicted CVD risk by SCORE2/SCORE2-OP (5% to <10% over 10 years), up-classification of risk may be considered in the presence of sex-specific or shared non-traditional risk modifiers. After considering sex-specific and shared non-traditional risk modifiers, if a risk-based BP-lowering treatment decision remains uncertain, it may be reasonable to measure CAC score, carotid or femoral plaque, high-sensitivity cardiac troponin or B-type natriuretic peptide biomarkers, or arterial stiffness.

Risk stratification for patients with non-elevated BP (systolic BP of <120 mmHg and diastolic BP of <70 mmHg) is not required for the purpose of allocating BP-lowering treatment, as the safety and efficacy of commencing BP-lowering treatment below this threshold is uncertain. Risk assessment may nonetheless be needed in this setting when considering other prevention therapies (e.g. lipid lowering).

## 7\. Diagnosing hypertension and investigating underlying causes

### 7.1. Screening for hypertension

Hypertension is predominantly an asymptomatic condition that is typically detected by systematic or opportunistic screening in a healthcare setting. Systematic screening refers to any process where individuals are identified and invited to a healthcare setting solely to measure their BP and CVD risk profile. Opportunistic screening refers to BP being measured when the patient presents to a healthcare setting for any reason, such as a routine check-up or the treatment of an acute or chronic condition. Self-screening and non-physician screening are also increasingly used.<sup><a href="javascript:;" reveal-id="ehae178-B227 ehae178-B228 ehae178-B229 ehae178-B230" data-open="ehae178-B227 ehae178-B228 ehae178-B229 ehae178-B230" class="link link-ref link-reveal xref-bibr">227–230</a></sup>

Few data are available on the effectiveness of different hypertension screening strategies to reduce the morbidity and mortality associated with hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B231 ehae178-B232 ehae178-B233" data-open="ehae178-B231 ehae178-B232 ehae178-B233" class="link link-ref link-reveal xref-bibr">231–233</a></sup> More evidence is needed before systematic screening programmes with BP measurement can be recommended in all adults to reduce CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B231" data-open="ehae178-B231" class="link link-ref link-reveal xref-bibr">231</a></sup>

Opportunistic BP screening in a primary care setting appears effective, with an estimated 90% of all adults aged >40 years in the UK having a BP check within a 5-year time period,<sup><a href="javascript:;" reveal-id="ehae178-B234" data-open="ehae178-B234" class="link link-ref link-reveal xref-bibr">234</a></sup> though these findings may not extrapolate to other countries. When patients provide HBPM recordings, these can also be used as part of an opportunistic screening programme (see _Section [5.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4.2)_).<sup><a href="javascript:;" reveal-id="ehae178-B235" data-open="ehae178-B235" class="link link-ref link-reveal xref-bibr">235</a></sup>

Despite ongoing uncertainty about the effect of hypertension screening programmes on CVD outcomes, many studies have demonstrated that screening (mostly opportunistic screening) increases hypertension detection, and that the benefits of screening likely outweigh harms.<sup><a href="javascript:;" reveal-id="ehae178-B70" data-open="ehae178-B70" class="link link-ref link-reveal xref-bibr">70</a></sup> Global initiatives to raise BP awareness, such as the May Measurement Month,<sup><a href="javascript:;" reveal-id="ehae178-B228" data-open="ehae178-B228" class="link link-ref link-reveal xref-bibr">228</a></sup> or targeted initiatives, such as the barbershop health outreach programmes,<sup><a href="javascript:;" reveal-id="ehae178-B229" data-open="ehae178-B229" class="link link-ref link-reveal xref-bibr">229</a></sup> are successful examples of BP screening campaigns.

Screening for hypertension, like for global CVD risk assessment, should be intermittently repeated, e.g. every 3 years. Considering the rate of progression to hypertension in European population samples,<sup><a href="javascript:;" reveal-id="ehae178-B236" data-open="ehae178-B236" class="link link-ref link-reveal xref-bibr">236</a></sup> it is reasonable to measure BP at least every 3 years in the case of non-elevated BP and low–moderate CVD risk (i.e. individuals aged <40 years). More frequent BP checks (i.e. yearly) should be considered in individuals 40 years or older and individuals with elevated BP not currently meeting indications for treatment<sup><a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup> (_[Figure 10](javascript:;)_).

![Protocol for confirming hypertension diagnosis.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f10.jpeg?Expires=1728462844&Signature=VaNkFtFyx71Aet5twLBY7UHGt~C8latTaQpDznqJXGA4l9LZbDVLt4ixkoFeshvvAXHB2P1Fh3xVBLI8jtlNMtyG-CGUr-tEsWBGBGv7U13KOhj1Hr8AM0lujgKiyddeDnsksj4p7i51pomIrBj9sSL828tYyADXR62y-0kev9M0mDSZ8~em1483gVG1guHyYU-oq0DOKp5TEBq~X0clbOHhyG-GqureWaSJF0WTmyUc2dXvlJunKw0EpryKuK0QQHkcxMuYHsN0blfCBpCZsfTgro3zf~yrtvYZwzHsvX9-Fq2aq4SIHms4YbXXe~jmIcCfI6RgC9oSc9ko08gyYQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 10

Protocol for confirming hypertension diagnosis.

BP, blood pressure; CVD, cardiovascular disease; SCORE2, Systematic COronary Risk Evaluation 2; SCORE2-OP, Systematic COronary Risk Evaluation 2–Older Persons.

[Open in new tab](https://academic.oup.com/view-large/figure/479375857/ehae178f10.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f10.jpeg?Expires=1728462844&Signature=2LQjABOtkrPJ4t70APxLvmve4-eYMKHamuxACGijYPTUWdlkAOsCUEOvoreEVNpZDTq5pvBWe~uGd6N4VxcCrCkiwNMFbS4cqK4OhVh7VgiWd5-M~4Y8Mya1MkFMLM0CDVgdYw7bbf4WV6BTgWciAJSC2qkNDl~BOtHFJuUFo~Gn2AFXyjg7iM-IwMGuCL6TaWfsr0FPnaqG7FxIrp8mfG9lbIFXfleild6DjnLE6t~ps8gQjbsTCN4W501IC2a62R60vRIbmsvsfAB7d9bGj0Ql~4k-lMtXpgeaMfE2KGKO35SBkOhwv9S~BPHAEs3ocMMVzMub9apK4WbsOHS2Rg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375857&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Recommendation Table 5

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375858)

Recommendations for blood pressure screening (see Evidence Table 15)

![Recommendations for blood pressure screening (see Evidence Table 15)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt5.jpeg?Expires=1728462844&Signature=G9GChx-2PZRUgLRHAZC8m6rQcnWXikUD0Yaz3LLico9rwbMMwuzyKWaA1Ga4BGAt0rrhkqd5Pqkcqvk5JdaQsS0VWJevWCEEPbT-i8Ds~-HuQh05MGR4pkJUXPUosm3EP2bwt~nRWHaSF2VKZSf4tIJ1Yvv3-~1j~0TrdYQsSO8fKzytEfzGy9diP2s2EYIR89V~fih8XQ3aPD9T-kovGw27jE-bT95fEZTrSnk9n8fJ3CeOMbJ2ka6E-blJJgFB2GvWPWUebNXEAHKIey-i5faSrrQBG0zq2vBR-OF90Hdg0Wzvkc3k7MWyeOnO2JbA3XX1V8w70v3HFLfQFclxcg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 7.2. Confirming the diagnosis of hypertension

As noted in _Section [5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4)_, assessment at a single visit by office BP has lower specificity compared with ABPM for diagnosing hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B70" data-open="ehae178-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae178-B238 ehae178-B239 ehae178-B240 ehae178-B241" data-open="ehae178-B238 ehae178-B239 ehae178-B240 ehae178-B241" class="link link-ref link-reveal xref-bibr">238–241</a></sup> Accordingly, a protocol for confirming the diagnosis of hypertension is proposed (_[Figure 10](javascript:;)_), with out-of-office BP measurement as the preferred method for confirming cases of elevated BP or hypertension. For initial screening systolic BP of >160 mmHg and/or diastolic BP of >100 mmHg, a prompt re-evaluation (within days to weeks but not >1 month) preferably with ABPM or HBPM is advisable.<sup><a href="javascript:;" reveal-id="ehae178-B71" data-open="ehae178-B71" class="link link-ref link-reveal xref-bibr">71</a></sup> BP of >180/110 mmHg at screening requires exclusion of hypertensive emergencies, which should be managed as appropriate (see <sup><a href="javascript:;" reveal-id="ehae178-B242" data-open="ehae178-B242" class="link link-ref link-reveal xref-bibr">242</a></sup> and _Section [10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s9)_) with prompt treatment. For individuals with BP of >180/110 mmHg at screening but without hypertensive emergency, prompt confirmation (preferably within a week) can be considered prior to commencing treatment.

Recommendation Table 6

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375861)

Recommendations for confirming hypertension diagnosis

![Recommendations for confirming hypertension diagnosis](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt6.jpeg?Expires=1728462844&Signature=gXCkjwIf3cuMYXfwgi8EqTSRZDJ09sBC9ceg3-nneclAwzBC0LRGZlnu2XqPZTJOehhFxALlGVlVOTkMjQeaUbFKRt1rUG~SaaZjgKUSDfwb3EcHWoMb2l8D069F07yWvQjHOxdzVxn1YruSPFlFvjl2QAeZ3-y7~xZ3AiSaTUO~eu12Q12mEzqBkF326OEzR71UEE7nUOQny4-vFq3Mvwvy3klnCOsV7wpit8~tYpS-9dUy1X5UmGRZ5Pb~ZFQvtt5qgiZnTjiDkEXE1q~5omeoBdqKBTVfLjeSD8miM3~13kk2Hey7mX1QXjRfV3sTyk73NRGClRv7MCPMb9B50A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 7.3. Communicating the diagnosis

Behavioural responses to health-related threats are strongly influenced by five core themes (termed ‘illness representations’), which are identity, timeline, cause, consequences, and control/cure.<sup><a href="javascript:;" reveal-id="ehae178-B243" data-open="ehae178-B243" class="link link-ref link-reveal xref-bibr">243</a>,<a href="javascript:;" reveal-id="ehae178-B244" data-open="ehae178-B244" class="link link-ref link-reveal xref-bibr">244</a></sup> These illness representations form the basis of how patients understand a diagnosis, and can influence their responses after being diagnosed with hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B243" data-open="ehae178-B243" class="link link-ref link-reveal xref-bibr">243</a></sup> This conceptual framework can help guide the clinical communication of a diagnosis of hypertension. For example, patients’ understanding of the chronic nature of hypertension (i.e. timeline theme) is key for ensuring long-term engagement with medical treatment.<sup><a href="javascript:;" reveal-id="ehae178-B245" data-open="ehae178-B245" class="link link-ref link-reveal xref-bibr">245</a></sup> Prior to commencing treatment, it is helpful to understand the extent to which patients believe that medications are necessary and ascertain if they have concerns.<sup><a href="javascript:;" reveal-id="ehae178-B246" data-open="ehae178-B246" class="link link-ref link-reveal xref-bibr">246</a></sup> The core illness representations and beliefs about medicines for clinicians to consider are included in _[Table 7](javascript:;)._

Table 7

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375864)

Key illness representations and treatment beliefs: how these apply to communicating a hypertension diagnosis to the patient (note that gender influences these representations)

| Illness representation | Example patient question | Application to a hypertension diagnosis conversation |
| --- | --- | --- |
| Identity | What is the disease/illness label and the related symptoms? | The condition where your systolic BP is ≥140 and/or diastolic BP ≥90 mmHg is called hypertension. We classify systolic BP 120–139 or diastolic BP 70–89 mmHg as elevated BP. For most people, this has no noticeable signs or symptoms, therefore, we need to monitor your BP to assess how medications and behavioural changes are working. |
| Control | Is the illness controllable through medical intervention or behavioural change? | Hypertension can usually be controlled with medication and behavioural changes such as dietary changes and regular physical activity. For some people we need to try a few different options before we get BP under control. |
| Timeline | Is this an acute or chronic problem? | This is a serious long-term or chronic condition condition that will require long-term management. This means that it may need to be managed throughout life. |
| Consequences | What are the physical and psychosocial consequences? | If hypertension is not controlled, then there is a risk of a serious acute cardiovascular disease event such as a stroke or heart attack; however, if it is managed through the right medical intervention and behavioural changes, then this risk can be reduced and the condition will have less consequences for your life. |
| Causes | What caused the condition? | Multiple factors contribute to someone developing hypertension. These include both non-modifiable factors (e.g. genetics and age) and modifiable factors (e.g. diet, weight, and physical activity). We are best focusing on those things that we can control to reduce your BP. |

| Treatment beliefs | Example patient question | Application to a hypertension diagnosis communication |
| --- | --- | --- |
| Necessity | To what extent is treatment necessary? | Taking BP-lowering medication every day is necessary to keep your BP under control and to help prevent a more serious health problem developing. Do you think that these medicines will help you? |
| Concerns | To what extent does treatment cause concern? | Some patients have concerns about taking daily medications throughout their life, e.g. about side effects. Do you have any concerns about taking your BP medications every day? |

BP, blood pressure.

© ESC 2024

The 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice recommend “an informed discussion about CVD risk and treatment benefits—tailored to the needs of a patient” as part of a diagnosis communication in hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup> This can be facilitated using an interdisciplinary healthcare-provided approach (see _Section [11](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s10)_) and by visual information or other more accessible material that might optimally communicate hypertension-related risk.<sup><a href="javascript:;" reveal-id="ehae178-B128" data-open="ehae178-B128" class="link link-ref link-reveal xref-bibr">128</a></sup> Visualizing risk by medical imaging to motivate risk-reducing behaviour changes may also be beneficial.<sup><a href="javascript:;" reveal-id="ehae178-B247" data-open="ehae178-B247" class="link link-ref link-reveal xref-bibr">247</a></sup>

### 7.4. Baseline assessment and diagnostic approach

#### 7.4.1. Medical history, medication history, and physical examination

The purpose of clinical evaluation is to diagnose hypertension, delineate factors potentially contributing to hypertension, identify other CVD risk factors, define relevant comorbidities, screen for potential secondary causes of hypertension (where indicated), and establish whether there is evidence of HMOD or existing cardiac, cerebrovascular, or renal disease.

Details on medical history and physical examination steps are summarized in the supplement (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Tables S2](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[S3](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_), as well as drugs or substances that may increase BP (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S4](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

#### 7.4.2. Drug adherence and persistence with treatment

Adherence is defined as the extent to which a patient’s behaviour, e.g. with respect to taking medication, coincides with agreed recommendations from a healthcare provider. Persistence represents the amount of time from initiation to discontinuation of therapy.<sup><a href="javascript:;" reveal-id="ehae178-B248" data-open="ehae178-B248" class="link link-ref link-reveal xref-bibr">248</a></sup> Adherence to medical therapies is especially suboptimal in asymptomatic conditions such as hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B249 ehae178-B250 ehae178-B251 ehae178-B252 ehae178-B253 ehae178-B254" data-open="ehae178-B249 ehae178-B250 ehae178-B251 ehae178-B252 ehae178-B253 ehae178-B254" class="link link-ref link-reveal xref-bibr">249–254</a></sup> Non-adherence to BP-lowering therapy correlates with a higher risk of CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B255" data-open="ehae178-B255" class="link link-ref link-reveal xref-bibr">255</a>,<a href="javascript:;" reveal-id="ehae178-B256" data-open="ehae178-B256" class="link link-ref link-reveal xref-bibr">256</a></sup> Objective methods to assess adherence, such as detecting prescribed drugs in blood or urine samples and directly observed treatment (witnessed pill intake during ABPM), have demonstrated their potential usefulness, particularly in the setting of apparently resistant hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B257" data-open="ehae178-B257" class="link link-ref link-reveal xref-bibr">257</a></sup> However, all methods for testing drug adherence have limitations.

Non-adherence to BP-lowering therapy depends on many factors (_[Figure 11](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae178-B253" data-open="ehae178-B253" class="link link-ref link-reveal xref-bibr">253</a></sup> Effective patient–physician communication is crucial to improve adherence.<sup><a href="javascript:;" reveal-id="ehae178-B258" data-open="ehae178-B258" class="link link-ref link-reveal xref-bibr">258</a>,<a href="javascript:;" reveal-id="ehae178-B259" data-open="ehae178-B259" class="link link-ref link-reveal xref-bibr">259</a></sup> Single-pill combinations improve persistence in BP-lowering treatment and are associated with lower all-cause mortality.<sup><a href="javascript:;" reveal-id="ehae178-B260" data-open="ehae178-B260" class="link link-ref link-reveal xref-bibr">260</a></sup>

![Definitions, assessments, and potential interventions for the three phases of adherence to BP-lowering medications.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f11.jpeg?Expires=1728462844&Signature=YKZ8wJztmO~ApfgnRBlUWFDWLB0S4zsx6ndlm2CAKKjV25JbqRE20dts~9s8XOGmidmO7M~LWlC9cAy1Qw4A0fGseDfFtyRIjP3OxzgTPikdb6u06G9BrkvtUUY26famm-R3IgOoDo3EWZpU0SOO6CUpdFbQfWEztw0pazWrOyRMTmbSdrjLK0g2YkJJLXLuk-P7rJCTdKwVP9Z67XjKHIXlt7NYEpdqOe7dPLvp~t38XMVyNAzbVsJEF7JxMBBFBCwtcBlMf2WR8XlcofmImmM9hDPTk-vQojqOqeiMfWJCEHsE9EElb8JRBRPStBIzh7OppElWzBqe7U2oSCDqeA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 11

Definitions, assessments, and potential interventions for the three phases of adherence to BP-lowering medications.

[Open in new tab](https://academic.oup.com/view-large/figure/479375873/ehae178f11.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f11.jpeg?Expires=1728462844&Signature=SJKORupXlbBXtkFLaWenL-61v5cKn61tFlZv-lW0gQHBBIzjVvzdRYiiTtAjPDK8RjWi08W7dLHI3k7iqYnshAbs9~crzpkrHpiy~pm5I8mffQjG8WZYBGTiAvWbKF5Giu4yeKGamen4YDFJkMpCtaxfZAO0FdMJdJ6CsThkXL2WIImMyfaXXW-l6f~xEUdjFNOzRSDfDCHgcIZjabRghOLjyFyYpkKLg~YsaC0S5pFk64qJ5Mt0i0hEh5gpxZrVt-nt1hxI~JCywlUhLDLsQKUyarILsI0LQY1bmyyUGj26TjA31ONWWGgFKdyfMX7mpAzO1kyKMMTTciXWEF3cEg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375873&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Recommendation Table 7

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375874)

Recommendations for assessing adherence and persistence with treatment (see Evidence Table 16)

![Recommendations for assessing adherence and persistence with treatment (see Evidence Table 16)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt7.jpeg?Expires=1728462844&Signature=s5-SHaCGdhHGuob~YYZTLgz4yodEItFm~gDAB70Jqh7Ghm-BXNko3d~1Zc7dkdxz6S8r4vBZsTp4JUo4EpZKPme-HF8odrQyJq27qDFtjBOAsRQsWugTcW4w4IykCl3s61e9B2hhdJm25K7oIfl66IKgbl525pR4nalc6N5vHrzDOGdY5Rb1HFcf9Dp4JqA0HllF2HcciqqHBlAxpHIPWU3AEaSde5dCBoMF5WNHmAQDm1JXF3AbyF9uomnsD0YUssxjffLMbmg~T6HaX6HZXnKjdAuKnAadVrU0u4zMftdmzz-OxG1CFgTfmJlZzCr6KFCxyU-g4I2xwuO1uelm1A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.4.3. Routine and optional tests

Routine tests include laboratory and clinical tests to detect increased CVD risk and relevant comorbidities (e.g. hyperlipidaemia and diabetes) (_[Table 8](javascript:;)_).

Table 8

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375877)

Routine tests recommended in the initial work-up of a patient with elevated blood pressure or hypertension

| Routine test | Clinical utility |
| --- | --- |
| Fasting blood glucose (and HbA1c if fasting blood glucose is elevated) | Assessing CVD risk and comorbidities |
| Serum lipids: total cholesterol, LDL cholesterol, HDL and non-HDL cholesterol, triglycerides | Assessing CVD risk |
| Blood sodium and potassium, haemoglobin and/or haematocrit, calcium, and TSH | Screening secondary hypertension (primary aldosteronism, Cushing’s disease, polycythaemia, hyperparathyroidism, and hyperthyroidism) |
| Blood creatinine and eGFR; urinalysis and urinary albumin-to-creatinine ratio | Assessing CVD risk and HMOD  
Guiding treatment choice  
Screening secondary hypertension (renoparenchymal and renovascular) |
| 12-lead ECG | Assessing HMOD (left atrial enlargement, left ventricular hypertrophy)  
Assessing irregular pulse and other comorbidities (AF, previous acute myocardial infarction) |

AF, atrial fibrillation; CVD, cardiovascular disease; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; HMOD, hypertension-mediated organ damage; LDL, low-density lipoprotein; TSH, thyroid-stimulating hormone.

© ESC 2024

Optional tests should be considered in the initial assessment if they are likely to change patient management, with the main rationale being to improve CVD risk stratification.<sup><a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup> As highlighted in _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_, for adults with elevated BP who also have a 10-year estimated CVD risk of 5% to <10%, optional tests including those for HMOD may be considered if up-classification of risk on the basis of an abnormal test result could prompt initiation of BP-lowering therapy.<sup><a href="javascript:;" reveal-id="ehae178-B31" data-open="ehae178-B31" class="link link-ref link-reveal xref-bibr">31</a>,<a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup> Evidence of subclinical microvascular neurodegeneration and/or lacunar brain disease due to small-vessel pathology may also indicate HMOD.<sup><a href="javascript:;" reveal-id="ehae178-B264" data-open="ehae178-B264" class="link link-ref link-reveal xref-bibr">264</a></sup>

While the role of optional tests for HMOD (_[Table 9](javascript:;)_) in the management of elevated BP is emphasized in these guidelines, we also note that these tests may help to optimize treatment in hypertensive adults with BP of >140/90 mmHg who are prescribed BP-lowering therapy (e.g. by facilitating patient adherence and overcoming clinician inertia in achieving an intensive BP treatment target of as low as 120 mmHg systolic). The role of visualizing HMOD in helping motivate risk-reducing changes in patients and overcome physician inertia has been tested in interventional trials (_Section [7.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6.3)_).<sup><a href="javascript:;" reveal-id="ehae178-B247" data-open="ehae178-B247" class="link link-ref link-reveal xref-bibr">247</a>,<a href="javascript:;" reveal-id="ehae178-B265 ehae178-B266 ehae178-B267" data-open="ehae178-B265 ehae178-B266 ehae178-B267" class="link link-ref link-reveal xref-bibr">265–267</a></sup>

Table 9

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375880)

Optional tests that may be used as clinically indicated in the initial work-up of a patient with elevated blood pressure or hypertension to assess hypertension-mediated organ damage or established cardiovascular disease

| Optional test | Clinical utility |
| --- | --- |
| Echocardiography | Assessing HMOD (hypertensive heart disease)  
Assessing established CVD (previous acute myocardial infarction, heart failure)  
Assessing thoracic aorta dilation |
| CAC by cardiac CT or carotid or femoral artery ultrasound imaging | Assessing HMOD (atherosclerotic plaque) |
| Large artery stiffness (carotid–femoral or brachial–ankle PWV) | Assessing HMOD (arterial stiffness) |
| High-sensitivity cardiac troponin and/or NT-proBNP | Assessing HMOD |
| Ankle–brachial index | Assessing established CVD (lower-extremity arterial disease) |
| Abdominal ultrasound | Assessing established CVD (abdominal aneurysm) |
| Fundoscopy | Assessing HMOD (hypertensive retinopathy)  
Diagnosing hypertensive emergency/malignant hypertension (haemorrhages and exudates, papilloedema) |

CAC, coronary artery calcium; CT, computed tomography; CVD, cardiovascular disease; HMOD, hypertension-mediated organ damage; NT-proBNP, N-terminal pro-brain natriuretic peptide; PWV, pulse wave velocity.

© ESC 2024

HMOD assessment is also an important way to identify young adults <40 years old who have increased CVD risk, since 10-year estimated CVD risk by SCORE2 cannot be calculated in this age group (see _Section [8.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7.1)_). More details on diagnostic thresholds for HMOD by the various assessment options, including important sex differences, are provided in [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Tables S1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[S5](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[Figure 12](javascript:;)_.

![Tests and criteria for defining hypertension-mediated organ damage and considerations for their use in clinical practice.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f12.jpeg?Expires=1728462844&Signature=uDV2m3oVzq~UiD~~4~kayV4iqp15J4FQOXuWLrqWT6A2ElffyjlZfl8RPgj0B0lP2Pl-nF3c-MPwTGEzzM2UgsoAOcQ3mjMb-aAhV-V3ColENYP1UTxnkwqe7A7XqfvpBp587lIXBTx3xmd5qCOReKVaMqeXd6KPRnx8yLWSkViyTDBntwynIS6su8ngkMYdj6Y1Vsa56301g3qy7ipmvMQh2VnQRh41iXbr8IB8u~rMvHGyUhxHUJ~r2hKv0O-dmz6-RhiIWmYWFnW6j4E0rul9hTviI5uLEhpTXCWhw2G1~~7TdWc2NFF8HkQv4jma9wYfkBQSW7h1~NgpdcgcgQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 12

Tests and criteria for defining hypertension-mediated organ damage and considerations for their use in clinical practice.

ACR, albumin:creatinine ratio; BP, blood pressure; BSA, body surface area; CT, computed tomography; CVD, cardiovascular disease; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HMOD, hypertension-mediated organ damage; hs-cTnT, high-sensitivity cardiac troponin T; LA, left atrial; LV, left ventricular; LVH, left ventricular hypertrophy; NT-proBNP, N-terminal pro-brain natriuretic peptide; PWV, pulse wave velocity; RWT, relative wall thickness; SCORE2, Systematic COronary Risk Evaluation 2; SCORE2-OP, Systematic COronary Risk Evaluation 2–Older Persons. More details and references can be found in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Tables S1 and S5](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_.

[Open in new tab](https://academic.oup.com/view-large/figure/479375882/ehae178f12.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f12.jpeg?Expires=1728462844&Signature=V8MWPQq~wVD8A6y4-KFub3NdyCIs9at~EOxCnnlTZSeaY4CSC-jUOPds7fvng6Cc4nDc-BSk1fUFEE5SptN6mOR4oT2inya1DCS-G1QW6EyRbHjuMzZ1rj1ANWIMXrA2e~PU20BY7f-2CxKV3WuisNK1rJAJ85RxchLdOC3XgeLsaMYaG6TFKpqE7bHwcN-SMD2o2yQpHHUQx6iIDAMk12G6evdZY0BSlUnZd9KOsqRISode6KMdvTVFn8Pdp-XXa~QY9J~gwOjsKXJwH5dQStL1WoY8Z4glIKCFUn~3LmpU0u5sQFgDQIMP54iGgVJCGOapb9ww3VRCfDRNSb2-Og__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375882&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Finally, some individuals may be at heightened risk for CVD events when cardiac and vascular HMOD measurements like LVH and increased PWV do not regress over time with appropriate treatment and BP control.<sup><a href="javascript:;" reveal-id="ehae178-B14" data-open="ehae178-B14" class="link link-ref link-reveal xref-bibr">14</a>,<a href="javascript:;" reveal-id="ehae178-B268 ehae178-B269 ehae178-B270 ehae178-B271" data-open="ehae178-B268 ehae178-B269 ehae178-B270 ehae178-B271" class="link link-ref link-reveal xref-bibr">268–271</a></sup>

Investigations aimed at screening for secondary hypertension are additional optional tests and are detailed in _Section [7.6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6.6)_. Of note, patients with an incidental adrenal nodule or nodules (typically detected on imaging of the abdomen done for other clinical reasons) warrant screening for elevated BP and hypertension. Those with adrenal incidentalomas and hypertension warrant a basic work-up for secondary hypertension to include screening for primary aldosteronism, Cushing's syndrome and phaeochromocytoma.

##### 7.4.3.1. The kidneys

CKD is defined as abnormalities of kidney structure or function, present for at least 3 months with implications for health.<sup><a href="javascript:;" reveal-id="ehae178-B272" data-open="ehae178-B272" class="link link-ref link-reveal xref-bibr">272</a></sup> Renal function is evaluated initially using serum creatinine and an estimated glomerular filtration rate (eGFR) equation (preferably race-free CKD-EPI) and typically for proteinuria.<sup><a href="javascript:;" reveal-id="ehae178-B273" data-open="ehae178-B273" class="link link-ref link-reveal xref-bibr">273</a></sup> Our definition of moderate-to-severe CKD requires an eGFR of <60 mL/min/1.73 m<sup>2</sup> or albuminuria of ≥30 mg/g (≥3 mg/mmol). Intensive BP control in patients with CKD reduces rates of CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B274" data-open="ehae178-B274" class="link link-ref link-reveal xref-bibr">274</a>,<a href="javascript:;" reveal-id="ehae178-B275" data-open="ehae178-B275" class="link link-ref link-reveal xref-bibr">275</a></sup> CKD can influence the choice of BP-lowering treatment (_Sections [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_ and _[9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_), as well as newer drugs for cardiovascular prevention, such as sodium–glucose co-transporter 2 (SGLT2) inhibitors and finerenone.

We recommend repeat measurement of eGFR and urine albumin:creatinine ratio (ACR) at least annually if clinically significant CKD is diagnosed. Renal ultrasound and Doppler examination to evaluate causes of CKD and to exclude renoparenchymal and renovascular hypertension (RVH) should also be considered.<sup><a href="javascript:;" reveal-id="ehae178-B276" data-open="ehae178-B276" class="link link-ref link-reveal xref-bibr">276</a>,<a href="javascript:;" reveal-id="ehae178-B277" data-open="ehae178-B277" class="link link-ref link-reveal xref-bibr">277</a></sup>

Recommendation Table 8

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375888)

Recommendations for assessing renal hypertension-mediated organ damage

![Recommendations for assessing renal hypertension-mediated organ damage](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt8.jpeg?Expires=1728462844&Signature=0J8sg7IWcnicYTR1oLAYY2pnsHG0gjr0cxcaoLjF04sUQ0YhObIGDrUZnC67Iv39Dnzs57~MxFOJjymvXqZyQPNRzxR80AJkJaTVcPUuwe4DCAA0~sy8lD7i0Ll6-D1PUnxeJT7fTBy8FTRPmlCaLbE6ULEcNcMNAMdjq1ZlslonDJVJFihvt7pJI95b2bfKJoLgIPo8-x24XGDHOoecEGOg36m4YIzwlxfagZXl46JixZ5vyLZ8p2L35JFpkki21g5RPhV2kRcqKMlEsHB1-2qUThR1U5kSFAZ8A-DIgVGgO9FATtCahRxSZMZ6qt-jTFYDu4CttscexKtLtKUylQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 7.4.3.2. The heart

A 12-lead ECG is a part of the initial routine work-up for all patients with hypertension and should be repeated whenever patients present with an irregular pulse or cardiac symptoms. The ECG should be analysed for LVH ([Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_) and AF.<sup><a href="javascript:;" reveal-id="ehae178-B31" data-open="ehae178-B31" class="link link-ref link-reveal xref-bibr">31</a>,<a href="javascript:;" reveal-id="ehae178-B278 ehae178-B279 ehae178-B280 ehae178-B281 ehae178-B282" data-open="ehae178-B278 ehae178-B279 ehae178-B280 ehae178-B281 ehae178-B282" class="link link-ref link-reveal xref-bibr">278–282</a></sup>

Echocardiography is recommended in patients with hypertension when the ECG is abnormal, murmurs are detected, or there are cardiac symptoms. A full, standardized, two-dimensional echocardiogram should be performed, preferably with tissue Doppler and strain assessment. Echocardiography can be considered for all patients with newly diagnosed hypertension, if local resources and reimbursement policies allow. Over 5 years of follow-up, subclinical left ventricular diastolic dysfunction predicts the incidence of CVD.<sup><a href="javascript:;" reveal-id="ehae178-B283 ehae178-B284 ehae178-B285" data-open="ehae178-B283 ehae178-B284 ehae178-B285" class="link link-ref link-reveal xref-bibr">283–285</a></sup> In addition, LVH detected by echocardiography predicts total and cardiovascular mortality and CVD events in the general population,<sup><a href="javascript:;" reveal-id="ehae178-B286" data-open="ehae178-B286" class="link link-ref link-reveal xref-bibr">286</a>,<a href="javascript:;" reveal-id="ehae178-B287" data-open="ehae178-B287" class="link link-ref link-reveal xref-bibr">287</a></sup> including in young adults.<sup><a href="javascript:;" reveal-id="ehae178-B26" data-open="ehae178-B26" class="link link-ref link-reveal xref-bibr">26</a>,<a href="javascript:;" reveal-id="ehae178-B268" data-open="ehae178-B268" class="link link-ref link-reveal xref-bibr">268</a>,<a href="javascript:;" reveal-id="ehae178-B288" data-open="ehae178-B288" class="link link-ref link-reveal xref-bibr">288</a>,<a href="javascript:;" reveal-id="ehae178-B289" data-open="ehae178-B289" class="link link-ref link-reveal xref-bibr">289</a></sup> Data on the associations with CVD of other metrics for detecting HMOD in the heart are also available.<sup><a href="javascript:;" reveal-id="ehae178-B26" data-open="ehae178-B26" class="link link-ref link-reveal xref-bibr">26</a>,<a href="javascript:;" reveal-id="ehae178-B268" data-open="ehae178-B268" class="link link-ref link-reveal xref-bibr">268</a>,<a href="javascript:;" reveal-id="ehae178-B290" data-open="ehae178-B290" class="link link-ref link-reveal xref-bibr">290</a></sup> Since cardiac size and function differ by sex, sex-specific thresholds for detecting HMOD in the heart are used to avoid under-diagnosis in women.<sup><a href="javascript:;" reveal-id="ehae178-B25" data-open="ehae178-B25" class="link link-ref link-reveal xref-bibr">25</a>,<a href="javascript:;" reveal-id="ehae178-B174" data-open="ehae178-B174" class="link link-ref link-reveal xref-bibr">174</a>,<a href="javascript:;" reveal-id="ehae178-B291" data-open="ehae178-B291" class="link link-ref link-reveal xref-bibr">291</a></sup>

Recommendation Table 9

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375892)

Recommendations for assessing cardiac hypertension-mediated organ damage

![Recommendations for assessing cardiac hypertension-mediated organ damage](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt9.jpeg?Expires=1728462844&Signature=fTJloJhr8wcFigzaJpW3DbmdQ9llLaPjECTcRr9CfQrbvq2J73bxUyRcXHzXDyPuOzNqZ2M8swCIxlwiRYoTUpva8l3aY6Qr677BtJQ6Xw08rX6~~RGoEukWxg25GtKX1LpnbHIX7si2UnTIZo5I0EWuwdFGzAONLygsAJg6DE~4DEn2KdPzSMpmrTT82zmGxcHNwCIvOcYs5DbAEenxK4qwYX6YlGvmgda4IWlwAz1~NTrt9d5wzUbILrqnAwVZP8BvR7N9fQbBvJP0XXzboyIsT4rW--KLYsmTdQK2a~dARkhWxqnowpmFsfbxAxrkuvMsoVITKtP3ywmZLjo75Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 7.4.3.3. The arteries

Cardiac computed tomography (CT) may be used to measure CAC and, if intravascular contrast is administered, fully visualize coronary artery disease to improve risk stratification.<sup><a href="javascript:;" reveal-id="ehae178-B211" data-open="ehae178-B211" class="link link-ref link-reveal xref-bibr">211</a>,<a href="javascript:;" reveal-id="ehae178-B293" data-open="ehae178-B293" class="link link-ref link-reveal xref-bibr">293</a></sup> As noted in _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_, CAC scoring can reclassify CVD risk upwards or downwards in addition to conventional risk factors.<sup><a href="javascript:;" reveal-id="ehae178-B127" data-open="ehae178-B127" class="link link-ref link-reveal xref-bibr">127</a>,<a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a>,<a href="javascript:;" reveal-id="ehae178-B211" data-open="ehae178-B211" class="link link-ref link-reveal xref-bibr">211</a>,<a href="javascript:;" reveal-id="ehae178-B233" data-open="ehae178-B233" class="link link-ref link-reveal xref-bibr">233</a>,<a href="javascript:;" reveal-id="ehae178-B294" data-open="ehae178-B294" class="link link-ref link-reveal xref-bibr">294</a></sup> Carotid ultrasound detects presence or absence of carotid plaque (wall thickness ≥ 1.5 mm) and stenosis. Presence of plaque in the carotid or femoral arteries improves risk prediction for CVD events in asymptomatic patients on top of conventional risk-factor assessment.<sup><a href="javascript:;" reveal-id="ehae178-B211" data-open="ehae178-B211" class="link link-ref link-reveal xref-bibr">211</a>,<a href="javascript:;" reveal-id="ehae178-B247" data-open="ehae178-B247" class="link link-ref link-reveal xref-bibr">247</a>,<a href="javascript:;" reveal-id="ehae178-B265" data-open="ehae178-B265" class="link link-ref link-reveal xref-bibr">265</a>,<a href="javascript:;" reveal-id="ehae178-B267" data-open="ehae178-B267" class="link link-ref link-reveal xref-bibr">267</a>,<a href="javascript:;" reveal-id="ehae178-B295" data-open="ehae178-B295" class="link link-ref link-reveal xref-bibr">295</a>,<a href="javascript:;" reveal-id="ehae178-B296" data-open="ehae178-B296" class="link link-ref link-reveal xref-bibr">296</a></sup> Systematic use of intima media thickness does not appear to consistently improve prediction of future CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B297" data-open="ehae178-B297" class="link link-ref link-reveal xref-bibr">297</a></sup> Arterial stiffness is measured as carotid–femoral PWV or brachial–ankle PWV, and can contribute to predictive value and risk reclassification.<sup><a href="javascript:;" reveal-id="ehae178-B28" data-open="ehae178-B28" class="link link-ref link-reveal xref-bibr">28</a>,<a href="javascript:;" reveal-id="ehae178-B31" data-open="ehae178-B31" class="link link-ref link-reveal xref-bibr">31</a>,<a href="javascript:;" reveal-id="ehae178-B215" data-open="ehae178-B215" class="link link-ref link-reveal xref-bibr">215</a>,<a href="javascript:;" reveal-id="ehae178-B216" data-open="ehae178-B216" class="link link-ref link-reveal xref-bibr">216</a></sup> PWV is currently used mostly for research purposes or in specialist referral centres. Checking for inter-arm BP difference may identify a subclavian stenosis as vascular HMOD.<sup><a href="javascript:;" reveal-id="ehae178-B38" data-open="ehae178-B38" class="link link-ref link-reveal xref-bibr">38</a></sup> Other tests assessing the vasculature \[such as abdominal ultrasound or ankle–brachial index (ABI)\] should also be considered in patients with hypertension, when specific cardiovascular complications (abdominal aneurysm, peripheral artery disease) are clinically suspected. Finally, microvascular HMOD can be assessed by fundoscopy. A simplified classification has been proposed and validated.<sup><a href="javascript:;" reveal-id="ehae178-B298" data-open="ehae178-B298" class="link link-ref link-reveal xref-bibr">298</a></sup> In hypertensive individuals, the presence of mild or moderate hypertensive retinopathy is associated with an increased risk of CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B299" data-open="ehae178-B299" class="link link-ref link-reveal xref-bibr">299</a></sup> Fundoscopy is recommended also in hypertensive diabetic patients and in the work-up of malignant hypertension and hypertensive emergencies.

Recommendation Table 10

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375895)

Recommendations for assessing vascular hypertension-mediated organ damage (see Evidence Table 17)

![Recommendations for assessing vascular hypertension-mediated organ damage (see Evidence Table 17)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt10.jpeg?Expires=1728462844&Signature=3TlO-zkCTvNmcfTHLgruFN78dnJkzDEVSRlIVx7kO6fBeFzwL0MFQJ6da7kESp9lhaAUq4W4bMvjWAdw8cSytSvm5jpIlaQk7GMEurPLh0ZTdSnQTygMQ7s4EKrtyrRDkpf8vFJ4wEQQVs2lNpJbBmFzxmmUf1WaRSB71e5v4Tvq0r-Y7mKfVRhT6qS4KJfvJwPXGI7GaSz4Ik7XGHyhwC3QITzviY4mIWj3Eg5DbmCcPxoj83J5xL8NTr0Gwdu8kfX18b6oi8BCnzL~879hk9zKHsj-iO8MAZ77AwqwGLeBTHQDCFzOKXRigkBjON9LWE4Cnq64cnV2KtjZCZgJwA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.4.4. Genetic testing

Hypertension is considered a complex polygenic disorder, because many genes or gene combinations influence BP.<sup><a href="javascript:;" reveal-id="ehae178-B300" data-open="ehae178-B300" class="link link-ref link-reveal xref-bibr">300</a>,<a href="javascript:;" reveal-id="ehae178-B301" data-open="ehae178-B301" class="link link-ref link-reveal xref-bibr">301</a></sup> However, some well-defined phenotypes relating to single-gene mutations (i.e. monogenic forms of hypertension) have been identified (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S6](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). These are rare, but knowledge of the genetic defect may allow targeted treatment of the proband and also proper management of the patient’s siblings.<sup><a href="javascript:;" reveal-id="ehae178-B302" data-open="ehae178-B302" class="link link-ref link-reveal xref-bibr">302</a>,<a href="javascript:;" reveal-id="ehae178-B303" data-open="ehae178-B303" class="link link-ref link-reveal xref-bibr">303</a></sup> As such, genetic testing should be considered only for those with a high prior probability of having a monogenic condition and such patients should be referred to specialized centres. In most patients with elevated BP or hypertension, routine genetic testing is not recommended. Family history and a pedigree analysis can help to find a heritable pattern of hypertension or hypotension.<sup><a href="javascript:;" reveal-id="ehae178-B304" data-open="ehae178-B304" class="link link-ref link-reveal xref-bibr">304</a></sup>

Recommendation Table 11

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375898)

Recommendations for genetic testing in hypertension management

![Recommendations for genetic testing in hypertension management](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt11.jpeg?Expires=1728462844&Signature=IWBQB3TvsHKotPHWLZH4J7JNQ8GVJJXbrEAVdX4i0nxThiC-zOcn4ctsRUXuQIITb~NbFF57SXHXZRXlbDVlY9keeL-zEcybbwPYMxAipUfzn0IPK9~cVGumZgiX-l7yFMzPxSQFSeHKVkHc07mJhGdSwL5RHxjBZMsKf6P6oamEnfdv89wHmO9GrY2ooRmEYQ3enG6OkZqwREL13f9rKQN4imNkxKTKb8vTz0MSD4BEuH0pLGwXYNVeo7tWdxL2xCB-Nh54mC3Cq5r7kHa8qWgxLbkHnyzyxH2rvDIEE-1-~FJJsUbvp553T87JpRV2majSf2i-CBOXKw5Ee6rw8w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 7.5. Resistant hypertension: definition and diagnosis

Despite availability and use of multiple BP-lowering medications, many patients worldwide have uncontrolled hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B306 ehae178-B307 ehae178-B308" data-open="ehae178-B306 ehae178-B307 ehae178-B308" class="link link-ref link-reveal xref-bibr">306–308</a></sup> Considering this, societies have introduced the term ‘drug-resistant hypertension’, or ‘treatment-resistant hypertension’, or ‘resistant hypertension’,<sup><a href="javascript:;" reveal-id="ehae178-B309" data-open="ehae178-B309" class="link link-ref link-reveal xref-bibr">309</a></sup> which has been reported in 10%–20% of patients with hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B310" data-open="ehae178-B310" class="link link-ref link-reveal xref-bibr">310</a>,<a href="javascript:;" reveal-id="ehae178-B311" data-open="ehae178-B311" class="link link-ref link-reveal xref-bibr">311</a></sup>

Resistant hypertension is not a disease _per se_. Compared with treated patients who achieve BP control, patients with resistant hypertension (by any definition) have a worse prognosis: risk of myocardial infarction, stroke, end-stage renal disease, and death in these adults may be two- to six-fold higher.<sup><a href="javascript:;" reveal-id="ehae178-B309" data-open="ehae178-B309" class="link link-ref link-reveal xref-bibr">309</a></sup> Secondary causes of hypertension are also more likely in the presence of resistant hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B312" data-open="ehae178-B312" class="link link-ref link-reveal xref-bibr">312</a></sup>

All resistant hypertension definitions require a diuretic in the prescribed multiple-drug regimen, because excess salt intake and salt and water retention are key players in resistance to BP-lowering treatments (_[Table 10](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae178-B309" data-open="ehae178-B309" class="link link-ref link-reveal xref-bibr">309</a></sup> In addition, excluding pseudo-resistance is a prerequisite. Specifically, pseudo-resistance indicates poor adherence to BP-lowering treatment, which should be verified by careful questioning of the patient in the first instance (_Section [7.4.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6.4.3)_).<sup><a href="javascript:;" reveal-id="ehae178-B257" data-open="ehae178-B257" class="link link-ref link-reveal xref-bibr">257</a></sup> In addition, white-coat hypertension must be excluded.<sup><a href="javascript:;" reveal-id="ehae178-B263" data-open="ehae178-B263" class="link link-ref link-reveal xref-bibr">263</a></sup> Contributors to pseudo-resistance are listed in _[Table 11](javascript:;)_. Objective evaluation of adherence (either directly observed treatment or detecting prescribed drugs in blood or urine samples) should also be considered, if resources allow.

Table 10

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375903)

Current definition of resistant hypertension

| Definition of resistant hypertension |
| --- |
| Hypertension is defined as resistant when a treatment strategy including appropriate lifestyle measures and treatment with maximum or maximally tolerated doses of a diuretic (thiazide or thiazide-like), a RAS blocker, and a calcium channel blocker fail to lower office systolic and diastolic BP values to <140 mmHg and/or <90 mmHg, respectively. These uncontrolled BP values must be confirmed by out-of-office BP measurements (HBPM or ABPM—_Section [5.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4.1)_ for relevant BP thresholds). |

| Key considerations |
| --- |
| 
-   Resistant hypertension is not a disease, but an indicator that should be used to identify patients at high risk for CVD, in which secondary hypertension is also frequent;
    
-   Pseudo-resistant hypertension must be excluded, including that caused by non-adherence to treatment;
    
-   In patients with decreased eGFR (i.e. <30 mL/min/1.73 m<sup>2</sup>) an adequately up-titrated loop diuretic is necessary to define resistant hypertension;
    
-   Patients with suspected resistant hypertension should be referred to specialized centres;
    
-   These ESC Guidelines do not include the terms ‘controlled resistant hypertension’ (BP at target but requiring ≥4 medications) or ‘refractory hypertension’ (BP not at target despite ≥5 medications).
    

 |

ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HBPM, home blood pressure monitoring; RAS, renin–angiotensin system.

© ESC 2024

Table 11

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375904)

Conditions found to cause pseudo-resistance or resistance to blood pressure-lowering treatment

| Causes of pseudo-resistant hypertension |
| --- |
| Poor adherence to and persistence with treatment  
White-coat phenomenon  
Poor BP measurement method  
Marked brachial artery calcification (Osler phenomenon)  
Clinician inertia (inadequate doses, inappropriate combinations of BP-lowering drugs)  
Munchausen syndrome (rare) |

| Causes of resistant hypertension |
| --- |
| _Behavioural factors_  
Overweight/obesity  
Physical inactivity  
Excess daily dietary sodium  
Excess habitual alcohol consumption |
| _Use of drugs or substances that may increase BP_  
See [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S4](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ |
| _Undetected secondary hypertension_  
See _[Table 13](javascript:;)_ |

BP, blood pressure.

© ESC 2024

The work-up of patients presumed to have resistant hypertension is complex and often requires technologies that are not available to GPs.<sup><a href="javascript:;" reveal-id="ehae178-B257" data-open="ehae178-B257" class="link link-ref link-reveal xref-bibr">257</a>,<a href="javascript:;" reveal-id="ehae178-B309" data-open="ehae178-B309" class="link link-ref link-reveal xref-bibr">309</a></sup> Accordingly, we recommend these patients are referred to specialized centres.

Recommendation Table 12

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375906)

Recommendations for resistant hypertension work-up (see Evidence Table 18)

![Recommendations for resistant hypertension work-up (see Evidence Table 18)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt12.jpeg?Expires=1728462844&Signature=caJR51vtBWj9AfwhUkA0wfGuXiWOJ-LNu491--CVN2B-6ZEQ4wJv47d6hQtJKAHJy~NuimuVWTqRFI5YDF-nmbDZOx4tVmbX1Zug229iBdJN0sATklrdKu8WASzhQUOHLOdfgZNY4ZfkOY5Xtz1nb5plnSfREzifhjgdrhLEKEEyH3G7Un0SLvi7yHG0V6MYYE2P5nmbRqortkU3xZZaC0Ty-Ti~pH4Lw6KHrMInuuNQSweLjmooi8c1OGSGJAoGAs6g2OZkMS29Vjg0LzR5rVtNOdfV8SO8utWJHieIPrqEz2HRad-zU-F4WzED0C8uml7SOcUDToYohD~kwO6VJg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 7.6. Secondary hypertension: when to screen/further investigations

#### 7.6.1. General considerations

Secondary hypertension is more prevalent than previously thought (_[Figures 13](javascript:;)–[15](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae178-B312 ehae178-B313 ehae178-B314 ehae178-B315 ehae178-B316 ehae178-B317" data-open="ehae178-B312 ehae178-B313 ehae178-B314 ehae178-B315 ehae178-B316 ehae178-B317" class="link link-ref link-reveal xref-bibr">312–317</a></sup> Depending on the definition used and the cohort studied, the prevalence of secondary hypertension is 10%–35% in all hypertensive patients<sup><a href="javascript:;" reveal-id="ehae178-B318" data-open="ehae178-B318" class="link link-ref link-reveal xref-bibr">318</a>,<a href="javascript:;" reveal-id="ehae178-B319" data-open="ehae178-B319" class="link link-ref link-reveal xref-bibr">319</a></sup> and up to 50% of patients with resistant hypertension (though the latter prevalence estimate included persons with eGFR < 40 mL/min/1.73 m<sup>2</sup>).<sup><a href="javascript:;" reveal-id="ehae178-B312" data-open="ehae178-B312" class="link link-ref link-reveal xref-bibr">312</a></sup> Primary aldosteronism is a common cause,<sup><a href="javascript:;" reveal-id="ehae178-B315" data-open="ehae178-B315" class="link link-ref link-reveal xref-bibr">315</a>,<a href="javascript:;" reveal-id="ehae178-B320" data-open="ehae178-B320" class="link link-ref link-reveal xref-bibr">320</a></sup> with, e.g. a high prevalence of hyperaldosteronism (up to 12%) observed in patients with BP of >180/110 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B316" data-open="ehae178-B316" class="link link-ref link-reveal xref-bibr">316</a></sup> Despite these numbers, screening rates for primary aldosteronism, even in high-risk groups such as those with resistant hypertension<sup><a href="javascript:;" reveal-id="ehae178-B321" data-open="ehae178-B321" class="link link-ref link-reveal xref-bibr">321</a></sup> and hypokalaemia,<sup><a href="javascript:;" reveal-id="ehae178-B322" data-open="ehae178-B322" class="link link-ref link-reveal xref-bibr">322</a></sup> are low (around 2% and 4% of eligible patients, respectively). In most healthcare systems, GPs are typically the ‘gatekeeper’ of access to specialized care and should be involved in screening patients for common causes of secondary hypertension, especially sleep apnoea and primary aldosteronism ([Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Tables S2](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[S3](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). Primary aldosteronism is associated with an increased risk of CVD events, which may be partly independent of BP.<sup><a href="javascript:;" reveal-id="ehae178-B323" data-open="ehae178-B323" class="link link-ref link-reveal xref-bibr">323</a>,<a href="javascript:;" reveal-id="ehae178-B324" data-open="ehae178-B324" class="link link-ref link-reveal xref-bibr">324</a></sup>

![Summary of primary aldosteronism as a common form of secondary hypertension.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f13.jpeg?Expires=1728462844&Signature=FlGb~NC-zR4AZZjkzNBaZDqkbw0xShKVNXHugkUFVC8fDGfJ0hU2xvmfGLKSxBkf8bdyIZ6My04d6umuvKbUHQ9YYgayTwhVdcEUZFsar5KvV2Lm71hsgRL93wRJowEpC3Hg7-61L3xtHMqqriXgiyG~EZrt-oSGG~vDpRLPo4KY4L2ojBKbJvGMXJbLYExcGBJ0X8fDaZP6f5L17XHtKVp1Vg~Uhk9EViHV91MmLUgAO59wYZipc5lHZyzxgCkb56AK6W7AR6hi1gDKbAw0QiRMUxB3ZkqClscdyAtil0i5y-EohZfCsRZCe6ES-UCVCXgXIHh3zMUogoiwohJK4g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 13

Summary of primary aldosteronism as a common form of secondary hypertension.

AF, atrial fibrillation; HMOD, hypertension-mediated organ damage.

[Open in new tab](https://academic.oup.com/view-large/figure/479375910/ehae178f13.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f13.jpeg?Expires=1728462844&Signature=ms6~Nz0iGMX0gd5xdMOtcOj278S6o6I2EBv0~saCvGUarCVUf5Wm8auvi3muYwy9pOPtkrboCvU2O5yP4r9v3UkCm0uRIL-0Zry7FM-gQbN1R3YWlLD9tQTiL9~k4Z2qVOFn-2XK9D4n4yQ4NfZrp3RxcZPec7AJ9znvmY~0M0BjwKi09IcGUEJh-aZ1OZbV4ip3yFcmAkyiM4xoeZE26KpJIBFuA1R1k-cTqy9fPZa8ApJ7odp5onOmRgKqzTCCiHe6Pcs7RO7nQmWf8Od1tkzqbxm7o8C4y9ThMWro-fSOBixjgeu2uhcu7qYBwF-rtVmjfbMThqR4WFWg0zkCtQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375910&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

![Summary of renovascular disease as a common form of secondary hypertension.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f14.jpeg?Expires=1728462844&Signature=tDoq1vXjtinRDCKLYgop8kHNobqQIUO-5hHaLreOx9Eoq~5sT-8XTZDGqPCfalKWE9JCi5Zc1ley4T2VtPr5x8~Xey2buNBhNxgj8-9O95o2fbVeP-r1LES4NTFzafil9OnidNjC~SeVzKJyHuBn22h~dueN7hGJQSCdParGKDUQVDr0zdKFTNV4yaMGqN5HmJV2M6XysQqfPWBOTvsYva9QNZmydnQWGib1UJKeZvzq4VFjPTE~pQuSX5zLt6zL4Oev5Cgpb-KKGZAwgW0vhUI~iryy1FyUipx1V4DcKVefnXKmDy4vjbtKH1PwJ04FLFZWYrO6GmD1JNyQCUdlLA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 14

Summary of renovascular disease as a common form of secondary hypertension.

CT-Angio, computed tomography angiography; CV, cardiovascular; FMD, fibromuscular dysplasia; GFR, glomerular filtration rate; MRI, magnetic resonance imaging; RAS, renin–angiotensin system.

[Open in new tab](https://academic.oup.com/view-large/figure/479375911/ehae178f14.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f14.jpeg?Expires=1728462844&Signature=kQ8jZSdpRpBdYptmK~LsG72V~GUYTkSsX~hqPDyy6AJSkj10HmbUwJDhUR0cv90exN6X1cumFmc17gHyHVr-G1t2VrqheZD4JuwJO5kTXxhR3zQU0Dn2GGYeyHHA1A9QG-Xj7JPAqCrx~Fqx9~1hc-hAuoSEmuMnfwwBmUye4CM9XJygQkJKv-rMCvf-bSJT6oB9WbnJfH1ZwqDdKnTntKsCArRG69WQN6UZuCQ3Mj4yhyb8oTTZ6IpKJa03qoPFHNPP3m9rk0K7lmv4Bnwbj9Ug5oW1rvvMxw~Q84aeOB4V5FcnuKrqlpYtsQt-5omWCyB3wpy3~GSHkIfNr6V5cg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375911&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

![Summary of obstructive sleep apnoea as a common form of secondary hypertension.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f15.jpeg?Expires=1728462844&Signature=zNYXlHSzFyreJ4gk2mAWaZ21L18DF9jWLSCkXEEPocj-nVEY7LromVEvoDPIIf2v1wiu-VxAD06HXDusbEV5sPmlwsIanCqy9PXYdDC8nDwnhrMiDmXezeNdrxJV8ALZ~mSB9r3u6taZPMTGfX4H82Sd9MnZ0~jeA1k9wxbJqXFKiuM7XzIZ5LW5Qyfw7eyk9OoKd57wSl5JN9cfYlG56BPeX6sBWzuV7iWlPITPwkchnVPAHPrN1qUNx5ADDue9DyOFXCoBAzt4F8AbjfcvuDiFZCl8OEiv6VYZ2mlO-Hq42G0A9u9y80i9aM8azxGjt153cVEEO9rnXS4PikcR6Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 15

Summary of obstructive sleep apnoea as a common form of secondary hypertension.

AF, atrial fibrillation; ABPM, ambulatory blood pressure monitor; CPAP, continuous positive airway pressure.

[Open in new tab](https://academic.oup.com/view-large/figure/479375912/ehae178f15.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f15.jpeg?Expires=1728462844&Signature=m17LUhkbS88oSnBdzxHX700dSXREM22wSngJA2Iqk03SaLzesY3J3KtX2EKZHWxLj8tFNZKsmm4pSEnUDYdKJ2uEXtxyY2y9iFunCXOHHCy5KPxqLRJrbPe-vt259C7~nikXqwEJxiNYnITk3YH-jVPZQZDPVnsgRSAAA7Jm7o2jwMlhS3C6cpuL3jXnXJA6X6SIaMaKWH4U~1wVrIAWK54ykui299L9-Zt4IxF2vTY6fhcgcd-3RvuJaL~W0ZYNXQitHqcJri3SFpOigMv58xQ21WRo8F6vo6IvuTKMDiuyTv4lTMc5VkXR9IFMYmiB5hD6Gnv8bJb9ml6Unju46Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375912&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

#### 7.6.2. Primary aldosteronism

Though spontaneous or diuretic-induced hypokalaemia are strongly suggestive of primary aldosteronism, a history of hypokalaemia is not present in most patients diagnosed with this condition. The aldosterone-to-renin ratio (ARR) is thus recommended for primary aldosteronism screening (see _[Figure 13](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae178-B325" data-open="ehae178-B325" class="link link-ref link-reveal xref-bibr">325</a></sup> This test can easily be done in treatment-naïve patients, though it is far more common for the ARR test to be considered when patients are already being treated for elevated BP or hypertension. This is relevant because ARR can be influenced by the drugs being taken at the time of testing. Accordingly, there are 2 approaches to screen for aldosteronism among patients who are already undergoing treatment for elevated BP or hypertension:

-   The first is to conduct ARR testing in treated patients with an indication for aldosteronism screening as efficiently as possible and without changing or stopping their baseline BP-lowering medications, simply to facilitate such testing. The ARR result then needs to be interpreted in the context of the specific medication(s) the patient is taking. Advantages of this approach include reducing barriers to screening and no change in medication in these patients, many of whom do not have BP controlled and in whom further deterioration in their BP control by stopping or changing medication may increase risk of CVD. Disadvantages include the interpretation of the ARR result, which depends on the specific medications taken at the time of testing.<sup><a href="javascript:;" reveal-id="ehae178-B326" data-open="ehae178-B326" class="link link-ref link-reveal xref-bibr">326</a></sup> Input from a hypertension specialist or endocrinologist may be necessary.
    
-   To reliably estimate renin and aldosterone status (and therefore ARR), and to facilitate a ‘clean’ screen for aldosteronism, a second approach is to discontinue drugs that affect these variables whenever feasible before ARR testing (_[Table 12](javascript:;)_). Such interfering drugs include, beta-blockers, centrally acting drugs (e.g., clonidine and alpha-methyldopa) renin-angiotensin system (RAS) blockers and diuretics.<sup><a href="javascript:;" reveal-id="ehae178-B326" data-open="ehae178-B326" class="link link-ref link-reveal xref-bibr">326</a></sup> Long-acting calcium channel blockers (CCBs), either dihydropyridine or non-dihydropyridine, and alpha-receptor antagonists do not interfere with the ARR and can be used instead of interfering medications before ARR testing. Should drugs that do not interfere with the ARR be contraindicated or insufficient to control BP, centrally acting sympatholytic drugs can also then be used, but at the risk of slightly more false positives (by renin suppression). Furthermore, when mineralocorticoid receptor antagonists (MRAs) cannot be stopped for safety reasons (i.e. severe hypokalaemia or severe hypertension among patients with severe hyperaldosteronism), recent evidence suggests that the accuracy of ARR testing under this treatment is only marginally impacted, particularly in the presence of florid primary aldosteronism.<sup><a href="javascript:;" reveal-id="ehae178-B327" data-open="ehae178-B327" class="link link-ref link-reveal xref-bibr">327</a></sup>
    

Assessing sodium intake (preferably 24 h urinary sodium, or sodium-to-creatinine ratio in the morning urine sample) is also important for interpreting the ARR, as is time in menstrual cycle for females. ARR cut-offs vary depending on unit of measurement and by local laboratory. For detailed information, readers are referred to the latest primary aldosteronism guidelines.<sup><a href="javascript:;" reveal-id="ehae178-B328" data-open="ehae178-B328" class="link link-ref link-reveal xref-bibr">328</a>,<a href="javascript:;" reveal-id="ehae178-B329" data-open="ehae178-B329" class="link link-ref link-reveal xref-bibr">329</a></sup>

Table 12

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375917)

Drugs and conditions that affect aldosterone, renin, and aldosterone-to-renin ratio

| Factor | Effect on plasma aldosterone levels | Effect on renin levels | Effect on ARR |
| --- | --- | --- | --- |
| **Serum potassium status** |
| Hypokalaemia | **↓** | **→↑** | **↓ (FN)** |
| Potassium loading | **↑** | **→↓** | **↑** |
| Sodium restriction | **↑** | **↑↑** | **↓ (FN)** |
| Sodium loading | **↓** | **↓↓** | **↑ (FP)** |
| **Drugs** |
| Beta-adrenergic blockers | **↓** | **↓↓** | **↑ (FP)** |
| Calcium channel blockers (DHPs) | **→↓** | **→↑** | **→↓ (FN** with short-acting DHPs**)** |
| ACE inhibitors | **↓** | **↑↑** | **↓ (FN)** |
| ARBs | **↓** | **↑↑** | **↓ (FN)** |
| Potassium-sparing diuretics | **↑** | **↑↑** | **↓ (FN)** |
| Potassium-wasting diuretics | **→↑** | **↑↑** | **↓ (FN)** |
| Alpha-2 agonists (clonidine, methyldopa) | **↓** | **↓↓** | **↑ (FP)** |
| NSAIDs | **↓** | **↓↓** | **↑ (FP)** |
| Steroids | **↓** | **→↓** | **↑ (FP)** |
| Contraceptive agents (drospirenone) | **↑** | **↑** | **↑ (FP)** |

↑, raised; ↓, lowered; →, no effect; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARR, aldosterone-to-renin ratio; DHPs, dihydropyridines; FN, false negative; FP, false positive; NSAID, non-steroidal anti-inflammatory drug.

© ESC 2024

#### 7.6.3. Renovascular hypertension

Renovascular hypertension (RVH) defines a condition where renal artery occlusion or stenosis decreases renal perfusion pressure to a level that activates the renin–angiotensin–aldosterone system (RAAS), thereby raising BP. Major causes are atherosclerosis and fibromuscular dysplasia (_[Figure 14](javascript:;)_ and [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Tables S1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[S2](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). Atherosclerosis is the most common form of RVH, especially in older adults.<sup><a href="javascript:;" reveal-id="ehae178-B318" data-open="ehae178-B318" class="link link-ref link-reveal xref-bibr">318</a></sup> Fibromuscular dysplasia is a systemic non-atherosclerotic vascular disease involving medium-sized muscular arteries. When renal arteries are involved, fibromuscular dysplasia may induce RVH (FMD-RVH), especially in children and younger women.<sup><a href="javascript:;" reveal-id="ehae178-B330 ehae178-B331 ehae178-B332" data-open="ehae178-B330 ehae178-B331 ehae178-B332" class="link link-ref link-reveal xref-bibr">330–332</a></sup>

Though not highly sensitive, very elevated renin levels raise the suspicion for RVH. The work-up of RVH (_[Table 13](javascript:;)_) is based on imaging tests, such as renal artery Doppler ultrasound, with bilateral assessment of renal arterial resistive index, or abdominal CT angiography, or magnetic resonance imaging (MRI), in line with current ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases,<sup><a href="javascript:;" reveal-id="ehae178-B277" data-open="ehae178-B277" class="link link-ref link-reveal xref-bibr">277</a></sup> which will be updated in 2024. Of note, bystander renal artery stenosis may be present in patients with essential hypertension, without causing secondary hypertension due to RVH. Since fibromuscular dysplasia is a systemic disease, CT or MRI angiography from head to pelvis is recommended in patients with FMD-RVH.<sup><a href="javascript:;" reveal-id="ehae178-B277" data-open="ehae178-B277" class="link link-ref link-reveal xref-bibr">277</a>,<a href="javascript:;" reveal-id="ehae178-B332" data-open="ehae178-B332" class="link link-ref link-reveal xref-bibr">332</a></sup>

Table 13

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375921)

Optional tests that should be used to screen for secondary hypertension in the presence of suggestive signs, symptoms, or medical history

| Cause of secondary hypertension | Screening test |
| --- | --- |
| Primary aldosteronism | Aldosterone-to-renin ratio  
Helpful information can also be provided by reviewing prior potassium levels (hypokalaemia increases the likelihood of coexistent primary hyperaldosteronism) |
| Renovascular hypertension | Renal doppler ultrasound  
Abdominal CT angiogram or MRI |
| Phaeochromocytoma/paraganglioma | 24 h urinary and/or plasma metanephrine and normetanephrine |
| Obstructive sleep apnoea syndrome | Overnight ambulatory polysomnography |
| Renal parenchymal disease | Plasma creatinine, sodium, and potassium  
eGFR  
Urine dipstick for blood and protein  
Urinary albumin-to-creatinine ratio  
Renal ultrasound |
| Cushing’s syndrome | 24 h urinary free cortisol  
Low-dose dexamethasone suppression test |
| Thyroid disease (hyper- or hypothyroidism) | TSH |
| Hyperparathyroidism | Parathyroid hormone  
Calcium and phosphate |
| Coarctation of the aorta | Echocardiogram  
Aortic CT angiogram |

CT, computed tomography; eGFR, estimated glomerular filtration rate; MRI, magnetic resonance imaging; TSH, thyroid-stimulating hormone.

© ESC 2024

#### 7.6.4. Obstructive sleep apnoea syndrome

Obstructive sleep apnoea syndrome (OSAS) is prevalent in hypertension and particularly in resistant hypertension, with studies indicating that up to 60% of patients with resistant hypertension have features of OSAS.<sup><a href="javascript:;" reveal-id="ehae178-B314" data-open="ehae178-B314" class="link link-ref link-reveal xref-bibr">314</a></sup> OSAS should be suspected in patients with hypertension and suggestive symptoms (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S2](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_), in all patients with resistant hypertension, and in patients with non-dipping or reverse-dipping pattern at 24 h BP monitoring, especially if obese (_[Figure 15](javascript:;)_). Using validated questionnaires may help identify patients at high risk of OSAS.<sup><a href="javascript:;" reveal-id="ehae178-B333" data-open="ehae178-B333" class="link link-ref link-reveal xref-bibr">333</a></sup> Lack of suggestive symptoms does not rule out OSAS. A simplified polysomnogram confirms the diagnosis \[apnoea–hypopnoea index (AHI) > 5\] and can quantify the severity of OSAS (mild: AHI < 15; moderate: AHI of 15–30; severe: AHI > 30).<sup><a href="javascript:;" reveal-id="ehae178-B334" data-open="ehae178-B334" class="link link-ref link-reveal xref-bibr">334</a></sup>

#### 7.6.5. Phaeochromocytoma/paraganglioma

Phaeochromocytomas/paragangliomas (PPGLs) are a rare form of secondary hypertension characterized by a highly heterogeneous clinical presentation.<sup><a href="javascript:;" reveal-id="ehae178-B335" data-open="ehae178-B335" class="link link-ref link-reveal xref-bibr">335</a>,<a href="javascript:;" reveal-id="ehae178-B336" data-open="ehae178-B336" class="link link-ref link-reveal xref-bibr">336</a></sup> PPGLs are usually discovered incidentally.<sup><a href="javascript:;" reveal-id="ehae178-B337" data-open="ehae178-B337" class="link link-ref link-reveal xref-bibr">337</a></sup>

A PPGL should be suspected in the presence of signs and symptoms of catecholamine excess or in syndromic PPGL, in patients with a family history of PPGL, and in carriers of a germline mutation in one of the PPGL-causing genes.<sup><a href="javascript:;" reveal-id="ehae178-B338" data-open="ehae178-B338" class="link link-ref link-reveal xref-bibr">338</a></sup> Since normetanephrine and metanephrine are secreted constitutively, as opposed to the highly variable nature of catecholamine secretion, they are preferred as screening tests for PPGL (_[Table 13](javascript:;)_).

Recommendation Table 13

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375927)

Recommendations for screening for secondary hypertension (see Evidence Tables 19 and 20)

![Recommendations for screening for secondary hypertension (see Evidence Tables 19 and 20)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt13.jpeg?Expires=1728462844&Signature=ujVZJHmDj6WAF3hX9uRHBPyJVM-sUAagb2962zh~wV8f4tjYSIaAy42IfxYi-bkCdsNG3A4i1VWDxC9ivUUtTwpDTN27zlevYGTs8cICOZbL3x9FGvJj1cGbUjzTj7bQ-ZtP2LFuk5gcTqv3goR36DYpq4FvsCZG8tl6XlYT35jKhtqbG6eOoC-1eiH6HHEZ0BKj8zGiB16TXbRUXiNYGtLtdUvGzZXSBJIg-lm~TputWFfWC3ndvwAwWsFR7bimqsS6rdkQzjcFb5X6oaXqRcu4srNO~aBi6T6OcxBy8dZln6qtF7CayycRIZ-ZWEKj35Rbt8Z0hNZp5-xogqaKxg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 8\. Preventing and treating elevated blood pressure and hypertension

The ultimate goal of preventing and treating elevated BP and hypertension is to reduce CVD, to improve quality of life, and to prevent premature death. Crucially, besides BP, other CVD risk factors need to be comprehensively addressed (e.g. smoking, glucose, dyslipidaemia) as detailed in the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.<sup><a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup> Indeed, it is worth emphasizing that, when combined, these CVD risk factors have multiplicative (not additive) effects on CVD risk.<sup><a href="javascript:;" reveal-id="ehae178-B340" data-open="ehae178-B340" class="link link-ref link-reveal xref-bibr">340</a></sup>

### 8.1. Prevention strategies in early life

Detailed information on this topic is provided in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA). High BP tracks from childhood to adulthood.<sup><a href="javascript:;" reveal-id="ehae178-B341" data-open="ehae178-B341" class="link link-ref link-reveal xref-bibr">341</a>,<a href="javascript:;" reveal-id="ehae178-B342" data-open="ehae178-B342" class="link link-ref link-reveal xref-bibr">342</a></sup> Hypertension in childhood was redefined in a 2022 ESC Consensus Document.<sup><a href="javascript:;" reveal-id="ehae178-B343" data-open="ehae178-B343" class="link link-ref link-reveal xref-bibr">343</a></sup>

Recommendation Table 14

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375932)

Recommendations for screening for hypertension in children and adolescents (see Evidence Table 21)

![Recommendations for screening for hypertension in children and adolescents (see Evidence Table 21)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt14.jpeg?Expires=1728462844&Signature=wzXORHHZIpEvS2BESTAdsgrR1QU625m5iUW88W7pLDAew7Q3zKbf2xs~nXXX6su5JwHEHGubm2tpUZVF7EMb4olfWtC8-c4OEr-O6Gi7Zv0sUb6AQBYTNxcDpLRe4XeJgTsvHI9FzuCSdWFE1XCbsf3VyXLKjxCcf7W~eGmrfSy3GY46rPW4bLd3DkdZoxvuLqq~Ds~xJpfGrlPFz5G4E5S7mDBhR9Q2zO820~6z-IulFBfvvufrHt~ytlssnGz8QECBOdJfzOM34IKnWaylAl3vekUhFTFDh7ml~5SaMZ4qbtqqy82oSL7hEy5jHlg8IlzQ~VjnXJoCN3dQyV5mtg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 8.2. Non-pharmacological interventions

A major underlying contributor to elevated BP and hypertension in the general adult population is unhealthy lifestyle, with severe consequences for all-cause and CVD mortality. As such, we give lifestyle interventions to reduce BP a special status in our recommendations throughout these guidelines (_[Figures 16](javascript:;)_ and _[17](javascript:;)_). This is reflected by a modified approach to the class of recommendations for lifestyle interventions compared with medical interventions (pharmacological or procedural). Given the salutary benefits of healthy lifestyle on a range of outcomes that extend well beyond BP-lowering effects,<sup><a href="javascript:;" reveal-id="ehae178-B347" data-open="ehae178-B347" class="link link-ref link-reveal xref-bibr">347</a></sup> including broad mental and physical health benefits, we do not require lifestyle interventions to have RCT evidence for efficacy in reducing CVD events through BP lowering to achieve a Class I recommendation. In deciding to give lifestyle interventions this status, the task force also recognizes that: (i) lifestyle interventions are less likely to be subjected to clinical outcomes trials (e.g. due to funding limitations and lack of interest from industry), and (ii) the risks of adverse effects and toxicity relating to healthy lifestyle interventions are low. In contrast, in these guidelines, to achieve a Class I recommendation (irrespective of level of evidence) there needs to be evidence that medical interventions that reduce BP also decrease CVD events by BP lowering.

![Physical activity according to different types of exercise and reduction of blood pressure and overall cardiovascular disease risk.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f16.jpeg?Expires=1728462844&Signature=vm-F8G6U5QVDf3R3wWZtcvxXzvAw899-fOdRDit9dj4R16UavCP~v0mS8waoBj~fyTdZ9ligmamXHmeWKKbNeoXyia3lLZu6PyNi2c3DnUdxYT4mOce25P2VZBesLNfix~EHBjKIIT6FfdnSlgK00CZW9bbIhgub4tlc4EHbZxpeyvbu0N19d4lMxx7eJI6oEGbt3PyPWMWxjx8ntr-AfzbyocJyphWkBvyFyYVBRGdpNUb3RZ4j0UZ-bBe67oxiGB1mLzE790I9AclI6cv6Z3B5LyEWqU0sS-nZJHFW~JdBm7g0wcm8G2546GPXPujIActrPiIQyjpGKPXM0tXG1w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 16

Physical activity according to different types of exercise and reduction of blood pressure and overall cardiovascular disease risk.

Priority is given to aerobic exercise training (green). BP, blood pressure; CVD, cardiovascular disease.

[Open in new tab](https://academic.oup.com/view-large/figure/479375935/ehae178f16.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f16.jpeg?Expires=1728462844&Signature=CnlLGIzk6SdgXQfdhoZYOAWarzop03mID5Ctva0mnBe~C50yg5s0UUQy5mvxc2MinMJL~MJimNqT9fHMzejjoCRvqdn0rSmEKawGZAJby7tqXNmDxex26CBEijgk7gJybo9oy0Xb15DIA4W7lcewPARZfeIB339zsdWAp9yjrtj97CJYdMS4dWmp2nl1g~mSfTxp4KdpmiXxchZ8M7h4YBEtLntkRiXfdyx4TSRVWP9bLJRNk7yJedDc1HfS54B7eVMy4gcm6Epmu0m4Xy--DCQgNbtUCUpGzCgh9bURI43s8ZoPNfnV6lPLXe1aP8xknJtmRHxIgQXQ3rehweyOSg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375935&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

![Effects of main lifestyle factors on blood pressure and cardiovascular risk reduction.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f17.jpeg?Expires=1728462844&Signature=FK-aP2Qky-gsFLmKHRcqYgsZQOeiSfYTfagaZQIEuaym2RntVPLJWVbxTfX-oT9QDlZEn6CghQ0KB~AR8TLvwWX-d59ykXzerBwPfOY~jV-FToguCcys~nmMtE4kvMk9YARf7tApXm60yYYjKXzemzq7OMba42kYhGinOLNv7F2XyuBPVQl7D8lz28f3Tn9slmCaEvfOUW31U-X43TXJxkfZ1oC80CyJP-kR9oAL5wzVsQ3fiUxd2xHEKwQWqZ-3d~m5tDhXCrrsQf3MhNdntAPbfMKl68y4QjWTDnyhKwGF2sJlxeO7t4Cv4z09c-hlKec7WPLEV7OCxicsGHdnLA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 17

Effects of main lifestyle factors on blood pressure and cardiovascular risk reduction.

BP, blood pressure; CV, cardiovascular. Smoking cessation reduces overall cardiovascular risk but not BP (long arrow). Salt reduction reduces BP and (for persons with high baseline intake) reduces cardiovascular risk. Increased potassium intake and higher physical activity, as well as optimized weight management, reduce BP and are associated with lower overall cardiovascular risk (short arrows).

[Open in new tab](https://academic.oup.com/view-large/figure/479375936/ehae178f17.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f17.jpeg?Expires=1728462844&Signature=H-bpnRL~IV4f9DErIypFFbjHP~XJjv0DG-MHq5mbQjEUayvwAzqIEm1LrC9-pGvyEup7RIvrtwiNRpwXlXvsOKJUqNa97kOaYyEQnMsNa3-AMU73lrpEDdeGDrscmjwH-Hnby6JQhovd5bsWLAQTsmy278-nBW7R9T37ZVhdKylY5XVxEKcu-w9oaFfY43T2eHommnhrspstrAbkyE5Cbsd4lRACZuLmme2C9pm2KqCRwSYrhEG6PSs97a58ovGBCxo--ibqPGrtI8-1tmlFhn-k8PiKyB2PdMAE~BhnCe-eifHLsHwSTgwdk-z04B53ruBj6AMBkkJaKBNHIeAjyw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375936&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

#### 8.2.1. Dietary sodium and potassium intake

##### 8.2.1.1. Sodium

Reducing dietary salt (sodium chloride) intake in individuals with high baseline intake lowers CVD event rates.<sup><a href="javascript:;" reveal-id="ehae178-B348" data-open="ehae178-B348" class="link link-ref link-reveal xref-bibr">348</a></sup> Extensive observational studies have reported dose–response associations between high dietary sodium intake and CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B349 ehae178-B350 ehae178-B351" data-open="ehae178-B349 ehae178-B350 ehae178-B351" class="link link-ref link-reveal xref-bibr">349–351</a></sup> The potential impact of salt reduction on population health is significant, particularly in countries where the population’s average salt intake is high. Pooled data from long-term follow-up salt-reduction trials demonstrate that reducing salt by 2.5 g/day is associated with an approximately 20% reduction in CVD events at the population level.<sup><a href="javascript:;" reveal-id="ehae178-B349" data-open="ehae178-B349" class="link link-ref link-reveal xref-bibr">349</a></sup>

The health benefits of salt reduction are likely mediated, largely, by BP-lowering effects.<sup><a href="javascript:;" reveal-id="ehae178-B352 ehae178-B353 ehae178-B354" data-open="ehae178-B352 ehae178-B353 ehae178-B354" class="link link-ref link-reveal xref-bibr">352–354</a></sup> An almost linear relationship has been described in a dose–response meta-analysis between sodium intake ranging from 0.4 to 7.6 g/day and reduction of systolic and diastolic BP is independent of baseline BP.<sup><a href="javascript:;" reveal-id="ehae178-B355" data-open="ehae178-B355" class="link link-ref link-reveal xref-bibr">355</a>,<a href="javascript:;" reveal-id="ehae178-B356" data-open="ehae178-B356" class="link link-ref link-reveal xref-bibr">356</a></sup> Women appear to be, on average, more sodium sensitive than men,<sup><a href="javascript:;" reveal-id="ehae178-B357" data-open="ehae178-B357" class="link link-ref link-reveal xref-bibr">357</a></sup> and may have greater outcome benefits when receiving comparable sodium-restricted diets.<sup><a href="javascript:;" reveal-id="ehae178-B358" data-open="ehae178-B358" class="link link-ref link-reveal xref-bibr">358</a></sup> Trial evidence for the BP-lowering benefits of salt reduction extend down to daily sodium intakes of <1.5 g/day.<sup><a href="javascript:;" reveal-id="ehae178-B356" data-open="ehae178-B356" class="link link-ref link-reveal xref-bibr">356</a>,<a href="javascript:;" reveal-id="ehae178-B358 ehae178-B359 ehae178-B360 ehae178-B361" data-open="ehae178-B358 ehae178-B359 ehae178-B360 ehae178-B361" class="link link-ref link-reveal xref-bibr">358–361</a></sup>

The task force acknowledges that the observational data linking sodium intake to CVD outcomes are mixed and that some studies have not found a link between salt intake and CVD.<sup><a href="javascript:;" reveal-id="ehae178-B362" data-open="ehae178-B362" class="link link-ref link-reveal xref-bibr">362</a>,<a href="javascript:;" reveal-id="ehae178-B363" data-open="ehae178-B363" class="link link-ref link-reveal xref-bibr">363</a></sup> In addition, a potential J-curve exists between sodium intake and CVD events (whereby some analyses suggest that sodium reduction to very low levels could be harmful).<sup><a href="javascript:;" reveal-id="ehae178-B363" data-open="ehae178-B363" class="link link-ref link-reveal xref-bibr">363</a>,<a href="javascript:;" reveal-id="ehae178-B364" data-open="ehae178-B364" class="link link-ref link-reveal xref-bibr">364</a></sup> While there are differences of opinion, the task force agreed that, on balance, (i) observational J-curve data are often due to reverse causality or confounding,<sup><a href="javascript:;" reveal-id="ehae178-B114" data-open="ehae178-B114" class="link link-ref link-reveal xref-bibr">114</a>,<a href="javascript:;" reveal-id="ehae178-B348" data-open="ehae178-B348" class="link link-ref link-reveal xref-bibr">348</a>,<a href="javascript:;" reveal-id="ehae178-B365" data-open="ehae178-B365" class="link link-ref link-reveal xref-bibr">365</a>,<a href="javascript:;" reveal-id="ehae178-B366" data-open="ehae178-B366" class="link link-ref link-reveal xref-bibr">366</a></sup> (ii) the relationship between dietary sodium and stroke is typically linear in shape, without any J-curve, (iii) if the J-curve were causal, the adverse effect of very low sodium on CVD would have to be mediated by some harmful mechanism that overcomes the expected benefit mediated by BP lowering (which is unlikely), and (iv) estimation of sodium intake using spot-urine sodium testing (which was commonly done in studies reporting a J-curve) may not be as valid as other methods.<sup><a href="javascript:;" reveal-id="ehae178-B367" data-open="ehae178-B367" class="link link-ref link-reveal xref-bibr">367</a></sup> For example, most (but not all)<sup><a href="javascript:;" reveal-id="ehae178-B362" data-open="ehae178-B362" class="link link-ref link-reveal xref-bibr">362</a></sup> reports measuring 24 h urine sodium excretion (a surrogate measure of sodium intake) have not reported a J-curve association with CVD.<sup><a href="javascript:;" reveal-id="ehae178-B350" data-open="ehae178-B350" class="link link-ref link-reveal xref-bibr">350</a>,<a href="javascript:;" reveal-id="ehae178-B364" data-open="ehae178-B364" class="link link-ref link-reveal xref-bibr">364</a></sup> Furthermore the causal evidence demonstrating reduced CVD with sodium restriction (using potassium-enriched salt substitutes) in the Salt Substitute and Stroke Study (SSaSS) and Diet, ExerCIse and carDiovascular hEalth-Salt (DECIDE-Salt) trials was compelling,<sup><a href="javascript:;" reveal-id="ehae178-B348" data-open="ehae178-B348" class="link link-ref link-reveal xref-bibr">348</a>,<a href="javascript:;" reveal-id="ehae178-B368" data-open="ehae178-B368" class="link link-ref link-reveal xref-bibr">368</a></sup> even though sodium restriction in these trials was not below 2 g/day.

It is recommended to restrict total dietary sodium intake to approximately 2 g/day or less (equivalent to approximately 5 g or about a teaspoon of salt per day). This includes added salt and salt already contained in food. While the feasibility of this sodium target can be debated, the evidence for the benefits of this sodium target among patients with elevated BP or hypertension is sufficient, particularly in terms of lowering BP. The optimal sodium intake in the general population with non-elevated BP is less clear (noting also that the BP-lowering effect of salt reduction among patients with non-elevated BP appears lower).<sup><a href="javascript:;" reveal-id="ehae178-B353" data-open="ehae178-B353" class="link link-ref link-reveal xref-bibr">353</a>,<a href="javascript:;" reveal-id="ehae178-B354" data-open="ehae178-B354" class="link link-ref link-reveal xref-bibr">354</a></sup> A more feasible compromise in the general population might be a target sodium intake range of 2–4 g/day.<sup><a href="javascript:;" reveal-id="ehae178-B369" data-open="ehae178-B369" class="link link-ref link-reveal xref-bibr">369</a>,<a href="javascript:;" reveal-id="ehae178-B370" data-open="ehae178-B370" class="link link-ref link-reveal xref-bibr">370</a></sup> It needs to be emphasized that large parts of daily sodium intake occur by means of sodium consumption contained in processed foods.

##### 8.2.1.2. Potassium

Optimal dietary potassium intake, e.g. by consuming diets rich in fruits and vegetables, has BP-lowering effects and may be associated with lower CVD risk.<sup><a href="javascript:;" reveal-id="ehae178-B348" data-open="ehae178-B348" class="link link-ref link-reveal xref-bibr">348</a>,<a href="javascript:;" reveal-id="ehae178-B364" data-open="ehae178-B364" class="link link-ref link-reveal xref-bibr">364</a>,<a href="javascript:;" reveal-id="ehae178-B368" data-open="ehae178-B368" class="link link-ref link-reveal xref-bibr">368</a>,<a href="javascript:;" reveal-id="ehae178-B371 ehae178-B372 ehae178-B373" data-open="ehae178-B371 ehae178-B372 ehae178-B373" class="link link-ref link-reveal xref-bibr">371–373</a></sup> The association between potassium intake, systolic BP, and CVD events may be sex-specific, being stronger in women.<sup><a href="javascript:;" reveal-id="ehae178-B374" data-open="ehae178-B374" class="link link-ref link-reveal xref-bibr">374</a></sup> The World Health Organization (WHO) recommends over 3.5 g/day (∼90 mmol/day) of dietary potassium.<sup><a href="javascript:;" reveal-id="ehae178-B375" data-open="ehae178-B375" class="link link-ref link-reveal xref-bibr">375</a></sup> Excessive potassium supplementation should, however, be avoided<sup><a href="javascript:;" reveal-id="ehae178-B374" data-open="ehae178-B374" class="link link-ref link-reveal xref-bibr">374</a></sup> and CKD guidelines recommend dietary potassium restriction to <2.4 g/day in persons with advanced CKD (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B376" data-open="ehae178-B376" class="link link-ref link-reveal xref-bibr">376</a></sup>

A lower urinary sodium-to-potassium ratio (Na<sup>+</sup>/K<sup>+</sup> ratio; a surrogate for reduced dietary sodium intake complemented by increased potassium intake) has been associated with a greater reduction in systolic and diastolic BP than with a higher ratio.<sup><a href="javascript:;" reveal-id="ehae178-B348" data-open="ehae178-B348" class="link link-ref link-reveal xref-bibr">348</a>,<a href="javascript:;" reveal-id="ehae178-B377" data-open="ehae178-B377" class="link link-ref link-reveal xref-bibr">377</a></sup>

In patients with hypertension and high dietary sodium, increased dietary intake of potassium (in addition to lower dietary sodium) should be considered.<sup><a href="javascript:;" reveal-id="ehae178-B348" data-open="ehae178-B348" class="link link-ref link-reveal xref-bibr">348</a>,<a href="javascript:;" reveal-id="ehae178-B350" data-open="ehae178-B350" class="link link-ref link-reveal xref-bibr">350</a>,<a href="javascript:;" reveal-id="ehae178-B378" data-open="ehae178-B378" class="link link-ref link-reveal xref-bibr">378</a></sup> In patients with persistently high sodium intake (>5 g/day) and without moderate-to-advanced CKD, particularly women, an increase in potassium intake by 0.5–1.0 g/day may be considered to achieve a favourable Na<sup>+</sup>/K<sup>+</sup> ratio of 1.5–2.0 and to reduce CVD risk. Potassium supplementation can be achieved by substituting sodium using potassium enriched salts (75% sodium chloride and 25% potassium chloride)<sup><a href="javascript:;" reveal-id="ehae178-B368" data-open="ehae178-B368" class="link link-ref link-reveal xref-bibr">368</a>,<a href="javascript:;" reveal-id="ehae178-B379" data-open="ehae178-B379" class="link link-ref link-reveal xref-bibr">379</a>,<a href="javascript:;" reveal-id="ehae178-B380" data-open="ehae178-B380" class="link link-ref link-reveal xref-bibr">380</a></sup> or by increasing dietary potassium intake \[e.g. a 125 g (medium) banana contains about 450 mg potassium, or unsalted boiled spinach (840 mg/cup) or mashed avocado (710 mg/cup)\]. In patients with CKD and/or those taking potassium-sparing medication, such as some diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) or spironolactone, serum levels of potassium should be monitored (noting that phlebotomy recommendations to avoid spuriously high potassium results should be followed).

#### 8.2.2. Physical activity and exercise

In a systematic review and meta-analyses, aerobic (endurance) exercise was suggested as the first-line exercise therapy for reducing BP in patients with elevated BP and hypertension vs. alternative forms of exercise, such as dynamic or isometric resistance training.<sup><a href="javascript:;" reveal-id="ehae178-B381" data-open="ehae178-B381" class="link link-ref link-reveal xref-bibr">381</a></sup> In patients with hypertension, regular aerobic exercise substantially lowers systolic BP by up to 7–8 mmHg and diastolic BP by up to 4–5 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B381" data-open="ehae178-B381" class="link link-ref link-reveal xref-bibr">381</a>,<a href="javascript:;" reveal-id="ehae178-B382" data-open="ehae178-B382" class="link link-ref link-reveal xref-bibr">382</a></sup> For non-white patients with hypertension, dynamic resistance training elicits BP reductions that appear comparable to aerobic exercise.<sup><a href="javascript:;" reveal-id="ehae178-B383" data-open="ehae178-B383" class="link link-ref link-reveal xref-bibr">383</a></sup> Isometric resistance training also achieves clinically relevant BP reductions in patients with hypertension, but results are inconsistent and more data from more high-quality intervention trials are required (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B381" data-open="ehae178-B381" class="link link-ref link-reveal xref-bibr">381</a>,<a href="javascript:;" reveal-id="ehae178-B384" data-open="ehae178-B384" class="link link-ref link-reveal xref-bibr">384</a>,<a href="javascript:;" reveal-id="ehae178-B385" data-open="ehae178-B385" class="link link-ref link-reveal xref-bibr">385</a></sup> With respect to mode and intensity of aerobic exercise, high-intensity interval training elicits comparable BP reductions to moderate continuous exercise, with high-intensity interval training achieving greater improvement in physical fitness.<sup><a href="javascript:;" reveal-id="ehae178-B386" data-open="ehae178-B386" class="link link-ref link-reveal xref-bibr">386</a></sup>

In patients with known hypertension, engaging in physical activity is associated with reduced CVD mortality risk vs. sedentary patients with hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B387" data-open="ehae178-B387" class="link link-ref link-reveal xref-bibr">387</a></sup>

An exaggerated BP response to exercise may yield diagnostic merits for predicting incident hypertension and CVD. In a meta-analysis, an exaggerated BP response to exercise was associated with an increased risk for masked hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B388" data-open="ehae178-B388" class="link link-ref link-reveal xref-bibr">388</a></sup> The risk of coronary heart disease also increases with higher systolic BP during exercise, independent of systolic BP at rest.<sup><a href="javascript:;" reveal-id="ehae178-B389" data-open="ehae178-B389" class="link link-ref link-reveal xref-bibr">389</a></sup>

Prior recommendations for at least 150 min/week of moderate intensity aerobic exercise (≥30 min, 5–7 days/week) can be maintained.<sup><a href="javascript:;" reveal-id="ehae178-B1" data-open="ehae178-B1" class="link link-ref link-reveal xref-bibr">1</a>,<a href="javascript:;" reveal-id="ehae178-B390" data-open="ehae178-B390" class="link link-ref link-reveal xref-bibr">390</a></sup> Alternatively, 75 min of vigorous-intensity exercise per week over 3 days may be performed, with additional benefits derived by achieving 300 min of moderate-intensity or 150 min of vigorous-intensity aerobic physical activity per week.<sup><a href="javascript:;" reveal-id="ehae178-B390" data-open="ehae178-B390" class="link link-ref link-reveal xref-bibr">390</a>,<a href="javascript:;" reveal-id="ehae178-B391" data-open="ehae178-B391" class="link link-ref link-reveal xref-bibr">391</a></sup> As acute aerobic exercise induces intensity-dependent short-term reductions in ambulatory BP after exercise, patients with elevated BP and hypertension may benefit from daily exercise to improve their 24 h BP profile and avoid BP peaks on sedentary days.<sup><a href="javascript:;" reveal-id="ehae178-B392" data-open="ehae178-B392" class="link link-ref link-reveal xref-bibr">392</a></sup> Aerobic exercise should be complemented by low- or moderate-intensity resistance training (2–3 times per week), e.g. dynamic resistance, starting at 2–3 sets of 10–15 repetitions at 40%–60% of one-repetition maximum<sup><a href="javascript:;" reveal-id="ehae178-B393" data-open="ehae178-B393" class="link link-ref link-reveal xref-bibr">393</a></sup> or isometric resistance training with three sets of 1–2 min contractions, such as hand-grip, plank, or wall sit (_[Figure 16](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae178-B381" data-open="ehae178-B381" class="link link-ref link-reveal xref-bibr">381</a>,<a href="javascript:;" reveal-id="ehae178-B394" data-open="ehae178-B394" class="link link-ref link-reveal xref-bibr">394</a></sup>

In uncontrolled hypertension at rest, high-intensity exercise should be applied with caution, with resting systolic BP of >200 mmHg and diastolic BP of >110 mmHg indicating relative contraindications.<sup><a href="javascript:;" reveal-id="ehae178-B395" data-open="ehae178-B395" class="link link-ref link-reveal xref-bibr">395</a></sup> Age, sex, gender,<sup><a href="javascript:;" reveal-id="ehae178-B396" data-open="ehae178-B396" class="link link-ref link-reveal xref-bibr">396</a></sup> ethnicity, and comorbidities, as well as individual preferences, should be considered for individual exercise prescription. Detailed information on exercise prescription in terms of frequency, intensity, time (duration) and type and progression are available in the 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease,<sup><a href="javascript:;" reveal-id="ehae178-B390" data-open="ehae178-B390" class="link link-ref link-reveal xref-bibr">390</a></sup> which include recommendations for pre-participation screening and cardiopulmonary exercise testing.<sup><a href="javascript:;" reveal-id="ehae178-B390" data-open="ehae178-B390" class="link link-ref link-reveal xref-bibr">390</a></sup>

#### 8.2.3. Weight reduction and diet

Visceral obesity is common and associated with incident hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B397" data-open="ehae178-B397" class="link link-ref link-reveal xref-bibr">397</a>,<a href="javascript:;" reveal-id="ehae178-B398" data-open="ehae178-B398" class="link link-ref link-reveal xref-bibr">398</a></sup> An average weight loss of 5 kg has been associated with an average systolic and diastolic BP reduction of 4.4 and 3.6 mmHg, respectively.<sup><a href="javascript:;" reveal-id="ehae178-B399" data-open="ehae178-B399" class="link link-ref link-reveal xref-bibr">399</a></sup> Data show that, starting at an index body mass index (BMI) of 40 kg/m<sup>2</sup>, a median weight loss of 13% is associated with a 22% lower risk for hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B400" data-open="ehae178-B400" class="link link-ref link-reveal xref-bibr">400</a>,<a href="javascript:;" reveal-id="ehae178-B401" data-open="ehae178-B401" class="link link-ref link-reveal xref-bibr">401</a></sup> Maintaining even moderate weight loss of 5%–10% of initial body weight can improve not only BP, but also glucose and lipid metabolism, and potentially reduce premature all-cause mortality.<sup><a href="javascript:;" reveal-id="ehae178-B402 ehae178-B403 ehae178-B404" data-open="ehae178-B402 ehae178-B403 ehae178-B404" class="link link-ref link-reveal xref-bibr">402–404</a></sup> However, achieving long-term effects in patients with hypertension via weight loss is challenging and the magnitude of these effects remains unclear.<sup><a href="javascript:;" reveal-id="ehae178-B405" data-open="ehae178-B405" class="link link-ref link-reveal xref-bibr">405</a>,<a href="javascript:;" reveal-id="ehae178-B406" data-open="ehae178-B406" class="link link-ref link-reveal xref-bibr">406</a></sup> Weight stabilization during middle-age appears to be an important and attainable goal to prevent obesity-related increase in BP later in life.<sup><a href="javascript:;" reveal-id="ehae178-B407" data-open="ehae178-B407" class="link link-ref link-reveal xref-bibr">407</a></sup>

Evidence-based diets, such as the Mediterranean diet and the Dietary Approaches to Stop Hypertension (DASH) diet, are established interventions in patients with hypertension to reduce their BP and CVD risk.<sup><a href="javascript:;" reveal-id="ehae178-B408" data-open="ehae178-B408" class="link link-ref link-reveal xref-bibr">408</a>,<a href="javascript:;" reveal-id="ehae178-B409" data-open="ehae178-B409" class="link link-ref link-reveal xref-bibr">409</a></sup> Additional information on healthy dietary patterns is provided in the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice and [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA).<sup><a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup>

In combination with weight-loss and exercise interventions<sup><a href="javascript:;" reveal-id="ehae178-B410" data-open="ehae178-B410" class="link link-ref link-reveal xref-bibr">410</a></sup> and low sodium intake,<sup><a href="javascript:;" reveal-id="ehae178-B411" data-open="ehae178-B411" class="link link-ref link-reveal xref-bibr">411</a></sup> the DASH diet has added effect on BP reduction.<sup><a href="javascript:;" reveal-id="ehae178-B412" data-open="ehae178-B412" class="link link-ref link-reveal xref-bibr">412</a></sup> Pharmacological treatment of obesity with orlistat achieved a slight reduction of 2.6 mmHg in systolic BP.<sup><a href="javascript:;" reveal-id="ehae178-B413" data-open="ehae178-B413" class="link link-ref link-reveal xref-bibr">413</a></sup> The greatest BP-lowering effects of weight-loss medications may be achieved with the glucagon-like peptide 1 (GLP-1) receptor agonists.<sup><a href="javascript:;" reveal-id="ehae178-B414 ehae178-B415 ehae178-B416" data-open="ehae178-B414 ehae178-B415 ehae178-B416" class="link link-ref link-reveal xref-bibr">414–416</a></sup> For example, in the Semaglutide Treatment Effect in People with Obesity (STEP-1) trial, the GLP-1 analogue semaglutide resulted in a mean weight reduction of 12.4% and a 5.1 mmHg reduction in systolic BP.<sup><a href="javascript:;" reveal-id="ehae178-B415" data-open="ehae178-B415" class="link link-ref link-reveal xref-bibr">415</a></sup>

#### 8.2.4. Alcohol, coffee, and soft drinks

In a 2020 Cochrane review, the short-term effects of alcohol on BP were dose dependent; low-dose alcohol (<14 g) did not affect BP within 6 h, medium-dose (14–28 g) decreased both systolic and diastolic BP, and high-dose alcohol (>30 g) first decreased BP up to 12 h and then increased BP following >13 h of consumption by 3.7 mmHg systolic and 2.4 mmHg diastolic.<sup><a href="javascript:;" reveal-id="ehae178-B417" data-open="ehae178-B417" class="link link-ref link-reveal xref-bibr">417</a></sup> The trials in this Cochrane review included small numbers of women. In the longer term, no evidence has been found for a protective effect of chronic alcohol consumption on hypertension, for either sex. In contrast, even low-dose alcohol consumption (10 g/day) increases chronic risk of hypertension by 14% in men, but not in women.<sup><a href="javascript:;" reveal-id="ehae178-B418" data-open="ehae178-B418" class="link link-ref link-reveal xref-bibr">418</a></sup> As per the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice, men and women are recommended to stay within the upper limit of drinking alcoholic beverages (100 g/week of pure alcohol). Defining number of drinks depends on portion size, the standards of which differ per country, but translates to 8–14 g/drink.<sup><a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup> Emerging data indicate it is likely healthiest to avoid all alcohol, where possible.<sup><a href="javascript:;" reveal-id="ehae178-B419" data-open="ehae178-B419" class="link link-ref link-reveal xref-bibr">419</a></sup>

Coffee intake is not associated with a higher risk of hypertension in the general population; in fact, higher coffee consumption may be associated with a lower risk for incident hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B420" data-open="ehae178-B420" class="link link-ref link-reveal xref-bibr">420</a></sup> Data regarding the association between tea drinking and CVD are inconclusive, though mechanistic trials have suggested benefits on BP lowering.<sup><a href="javascript:;" reveal-id="ehae178-B421" data-open="ehae178-B421" class="link link-ref link-reveal xref-bibr">421</a></sup> In contrast, energy drinks with high concentrations of ingredients such as taurine and caffeine increase BP and may lead to acute or chronic cardiovascular complications in young adults.<sup><a href="javascript:;" reveal-id="ehae178-B422 ehae178-B423 ehae178-B424" data-open="ehae178-B422 ehae178-B423 ehae178-B424" class="link link-ref link-reveal xref-bibr">422–424</a></sup>

Consuming two or more servings per day of sugar-sweetened beverages was associated with a 35% higher risk of coronary artery disease in women in the Nurses’ Health Study.<sup><a href="javascript:;" reveal-id="ehae178-B425" data-open="ehae178-B425" class="link link-ref link-reveal xref-bibr">425</a></sup> In the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, both sugar- and artificially sweetened soft drinks were associated with higher all-cause mortality.<sup><a href="javascript:;" reveal-id="ehae178-B426" data-open="ehae178-B426" class="link link-ref link-reveal xref-bibr">426</a></sup> In children and adolescents, sugar-sweetened beverages increased systolic BP and the risk for incident hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B427" data-open="ehae178-B427" class="link link-ref link-reveal xref-bibr">427</a></sup> It is recommended to restrict free sugar consumption, in particular sugar-sweetened beverages, to a maximum of 10% of energy intake.

#### 8.2.5. Smoking

To stop smoking is arguably the most effective measure in preventing major CVD events at the individual level, likely through improved vascular health.<sup><a href="javascript:;" reveal-id="ehae178-B428 ehae178-B429 ehae178-B430 ehae178-B431" data-open="ehae178-B428 ehae178-B429 ehae178-B430 ehae178-B431" class="link link-ref link-reveal xref-bibr">428–431</a></sup> Estimated health benefits will be even more substantial looking at all-cause morbidity and mortality, e.g. including smoking cessation for cancer prevention.

The effects of electronic cigarettes (e-cigarettes) on BP remain unclear and to date there are no robust outcomes data. However, growing evidence suggests that e-cigarettes can increase BP (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B432" data-open="ehae178-B432" class="link link-ref link-reveal xref-bibr">432</a>,<a href="javascript:;" reveal-id="ehae178-B433" data-open="ehae178-B433" class="link link-ref link-reveal xref-bibr">433</a></sup>

Among adults, smoking affects ambulatory BP by raising daily BP,<sup><a href="javascript:;" reveal-id="ehae178-B434" data-open="ehae178-B434" class="link link-ref link-reveal xref-bibr">434</a></sup> but effects of chronic smoking on office BP appear to be small.<sup><a href="javascript:;" reveal-id="ehae178-B435" data-open="ehae178-B435" class="link link-ref link-reveal xref-bibr">435</a></sup> Smoking cessation advice helps, but more intensive interventions are superior.<sup><a href="javascript:;" reveal-id="ehae178-B436" data-open="ehae178-B436" class="link link-ref link-reveal xref-bibr">436</a>,<a href="javascript:;" reveal-id="ehae178-B437" data-open="ehae178-B437" class="link link-ref link-reveal xref-bibr">437</a></sup> As recommended by previous ESC Guidelines, smoking cessation is recommended to reduce CVD risk and improve non-CVD health.<sup><a href="javascript:;" reveal-id="ehae178-B1" data-open="ehae178-B1" class="link link-ref link-reveal xref-bibr">1</a>,<a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup>

Recommendation Table 15

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375965)

Recommendations for non-pharmacological treatment of blood pressure and cardiovascular risk reduction (see Evidence Tables 22–26)

![Recommendations for non-pharmacological treatment of blood pressure and cardiovascular risk reduction (see Evidence Tables 22–26)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt15.jpeg?Expires=1728462844&Signature=C3~W0a8CE1JbRc03OCvOmuncFYsOYufN1NKvhJCzjSNBBMRCDgbZNtxhnuYb3JMv28x1Za--WOM-DzsGGzBKSciEikkveo7jS0lzpaV7l5VA899Y4-D6vX38utBgBxN7OfpsgF~Fm2SqxpeFFxnwVr0x1lMvjL3aUD7rEtisE~lMi61BlTj~ic3dBxTDhGxDT4htSmBZhTA0j0a9zEq1ylVd4KUJItoukxSofLPFwr3JC-tFpwZpnBZ3j6buTl8sFHfk2~Z~1Svst8ORDIry36gEafXBwYDjTIByH6koRia1zexcDFB0mDZSSkHf9kvzJF-PCRLIqQEIcHyzspi7AQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 8.3. Pharmacological interventions

#### 8.3.1. Treatment strategy to reduce adverse cardiovascular disease outcomes

The main goal of reducing BP is to prevent adverse CVD outcomes. The relative risk reduction afforded by a fixed degree of BP reduction is largely independent of pre-treatment BP.<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a></sup> There is a clear relationship between the intensity of BP lowering and the relative and absolute reduction in risk of CVD events for all adults, regardless of age (at least up to 85 years), sex, prior CVD, diabetes, or AF.<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a>,<a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a>,<a href="javascript:;" reveal-id="ehae178-B443 ehae178-B444 ehae178-B445" data-open="ehae178-B443 ehae178-B444 ehae178-B445" class="link link-ref link-reveal xref-bibr">443–445</a></sup> With this strong evidence for the ‘the lower the better, but within reason’ paradigm, decision rules are required for selecting patients most likely to benefit from treatment.<sup><a href="javascript:;" reveal-id="ehae178-B172" data-open="ehae178-B172" class="link link-ref link-reveal xref-bibr">172</a></sup> In this section, a summary of evidence for BP-lowering drug treatment is provided, followed by strategies for their use for preventing CVD.

#### 8.3.2. Drug classes with evidence on clinical outcomes in the target population

The major drug classes with robust evidence for BP-mediated reduction in CVD events are ACE inhibitors, ARBs, dihydropyridine CCBs, diuretics (thiazides and thiazide-like diuretics such as hydrochlorothiazide, chlorthalidone, and indapamide), and beta-blockers (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Tables S7](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[S8](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><a href="javascript:;" reveal-id="ehae178-B122" data-open="ehae178-B122" class="link link-ref link-reveal xref-bibr">122</a>,<a href="javascript:;" reveal-id="ehae178-B446" data-open="ehae178-B446" class="link link-ref link-reveal xref-bibr">446</a>,<a href="javascript:;" reveal-id="ehae178-B447" data-open="ehae178-B447" class="link link-ref link-reveal xref-bibr">447</a></sup> The first four are recommended as first-line options for starting hypertension treatment in the general population. Beta-blockers can be added preferentially in circumstances such as in the presence of angina or heart failure, after myocardial infarction, or for controlling heart rate, where they are the cornerstone of therapy.<sup><a href="javascript:;" reveal-id="ehae178-B122" data-open="ehae178-B122" class="link link-ref link-reveal xref-bibr">122</a>,<a href="javascript:;" reveal-id="ehae178-B448" data-open="ehae178-B448" class="link link-ref link-reveal xref-bibr">448</a>,<a href="javascript:;" reveal-id="ehae178-B449" data-open="ehae178-B449" class="link link-ref link-reveal xref-bibr">449</a></sup> In such settings, second-generation (cardioselective) and, specifically, third-generation (vasodilating) beta-blockers are preferred.<sup><a href="javascript:;" reveal-id="ehae178-B450" data-open="ehae178-B450" class="link link-ref link-reveal xref-bibr">450</a></sup> However, beta-blockers are less effective than ACE inhibitors, ARBs, CCBs, or diuretics at preventing stroke, and have a higher discontinuation rate due to side effects.<sup><a href="javascript:;" reveal-id="ehae178-B451" data-open="ehae178-B451" class="link link-ref link-reveal xref-bibr">451</a>,<a href="javascript:;" reveal-id="ehae178-B452" data-open="ehae178-B452" class="link link-ref link-reveal xref-bibr">452</a></sup> Beta-blockers and diuretics, especially when combined, are associated with an increased risk of new-onset diabetes in predisposed patients.<sup><a href="javascript:;" reveal-id="ehae178-B453" data-open="ehae178-B453" class="link link-ref link-reveal xref-bibr">453</a>,<a href="javascript:;" reveal-id="ehae178-B454" data-open="ehae178-B454" class="link link-ref link-reveal xref-bibr">454</a></sup> The effect of RAS blockers and CCBs on preventing progression of HMOD also appears to be superior to beta-blockers.<sup><a href="javascript:;" reveal-id="ehae178-B455 ehae178-B456 ehae178-B457 ehae178-B458" data-open="ehae178-B455 ehae178-B456 ehae178-B457 ehae178-B458" class="link link-ref link-reveal xref-bibr">455–458</a></sup> Beta-blockers should also be avoided in patients with isolated systolic hypertension or more generally with arterial stiffness, as they increase stroke volume (given the lower heart rate).<sup><a href="javascript:;" reveal-id="ehae178-B218" data-open="ehae178-B218" class="link link-ref link-reveal xref-bibr">218</a></sup>

When therapy and adherence with the above-mentioned drug classes is optimized but insufficient to reach BP goals, other drug classes can be used for treating hypertension. Of these, spironolactone, an MRA, appears to be the most effective at further lowering BP in resistant hypertension; however, more evidence of CVD risk-lowering effects with MRAs among all hypertensive populations, especially those without resistant hypertension, is needed.<sup><a href="javascript:;" reveal-id="ehae178-B459" data-open="ehae178-B459" class="link link-ref link-reveal xref-bibr">459</a></sup> Specifically, while use of MRAs in patients with heart failure has provided clinical evidence on the effectiveness of MRAs for preventing CVD events, dedicated outcome trials in patients with primary hypertension without heart failure are lacking. Because the present guidelines require trial evidence for CVD outcome benefit for a BP-lowering drug or procedure to achieve a Class I recommendation, and given no outcome trials of MRAs have been conducted in general samples of patients with primary hypertension, we have given MRAs a Class IIa recommendation (see below). We acknowledge that spironolactone was provided a Class I recommendation in the 2018 ESC/ESH Guidelines on the management of arterial hypertension. However, to be consistent with our requirement for trial evidence for CVD outcomes benefit in patients with hypertension, the task force agreed to provide a Class IIa recommendation for spironolactone in these 2024 Guidelines. Importantly, it was also agreed that a Class IIa recommendation (i.e. should be considered) is an endorsement of MRAs for treating resistant hypertension but one that acknowledges some uncertainty of outcomes benefit. Future outcome trials of MRAs, perhaps including finerenone,<sup><a href="javascript:;" reveal-id="ehae178-B460 ehae178-B461 ehae178-B462" data-open="ehae178-B460 ehae178-B461 ehae178-B462" class="link link-ref link-reveal xref-bibr">460–462</a></sup> are encouraged in patients with hypertension.

Clinical outcome evidence from trials for other BP-lowering drug classes, such as alpha-blockers, hydralazine, minoxidil, other potassium-sparing diuretics, and centrally acting agents, is less compelling and caution regarding adverse effects is warranted. However, they may be a final addition if all other therapeutic efforts are insufficient to decrease BP. Of note, in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) trial, the alpha-blocker arm was stopped early due to futility of benefit for the CVD outcome.<sup><a href="javascript:;" reveal-id="ehae178-B463" data-open="ehae178-B463" class="link link-ref link-reveal xref-bibr">463</a></sup>

#### 8.3.3. New therapies with blood pressure-lowering properties that await supportive evidence from cardiovascular outcomes trials prior to guideline endorsement and routine use in hypertension

A few other drug classes with indication in heart failure have emerged that also have BP-lowering properties. For example, the angiotensin receptor–neprilysin inhibitor (ARNi) sacubitril/valsartan, which was initially developed for hypertension,<sup><a href="javascript:;" reveal-id="ehae178-B464" data-open="ehae178-B464" class="link link-ref link-reveal xref-bibr">464</a></sup> reduces CVD mortality and morbidity in patients with heart failure, an effect that may have been mediated, in part, by superior BP lowering compared with enalapril alone.<sup><a href="javascript:;" reveal-id="ehae178-B465" data-open="ehae178-B465" class="link link-ref link-reveal xref-bibr">465</a>,<a href="javascript:;" reveal-id="ehae178-B466" data-open="ehae178-B466" class="link link-ref link-reveal xref-bibr">466</a></sup> In a _post hoc_ subgroup analysis, sacubitril/valsartan lowered BP in adults with both heart failure with preserved ejection fraction (HFpEF) and resistant hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B467" data-open="ehae178-B467" class="link link-ref link-reveal xref-bibr">467</a></sup> In the context of research studies, sacubitril/valsartan has been used in higher doses (200 mg or 400 mg once daily) for treating hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B464" data-open="ehae178-B464" class="link link-ref link-reveal xref-bibr">464</a>,<a href="javascript:;" reveal-id="ehae178-B466" data-open="ehae178-B466" class="link link-ref link-reveal xref-bibr">466</a>,<a href="javascript:;" reveal-id="ehae178-B468" data-open="ehae178-B468" class="link link-ref link-reveal xref-bibr">468</a>,<a href="javascript:;" reveal-id="ehae178-B469" data-open="ehae178-B469" class="link link-ref link-reveal xref-bibr">469</a></sup>

SGLT2 inhibitors have shown favourable effects on CVD events and renal haemodynamics in patients with and without type 2 diabetes, and in heart failure trials.<sup><a href="javascript:;" reveal-id="ehae178-B470" data-open="ehae178-B470" class="link link-ref link-reveal xref-bibr">470</a></sup> In these trials, SGLT2 inhibitors did lower BP, though only modestly.<sup><a href="javascript:;" reveal-id="ehae178-B471" data-open="ehae178-B471" class="link link-ref link-reveal xref-bibr">471</a></sup> Small trials among adults with hypertension have confirmed the potential for BP lowering with this drug class.<sup><a href="javascript:;" reveal-id="ehae178-B472" data-open="ehae178-B472" class="link link-ref link-reveal xref-bibr">472</a>,<a href="javascript:;" reveal-id="ehae178-B473" data-open="ehae178-B473" class="link link-ref link-reveal xref-bibr">473</a></sup>

Other new drugs with preliminary data include GLP-1 agonists and the new non-steroidal MRAs, e.g. finerenone, in managing hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B415" data-open="ehae178-B415" class="link link-ref link-reveal xref-bibr">415</a>,<a href="javascript:;" reveal-id="ehae178-B460" data-open="ehae178-B460" class="link link-ref link-reveal xref-bibr">460</a>,<a href="javascript:;" reveal-id="ehae178-B461" data-open="ehae178-B461" class="link link-ref link-reveal xref-bibr">461</a></sup> In addition, novel aldosterone synthase inhibitors (baxdrostat and lorundrostat) have significantly lowered BP in patients with uncontrolled hypertension in phase 2 trials.<sup><a href="javascript:;" reveal-id="ehae178-B474" data-open="ehae178-B474" class="link link-ref link-reveal xref-bibr">474</a>,<a href="javascript:;" reveal-id="ehae178-B475" data-open="ehae178-B475" class="link link-ref link-reveal xref-bibr">475</a></sup>

The dual endothelin-A and -B receptor antagonist aprocitentan also reduced office and 24 h BP compared with placebo at 4 weeks in patients with resistant hypertension in a phase 3 trial.<sup><a href="javascript:;" reveal-id="ehae178-B476" data-open="ehae178-B476" class="link link-ref link-reveal xref-bibr">476</a></sup> Zilebesiran, an investigational RNA interference agent administered subcutaneously, inhibits hepatic angiotensinogen synthesis and a single dose reduced 24 h BP over approximately 6 months.<sup><a href="javascript:;" reveal-id="ehae178-B477" data-open="ehae178-B477" class="link link-ref link-reveal xref-bibr">477</a></sup>

#### 8.3.4. Drug combinations and up-titrating strategies

To treat hypertension, many patients will require more than one BP-lowering medication. Combining drugs from different drug classes can have additive or synergistic effects and lead to greater BP reduction than increasing the dose of one drug.<sup><a href="javascript:;" reveal-id="ehae178-B478 ehae178-B479 ehae178-B480 ehae178-B481 ehae178-B482 ehae178-B483" data-open="ehae178-B478 ehae178-B479 ehae178-B480 ehae178-B481 ehae178-B482 ehae178-B483" class="link link-ref link-reveal xref-bibr">478–483</a></sup> The superior BP-lowering efficacy of combination therapy is mediated, at least in part, by the potential of combination therapy to target multiple pathophysiological pathways contributing to perturbed BP in each patient.<sup><a href="javascript:;" reveal-id="ehae178-B484" data-open="ehae178-B484" class="link link-ref link-reveal xref-bibr">484</a></sup> A further benefit of combination therapy is the potential to use lower doses of each individual BP-lowering agent, which may reduce side effects and improve adherence and persistence,<sup><a href="javascript:;" reveal-id="ehae178-B485" data-open="ehae178-B485" class="link link-ref link-reveal xref-bibr">485</a></sup> though the evidence for this hypothesis has been questioned.<sup><a href="javascript:;" reveal-id="ehae178-B486" data-open="ehae178-B486" class="link link-ref link-reveal xref-bibr">486</a></sup>

Upfront low-dose combination therapy is therefore recommended in persons with hypertension, with the potential advantages of fewer side effects and swifter BP control being important for long-term adherence.<sup><a href="javascript:;" reveal-id="ehae178-B487 ehae178-B488 ehae178-B489" data-open="ehae178-B487 ehae178-B488 ehae178-B489" class="link link-ref link-reveal xref-bibr">487–489</a></sup> If combination BP-lowering therapy is pursued, single-pill combinations are preferred. For those with elevated BP who have an indication for BP-lowering treatment, monotherapy is recommended in the first instance.

One caveat to combination therapy in hypertension is that patient-level response to individual BP-lowering drug classes can be heterogeneous (suggesting some patients may benefit from more personalized treatment compared with routine combinations).<sup><a href="javascript:;" reveal-id="ehae178-B490" data-open="ehae178-B490" class="link link-ref link-reveal xref-bibr">490</a></sup> This is relevant also with respect to race/ethnicity (see _Section [9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_). Another caveat is that the evidence for reduced CVD outcomes with BP-lowering drugs in combination therapy is based on observational studies.<sup><a href="javascript:;" reveal-id="ehae178-B491 ehae178-B492 ehae178-B493" data-open="ehae178-B491 ehae178-B492 ehae178-B493" class="link link-ref link-reveal xref-bibr">491–493</a></sup> There are no outcomes data from prospective trials that prove superiority of upfront combination therapy (either as single-pill combinations or as separate pills) over upfront monotherapy in the isolated treatment of hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B486" data-open="ehae178-B486" class="link link-ref link-reveal xref-bibr">486</a></sup> Therefore, we considered giving upfront combination therapy (either as separate pills or as single-pill combinations) a Class IIa recommendation in these guidelines. However, given the totality of evidence for outcomes benefit in observational studies, randomized trial data for better BP control and adherence, and importantly, also given CVD outcomes benefit for polypills (a form of single-pill combination) in randomized trials,<sup><a href="javascript:;" reveal-id="ehae178-B494 ehae178-B495 ehae178-B496" data-open="ehae178-B494 ehae178-B495 ehae178-B496" class="link link-ref link-reveal xref-bibr">494–496</a></sup> we chose to provide a Class I recommendation for upfront combination therapy in adults with confirmed hypertension, in agreement with 2018 ESC recommendations.

The major four drug classes (ACE inhibitors, ARBs, dihydropyridine CCBs, and thiazide or thiazide-like diuretics) are recommended as first-line BP-lowering medications, either alone or in combination.<sup><a href="javascript:;" reveal-id="ehae178-B122" data-open="ehae178-B122" class="link link-ref link-reveal xref-bibr">122</a>,<a href="javascript:;" reveal-id="ehae178-B447" data-open="ehae178-B447" class="link link-ref link-reveal xref-bibr">447</a>,<a href="javascript:;" reveal-id="ehae178-B484" data-open="ehae178-B484" class="link link-ref link-reveal xref-bibr">484</a>,<a href="javascript:;" reveal-id="ehae178-B497" data-open="ehae178-B497" class="link link-ref link-reveal xref-bibr">497</a></sup> An exception is the combination of two RAS blockers, which is not recommended.<sup><a href="javascript:;" reveal-id="ehae178-B498 ehae178-B499 ehae178-B500" data-open="ehae178-B498 ehae178-B499 ehae178-B500" class="link link-ref link-reveal xref-bibr">498–500</a></sup> For most hypertensive patients, a single-pill combination, initially containing two of these major drug classes, and initially at low dose, is recommended.<sup><a href="javascript:;" reveal-id="ehae178-B489" data-open="ehae178-B489" class="link link-ref link-reveal xref-bibr">489</a>,<a href="javascript:;" reveal-id="ehae178-B501" data-open="ehae178-B501" class="link link-ref link-reveal xref-bibr">501</a>,<a href="javascript:;" reveal-id="ehae178-B502" data-open="ehae178-B502" class="link link-ref link-reveal xref-bibr">502</a></sup> Doses of BP-lowering drugs are presented in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Tables S7](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[S8](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_.

When BP is still uncontrolled under maximally tolerated triple-combination (RAS blocker, CCB, and diuretic) therapy, and after adherence is assessed, the patient should be considered resistant and referred to an expert centre for appropriate work-up (see _Section [7.5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6.5)_). At the same time, the addition of spironolactone should be considered.<sup><a href="javascript:;" reveal-id="ehae178-B459" data-open="ehae178-B459" class="link link-ref link-reveal xref-bibr">459</a></sup> If spironolactone is not tolerated, eplerenone or other MRA, or beta-blockers (if not already indicated), should be considered. Eplerenone may need to be dosed higher (50–200 mg) for effective BP lowering. In a meta-analysis, eplerenone 25 mg did not lower BP.<sup><a href="javascript:;" reveal-id="ehae178-B503" data-open="ehae178-B503" class="link link-ref link-reveal xref-bibr">503</a></sup> Due to the shorter time of action than spironolactone, eplerenone may need to be administered twice daily for treating hypertension. An alternative to MRA as fourth-line treatment for BP lowering is the use of beta-blockers for persons who do not already have a compelling indication. A vasodilating beta-blocker (e.g. labetalol, carvedilol, or nebivolol) is preferred when a beta-blocker is chosen.<sup><a href="javascript:;" reveal-id="ehae178-B504" data-open="ehae178-B504" class="link link-ref link-reveal xref-bibr">504</a></sup> However, we note that the BP-lowering effects of beta-blockade appears to be less potent than spironolactone in the setting of resistant hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B459" data-open="ehae178-B459" class="link link-ref link-reveal xref-bibr">459</a></sup>

Only thereafter should hydralazine, other potassium-sparing diuretics (amiloride and triamterene), centrally acting BP-lowering medications, or alpha-blockers be considered. Given multiple side-effects, minoxidil should only be considered if all other pharmacological agents prove ineffective in resistant hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B505" data-open="ehae178-B505" class="link link-ref link-reveal xref-bibr">505</a></sup>

As noted above, polypills combining fixed doses of BP-lowering treatment, lipid-lowering therapy and, if indicated, aspirin are effective in more general CVD prevention.<sup><a href="javascript:;" reveal-id="ehae178-B496" data-open="ehae178-B496" class="link link-ref link-reveal xref-bibr">496</a>,<a href="javascript:;" reveal-id="ehae178-B506 ehae178-B507 ehae178-B508 ehae178-B509" data-open="ehae178-B506 ehae178-B507 ehae178-B508 ehae178-B509" class="link link-ref link-reveal xref-bibr">506–509</a></sup> However, the polypill is not available for routine clinical use in many European countries.

#### 8.3.5. A practical algorithm for intensive, effective, and tolerable blood pressure lowering with drug therapy, including considerations around single-pill combinations

The aim of the algorithm in _[Figure 18](javascript:;)_ is to introduce a low-dose double- and then triple-combination strategy while monitoring tolerance among patients with hypertension, and only afterwards to start up-titrating doses to maximum amounts.

![Practical algorithm for pharmacological blood pressure lowering.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f18.jpeg?Expires=1728462844&Signature=2KNQj2adxGPNI4m7Wd7obTBu~7FiQKHjXH4QXA~CNK6Ti5-6LClOzNzRxeYkYyJSXzNaUZTgPHTqzAvG0HBHNu4AUEFMyzr0o1dVksavHjM9ghT4Fh3FRX4Xanrd089OevO4D4gHSeTKyWC70gReY~YvIeLQTnOIjWusnBGYzzeIK3Sr0bWF5kRMxRUmBidBeKSLShN-q6heN7FxkrtpsO1RfzZnCh3k2hiOy-Xy~iqFmROG~2TqcRoF7gNyFXiunNRkD1lrKDMSwXsJYxNnctNmdwG~jiY4LxAng5EYg51~RKbnjwP7~n~Q1Fvk1UmvyvzbaZJ~mLtiUlOdnbC~TA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 18

Practical algorithm for pharmacological blood pressure lowering.

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker; FU, follow-up.

[Open in new tab](https://academic.oup.com/view-large/figure/479375988/ehae178f18.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f18.jpeg?Expires=1728462844&Signature=D1cS58AvkVl5PygtESQNf48sL9GEtPql442uHFhLTTsfJCMjZDZf19T0riidIgbJ0czQ0-hAGxGOprBhxjLiFX4BSQJoV78AjLGq4XoHrS3F7zW7EH3b6zl7qvBg9g4bLUvTOMgdYRUggYC8xNQ-S7LrSXVtHa3jMxuvwbkRGbtBYxqN2V-adSJb5zRh~ff3sF4Idlkv9XDJD5gyAWQpHvnQVx14PS9WNT6mT8APqGfHuw-ZvXmPqnE6F~INGQvVv8Uu0vUaS4hk4J-eYFlx5UdxtRDOi0UyZvB4cFAP~W3HwBPEfZFzzJGo8K~ypYpKrmDsqvRV4rO7RE9kRWo2Ng__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375988&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Initiation with monotherapy, slower up-titration, and lower dosing should be considered in the setting of elevated BP and increased CVD risk, or in moderate-to-severe frailty, limited life expectancy, symptomatic orthostatic hypotension, or older people (aged ≥85 years). Ideally, BP should be treated to target within 3 months to retain the confidence of the patient, to ensure long-term adherence, and to reduce CVD risk.<sup><a href="javascript:;" reveal-id="ehae178-B71" data-open="ehae178-B71" class="link link-ref link-reveal xref-bibr">71</a></sup>

An overview of the recommended approach to BP management in all adult patients is provided in _[Figure 19](javascript:;)_ (Central Illustration). Also, of note, teleconsultation, multidisciplinary or nurse-led care, or patient self-monitoring can help with achieving BP control in certain healthcare systems.<sup><a href="javascript:;" reveal-id="ehae178-B75" data-open="ehae178-B75" class="link link-ref link-reveal xref-bibr">75</a>,<a href="javascript:;" reveal-id="ehae178-B510" data-open="ehae178-B510" class="link link-ref link-reveal xref-bibr">510</a>,<a href="javascript:;" reveal-id="ehae178-B511" data-open="ehae178-B511" class="link link-ref link-reveal xref-bibr">511</a></sup>

![Central Illustration.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f19.jpeg?Expires=1728462844&Signature=fd2UxUVZPjy4yRnbvL2bRZY4mgexTYvU3f2WaEzqqxv~0aOljojNaQse4~stOMrvj-lMLOp02gLntJA3kPHEFjTs6t-5e0PlLHxEw6OorZSVwU~ncyl9u2MixNGvuaLQuEVHWndnFAwnb1ZgOawzy1qnMsUMqdKl7UDd-PReKwcxSdlCj8zt1iXbXWu8pqZjMT6cwjvTWFpJHe3T9lnyJgO~0zb~SqTgMuQ-3T1NeEpAy1rA0z4ZH0-19QFcyaEbzz~F7NL-HTfhs-rwB8KmD-yqoJxBx-d4kDIRenkVzUGhVSqyRa6ipinFUZn~4-HlQG14IG14tuVvnULqW2wDVQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 19

Central Illustration.

ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CVD, cardiovascular disease; CKD, chronic kidney disease; DBP, diastolic blood pressure; HBPM, home blood pressure monitoring; OH, orthostatic hypotension; SBP, systolic blood pressure; SCORE2, Systematic COronary Risk Evaluation 2; SCORE2-OP, Systematic COronary Risk Evaluation 2–Older Persons. Summary algorithm for BP classification and management. See _Section [5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4)_ for recommendations on out-of-office confirmation of the three BP categories. <sup>a</sup>Adults with type 2 diabetes mellitus only and younger than 60 years should be considered for SCORE2-Diabetes assessment. <sup>b</sup>Though scientific data demonstrate that, under research conditions, the optimal target BP is ≤120/70 mmHg, the target BP recommended by these guidelines in routine practice is 120–129/70–79 mmHg. If achieving this target is not possible, or if treatment is not well tolerated, then BP should be treated to as low as reasonably achievable. For persons with elevated BP, treatment with lifestyle measures for 3 months is first recommended, prior to considering medications.

[Open in new tab](https://academic.oup.com/view-large/figure/479375991/ehae178f19.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f19.jpeg?Expires=1728462844&Signature=u9oN6lnEXVtVytTsdCC6LW2Gs-PsiynaW0LqD1wvCEJGXchoM3wNZtJQpZd6A9QWb3IPA3SXogMzFAahiXWuxurcHDsQhZNN9EhTTKbZlNt-xAOdBSJJGNuDvWYN~ra90ZHPenOxZq4mcm5hoGLWT0o6tCOawAhCBgK7Tv1Pk1XgfDOfc~w1FSSMsyJjlhhJQeabGh~0KjuXMZpN8ge2DeiLaPyK3D8CZiM1vn3OWk6nVDRFAYWbW2r0oK8-heGIzCkL-7OtYw8x~7cRCvogWM4ZjYNK6WMun60gSbs2lbATSwZmuI8GHgVyVISRiaUgPlYnyvhCO~1uRfuY~adv7w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375991&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

#### 8.3.6. Timing of blood pressure-lowering drug treatment

Current evidence does not show benefit of diurnal timing of BP-lowering drug administration on major CVD outcomes.<sup><a href="javascript:;" reveal-id="ehae178-B512" data-open="ehae178-B512" class="link link-ref link-reveal xref-bibr">512</a></sup> It is important that medication is taken at the most convenient time of day to improve adherence. Patients should also be encouraged to take medications at the same time each day and in a consistent setting, to help ensure adherence.<sup><a href="javascript:;" reveal-id="ehae178-B246" data-open="ehae178-B246" class="link link-ref link-reveal xref-bibr">246</a>,<a href="javascript:;" reveal-id="ehae178-B513" data-open="ehae178-B513" class="link link-ref link-reveal xref-bibr">513</a></sup>

Recommendation Table 16

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375994)

Recommendations for pharmacological treatment of hypertension (see Evidence Tables 27, 28, and 29)

![Recommendations for pharmacological treatment of hypertension (see Evidence Tables 27, 28, and 29)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt16.jpeg?Expires=1728462844&Signature=llkC13seG1jrw3kgayghPjoH6eJ2rDa~Ms5IsN5HPJoGg~lVh9Ijo6mZaQugbUV5j4J3b8M5ghkTM7yQ4lTotbh8HdseAKPyma6etpW7iFp2jzaNWi8~jAxEKI2PZ~Bz6n2yTwhmvhBZDYr4864QnYmnokLTNrsZxhA6b9DuFnntkl8RtnJIX6znnbi1AJ3PMuMeGLKBe5XMGuu0vExzE4ZHUMO-Tn~UBXLUlxrlK7EJXOXaeWl9qyBCW9rE0ts5Y~xRgn0iy6A42kCg~nMbnYVj1mc-nLv~clnufzgqT382LqobbEoOV~WPneGHlLMKttywUHhjLv1Fk646grgCYw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 8.4. Selecting patients for pharmacological blood pressure-lowering treatment

Commencement of BP-lowering treatment is often decided based on office BP measurements but, where possible, the present guidelines strongly recommend using out-of-office BP measurement for confirming elevated BP and hypertension (see _Section [5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4))_. As detailed in _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_, an office BP of <120/70 mmHg is categorized in these guidelines as non-elevated BP.

When a patient is diagnosed with confirmed hypertension (sustained BP ≥ 140/90 mmHg), starting BP-lowering treatment is recommended irrespective of CVD risk, which should consist of a simultaneous combination of lifestyle interventions and pharmacological therapy. Lifestyle interventions are crucial as an initial treatment step, and must be strongly emphasized with the patient, but concurrent pharmacological therapy is recommended. This concurrent initiation of lifestyle and pharmacological therapy should not give patients the impression that lifestyle changes are of lesser importance, and the patient should be counselled that these lifestyle changes may allow subsequent discontinuation or down-titration of medication, which can be used as motivation to persist with lifestyle changes. After treatment initiation, the patient should be seen frequently (e.g. every 1–3 months with a GP or specialist) until BP is controlled. BP should be controlled, preferably within 3 months (see also _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_ and algorithm _[Figure 18](javascript:;)_). If lifestyle changes are effective in BP lowering, pharmacological treatments may subsequently be down-titrated or stopped as appropriate.

When office BP is 120–139/70–89 mmHg, the patient is considered as having elevated BP, and further CVD risk stratification is recommended to guide therapy (_[Table 14](javascript:;)_).

-   In patients with elevated BP who are not at increased risk for CVD (10-year CVD risk <10%) and do not have other high-risk conditions or risk modifiers, BP-lowering lifestyle measures are recommended. While there are not enough outcomes data for a drug recommendation in lower CVD risk adults with elevated BP, there is some evidence to suggest that relative treatment effects of BP lowering are similar across a wide range of predicted risk categories, including among those with a <10% risk.<sup><a href="javascript:;" reveal-id="ehae178-B518" data-open="ehae178-B518" class="link link-ref link-reveal xref-bibr">518</a></sup> Therefore, while we do not provide a formal recommendation for this, if initial lifestyle measures are not successful after 6–12 months, drug treatment might be discussed on an individual basis among lower CVD-risk adults when BP is between 130/80 and <140/90 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B518" data-open="ehae178-B518" class="link link-ref link-reveal xref-bibr">518</a></sup>
    
-   In patients with elevated BP (office BP of 120–139/70–89 mmHg) who are at sufficiently high risk for CVD (e.g. 10-year CVD risk ≥ 10%) or in the presence of high-risk conditions or borderline 10-year CVD risk (5% - <10%) combined with risk modifiers or abnormal risk tool tests, BP-lowering lifestyle measures should be initiated for 3 months. Following this, pharmacological therapy is recommended for persons with confirmed BP of ≥130/80 mmHg, when these lifestyle changes have not worked or are not being implemented (_Section [8.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7.2)_) Prompt addition of pharmacological therapy, if needed by 3 months, should be emphasized, to avoid therapeutic inertia.<sup><a href="javascript:;" reveal-id="ehae178-B519" data-open="ehae178-B519" class="link link-ref link-reveal xref-bibr">519</a></sup> For those with BP of 120–129/70–79 mmHg, ongoing and intensified lifestyle intervention is preferred.
    

The above recommendations apply to all individuals with elevated BP, irrespective of age. However, recognizing the lack of conclusive evidence and added risk of side effects among certain subgroups, the task force also recommends that, among patients with elevated BP, BP-lowering treatment should always be started based on individual clinical judgment and shared decision-making.

Table 14

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376001)

Initiation of blood pressure-lowering treatment based on confirmed blood pressure category and cardiovascular disease risk

| Blood pressure (mmHg) | Non-elevated BP (<120/70) | Elevated BP (120/70 to 139/89) | Hypertension (≥140/90) |
| --- | --- | --- | --- |
| **Risk** |  | 
-   All adults with SBP 120–129 mmHg
    
-   SBP 130–139 AND 10-year estimated CVD risk <10% AND no high-risk conditions or risk modifiers or abnormal risk tool tests
    

 | 

-   SBP 130–139 AND high-risk conditions (e.g. established CVD, diabetes mellitus, CKD, FH or HMOD)
    
-   SBP 130–139 AND 10-year estimated CVD risk ≥10%
    
-   SBP 130–139 AND 10-year estimated CVD risk 5% - <10% AND risk modifiers or abnormal risk tool tests
    

 | Assumed all at sufficiently high risk to benefit from pharmacological treatment |
| **Treatment** | Lifestyle measures for prevention  
Screen BP and CVD risk opportunistically | Lifestyle measures for treatment  
Monitor BP and CVD risk yearly | Lifestyle measures and pharmacological treatment (after 3-month delay).  
Monitor BP yearly once treatment control is established | Lifestyle measures and pharmacological treatment (immediate)  
Monitor BP yearly once treatment control is established |
| **Target (mmHg)** | **Maintain BP <120/70** | **Aim BP 120–129/70–79**  **mmHg**<sup><a href="javascript:;" reveal-id="tblfn126" data-open="tblfn126" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> |

BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; FH, familial hypercholesterolaemia; HMOD, hypertension-mediated organ damage; SBP, systolic blood pressure.

<sup>a</sup>Caution in adults with orthostatic hypotension, moderate-to-severe frailty, limited life expectancy, and older patients (aged ≥85 years).

© ESC 2024

In addition, consideration of BP-lowering drug treatment should be deferred until BP is >140/90 mmHg in the following settings: pre-treatment symptomatic orthostatic hypotension, age ≥85 years, clinically significant moderate-to-severe frailty, and/or limited predicted lifespan (<3 years) due to high competing risk (including eGFR < 30 mL/min/1.73 m<sup>2</sup>). Patients with elevated BP in these settings are less likely to obtain sufficient net benefit from BP-lowering drug therapy or to tolerate intensive drug therapy. _Section [9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_ contains more information on the treatment of specific subgroups, including older and frail adults.

Recommendation Table 17

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376003)

Recommendations for initiating blood pressure-lowering treatment (see Evidence Tables 30–32)

![Recommendations for initiating blood pressure-lowering treatment (see Evidence Tables 30–32)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt17.jpeg?Expires=1728462844&Signature=NRCozzD2Em0XBN28BWV9wq2mJfESjiKzfzw5-XJo6TorVZG81stKRWzKg4RJzsfwLBJlQkrzGCm7dy5LL6z680cbEsb6SW72n3fKaxifeUFGMSOZwa93sMchm81z6ndTIm5mh296ouxy3W0gh-XduC02Gxy3M7rVB145mDPqBOFXhYxukq5m2INVZFSMnUBptEosNI0PS8KXcSuMSt-XdKIEs9K6vtODOVuCMoWpSnpUFaOKrrGLmNgehcOMLeiJpi5Kqk7jo6et3og1dPuyjyWCGtekxmsAzwrQ446pukDYbJoqVxg9~Ms9PDYCl0WJwadHiMpeklsO-2tN29kKpw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 8.5. Intensity of blood pressure-lowering therapy and ideal treatment targets

#### 8.5.1. Expected degree of blood pressure reduction with approved drugs

The magnitude of BP reduction achieved with the main classes of BP-lowering medications (ACE inhibitors, ARBs, dihydropyridine CCBs, diuretics, and beta-blockers) as monotherapy is similar overall.<sup><a href="javascript:;" reveal-id="ehae178-B528" data-open="ehae178-B528" class="link link-ref link-reveal xref-bibr">528</a>,<a href="javascript:;" reveal-id="ehae178-B529" data-open="ehae178-B529" class="link link-ref link-reveal xref-bibr">529</a></sup> BP reduction with standard doses of any of these five classes can be expected to be approximately 9/5 mmHg with office BP and 5/3 mmHg with ABPM.<sup><a href="javascript:;" reveal-id="ehae178-B478" data-open="ehae178-B478" class="link link-ref link-reveal xref-bibr">478</a></sup> These BP-lowering effects may attenuate over time.<sup><a href="javascript:;" reveal-id="ehae178-B530" data-open="ehae178-B530" class="link link-ref link-reveal xref-bibr">530</a></sup> Combination therapy (e.g. with three drugs at half standard dose) over the short term can lower office BP by up to 20/11 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B478" data-open="ehae178-B478" class="link link-ref link-reveal xref-bibr">478</a>,<a href="javascript:;" reveal-id="ehae178-B531" data-open="ehae178-B531" class="link link-ref link-reveal xref-bibr">531</a></sup> The reason why beta-blockers are not considered first-line BP-lowering medications (outside of compelling indications) is not because of inferior BP-lowering properties (particularly for vasodilating beta-blockers),<sup><a href="javascript:;" reveal-id="ehae178-B532" data-open="ehae178-B532" class="link link-ref link-reveal xref-bibr">532</a></sup> but because of inferior efficacy in reducing CVD events (particularly stroke) among patients with hypertension, and tolerance issues.<sup><a href="javascript:;" reveal-id="ehae178-B533 ehae178-B534 ehae178-B535 ehae178-B536" data-open="ehae178-B533 ehae178-B534 ehae178-B535 ehae178-B536" class="link link-ref link-reveal xref-bibr">533–536</a></sup>

The BP-lowering effect of each BP medication class generally increases with the dose administered, though this relationship is not linear.<sup><a href="javascript:;" reveal-id="ehae178-B537" data-open="ehae178-B537" class="link link-ref link-reveal xref-bibr">537</a></sup> Effects of each medication can also vary at the individual level, sometimes requiring personalization by matching the patient with the best medication for them.<sup><a href="javascript:;" reveal-id="ehae178-B490" data-open="ehae178-B490" class="link link-ref link-reveal xref-bibr">490</a></sup> The magnitude of BP reduction for any BP-lowering medication may increase as a function of the pre-treatment BP, which is also known as Wilders principle.<sup><a href="javascript:;" reveal-id="ehae178-B538" data-open="ehae178-B538" class="link link-ref link-reveal xref-bibr">538</a>,<a href="javascript:;" reveal-id="ehae178-B539" data-open="ehae178-B539" class="link link-ref link-reveal xref-bibr">539</a></sup>

The BP-lowering effect of pharmacological therapy is typically evident after 1–2 weeks of treatment,<sup><a href="javascript:;" reveal-id="ehae178-B540" data-open="ehae178-B540" class="link link-ref link-reveal xref-bibr">540</a></sup> but the maximum effect might take longer to manifest. Therefore, the advised follow-up after 1–3 months (1 month preferred with a GP or specialist) allows for assessment of tolerance/safety, but also allows enough time to gauge the full BP-lowering effect of each drug titration (see _Section [8.3.4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7.3.4)_).

#### 8.5.2. The ideal target of blood pressure-lowering treatment

As discussed in _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_, optimal control of BP translates into CVD risk reduction, thereby reducing morbidity and mortality in the population.<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a>,<a href="javascript:;" reveal-id="ehae178-B478" data-open="ehae178-B478" class="link link-ref link-reveal xref-bibr">478</a>,<a href="javascript:;" reveal-id="ehae178-B541" data-open="ehae178-B541" class="link link-ref link-reveal xref-bibr">541</a></sup>

BP threshold is defined as the BP at which BP-lowering treatment is initiated, while BP target is the BP goal with treatment.

The BP threshold to initiate BP-lowering therapy is not necessarily the same as the recommended BP target once therapy is commenced (in other words, treatment threshold and treatment target may not be the same for a given patient). Specifically, for hypertensive patients in whom BP-lowering treatment is recommended above a baseline BP of ≥140/90 mmHg, the recommended target of BP-lowering therapy is 120–129/70–79 mmHg, provided treatment is well tolerated (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)). Persons with elevated BP who receive treatment are also recommended to achieve a target of 120–129/70–79 mmHg.

Therefore, the treatment target in the 2024 Guidelines is always 120–129/70–79 mmHg (but only if treatment is tolerated and with certain exceptions where more lenient targets are advised). In contrast, the treatment threshold may differ based on CVD risk, specifically in the elevated BP category. For example, in addition to hypertensive adults with BP ≥140/90 mmHg, there are individuals with an office systolic BP of 130–139 mmHg and/or diastolic BP of 80–89 mmHg who have sufficiently high CVD risk to recommend BP-lowering drug treatment.

The BP target range of 120–129/70–79 mmHg recommended in these guidelines reflects the most current evidence from contemporaneous RCTs<sup><a href="javascript:;" reveal-id="ehae178-B135" data-open="ehae178-B135" class="link link-ref link-reveal xref-bibr">135</a>,<a href="javascript:;" reveal-id="ehae178-B136" data-open="ehae178-B136" class="link link-ref link-reveal xref-bibr">136</a>,<a href="javascript:;" reveal-id="ehae178-B146" data-open="ehae178-B146" class="link link-ref link-reveal xref-bibr">146</a>,<a href="javascript:;" reveal-id="ehae178-B542 ehae178-B543 ehae178-B544 ehae178-B545" data-open="ehae178-B542 ehae178-B543 ehae178-B544 ehae178-B545" class="link link-ref link-reveal xref-bibr">542–545</a></sup> and from meta-analyses of RCTs.<sup><a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a></sup> Of note, this treatment target reduces CVD events in older adults<sup><a href="javascript:;" reveal-id="ehae178-B136" data-open="ehae178-B136" class="link link-ref link-reveal xref-bibr">136</a>,<a href="javascript:;" reveal-id="ehae178-B523" data-open="ehae178-B523" class="link link-ref link-reveal xref-bibr">523</a></sup> with evidence for efficacy of more intensive BP-lowering treatment targets established up to age 85 years.<sup><a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a></sup> Furthermore, research data indicate that, to optimally reduce CVD risk, achieving an on-treatment BP of 120/70 mmHg is the best point on the BP target range provided in our guideline recommendations (_[Figure 20](javascript:;)_). However, while we strongly considered recommending a treatment target of exactly 120/70 mmHg with out-of-office BP confirmation, we instead chose a target range of 120–129/70–79 mmHg (preferably with out-of-office BP confirmation but also allowing for office BP) for the following reasons: providing flexibility to patients and clinicians; feedback from external peer review; feedback from patients that lifestyle is preferred to medication unless BP is in the hypertensive range; the knowledge that contemporary treat-to-target intensive BP trials included only persons with baseline systolic BP of ≥130 mmHg; and a recognition that the BP values recorded under research conditions using systematic approaches to measurement (while strongly recommended by these guidelines) are not always the same as BP values recorded under routine clinical care, which can be 5–10 mmHg higher.<sup><a href="javascript:;" reveal-id="ehae178-B65" data-open="ehae178-B65" class="link link-ref link-reveal xref-bibr">65</a>,<a href="javascript:;" reveal-id="ehae178-B66" data-open="ehae178-B66" class="link link-ref link-reveal xref-bibr">66</a></sup>

![Systolic blood pressure categories and treatment target range.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f20.jpeg?Expires=1728462844&Signature=rAGjE9GaQ0GOmcIGO17jBPs1Q93~5J0BLxR8C6w2Rsva~~~ff3GqfOwh6GGA9g4YlIgJr~fh8Pmsv40MryNB7L5uJGrOsDJCdc-V4xWe-vPes8fQWpWKSpbkj93p7WYBnYNf74dRpj9NzWbQVW17wWaICnETKy2d1MOkkeivCipKOa4ZJvkgoe6u2r45y3ZNGbyXIvsB13hoJevf6AB4t-lUQ6zN2Ff07KL8evLHrvYx59T7-1CUwn6QoNZFojIPDrG6IHNtmEEGXP0JjLaBHj-b8ld33fC6zZVYRFfRXoLKHQPy1seJTPX0Hi9YTHvpI2fql92ErN1xT3u6SoI0mg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 20

Systolic blood pressure categories and treatment target range.

BP, blood pressure; SBP, systolic blood pressure.

[Open in new tab](https://academic.oup.com/view-large/figure/479376015/ehae178f20.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f20.jpeg?Expires=1728462844&Signature=bz6qU4ADGHuhjQd9LrqDBoPDRSDjAfLzeJjvgY1F7d6fTXhfm~P85mn5Dcifz~LZJAGfPx5y3YiZxXTC7OL6xNjBRGjCYL5eutUThNlmVAXJ206y1MVh~HZvrhP8yk5i2daMYH4XuG~qZGYUvkfz1~gIOg9xgMRcc0Vv68lMfd86dyFXmGELXn-XfTG~qUINW6B8OL5zxln51kqUucL7a80xzH0jKP8fcQpWmdYrObgW9nIlmnO2IqtTZbTwBWUa9WctB0SEEot1g-pvYECWo5V6gdD-lRca74ElFhhrSOSvLWRmKy~QOooEFjpv-afSSWCColKbhCvsYBFk0kAz5Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479376015&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

In addition, the trial data confirming efficacy for our recommended treatment target of 120–129/70–79 mmHg do not necessarily apply to moderately-to-severely frail adults who were generally excluded from trials. Furthermore, the data supporting this BP target among adults aged >85 years are inconclusive.<sup><a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a></sup> Frailty can occur at different ages and is, together with tolerability of BP-lowering treatment, an important characteristic when considering the BP target for a given patient. Accordingly, personalized BP-lowering treatment should be instituted in people aged ≥85 years and/or those with significant frailty. Recommended indicators of frailty in guiding BP-lowering treatment are given in _Section [9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_.

Several important nuances are highlighted and warrant consideration prior to implementing the new BP target of 120–129/70–79 mmHg among patients receiving BP-lowering therapy:

-   Evidence for a systolic BP-lowering treatment target of 120–129 mmHg is strong (Class I, level of evidence A).
    
-   Evidence for a specific diastolic BP-lowering treatment target is less strong in those who are treated to a systolic target of 120–129 mmHg. While most adults treated to a systolic BP target of 120–129 mmHg will also achieve a diastolic BP of 70–79 mmHg, not all will.<sup><a href="javascript:;" reveal-id="ehae178-B543" data-open="ehae178-B543" class="link link-ref link-reveal xref-bibr">543</a>,<a href="javascript:;" reveal-id="ehae178-B546" data-open="ehae178-B546" class="link link-ref link-reveal xref-bibr">546</a></sup> Furthermore, adults who achieve systolic BP control are generally at low relative risk for CVD, even when diastolic BP is 70–90 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B547" data-open="ehae178-B547" class="link link-ref link-reveal xref-bibr">547</a>,<a href="javascript:;" reveal-id="ehae178-B548" data-open="ehae178-B548" class="link link-ref link-reveal xref-bibr">548</a></sup> Nonetheless, due in part to the known higher risk of isolated diastolic hypertension among younger adults,<sup><a href="javascript:;" reveal-id="ehae178-B549" data-open="ehae178-B549" class="link link-ref link-reveal xref-bibr">549</a></sup> the task force agreed that it is reasonable to target an on-treatment diastolic BP of 70–79 mmHg among patients with diastolic BP of ≥80 mmHg who are already at the systolic BP target of 120–129 mmHg (Class IIb, level of evidence C).
    
-   The task force acknowledges the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice,<sup><a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup> which take a stepwise approach to their recommendations for BP-lowering treatment. The 2021 Guidelines recommended an on-treatment systolic BP target of 130–139 mmHg as the first step and then—based on patient preferences, risk, and frailty—to aim for a target on-treatment systolic BP of <130 mmHg as the second step. While we recognize the potential value of this two-step approach, which many clinicians may choose to follow, the current guidelines emphasize one on-treatment BP target (120–129/70–79 mmHg, provided treatment is tolerated). This one-step approach is based on the evidence, and motivated to discourage therapeutic inertia around BP lowering. As an illustrative example of the latter concern for therapeutic inertia, an on-treatment systolic BP of 135 mmHg (office) may be considered reasonable when reviewing the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice but, we hope, will not be considered reasonable to those who follow the updated 2024 ESC Guidelines presented here. Specifically, it is well established that an on-treatment systolic BP of 135 mmHg is not optimal relative to more intensive control.<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a>,<a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a>,<a href="javascript:;" reveal-id="ehae178-B135" data-open="ehae178-B135" class="link link-ref link-reveal xref-bibr">135</a>,<a href="javascript:;" reveal-id="ehae178-B136" data-open="ehae178-B136" class="link link-ref link-reveal xref-bibr">136</a>,<a href="javascript:;" reveal-id="ehae178-B445" data-open="ehae178-B445" class="link link-ref link-reveal xref-bibr">445</a>,<a href="javascript:;" reveal-id="ehae178-B542" data-open="ehae178-B542" class="link link-ref link-reveal xref-bibr">542</a>,<a href="javascript:;" reveal-id="ehae178-B543" data-open="ehae178-B543" class="link link-ref link-reveal xref-bibr">543</a>,<a href="javascript:;" reveal-id="ehae178-B545" data-open="ehae178-B545" class="link link-ref link-reveal xref-bibr">545</a></sup>
    
-   We acknowledge that the results from RCTs cannot always be extrapolated to routine clinical care. In addition, we recognize the increased risk of side effects among patients receiving more intensive BP-lowering treatments, compared with traditional BP targets.<sup><a href="javascript:;" reveal-id="ehae178-B545" data-open="ehae178-B545" class="link link-ref link-reveal xref-bibr">545</a>,<a href="javascript:;" reveal-id="ehae178-B550" data-open="ehae178-B550" class="link link-ref link-reveal xref-bibr">550</a></sup> Accordingly, an important caveat to our treatment target of 120–129/70–79 mmHg is the recommendation to pursue this target only when treatment is well tolerated. In cases where BP-lowering treatment is not well tolerated and a target of 120–129/70–79 mmHg is not possible, it is recommended to follow the ‘as low as reasonably achievable’ (ALARA) principle, by targeting treatment to a BP that is as low as reasonably achievable.
    
-   In addition to adults with significant frailty and/or who are ≥85 years of age, the evidence for a BP-lowering treatment target of 120–129/70–79 mmHg may also not generalize to patients with: (i) pre-treatment symptomatic orthostatic hypotension, (ii) limited predicted lifespan (e.g. <3 years),<sup><a href="javascript:;" reveal-id="ehae178-B527" data-open="ehae178-B527" class="link link-ref link-reveal xref-bibr">527</a></sup> and/or (iii) high levels of competing risk for non-CVD death including CKD with eGFR < 30 mL/min/1.73 m<sup>2</sup>) (see _Section [9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_).
    

Finally, as outlined in _Section [5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4)_, these guidelines endorse a ‘trust but verify’ approach to office BP measurements, and, where possible, confirming BP with accurate out-of-office BP measurements (ABPM, HBPM) is recommended prior to starting treatment, to monitor the treatment effect of BP-lowering medication.

Recommendation Table 18

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376020)

Recommendations for blood pressure targets with treatment (see Evidence Table 34)

![Recommendations for blood pressure targets with treatment (see Evidence Table 34)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt18.jpeg?Expires=1728462844&Signature=vYRXnZ2Vzot~aQGC8adEzUhe4je5RYwSX2lWlkx6hqxzfS4QersEWdItthIeLcQt1r24IR5qW~l-7PqjtLb09VkEdqOIMgiYqnEV3m1RAdVeDwcJKxZHzGJmrsE0E1KbclVu8HoxLpdjIFzybdVF8vD5LSOskbUqXvqj1G03KRj~AgDvESHgmcUP1otSgEDV~dkJzFLMOlwdLm1hXMDmw5WNnlF9N4MS~z97TkJYKRRNeyDUg~V63fz-R8zPyRity9tTvG~9DMU7r0CYVDb3L9takHGfR~CIMN3cCI5WH2d3Dee6GedbR-EGgsDJoliSFRiZ3eZpq-wcikEne3bsFQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 8.5.3. Personalizing treatment strategies

Though promising, there is little to no evidence to date from CVD outcome trials to use novel biomarkers for individualizing BP-lowering treatment.<sup><a href="javascript:;" reveal-id="ehae178-B551" data-open="ehae178-B551" class="link link-ref link-reveal xref-bibr">551</a>,<a href="javascript:;" reveal-id="ehae178-B552" data-open="ehae178-B552" class="link link-ref link-reveal xref-bibr">552</a></sup> Nonetheless, different patient groups can be identified, and medication initiation can be tailored to pre-existing conditions, such as diabetes mellitus, CKD, AF, post-myocardial infarction, heart failure, metabolic syndrome, and proteinuria/albuminuria (_Section [9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_). History of previous side effects and possible and compelling indications also need to be considered when selecting treatment (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Tables S9](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[S10](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). Cardioselective beta-blockers may be used in low dose in chronic asthma,<sup><a href="javascript:;" reveal-id="ehae178-B553" data-open="ehae178-B553" class="link link-ref link-reveal xref-bibr">553</a>,<a href="javascript:;" reveal-id="ehae178-B554" data-open="ehae178-B554" class="link link-ref link-reveal xref-bibr">554</a></sup> in line with their use in patients with heart failure with chronic asthma.

For considerations of BP-lowering treatment among specific patient populations of interest, including different racial/ethnic populations, see _Section [9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_.

#### 8.5.4. Duration and monitoring of drug therapy

BP-lowering treatment is usually chronic, often lifelong. This raises the question of long-term efficiency, long-term side effects, adherence, and persistence with therapy. While BP-lowering therapies typically provide an overall durable effect, some attenuation of effect may be seen over time.<sup><a href="javascript:;" reveal-id="ehae178-B66" data-open="ehae178-B66" class="link link-ref link-reveal xref-bibr">66</a>,<a href="javascript:;" reveal-id="ehae178-B530" data-open="ehae178-B530" class="link link-ref link-reveal xref-bibr">530</a></sup> First-line BP-lowering medication classes appear to be safe for long-term use.<sup><a href="javascript:;" reveal-id="ehae178-B555 ehae178-B556 ehae178-B557" data-open="ehae178-B555 ehae178-B556 ehae178-B557" class="link link-ref link-reveal xref-bibr">555–557</a></sup> Once BP is controlled, at least a yearly follow-up is advised. Because of the known temporal variability in BP<sup><a href="javascript:;" reveal-id="ehae178-B558" data-open="ehae178-B558" class="link link-ref link-reveal xref-bibr">558</a>,<a href="javascript:;" reveal-id="ehae178-B559" data-open="ehae178-B559" class="link link-ref link-reveal xref-bibr">559</a></sup> and medication efficacy in the long term,<sup><a href="javascript:;" reveal-id="ehae178-B530" data-open="ehae178-B530" class="link link-ref link-reveal xref-bibr">530</a></sup> medication changes may be necessary over time (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).

Recommendation Table 19

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376026)

Recommendations for follow-up in patients with treated hypertension (see Evidence Table 33)

![Recommendations for follow-up in patients with treated hypertension (see Evidence Table 33)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt19.jpeg?Expires=1728462844&Signature=UlndsEzarvniwN4EcFsmPdndKI19K2t96wKGbIcxrFqnESCYiuJB5Lre7n~ku8isms6V~VsHpYOXkR9meI4N53YNu7TxM4YsVBXMb8FL8Xdja6mPu9yXZ6ojDYjA4POS3V6e8Dn3DnU6aFYMDWTnj6330xkDzk60G53AWkXIoUphGS0iGeb54S0xe1ZgXemiTceKnQUdNoEagal35UMK1mqkz2jI8nPZYzA~xUqKPfsMaL0YbF7I~4q5-uhZUvcpthpZKZCsUZmcG08gR4QdMo5y8P-d0BfrVMV-k71eMDO1DsHtczWuuY-HD1TRQmurNkqe-tTmVKLmpw~0ZyTy5Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 8.6. Device-based blood pressure lowering

Several device-based therapies designed to lower BP have been investigated.<sup><a href="javascript:;" reveal-id="ehae178-B560" data-open="ehae178-B560" class="link link-ref link-reveal xref-bibr">560</a>,<a href="javascript:;" reveal-id="ehae178-B561" data-open="ehae178-B561" class="link link-ref link-reveal xref-bibr">561</a></sup> To date, the best evidence exists for catheter-based renal denervation.

#### 8.6.1. Catheter-based renal denervation

Sympathetic nervous system overactivity contributes to the development and progression of hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B562" data-open="ehae178-B562" class="link link-ref link-reveal xref-bibr">562</a></sup> Renal denervation aims to interrupt afferent and efferent sympathetic nerves in the adventitia and perivascular tissue of the renal arteries.<sup><a href="javascript:;" reveal-id="ehae178-B563" data-open="ehae178-B563" class="link link-ref link-reveal xref-bibr">563</a></sup> The 2018 ESC/ESH Guidelines on the management of arterial hypertension did not recommend the use of device-based therapies for routine treatment of hypertension, unless in the context of clinical studies and RCTs.<sup><a href="javascript:;" reveal-id="ehae178-B1" data-open="ehae178-B1" class="link link-ref link-reveal xref-bibr">1</a></sup> This was based on negative data using first-generation radiofrequency catheters (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).

More recent data from sham-controlled trials investigating second-generation radiofrequency and ultrasound catheters demonstrated a BP-lowering efficacy in a broad range of patients, with and without concomitant BP-lowering medications, including those with resistant hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B564 ehae178-B565 ehae178-B566 ehae178-B567 ehae178-B568" data-open="ehae178-B564 ehae178-B565 ehae178-B566 ehae178-B567 ehae178-B568" class="link link-ref link-reveal xref-bibr">564–568</a></sup> Long-term, non-randomized, follow-up data from the Global Symplicity Registry,<sup><a href="javascript:;" reveal-id="ehae178-B569" data-open="ehae178-B569" class="link link-ref link-reveal xref-bibr">569</a></sup> Symplicity HTN-3 trial,<sup><a href="javascript:;" reveal-id="ehae178-B570" data-open="ehae178-B570" class="link link-ref link-reveal xref-bibr">570</a></sup> Spyral HTN-ON MED pilot trial,<sup><a href="javascript:;" reveal-id="ehae178-B571" data-open="ehae178-B571" class="link link-ref link-reveal xref-bibr">571</a></sup> and A Study of the Recor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN) SOLO trial<sup><a href="javascript:;" reveal-id="ehae178-B572" data-open="ehae178-B572" class="link link-ref link-reveal xref-bibr">572</a></sup> indicate a sustained BP-lowering effect for up to 3 years. A single-centre open-label study suggested sustained BP reductions up to 10 years.<sup><a href="javascript:;" reveal-id="ehae178-B573" data-open="ehae178-B573" class="link link-ref link-reveal xref-bibr">573</a></sup> These data also highlight a potentially important advantage of renal denervation, namely that the BP-lowering effect of this intervention might be ‘always on’, making this approach attractive for patients with suboptimal medication adherence.<sup><a href="javascript:;" reveal-id="ehae178-B254" data-open="ehae178-B254" class="link link-ref link-reveal xref-bibr">254</a></sup> Some patients may prefer a one-off procedure rather than taking daily medications chronically and may request renal denervation.

Of significance, there are no reported procedure-related serious safety signals in the first- and second-generation trials beyond the usual risk of femoral arterial access procedures (noting that most trials to date were not powered for safety outcomes and that the task force could find no published meta-analysis data on exact rates of major bleeding and major femoral artery vascular access complications after renal denervation procedures). However, the rate of major bleeding and major femoral artery vascular access complications for coronary angiography using a femoral approach is typically reported as 1%–4%<sup><a href="javascript:;" reveal-id="ehae178-B574" data-open="ehae178-B574" class="link link-ref link-reveal xref-bibr">574</a>,<a href="javascript:;" reveal-id="ehae178-B575" data-open="ehae178-B575" class="link link-ref link-reveal xref-bibr">575</a></sup> but has been reported as 5%–10% in some studies.<sup><a href="javascript:;" reveal-id="ehae178-B575" data-open="ehae178-B575" class="link link-ref link-reveal xref-bibr">575</a></sup> Trials investigating radial access for renal denervation are currently ongoing ([ClinicalTrials.gov](https://ClinicalTrials.gov) identifier: NCT05234788). After renal denervation, there is a 0.25%–0.5% rate of renal artery stenosis/dissection requiring stenting.<sup><a href="javascript:;" reveal-id="ehae178-B576" data-open="ehae178-B576" class="link link-ref link-reveal xref-bibr">576</a></sup> Long-term follow-up data up to 3 years have not suggested worsening of renal function beyond the expected rates in patients with hypertension with mildly-to-moderately reduced renal function.<sup><a href="javascript:;" reveal-id="ehae178-B569" data-open="ehae178-B569" class="link link-ref link-reveal xref-bibr">569</a>,<a href="javascript:;" reveal-id="ehae178-B577" data-open="ehae178-B577" class="link link-ref link-reveal xref-bibr">577</a></sup> Of note, sham-controlled trials to date excluded patients with severely reduced kidney function at baseline.<sup><a href="javascript:;" reveal-id="ehae178-B564" data-open="ehae178-B564" class="link link-ref link-reveal xref-bibr">564</a>,<a href="javascript:;" reveal-id="ehae178-B566 ehae178-B567 ehae178-B568" data-open="ehae178-B566 ehae178-B567 ehae178-B568" class="link link-ref link-reveal xref-bibr">566–568</a></sup>

Despite the clear promise of renal denervation in reducing BP, there are some concerns that warrant consideration, as we indicate in the recommendations. First, the effect of current renal denervation catheter technologies on BP lowering is relatively modest for an invasive procedure (meta-analyses report placebo-corrected systolic BP lowering of approximately 6 mmHg on office BP assessment and 4 mmHg on 24 h ABPM).<sup><a href="javascript:;" reveal-id="ehae178-B578" data-open="ehae178-B578" class="link link-ref link-reveal xref-bibr">578</a></sup> As such, the average BP-lowering effect of renal denervation appears no more than for one standard BP-lowering medication. Accordingly, many adults undergoing renal denervation will likely require ongoing, post-procedural, BP-lowering drugs.

Second, the cost-effectiveness of renal denervation has not been fully established. Since effects of current renal denervation technologies are similar to that of one standard BP-lowering medication, most of which are generic, it is difficult to see a scenario where renal denervation could be proven cost-effective for most patients. An exception might be patients who are at very high risk of CVD events and who have uncontrolled BP due to resistant hypertension (with or without non-adherence).<sup><a href="javascript:;" reveal-id="ehae178-B579" data-open="ehae178-B579" class="link link-ref link-reveal xref-bibr">579</a>,<a href="javascript:;" reveal-id="ehae178-B580" data-open="ehae178-B580" class="link link-ref link-reveal xref-bibr">580</a></sup>

Third, there are no adequately powered outcomes trials demonstrating that renal denervation reduces CVD events and is safe in the long term. While observational reports have suggested associations between renal denervation and reduced risk for CVD events,<sup><a href="javascript:;" reveal-id="ehae178-B581" data-open="ehae178-B581" class="link link-ref link-reveal xref-bibr">581</a>,<a href="javascript:;" reveal-id="ehae178-B582" data-open="ehae178-B582" class="link link-ref link-reveal xref-bibr">582</a></sup> these observational data have major inferential limitations including a significant potential for confounding. While BP lowering is typically a good surrogate for CVD benefit, there is no guarantee that this is true with renal denervation and, furthermore, off-target effects independent of BP could influence CVD and other adverse-event rates after the procedure. Because of the lack of outcomes trials, renal denervation cannot reach the Class I indication threshold set by this task force. Arguments that outcomes trials will not be funded are insufficient to influence guideline recommendations. However, it is hoped that the position of these guidelines will motivate industry to sponsor the necessary renal denervation outcomes trials.

Fourth, related to the lack of outcomes data, the potentially ‘always on’ effect of renal denervation could backfire if late complications emerge. Medications causing complications or side effects can simply be stopped and replaced with alternative medications when such problems emerge; this is not true with renal denervation.

Fifth, the impact of scaling up renal denervation on usual cardiac department catheterization laboratory workflows is of some concern. Specifically, it is important that renal denervation procedures do not delay timely access to other elective procedures with proven efficacy in reducing CVD outcomes.<sup><a href="javascript:;" reveal-id="ehae178-B583" data-open="ehae178-B583" class="link link-ref link-reveal xref-bibr">583</a></sup>

Sixth, there is still no direct evidence to gauge whether renal denervation procedures are successful and that the kidneys are denervated and do not reinnervate over time.<sup><a href="javascript:;" reveal-id="ehae178-B584" data-open="ehae178-B584" class="link link-ref link-reveal xref-bibr">584</a></sup> Relatedly, the concept of responders and non-responders to renal denervation (and the hypothesis that predictors of response might be found to help identify patients most suitable for the procedure) is questioned. Medical interventions, including drugs, are naturally subject to inter-individual variability in response.<sup><a href="javascript:;" reveal-id="ehae178-B567" data-open="ehae178-B567" class="link link-ref link-reveal xref-bibr">567</a></sup> Additionally, there are few examples in medicine of consistent and clinically useful predictors of treatment response for medical conditions that have complex genetic and environmental underpinnings (i.e. conditions like hypertension).

A multidisciplinary hypertension team, including experts in hypertension and percutaneous cardiovascular interventions, is recommended to evaluate the indication and to perform the procedure.<sup><a href="javascript:;" reveal-id="ehae178-B585" data-open="ehae178-B585" class="link link-ref link-reveal xref-bibr">585</a></sup> Based on the available evidence, renal denervation may be considered for patients who have uncontrolled, true resistant hypertension with a three-drug combination and who express a preference to undergo renal denervation.<sup><a href="javascript:;" reveal-id="ehae178-B566" data-open="ehae178-B566" class="link link-ref link-reveal xref-bibr">566</a>,<a href="javascript:;" reveal-id="ehae178-B568" data-open="ehae178-B568" class="link link-ref link-reveal xref-bibr">568</a>,<a href="javascript:;" reveal-id="ehae178-B585" data-open="ehae178-B585" class="link link-ref link-reveal xref-bibr">585</a></sup> This recommendation is informed, in part, by the higher risk of CVD events in this subgroup, which represents a major unmet clinical need and which also means that cost-effectiveness considerations are likely to be optimal in this setting. In patients who are non-adherent or intolerant to multiple BP-lowering medications, particularly first-line agents, and who have high predicted CVD risk and a BP that is not at target, renal denervation may, for the same reasons, be considered if the patients express a preference to undergo renal denervation after a tailored shared decision-making process. The shared decision-making process requires that the patients are fully informed about the benefits, limitations, and risks associated with renal denervation.

Recommendation Table 20

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376040)

Recommendations for device-based treatment of hypertension (see Evidence Table 35)

![Recommendations for device-based treatment of hypertension (see Evidence Table 35)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt20.jpeg?Expires=1728462844&Signature=Ez3ME3JRivuUZ4tGO8L4ZoLmiEQ-vfkYAXDZ6pF6wkFQLBRZ9FHzN0uK0Hmt~xVPW8tQpzSqCwXbj7PjbdH866TjkQBGahxH5~v9cOHdchLJi70hYpifpJB-fPUOK-rxfLZbEhzb-JJiTrljGufuyzFADtKHXDXcl628cVrDN4vFoXEm6wBJIvnj3ObkFzo5YL46~LEE29I-ICjheXn7KTIL-FgcemmWDAumNwmTdNoTf8tshsAKOI4Tig5oRyIGvaL29xpTc1SyXJvWHHS-WCDAwUpH-lxiHSZvotjTp69HdPtMso5i8EiuK4B8zims3Sy4-UceGWbUg6ddCA2Wvw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 8.6.2. Other devices

Most device-based therapies investigated for BP-lowering therapy in hypertension have been aimed at modulating the autonomic nervous system activity (baroreflex activation therapy, endovascular baroreflex amplification therapy, and carotid body ablation).<sup><a href="javascript:;" reveal-id="ehae178-B560" data-open="ehae178-B560" class="link link-ref link-reveal xref-bibr">560</a></sup> Cardiac neuromodulation therapy aims to lower left ventricular preload by variably altering the atrioventricular interval using a dual-chamber, rate-responsive, implantable pulse generator in patients indicated for implantation or replacement of a dual-chamber pacemaker.<sup><a href="javascript:;" reveal-id="ehae178-B591" data-open="ehae178-B591" class="link link-ref link-reveal xref-bibr">591</a>,<a href="javascript:;" reveal-id="ehae178-B592" data-open="ehae178-B592" class="link link-ref link-reveal xref-bibr">592</a></sup> Some, though not all, of these devices have shown promising results in non-randomized, single-arm studies. A sham-controlled trial investigating central iliac arteriovenous stent anastomosis was terminated early after longer-term follow-up data indicated an increase in heart failure in the stent group.<sup><a href="javascript:;" reveal-id="ehae178-B561" data-open="ehae178-B561" class="link link-ref link-reveal xref-bibr">561</a></sup> Therefore, the use of these device-based therapies is not recommended for routinely treating hypertension until further evidence regarding their safety and efficacy becomes available (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).

### 8.7. Unintended and potentially harmful consequences of blood pressure lowering and implications for treatment targets

#### 8.7.1. Adverse effects of blood pressure-lowering medications

##### 8.7.1.1. Symptomatic adverse effects

BP-lowering medications have multiple side effects, which may be more common in females.<sup><a href="javascript:;" reveal-id="ehae178-B536" data-open="ehae178-B536" class="link link-ref link-reveal xref-bibr">536</a>,<a href="javascript:;" reveal-id="ehae178-B593" data-open="ehae178-B593" class="link link-ref link-reveal xref-bibr">593</a>,<a href="javascript:;" reveal-id="ehae178-B594" data-open="ehae178-B594" class="link link-ref link-reveal xref-bibr">594</a></sup> Although generally well tolerated, common side effects include headaches, cough, dizziness or light-headedness, diarrhoea or constipation, fatigue, ankle swelling, and erectile problems, depending on the drug class (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S9](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><a href="javascript:;" reveal-id="ehae178-B536" data-open="ehae178-B536" class="link link-ref link-reveal xref-bibr">536</a>,<a href="javascript:;" reveal-id="ehae178-B550" data-open="ehae178-B550" class="link link-ref link-reveal xref-bibr">550</a>,<a href="javascript:;" reveal-id="ehae178-B593 ehae178-B594 ehae178-B595 ehae178-B596 ehae178-B597" data-open="ehae178-B593 ehae178-B594 ehae178-B595 ehae178-B596 ehae178-B597" class="link link-ref link-reveal xref-bibr">593–597</a></sup>

In randomized trials of adults aged >60 years, the overall rate of symptomatic BP-lowering drug withdrawal was higher than the rate of placebo withdrawal (approximately 15% vs. 5%).<sup><a href="javascript:;" reveal-id="ehae178-B593" data-open="ehae178-B593" class="link link-ref link-reveal xref-bibr">593</a></sup> A systematic review, which included 280 638 participants in 58 RCTs, reported no evidence for an increased relative risk of falls in those taking BP-lowering drugs.<sup><a href="javascript:;" reveal-id="ehae178-B550" data-open="ehae178-B550" class="link link-ref link-reveal xref-bibr">550</a></sup> There was, however, an increased relative risk of mild hyperkalaemia, acute kidney injury, hypotension, and syncope. Furthermore, very frail adults were excluded from BP-lowering trials, which is relevant because such patients are more prone to adverse effects and polypharmacy (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B596" data-open="ehae178-B596" class="link link-ref link-reveal xref-bibr">596</a></sup>

##### 8.7.1.2. Renal effects

A systematic review reported an increased risk of acute kidney injury and hyperkalaemia associated with BP-lowering treatment.<sup><a href="javascript:;" reveal-id="ehae178-B550" data-open="ehae178-B550" class="link link-ref link-reveal xref-bibr">550</a></sup> Analyses of outcomes by specific drug class showed that drugs affecting the RAAS were more likely to be associated with acute kidney injury and hyperkalaemia.<sup><a href="javascript:;" reveal-id="ehae178-B550" data-open="ehae178-B550" class="link link-ref link-reveal xref-bibr">550</a></sup>

Patients with significant CKD tend to be excluded from RCTs.<sup><a href="javascript:;" reveal-id="ehae178-B137" data-open="ehae178-B137" class="link link-ref link-reveal xref-bibr">137</a>,<a href="javascript:;" reveal-id="ehae178-B545" data-open="ehae178-B545" class="link link-ref link-reveal xref-bibr">545</a>,<a href="javascript:;" reveal-id="ehae178-B598" data-open="ehae178-B598" class="link link-ref link-reveal xref-bibr">598</a></sup> It is important to remember these exclusion criteria, and that patients with CKD are more likely to suffer from resistant hypertension, when extrapolating the results of more intensive BP lowering to patients with moderate-to-severe CKD (see _Section [9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_).<sup><a href="javascript:;" reveal-id="ehae178-B599" data-open="ehae178-B599" class="link link-ref link-reveal xref-bibr">599</a></sup>

##### 8.7.1.3. Erectile dysfunction

Older classes of BP-lowering drugs (including diuretics, beta-blockers, and centrally acting medications) are associated with erectile dysfunction.<sup><a href="javascript:;" reveal-id="ehae178-B600" data-open="ehae178-B600" class="link link-ref link-reveal xref-bibr">600</a></sup> However, newer classes have neutral effects.<sup><a href="javascript:;" reveal-id="ehae178-B601" data-open="ehae178-B601" class="link link-ref link-reveal xref-bibr">601</a></sup> Angiotensin receptor antagonists may have beneficial effect on erectile function.<sup><a href="javascript:;" reveal-id="ehae178-B602" data-open="ehae178-B602" class="link link-ref link-reveal xref-bibr">602</a></sup>

#### 8.7.2. Pill burden and non-adherence

More intensive treatment of elevated BP and hypertension may be associated with an increased risk of polypharmacy and pill burden, which are themselves associated with non-adherence.<sup><a href="javascript:;" reveal-id="ehae178-B603" data-open="ehae178-B603" class="link link-ref link-reveal xref-bibr">603</a>,<a href="javascript:;" reveal-id="ehae178-B604" data-open="ehae178-B604" class="link link-ref link-reveal xref-bibr">604</a></sup> Single-pill, fixed-dose drug combinations can help to reduce pill burden and are recommended to improve adherence (refer to _Section [8.3.4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7.3.4)_).

Increased intensity of BP lowering (while ultimately cost reducing in terms of CVD reduction)<sup><a href="javascript:;" reveal-id="ehae178-B605" data-open="ehae178-B605" class="link link-ref link-reveal xref-bibr">605</a></sup> can also result in higher upfront direct and indirect healthcare costs, with more people requiring medication and higher demand for technology-based adherence strategies, which can be challenging to implement, especially in resource-poor settings.<sup><a href="javascript:;" reveal-id="ehae178-B604" data-open="ehae178-B604" class="link link-ref link-reveal xref-bibr">604</a></sup>

#### 8.7.3. Potentially harmful consequences of blood pressure lowering for frail older people

Unintended consequences of BP lowering (hypotension, syncope, falls) can be hazardous for frail older people in particular.<sup><a href="javascript:;" reveal-id="ehae178-B606" data-open="ehae178-B606" class="link link-ref link-reveal xref-bibr">606</a></sup> Retrospective studies have shown that adults aged >75 years from the general population, who would have met the criteria for inclusion in the Systolic Blood Pressure Intervention Trial (SPRINT), had a rate of injurious falls and syncope that was nearly five times that of the standard care group in the trial. This suggests that healthy participant bias may have contributed to the findings of SPRINT and other similar BP-lowering trials, and that the results may not fully generalize to older adults in more routine clinical care.<sup><a href="javascript:;" reveal-id="ehae178-B607" data-open="ehae178-B607" class="link link-ref link-reveal xref-bibr">607</a></sup>

Patients’ functional ability should be considered in addition to age to help negate any unintended consequences of BP lowering in a frailer cohort. Despite their chronological age, older patients with hypertension who are fit and can independently carry out activities of daily living will benefit from guideline-directed treatment similar to younger cohorts.<sup><a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a></sup> However, tailoring treatment targets and treatment plans for frail older patients is necessary to avoid unintended consequences. This should include assessing frailty, including cognitive status, risk of falls, propensity for symptomatic orthostatic hypotension, polypharmacy, and other comorbid conditions.<sup><a href="javascript:;" reveal-id="ehae178-B608" data-open="ehae178-B608" class="link link-ref link-reveal xref-bibr">608</a>,<a href="javascript:;" reveal-id="ehae178-B609" data-open="ehae178-B609" class="link link-ref link-reveal xref-bibr">609</a></sup> Of note, and as detailed in _Section [9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_, some data indicate a benefit of more intensive BP-lowering on cognitive function.<sup><a href="javascript:;" reveal-id="ehae178-B523" data-open="ehae178-B523" class="link link-ref link-reveal xref-bibr">523</a>,<a href="javascript:;" reveal-id="ehae178-B610" data-open="ehae178-B610" class="link link-ref link-reveal xref-bibr">610</a>,<a href="javascript:;" reveal-id="ehae178-B611" data-open="ehae178-B611" class="link link-ref link-reveal xref-bibr">611</a></sup> For those with loss of function but preserved activities of daily living, a more detailed geriatric assessment is required to explore the risks and benefits of treatment, as well as considerations for tailoring therapeutic strategies where appropriate. For patients who are both functionally impaired and unable to carry out activities of daily living, the therapeutic goals of hypertension treatment should be personalized, and medications discontinued where appropriate (see _Section [9.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8.3)_).<sup><a href="javascript:;" reveal-id="ehae178-B596" data-open="ehae178-B596" class="link link-ref link-reveal xref-bibr">596</a></sup>

#### 8.7.4. Clinical inertia in blood pressure lowering

The fear of serious adverse events with BP-lowering medications is often cited as a reason for clinical inertia, although the evidence to date from meta-analyses of RCTs suggests these side-effect concerns may be exaggerated.<sup><a href="javascript:;" reveal-id="ehae178-B550" data-open="ehae178-B550" class="link link-ref link-reveal xref-bibr">550</a>,<a href="javascript:;" reveal-id="ehae178-B612" data-open="ehae178-B612" class="link link-ref link-reveal xref-bibr">612</a></sup> However, RCTs often select populations with less frailty and multimorbidity who are more likely to tolerate treatment.<sup><a href="javascript:;" reveal-id="ehae178-B613" data-open="ehae178-B613" class="link link-ref link-reveal xref-bibr">613</a></sup> Consequently, fewer adverse effects might be reported than would be expected in the general population. It remains up to individual clinicians to initiate shared decision-making with each patient, especially patients in vulnerable groups and those who have experienced previous adverse events, weighing up potential benefits against risks of treatment.<sup><a href="javascript:;" reveal-id="ehae178-B614" data-open="ehae178-B614" class="link link-ref link-reveal xref-bibr">614</a>,<a href="javascript:;" reveal-id="ehae178-B615" data-open="ehae178-B615" class="link link-ref link-reveal xref-bibr">615</a></sup>

## 9\. Managing specific patient groups or circumstances

### 9.1. Young adulthood (18–40 years)

#### 9.1.1. Definition and epidemiology

In the present guidelines ‘young adulthood’ is defined as age 18–40 years. The prevalence of hypertension in young adults is increasing in men and women.<sup><a href="javascript:;" reveal-id="ehae178-B616 ehae178-B617 ehae178-B618" data-open="ehae178-B616 ehae178-B617 ehae178-B618" class="link link-ref link-reveal xref-bibr">616–618</a></sup> Unhealthy lifestyle, gender, obesity, and socio-economic factors contribute.<sup><a href="javascript:;" reveal-id="ehae178-B617" data-open="ehae178-B617" class="link link-ref link-reveal xref-bibr">617</a>,<a href="javascript:;" reveal-id="ehae178-B619 ehae178-B620 ehae178-B621" data-open="ehae178-B619 ehae178-B620 ehae178-B621" class="link link-ref link-reveal xref-bibr">619–621</a></sup> Hypertension-attributable CVD burden in young adults, evaluated as mortality or years of living with disability, has increased in the last decades, especially in low- and middle-income countries and in men.<sup><a href="javascript:;" reveal-id="ehae178-B622" data-open="ehae178-B622" class="link link-ref link-reveal xref-bibr">622</a></sup> Hypertension awareness, treatment, and control in young adults is lower than in other age categories, a result driven by worse control in young men.<sup><a href="javascript:;" reveal-id="ehae178-B623" data-open="ehae178-B623" class="link link-ref link-reveal xref-bibr">623</a></sup>

Systolic and diastolic hypertension and isolated diastolic hypertension are associated with increased CVD risk in the young (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B624" data-open="ehae178-B624" class="link link-ref link-reveal xref-bibr">624</a></sup> Isolated systolic hypertension in the young is discussed in _Section [9.4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8.4)._

#### 9.1.2. Secondary hypertension in young adulthood

Secondary hypertension is more frequent in younger than in later-onset hypertension, with a prevalence of 15%–30% in hypertensive young adults reported from some referral centres.<sup><a href="javascript:;" reveal-id="ehae178-B625" data-open="ehae178-B625" class="link link-ref link-reveal xref-bibr">625</a>,<a href="javascript:;" reveal-id="ehae178-B626" data-open="ehae178-B626" class="link link-ref link-reveal xref-bibr">626</a></sup> Major causes of secondary hypertension include drug-induced hypertension (e.g. oestrogen-progesterone oral contraceptives; cold medication) and primary aldosteronism. The use of recreational drugs/substances, as well as supplements and energy drinks should be investigated (see _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6)_).

Combined oestrogen-progesterone contraceptives are among the most common causes of drug-induced hypertension in young women,<sup><a href="javascript:;" reveal-id="ehae178-B627" data-open="ehae178-B627" class="link link-ref link-reveal xref-bibr">627</a>,<a href="javascript:;" reveal-id="ehae178-B628" data-open="ehae178-B628" class="link link-ref link-reveal xref-bibr">628</a></sup> and should not be used in hypertensive women unless there is no other method available or acceptable to the patient.<sup><a href="javascript:;" reveal-id="ehae178-B629" data-open="ehae178-B629" class="link link-ref link-reveal xref-bibr">629</a></sup> Conversely, progestin-only contraceptives are generally considered safe in women with hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B89" data-open="ehae178-B89" class="link link-ref link-reveal xref-bibr">89</a>,<a href="javascript:;" reveal-id="ehae178-B630" data-open="ehae178-B630" class="link link-ref link-reveal xref-bibr">630</a>,<a href="javascript:;" reveal-id="ehae178-B631" data-open="ehae178-B631" class="link link-ref link-reveal xref-bibr">631</a></sup> Fibromuscular dysplasia should be considered as a cause of secondary hypertension in young women,<sup><a href="javascript:;" reveal-id="ehae178-B626" data-open="ehae178-B626" class="link link-ref link-reveal xref-bibr">626</a>,<a href="javascript:;" reveal-id="ehae178-B632" data-open="ehae178-B632" class="link link-ref link-reveal xref-bibr">632</a></sup> whereas primary aldosteronism, the most common form of secondary hypertension, is equally common in different age classes.<sup><a href="javascript:;" reveal-id="ehae178-B316" data-open="ehae178-B316" class="link link-ref link-reveal xref-bibr">316</a></sup> Screening for secondary hypertension is thus recommended in young adults with hypertension. However, in obese young adults, primary hypertension is more common, though OSAS should also be considered in this instance.<sup><a href="javascript:;" reveal-id="ehae178-B633" data-open="ehae178-B633" class="link link-ref link-reveal xref-bibr">633</a></sup>

#### 9.1.3. Measurement and management of blood pressure in young adults

Out-of-office BP measurement is recommended in young adults for confirming diagnosis, since the white-coat phenomenon occurs in the young.<sup><a href="javascript:;" reveal-id="ehae178-B634" data-open="ehae178-B634" class="link link-ref link-reveal xref-bibr">634</a></sup> Because of the lower absolute CVD risk in this age category compared with older adults, hard-endpoint randomized trials of BP lowering in young adults have not been performed. However, since relative risk reduction by BP-lowering treatment is homogeneous in any age group, including those <55 years old,<sup><a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a></sup> young adults with suitable indications are also expected to benefit from BP-lowering therapy. The hypertension management algorithm based on CVD risk proposed in _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_ is not fully applicable in young adults, since SCORE2 has not been validated for individuals <40 years old. Even risk stratification based on lifetime risk assessment does not apply to very young adults (e.g. 20–30 years of age).<sup><a href="javascript:;" reveal-id="ehae178-B128" data-open="ehae178-B128" class="link link-ref link-reveal xref-bibr">128</a></sup> In the absence of established CVD, diabetes mellitus, familial hypercholesterolaemia, and moderate or severe CKD a BP-lowering treatment initiation threshold of office 140/90 mmHg is appropriate in most young adults. However, HMOD assessment may be considered in patients aged <40 years to stratify individuals with elevated BP into a higher risk category. For example, arterial stiffness better reclassifies CVD risk in individuals aged <50 years than in older individuals.<sup><a href="javascript:;" reveal-id="ehae178-B28" data-open="ehae178-B28" class="link link-ref link-reveal xref-bibr">28</a>,<a href="javascript:;" reveal-id="ehae178-B215" data-open="ehae178-B215" class="link link-ref link-reveal xref-bibr">215</a></sup> Echocardiographic left ventricular mass also maintains its added reclassification and discrimination on top of risk scores in young adults (see _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_ for discussion of risk modifiers).<sup><a href="javascript:;" reveal-id="ehae178-B289" data-open="ehae178-B289" class="link link-ref link-reveal xref-bibr">289</a></sup>

Irrespective of cardiovascular risk, all young adults with elevated BP are recommended to follow lifestyle guidance for BP lowering. A discussion about family planning should be taken with young women of childbearing potential at each visit.<sup><a href="javascript:;" reveal-id="ehae178-B635" data-open="ehae178-B635" class="link link-ref link-reveal xref-bibr">635</a>,<a href="javascript:;" reveal-id="ehae178-B636" data-open="ehae178-B636" class="link link-ref link-reveal xref-bibr">636</a></sup>

Adherence to treatment is low in young adults, <50% in some studies.<sup><a href="javascript:;" reveal-id="ehae178-B251" data-open="ehae178-B251" class="link link-ref link-reveal xref-bibr">251</a></sup> Therefore, communicating the importance of adherence, education, and follow-up clinics is important. (see _Sections [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6)_ and _[11](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s10)_).

Recommendation Table 21

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376073)

Recommendations for managing hypertension in young adults (see Evidence Tables 36 and 37)

![Recommendations for managing hypertension in young adults (see Evidence Tables 36 and 37)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt21.jpeg?Expires=1728462844&Signature=IbGHsT7m26h6J0O1EWY7rinCj-Zyv3mRLTYG1nX88vx4JYMLE4qjXLCHa6o-aeXUL0LPXO7VNrSF5SZGO4mN05eyAm4x4fhhvHhKcLfTRTfHxxnZ7~piDOM~~weFdOsBBUFxPanPmzsIVkwY9xSD72KxUfzvp8-ajpmMEK5DxH7E~mj~MX8lL6xKvDSM8s4f7EKH4M87LzagY8S5VsNsREskSlVwSR5~dJl4RxkRRUISObpayk1yA1GLmt9TJqbYF-H~vMU6XCJnhgCq2rI1tV26vW1niex1frPbPgacfntd1PzDAiCombYodzT4a-RWLZShWnLdojSe40Lkv09zkA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.2. Pregnancy

#### 9.2.1. Definition and epidemiology

Hypertension in pregnancy is typically defined as systolic BP of ≥140 mmHg and/or diastolic BP of ≥90 mmHg, measured using repeated BP readings in the office or hospital on two separate occasions or ≥15 min apart in severe hypertension (≥160/110 mmHg).<sup><a href="javascript:;" reveal-id="ehae178-B1" data-open="ehae178-B1" class="link link-ref link-reveal xref-bibr">1</a>,<a href="javascript:;" reveal-id="ehae178-B637" data-open="ehae178-B637" class="link link-ref link-reveal xref-bibr">637</a>,<a href="javascript:;" reveal-id="ehae178-B638" data-open="ehae178-B638" class="link link-ref link-reveal xref-bibr">638</a></sup>

Hypertension in pregnancy is the second leading cause of maternal death after maternal peri-partum haemorrhage.<sup><a href="javascript:;" reveal-id="ehae178-B639" data-open="ehae178-B639" class="link link-ref link-reveal xref-bibr">639</a></sup> Approximately 7% of pregnancies are complicated by hypertension, of which 3% are due to pre-eclampsia and around 1% are chronic or pre-existing hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B640" data-open="ehae178-B640" class="link link-ref link-reveal xref-bibr">640</a></sup> Women with a history of hypertensive disorders during pregnancy are at increased risk of subsequent hypertension and CVD.<sup><a href="javascript:;" reveal-id="ehae178-B640 ehae178-B641 ehae178-B642" data-open="ehae178-B640 ehae178-B641 ehae178-B642" class="link link-ref link-reveal xref-bibr">640–642</a></sup>

#### 9.2.2. Classifying hypertension in pregnancy

Hypertension in pregnancy includes:

-   **Chronic hypertension:** precedes pregnancy, develops before 20 weeks of gestation, persists for >6 weeks post-partum, and may be associated with proteinuria.
    
-   **Gestational hypertension:** develops after 20 weeks of gestation and usually resolves within 6 weeks post-partum.
    
-   **Antenatally unclassifiable hypertension:** BP is first recorded after 20 weeks of gestation, and hypertension is diagnosed but it is unclear if chronic or not; reassessment is necessary 6 weeks post-partum.
    
-   **Pre-eclampsia:** gestational hypertension accompanied by new-onset: (i) proteinuria (>0.3 g/day or ≥30 mg/mmol ACR), (ii) other maternal organ dysfunction, including acute kidney injury (serum creatinine ≥ 1 mg/dL), liver dysfunction (elevated transaminases > 40 UI/L with or without right upper quadrant or epigastric abdominal pain), neurological complications (convulsions, altered mental status, blindness, stroke, severe headaches, and persistent visual scotomata), or haematological complications (platelet count < 150 000/µL, disseminated intravascular coagulation, haemolysis), or (iii) uteroplacental dysfunction (such as foetal growth restriction, abnormal umbilical artery Doppler waveform analysis, or stillbirth).<sup><a href="javascript:;" reveal-id="ehae178-B643" data-open="ehae178-B643" class="link link-ref link-reveal xref-bibr">643</a></sup> The only cure for pre-eclampsia is delivery, which is recommended at 37 weeks’ gestation, or earlier in high-risk cases. Of note, proteinuria is not mandatory for diagnosing pre-eclampsia but is present in about 70% of cases.<sup><a href="javascript:;" reveal-id="ehae178-B644" data-open="ehae178-B644" class="link link-ref link-reveal xref-bibr">644</a></sup> Also, as proteinuria may be a late manifestation of pre-eclampsia, it should be suspected when _de novo_ hypertension is accompanied by headache, visual disturbances, abdominal pain, or abnormal laboratory tests, specifically low platelets and/or abnormal liver function.
    

Other potential causes for high BP, including pain and anxiety, must be excluded when treating hypertension during pregnancy.

#### 9.2.3. Measuring blood pressure in pregnancy

See _Section [5.5.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4.5.1)_ for information on BP measurement approaches in pregnancy.<sup><a href="javascript:;" reveal-id="ehae178-B645" data-open="ehae178-B645" class="link link-ref link-reveal xref-bibr">645</a></sup> It is important to restate here that oscillometric devices tend to under-estimate the true BP and are unreliable in severe pre-eclampsia; only a few have been validated in pregnancy. Importantly, only the relatively few devices validated for measuring BP in pregnancy and pre-eclampsia should be used ([https://stridebp.org](https://stridebp.org)).

#### 9.2.4. Investigating hypertension in pregnancy

Basic laboratory investigations include urinalysis, blood count, haematocrit, liver enzymes, serum creatinine, and serum uric acid. Serum uric acid is increased in pre-eclampsia and identifies women at increased risk of adverse maternal and foetal outcomes in hypertensive pregnancies.<sup><a href="javascript:;" reveal-id="ehae178-B646" data-open="ehae178-B646" class="link link-ref link-reveal xref-bibr">646</a></sup>

All pregnant women should be assessed for proteinuria in early pregnancy (e.g. 11–14 weeks’ gestation).<sup><a href="javascript:;" reveal-id="ehae178-B647" data-open="ehae178-B647" class="link link-ref link-reveal xref-bibr">647</a></sup> A dipstick test of ≥1+ should prompt further investigations, including ACR, which can be quickly determined in a single spot-urine sample.<sup><a href="javascript:;" reveal-id="ehae178-B648" data-open="ehae178-B648" class="link link-ref link-reveal xref-bibr">648</a></sup> An ACR of <30 mg/mmol (<0.3 mg/mg) can rule out proteinuria.<sup><a href="javascript:;" reveal-id="ehae178-B649" data-open="ehae178-B649" class="link link-ref link-reveal xref-bibr">649</a></sup> Higher values should prompt 24 h urine collection.

In one study, 10% of pregnant women with chronic hypertension had secondary hypertension (estimated to affect 0.24% of all pregnancies).<sup><a href="javascript:;" reveal-id="ehae178-B650" data-open="ehae178-B650" class="link link-ref link-reveal xref-bibr">650</a></sup> Secondary hypertension during pregnancy is associated with an increased risk of adverse outcomes.<sup><a href="javascript:;" reveal-id="ehae178-B650" data-open="ehae178-B650" class="link link-ref link-reveal xref-bibr">650</a></sup> The most common cause of secondary hypertension during pregnancy is CKD. The onset of hypertension during the first trimester, at the peak of human chorionic gonadotropin (HCG) secretion, should prompt consideration of primary aldosteronism.<sup><a href="javascript:;" reveal-id="ehae178-B651" data-open="ehae178-B651" class="link link-ref link-reveal xref-bibr">651</a></sup> Phaeochromocytoma in pregnant women is rare (0.002% of all pregnancies) but highly morbid.<sup><a href="javascript:;" reveal-id="ehae178-B652" data-open="ehae178-B652" class="link link-ref link-reveal xref-bibr">652</a>,<a href="javascript:;" reveal-id="ehae178-B653" data-open="ehae178-B653" class="link link-ref link-reveal xref-bibr">653</a></sup>

#### 9.2.5. Preventing hypertension and pre-eclampsia

Low-to-moderate-intensity exercise, especially if supervised and initiated during the first trimester of pregnancy, decreases the incidence of developing gestational hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B654" data-open="ehae178-B654" class="link link-ref link-reveal xref-bibr">654</a></sup> As such, after consultation with their obstetrician, all pregnant women should participate in physical activity, unless contraindicated.<sup><a href="javascript:;" reveal-id="ehae178-B655" data-open="ehae178-B655" class="link link-ref link-reveal xref-bibr">655</a></sup> Factors indicating risk of pre-eclampsia are discussed in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA).

Women at high or moderate risk of pre-eclampsia should be advised to take 100–150 mg of aspirin daily at bedtime from gestational weeks 12–36.<sup><a href="javascript:;" reveal-id="ehae178-B647" data-open="ehae178-B647" class="link link-ref link-reveal xref-bibr">647</a>,<a href="javascript:;" reveal-id="ehae178-B656" data-open="ehae178-B656" class="link link-ref link-reveal xref-bibr">656</a>,<a href="javascript:;" reveal-id="ehae178-B657" data-open="ehae178-B657" class="link link-ref link-reveal xref-bibr">657</a></sup>

Oral calcium supplementation of 0.5–2 g daily is recommended for preventing pre-eclampsia in women with low dietary intake of calcium (<600 mg daily).<sup><a href="javascript:;" reveal-id="ehae178-B658" data-open="ehae178-B658" class="link link-ref link-reveal xref-bibr">658</a>,<a href="javascript:;" reveal-id="ehae178-B659" data-open="ehae178-B659" class="link link-ref link-reveal xref-bibr">659</a></sup>

#### 9.2.6. Treatment initiation and blood pressure targets

Acute management of BP in pre-eclampsia and eclampsia is detailed in _Section [10.4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s9.4)_.

Meta-analyses have found no evidence for an increased risk for delivering small-for-gestational-age babies in pregnant women with mild hypertension receiving BP-lowering medications.<sup><a href="javascript:;" reveal-id="ehae178-B660" data-open="ehae178-B660" class="link link-ref link-reveal xref-bibr">660</a></sup> Despite a historical paucity of trial data, previous European guidelines<sup><a href="javascript:;" reveal-id="ehae178-B1" data-open="ehae178-B1" class="link link-ref link-reveal xref-bibr">1</a>,<a href="javascript:;" reveal-id="ehae178-B89" data-open="ehae178-B89" class="link link-ref link-reveal xref-bibr">89</a></sup> recommended initiating BP-lowering drug treatment (i) in all women with persistently elevated office BP of ≥150/90 mmHg, and (ii) in women with gestational hypertension (with or without proteinuria), pre-existing hypertension with superimposed gestational hypertension, or hypertension with subclinical HMOD, when office BP is >140/90 mmHg.

In the CHAP trial, treating pregnant women with chronic hypertension and BP of ≥140/90 mmHg reduced the occurrence of pre-eclampsia with severe features, and reduced medically indicated pre-term birth <35 weeks, compared with only treating severe hypertension (BP ≥ 160/105 mmHg).<sup><a href="javascript:;" reveal-id="ehae178-B88" data-open="ehae178-B88" class="link link-ref link-reveal xref-bibr">88</a></sup> Tight BP control (target diastolic BP < 85 mmHg) compared with less-tight BP control (target diastolic BP < 100 mmHg) reduces the incidence of subsequent severe maternal hypertension (BP ≥ 160/110 mmHg), but not foetal or other maternal outcomes in women with mild hypertension at baseline (diastolic BP of 85–105 mmHg).<sup><a href="javascript:;" reveal-id="ehae178-B661" data-open="ehae178-B661" class="link link-ref link-reveal xref-bibr">661</a></sup>

Treatment with BP-lowering drugs in all pregnant women with confirmed BP of ≥140/90 mmHg is recommended to reduce the progression to severe hypertension and the related risks for adverse pregnancy outcomes.<sup><a href="javascript:;" reveal-id="ehae178-B660" data-open="ehae178-B660" class="link link-ref link-reveal xref-bibr">660</a>,<a href="javascript:;" reveal-id="ehae178-B661" data-open="ehae178-B661" class="link link-ref link-reveal xref-bibr">661</a></sup> In women with pre-existing and gestational hypertension with and without pre-eclampsia, we recommend lowering BP below 140 mmHg for systolic and to 80–90 mmHg for diastolic BP.<sup><a href="javascript:;" reveal-id="ehae178-B661" data-open="ehae178-B661" class="link link-ref link-reveal xref-bibr">661</a></sup> Evidence to support a BP target as low as 120–129/70–79 mmHg is lacking in pregnancy, though such evidence exists for non-pregnant patients receiving BP-lowering medication.

#### 9.2.7. Managing mild hypertension in pregnancy (office blood pressure 140–159/90–109 mmHg)

RAS inhibitors are not recommended in pregnancy due to adverse foetal and neonatal outcomes. The BP-lowering drugs of choice are: beta-blockers (most data are available for labetalol, a non-selective beta-blocker that also acts as an alpha-blocker in higher doses; metoprolol and bisoprolol are also considered safe), dihydropyridine CCBs (most data are available for nifedipine, which is generally considered first choice, also felodipine, nitrendipine, amlodipine, and isradipine can be used), and methyldopa.<sup><a href="javascript:;" reveal-id="ehae178-B662" data-open="ehae178-B662" class="link link-ref link-reveal xref-bibr">662</a>,<a href="javascript:;" reveal-id="ehae178-B663" data-open="ehae178-B663" class="link link-ref link-reveal xref-bibr">663</a></sup> A meta-analysis suggests that beta-blockers and CCBs are more effective than methyldopa in preventing severe hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B660" data-open="ehae178-B660" class="link link-ref link-reveal xref-bibr">660</a></sup> Of note, however, atenolol should be avoided, as it is associated with foetal growth restriction.<sup><a href="javascript:;" reveal-id="ehae178-B664" data-open="ehae178-B664" class="link link-ref link-reveal xref-bibr">664</a>,<a href="javascript:;" reveal-id="ehae178-B665" data-open="ehae178-B665" class="link link-ref link-reveal xref-bibr">665</a></sup> Methyldopa has been associated with an increased risk of post-partum depression and caution is therefore advised both intra-partum and post-partum.<sup><a href="javascript:;" reveal-id="ehae178-B637" data-open="ehae178-B637" class="link link-ref link-reveal xref-bibr">637</a></sup> Hydralazine can be particularly effective for severe hypertension in pregnancy and can be administered intravenously in hypertensive admissions (_Section [10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s9)_).<sup><a href="javascript:;" reveal-id="ehae178-B666 ehae178-B667 ehae178-B668" data-open="ehae178-B666 ehae178-B667 ehae178-B668" class="link link-ref link-reveal xref-bibr">666–668</a></sup> While thiazide diuretics in pregnancy have limited safety data and should be used with caution, other diuretics such as furosemide are not contraindicated and may be necessary in some situations (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B669" data-open="ehae178-B669" class="link link-ref link-reveal xref-bibr">669</a></sup>

#### 9.2.8. Managing severe hypertension in pregnancy (>160/110 mmHg)

Acute onset of severe hypertension persisting for more than 15 min is considered a hypertensive emergency in pregnancy and is covered in _Section [10.4.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s9.4.2)._

#### 9.2.9. Managing blood pressure post-partum

For women with hypertension during pregnancy, BP should be measured within 6 h of delivery and, if possible, daily for at least a week after discharge from the hospital.<sup><a href="javascript:;" reveal-id="ehae178-B637" data-open="ehae178-B637" class="link link-ref link-reveal xref-bibr">637</a></sup> Post-partum hypertension is common in the first week and associated with prolonged hospitalization.<sup><a href="javascript:;" reveal-id="ehae178-B670" data-open="ehae178-B670" class="link link-ref link-reveal xref-bibr">670</a></sup>

Women with hypertension in pregnancy are at increased risk of chronic hypertension,<sup><a href="javascript:;" reveal-id="ehae178-B671" data-open="ehae178-B671" class="link link-ref link-reveal xref-bibr">671</a></sup> CKD,<sup><a href="javascript:;" reveal-id="ehae178-B672" data-open="ehae178-B672" class="link link-ref link-reveal xref-bibr">672</a></sup> and CVD.<sup><a href="javascript:;" reveal-id="ehae178-B177" data-open="ehae178-B177" class="link link-ref link-reveal xref-bibr">177</a>,<a href="javascript:;" reveal-id="ehae178-B223" data-open="ehae178-B223" class="link link-ref link-reveal xref-bibr">223</a>,<a href="javascript:;" reveal-id="ehae178-B640" data-open="ehae178-B640" class="link link-ref link-reveal xref-bibr">640</a></sup> The relative risk of chronic hypertension is highest in the first 6 months following delivery, motivating regular screening in these women.<sup><a href="javascript:;" reveal-id="ehae178-B673" data-open="ehae178-B673" class="link link-ref link-reveal xref-bibr">673</a></sup> Women with gestational hypertension, especially those with pre-eclampsia, have higher risk of masked hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B674" data-open="ehae178-B674" class="link link-ref link-reveal xref-bibr">674</a></sup> BP measurements, ideally including out-of-office measurements, urine analyses, and CVD risk assessment, should at least be performed 6–12 weeks, 6 months, and 12 months post-partum and, after that, annually. Recent data indicate the potential utility of self-monitoring of BP during the busy early post-partum period.<sup><a href="javascript:;" reveal-id="ehae178-B675" data-open="ehae178-B675" class="link link-ref link-reveal xref-bibr">675</a></sup>

All BP-lowering drugs are excreted into breast milk.<sup><a href="javascript:;" reveal-id="ehae178-B637" data-open="ehae178-B637" class="link link-ref link-reveal xref-bibr">637</a></sup> Except for propranolol, atenolol, acebutolol, and nifedipine, most drugs are excreted in very low concentrations in breast milk (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S11](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><a href="javascript:;" reveal-id="ehae178-B637" data-open="ehae178-B637" class="link link-ref link-reveal xref-bibr">637</a></sup>

#### 9.2.10. Risk of recurrence of hypertensive disorders in a subsequent pregnancy

About 20%–30% of women with hypertensive disorders in a previous pregnancy will experience recurrence in a subsequent pregnancy.<sup><a href="javascript:;" reveal-id="ehae178-B676" data-open="ehae178-B676" class="link link-ref link-reveal xref-bibr">676</a>,<a href="javascript:;" reveal-id="ehae178-B677" data-open="ehae178-B677" class="link link-ref link-reveal xref-bibr">677</a></sup> The earlier the onset of hypertension in the first pregnancy, the higher the risk of recurrence in a subsequent pregnancy.<sup><a href="javascript:;" reveal-id="ehae178-B677" data-open="ehae178-B677" class="link link-ref link-reveal xref-bibr">677</a></sup>

Further details on managing hypertension and other cardiovascular disorders in pregnancy are available elsewhere.<sup><a href="javascript:;" reveal-id="ehae178-B89" data-open="ehae178-B89" class="link link-ref link-reveal xref-bibr">89</a>,<a href="javascript:;" reveal-id="ehae178-B637" data-open="ehae178-B637" class="link link-ref link-reveal xref-bibr">637</a></sup>

Recommendation Table 22

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376108)

Recommendations for managing hypertension in pregnancy (see Evidence Tables 38–40)

![Recommendations for managing hypertension in pregnancy (see Evidence Tables 38–40)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt22.jpeg?Expires=1728462845&Signature=El5Koazz9cNjasY3XqAEjoNmf9LPaVZWenHUIkNkJF28zetFzkHxs1765jImVGwzWSjws~RzWR1FXp1MqAo4d5TwUwLIiU3GRoBjsFx2ihiI6QBgp11JfTnbicouCgjMZk7Wi17-SDnVJpEcqxiJMuJiCnY5L9X4CjuudLasOsH3RYzqv8YGhUi6ORp5hJaYWTDB7BWbXO2Ds~duDAaB-Kk8ZmUm4G2PgnRsvKr4hvAL0VLnl-kYyt50evrqlH77X7N5MCZ-8bqGAdUXCf2qhdtuRRhhqHOzrURZbA96E5qHYH4cqIFNklmHH41A0lk-oMvJyqI1KRpfMjn9VwV1CQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.3. Very old age (≥85 years), frailty, multimorbidity, and polypharmacy

#### 9.3.1. Definition of frailty

The most common definition of frailty is an age-associated, biological syndrome characterized by decreased biological reserves, due to dysregulation of several physiological systems.<sup><a href="javascript:;" reveal-id="ehae178-B682" data-open="ehae178-B682" class="link link-ref link-reveal xref-bibr">682</a></sup> This puts an individual at risk when facing physiological stressors, and is associated with poor outcomes, such as disability, hospitalization, and death.<sup><a href="javascript:;" reveal-id="ehae178-B683" data-open="ehae178-B683" class="link link-ref link-reveal xref-bibr">683</a></sup> The estimated prevalence of frailty in people aged >65 years is 7%–16% and is greater in women than in men.<sup><a href="javascript:;" reveal-id="ehae178-B684" data-open="ehae178-B684" class="link link-ref link-reveal xref-bibr">684</a>,<a href="javascript:;" reveal-id="ehae178-B685" data-open="ehae178-B685" class="link link-ref link-reveal xref-bibr">685</a></sup> Although the main determinant of frailty is age, chronological age must be differentiated from biological age.<sup><a href="javascript:;" reveal-id="ehae178-B686" data-open="ehae178-B686" class="link link-ref link-reveal xref-bibr">686</a></sup> An older patient can be fit and robust while a multimorbid young patient can be frail. Using multiple drugs may have more unpredictable effects on BP in older patients, because of increased competition for underlying mechanisms responsible for their degradation and elimination, and because the ability of the baro-<sup><a href="javascript:;" reveal-id="ehae178-B687" data-open="ehae178-B687" class="link link-ref link-reveal xref-bibr">687</a></sup> and chemo-reflex<sup><a href="javascript:;" reveal-id="ehae178-B688" data-open="ehae178-B688" class="link link-ref link-reveal xref-bibr">688</a></sup> systems in maintaining a steady treated BP level can decline with ageing.

With respect to BP, two issues compound interpretation of the frailty literature. First, frailty on its own is a strong predictor of mortality and cardiovascular complications<sup><a href="javascript:;" reveal-id="ehae178-B689" data-open="ehae178-B689" class="link link-ref link-reveal xref-bibr">689</a></sup> and is accompanied by a decrease in systolic BP.<sup><a href="javascript:;" reveal-id="ehae178-B690" data-open="ehae178-B690" class="link link-ref link-reveal xref-bibr">690</a></sup> This raises the issue of the so-called BP J-curve (see _Section [9.8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8.8)_) and reverse causality, with frailty rather than excessive BP lowering being the root cause of adverse health outcomes. Only properly randomized and controlled clinical trials can differentiate between the effects of frailty vs. overly intensive BP-lowering treatment, but unfortunately, few BP-lowering trials have included a substantial proportion of frail patients. Second, there is no consensus on how to grade frailty in day-to-day clinical practice.<sup><a href="javascript:;" reveal-id="ehae178-B606" data-open="ehae178-B606" class="link link-ref link-reveal xref-bibr">606</a></sup> Complex frailty scales exist for application in research,<sup><a href="javascript:;" reveal-id="ehae178-B523" data-open="ehae178-B523" class="link link-ref link-reveal xref-bibr">523</a>,<a href="javascript:;" reveal-id="ehae178-B691" data-open="ehae178-B691" class="link link-ref link-reveal xref-bibr">691</a></sup> but unless they are electronically generated,<sup><a href="javascript:;" reveal-id="ehae178-B692" data-open="ehae178-B692" class="link link-ref link-reveal xref-bibr">692</a></sup> they are typically not practical in routine clinical care. Nonetheless, the clinical frailty scale (_[Figure 21](javascript:;)_) is intuitive and easy to administer and has been validated against 5-year risk of death.<sup><a href="javascript:;" reveal-id="ehae178-B596" data-open="ehae178-B596" class="link link-ref link-reveal xref-bibr">596</a>,<a href="javascript:;" reveal-id="ehae178-B693" data-open="ehae178-B693" class="link link-ref link-reveal xref-bibr">693</a></sup>

![Frailty assessment in the management of blood pressure.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f21.jpeg?Expires=1728462845&Signature=G~uJ3Zba~oV5w9jc-H-slAdvR76ONw8eMn7eHj0nlGoXsiRp7hwh9PaLV~aj7ne9lYR5S1SFO0l9LLN1WVwn~W-1d0CZH3mF2zJBMe9n1mVq5e~lT4inGBDty9Tubp1j9M74HvTmLUN8YdItdBMEIN3vDlUweOxAA2lTD8L-I4I2LVztBiU10tu~8bEUv3TTyV1U0OscU-dJtL46uGjbfHQ9u0HLJfL8UF~2W6QqFx8q4V4XK8PSiT0~XL52do3UgeCl2U056nNopDXeftkfR9wi4nQ5Lxz5j4SbF3rxc-V4Nt6IvD2NH7PO~BLevCTNYf8zaxkNqF4v71CJtzwkgw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 21

Frailty assessment in the management of blood pressure.

ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CV, cardiovascular; CVD, cardiovascular disease; HBPM, home blood pressure monitoring; IADLs, independent activities of daily living; OH, orthostatic hypotension. Adapted from Rockwood _et al_.<sup><a href="javascript:;" reveal-id="ehae178-B693" data-open="ehae178-B693" class="link link-ref link-reveal xref-bibr">693</a></sup>

[Open in new tab](https://academic.oup.com/view-large/figure/479376113/ehae178f21.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f21.jpeg?Expires=1728462845&Signature=HjsQxuDErWKqpFc-a9a3KA1wbXKdg5tRqgH5IBdVqQuuQKdrgu10HaQe-sE3k5qGbkx7l7EslTzGesOYFdFgjl-5c0kigTi3WM5w22jTjkEvRhvao40s5AGuyO52mSdFNIeRees~jQgFJ2odiHDxCDLeRAXooYGgQhwnOYgWGWeITpjTHyfkgi1WUeFIm5Xx1HkFN6FAh9M66jXDowVeQ0bq5~4Q-2RTKFL7g~ItEC5mQkz~NCi8LTHOolxbw3j~VkgBFWG4YLn2e9hcRZRpvK82Oyk0lHiPQaWR5MHegfEZHh2bV07RIyLhpxh~JwjlacSHU0yCLq-XYpDT6YqI6w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479376113&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

#### 9.3.2. Randomized controlled trials of blood pressure lowering in frail older patients

Few adults aged ≥85 years have been included in trials.<sup><a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a></sup> In addition, generalizing data from RCTs to very frail patients may not be possible.<sup><a href="javascript:;" reveal-id="ehae178-B692" data-open="ehae178-B692" class="link link-ref link-reveal xref-bibr">692</a>,<a href="javascript:;" reveal-id="ehae178-B694 ehae178-B695 ehae178-B696 ehae178-B697" data-open="ehae178-B694 ehae178-B695 ehae178-B696 ehae178-B697" class="link link-ref link-reveal xref-bibr">694–697</a></sup> However, the currently available evidence from RCTs has not demonstrated weakening of the benefits of BP-lowering treatment (i.e. no effect modification) among frailer patients enrolled in these trials, although these participants likely had no more than mild frailty (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B523" data-open="ehae178-B523" class="link link-ref link-reveal xref-bibr">523</a>,<a href="javascript:;" reveal-id="ehae178-B694" data-open="ehae178-B694" class="link link-ref link-reveal xref-bibr">694</a>,<a href="javascript:;" reveal-id="ehae178-B698" data-open="ehae178-B698" class="link link-ref link-reveal xref-bibr">698</a></sup>

In the absence of robust randomized evidence, several observational studies have suggested that lowering BP might not be warranted or even be harmful in patients with significant frailty or multimorbidity, particularly when BP is not very high. For instance, a systematic review and meta-analysis of non-randomized studies that investigated associations between BP and risk of mortality in older patients found evidence for interaction by frailty status, suggesting that lowering BP might be harmful in this patient group.<sup><a href="javascript:;" reveal-id="ehae178-B699" data-open="ehae178-B699" class="link link-ref link-reveal xref-bibr">699</a></sup> However, as noted above and in _Section [9.8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8.8)_, these observational J-curve findings are unreliable when guiding clinical care, as unidentified biases potentially confound the results. For instance, in addition to reverse causality, stiffness of the large arteries is associated with both low diastolic BP and increased mortality.<sup><a href="javascript:;" reveal-id="ehae178-B697" data-open="ehae178-B697" class="link link-ref link-reveal xref-bibr">697</a></sup> In addition, absolute CVD risk increases with age, indicating that fewer older than younger patients with hypertension may need to be treated to prevent one adverse health outcome.<sup><a href="javascript:;" reveal-id="ehae178-B700" data-open="ehae178-B700" class="link link-ref link-reveal xref-bibr">700</a></sup>

Therefore, given the totality of evidence from clinical trials,<sup><a href="javascript:;" reveal-id="ehae178-B523" data-open="ehae178-B523" class="link link-ref link-reveal xref-bibr">523</a>,<a href="javascript:;" reveal-id="ehae178-B694" data-open="ehae178-B694" class="link link-ref link-reveal xref-bibr">694</a>,<a href="javascript:;" reveal-id="ehae178-B701" data-open="ehae178-B701" class="link link-ref link-reveal xref-bibr">701</a>,<a href="javascript:;" reveal-id="ehae178-B702" data-open="ehae178-B702" class="link link-ref link-reveal xref-bibr">702</a></sup> very old and frail patients with hypertension should not be denied the potential benefits of BP-lowering treatment down to a target of 120–129/70–79 mmHg. However, personalized decision-making should be a priority in the very old and frail. Together with management of BP, a major consideration should also be whether reversible causes of frailty can be addressed,<sup><a href="javascript:;" reveal-id="ehae178-B609" data-open="ehae178-B609" class="link link-ref link-reveal xref-bibr">609</a></sup> e.g. by treating underlying comorbidities or undergoing supervised muscle-strengthening physiotherapy or supervised exercise and co-ordination and balance training.<sup><a href="javascript:;" reveal-id="ehae178-B703" data-open="ehae178-B703" class="link link-ref link-reveal xref-bibr">703</a></sup>

#### 9.3.3. Starting blood pressure-lowering treatment in very old or frail patients

All patients must be fully informed about the benefits and risks of starting BP-lowering treatment, so that their preference is considered. Among 34 hypertension guidelines, 18 recommended 150 mmHg as the systolic goal in frailer and/or older patients, but four endorsed systolic targets <130 mmHg or <120 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B704" data-open="ehae178-B704" class="link link-ref link-reveal xref-bibr">704</a></sup> Treatment can be started with a long-acting dihydropyridine calcium channel antagonist.<sup><a href="javascript:;" reveal-id="ehae178-B596" data-open="ehae178-B596" class="link link-ref link-reveal xref-bibr">596</a>,<a href="javascript:;" reveal-id="ehae178-B705" data-open="ehae178-B705" class="link link-ref link-reveal xref-bibr">705</a></sup> To achieve BP control, an ACE inhibitor, or if contraindicated, an ARB, can also be used. Thereafter, low-dose thiazides or thiazide-like diuretics are preferred unless there is a specific contraindication, such as gout, orthostatic hypotension, or disturbed micturition (including micturition syncope).<sup><a href="javascript:;" reveal-id="ehae178-B596" data-open="ehae178-B596" class="link link-ref link-reveal xref-bibr">596</a>,<a href="javascript:;" reveal-id="ehae178-B705" data-open="ehae178-B705" class="link link-ref link-reveal xref-bibr">705</a></sup> Beta-blockers are less desirable as they reduce heart rate, cause fatigue, and increase the systolic pulse wave amplitude, which is insufficiently buffered in stiff central elastic arteries. Vasodilating beta-blockers and direct vasodilators (e.g. hydralazine and minoxidil) are associated with increased risk of orthostasis. Though data are conflicting,<sup><a href="javascript:;" reveal-id="ehae178-B706" data-open="ehae178-B706" class="link link-ref link-reveal xref-bibr">706</a></sup> alpha-blockers are also considered less desirable as they appear to be associated with an increased risk of orthostasis and falls in very old patients (aged ≥85 years).<sup><a href="javascript:;" reveal-id="ehae178-B707" data-open="ehae178-B707" class="link link-ref link-reveal xref-bibr">707</a>,<a href="javascript:;" reveal-id="ehae178-B708" data-open="ehae178-B708" class="link link-ref link-reveal xref-bibr">708</a></sup> Alpha-1 blockers, such as doxazosin, prazosin, terazosin (also used to treat prostate symptoms), are particularly prone to causing orthostasis.<sup><a href="javascript:;" reveal-id="ehae178-B98" data-open="ehae178-B98" class="link link-ref link-reveal xref-bibr">98</a></sup> Once the appropriate combination is found, a combination tablet with variable composition of two agents may optimize adherence. Starting with combination therapy is not advised in most very old and/or frail patients, unless BP is very high.

#### 9.3.4. Maintaining blood pressure lowering in very old or frail patients

If very old and frail patients tolerate BP-lowering treatment well, there is no automatic need to deprescribe or discontinue treatment; however, this should be kept under review. In the case of progressive frailty, systolic BP tends to drop,<sup><a href="javascript:;" reveal-id="ehae178-B709" data-open="ehae178-B709" class="link link-ref link-reveal xref-bibr">709</a></sup> such that deprescription of a BP-lowering drug might become necessary. To identify candidate drugs for deprescribing, a patient’s current medications should be reviewed to identify BP-lowering drugs that may have become contraindicated due to concomitant prescriptions or newly developed comorbidities.<sup><a href="javascript:;" reveal-id="ehae178-B705" data-open="ehae178-B705" class="link link-ref link-reveal xref-bibr">705</a></sup> To help guide deprescription of BP-lowering agents, ABPM can be used to detect orthostatic hypotension or a highly variable BP not buffered by autonomic nervous reflexes.<sup><a href="javascript:;" reveal-id="ehae178-B687" data-open="ehae178-B687" class="link link-ref link-reveal xref-bibr">687</a>,<a href="javascript:;" reveal-id="ehae178-B688" data-open="ehae178-B688" class="link link-ref link-reveal xref-bibr">688</a></sup>

Recommendation Table 23

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376122)

Recommendations for managing hypertension in patients who are very old or frail (see Evidence Table 41)

![Recommendations for managing hypertension in patients who are very old or frail (see Evidence Table 41)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt23.jpeg?Expires=1728462845&Signature=V~U2W9wiyBQI9g9QDdcPXmaExuXuX~30UZ6I0NDnAsUXtD0-jbEfcvyPaCZmxNb6omuDVQMuOWt77HoVX7cMcupRJYrrQ1LFpCGR3gY2WOUF2MEwAWIDmk~ppO6NK7CPfiLvn7JWsHp8jwxAbUNwxq51E9Qw8SopEIG0SNz3o1ZNmd6AtBV5odqtrpE8E1XELfh8olLOwFk3wnnHWi1QnKkTwAAblfC33mkRxC835xF6N9tPyPa7DPgbe5-3QDWpWEHgFE8B45hSRB9BczkxjRoICa0j7ZuEcevJsATzywwaR3SUMNSthHF58Wx5vGqa-TiET7JbkXE6IhqTqCPqLQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.4. Isolated systolic and diastolic hypertension

#### 9.4.1. Definition of isolated systolic hypertension

Isolated systolic hypertension is typically defined as systolic BP of ≥140 mmHg with a diastolic BP of <90 mmHg. While isolated systolic hypertension is uncommon in younger patients,<sup><a href="javascript:;" reveal-id="ehae178-B713" data-open="ehae178-B713" class="link link-ref link-reveal xref-bibr">713</a></sup> it is the most common type of hypertension in older patients; >80% of untreated patients with hypertension aged >60 years have isolated systolic hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B714" data-open="ehae178-B714" class="link link-ref link-reveal xref-bibr">714</a></sup>

#### 9.4.2. Isolated systolic hypertension, risk factors, and ageing

Systolic BP increases with age in men and women until the eighth decade of life, while diastolic BP gradually increases up until the fifth or sixth decade of life, after which it either plateaus or decreases. As a result, the pulse pressure (the difference between the systolic and diastolic BP) gradually widens from middle age.<sup><a href="javascript:;" reveal-id="ehae178-B34" data-open="ehae178-B34" class="link link-ref link-reveal xref-bibr">34</a></sup> These BP changes are related to increased aortic stiffening with age.<sup><a href="javascript:;" reveal-id="ehae178-B715" data-open="ehae178-B715" class="link link-ref link-reveal xref-bibr">715</a>,<a href="javascript:;" reveal-id="ehae178-B716" data-open="ehae178-B716" class="link link-ref link-reveal xref-bibr">716</a></sup>

Since most older patients with hypertension have isolated systolic hypertension, and since with advancing age, risk of CVD events is driven by systolic rather than diastolic BP,<sup><a href="javascript:;" reveal-id="ehae178-B717" data-open="ehae178-B717" class="link link-ref link-reveal xref-bibr">717</a></sup> management of isolated systolic hypertension in older adults is broadly in line with that of combined systolic-diastolic hypertension seen in younger adults.<sup><a href="javascript:;" reveal-id="ehae178-B718" data-open="ehae178-B718" class="link link-ref link-reveal xref-bibr">718</a></sup> Early isolated systolic hypertension studies used systolic BP treatment targets of 160 or 150 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B718" data-open="ehae178-B718" class="link link-ref link-reveal xref-bibr">718</a></sup> However, results from the SPRINT and the Strategy of Blood Pressure Intervention in Elderly Hypertensive Patients (STEP) trials (mean BP at study entry of 140/78 mmHg and 146/82 mmHg, respectively, indicating that many of the patients had isolated systolic hypertension) confirm that lower systolic BP targets are effective in reducing CVD events in patients with isolated systolic hypertension (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B135" data-open="ehae178-B135" class="link link-ref link-reveal xref-bibr">135</a>,<a href="javascript:;" reveal-id="ehae178-B136" data-open="ehae178-B136" class="link link-ref link-reveal xref-bibr">136</a></sup>

Since relative risk reduction by BP-lowering treatment is homogeneous in any age group, whereas absolute risk reduction is larger with advancing age,<sup><a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a></sup> therapeutic inertia in older patients with isolated systolic hypertension should be avoided (see _Section [9.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8.3)_). As noted earlier, beta-blockers should be avoided in patients with isolated systolic hypertension or more generally with arterial stiffness, as they increase stroke volume (given the lower heart rate).<sup><a href="javascript:;" reveal-id="ehae178-B218" data-open="ehae178-B218" class="link link-ref link-reveal xref-bibr">218</a></sup>

#### 9.4.3. Isolated systolic hypertension in young adults

In young adults (<40 years old), the presence of isolated systolic hypertension poses different pathophysiological and clinical considerations. In young patients with isolated systolic hypertension, arterial stiffness<sup><a href="javascript:;" reveal-id="ehae178-B713" data-open="ehae178-B713" class="link link-ref link-reveal xref-bibr">713</a></sup> and relative risk of CVD events<sup><a href="javascript:;" reveal-id="ehae178-B624" data-open="ehae178-B624" class="link link-ref link-reveal xref-bibr">624</a></sup> appear to be similar to those without isolated systolic hypertension and lower than young adults with combined systolic-diastolic hypertension and isolated diastolic hypertension. Indeed, younger patients with isolated systolic hypertension appear to comprise a heterogeneous group.<sup><a href="javascript:;" reveal-id="ehae178-B719" data-open="ehae178-B719" class="link link-ref link-reveal xref-bibr">719</a></sup> For these reasons, it might be reasonable to assess central BP and arterial stiffness in these individuals, as recommended by other scientific societies.<sup><a href="javascript:;" reveal-id="ehae178-B720" data-open="ehae178-B720" class="link link-ref link-reveal xref-bibr">720</a>,<a href="javascript:;" reveal-id="ehae178-B721" data-open="ehae178-B721" class="link link-ref link-reveal xref-bibr">721</a></sup> Out-of-office BP measurement is recommended to exclude white-coat hypertension, which is often associated with isolated systolic hypertension in the young.<sup><a href="javascript:;" reveal-id="ehae178-B634" data-open="ehae178-B634" class="link link-ref link-reveal xref-bibr">634</a></sup>

#### 9.4.4. Isolated diastolic hypertension

Isolated diastolic hypertension is defined as a systolic BP of <140 mmHg with a diastolic BP of ≥90 mmHg. The isolated diastolic hypertension phenotype is more commonly seen in younger adults and, particularly, younger adults with obesity or other metabolic derangements.<sup><a href="javascript:;" reveal-id="ehae178-B722" data-open="ehae178-B722" class="link link-ref link-reveal xref-bibr">722</a>,<a href="javascript:;" reveal-id="ehae178-B723" data-open="ehae178-B723" class="link link-ref link-reveal xref-bibr">723</a></sup> In older adults with this phenotype, consideration should be given to whether the diastolic BP was accurately measured.<sup><a href="javascript:;" reveal-id="ehae178-B724" data-open="ehae178-B724" class="link link-ref link-reveal xref-bibr">724</a></sup>

Patients with isolated diastolic hypertension appear to have a slightly increased relative risk for CVD of 5%–30%.<sup><a href="javascript:;" reveal-id="ehae178-B548" data-open="ehae178-B548" class="link link-ref link-reveal xref-bibr">548</a>,<a href="javascript:;" reveal-id="ehae178-B723" data-open="ehae178-B723" class="link link-ref link-reveal xref-bibr">723</a>,<a href="javascript:;" reveal-id="ehae178-B725" data-open="ehae178-B725" class="link link-ref link-reveal xref-bibr">725</a></sup> However, because patients with isolated diastolic hypertension are younger, they tend to have few events, and very large samples are required to show this association. Furthermore, because the absolute risk for CVD among these individuals is low (typically <10% over 10 years), it is less clear if isolated diastolic hypertension should prompt initiation of BP-lowering medication, particularly among persons in whom baseline systolic BP is already at the target of 120–129 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B723" data-open="ehae178-B723" class="link link-ref link-reveal xref-bibr">723</a></sup> Irrespective, patients with isolated diastolic hypertension should be followed up, as they are at increased risk for systolic hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B723" data-open="ehae178-B723" class="link link-ref link-reveal xref-bibr">723</a></sup>

Finally, it is also worth noting that when a patient achieves a target systolic BP of 120–129 mmHg with BP-lowering treatment, there is little to no high-quality trial evidence that further intensifying BP-lowering medication to achieve both systolic BP of <120 mmHg and also diastolic BP of <70 mmHg improves CVD prognosis.<sup><a href="javascript:;" reveal-id="ehae178-B547" data-open="ehae178-B547" class="link link-ref link-reveal xref-bibr">547</a>,<a href="javascript:;" reveal-id="ehae178-B723" data-open="ehae178-B723" class="link link-ref link-reveal xref-bibr">723</a></sup>

### 9.5. Orthostatic hypotension with supine hypertension

Patients with orthostatic hypotension need not be hypotensive and indeed, many have supine elevated BP or supine hypertension. Furthermore, many patients with orthostatic hypotension are asymptomatic. Orthostatic hypotension is present in around 10% of all adults with hypertension and is defined as a drop in BP of ≥20/10 mmHg after rising from either a sitting or lying position to a standing position (see _Section [5.5.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4.5.3)_).<sup><a href="javascript:;" reveal-id="ehae178-B97" data-open="ehae178-B97" class="link link-ref link-reveal xref-bibr">97</a>,<a href="javascript:;" reveal-id="ehae178-B99" data-open="ehae178-B99" class="link link-ref link-reveal xref-bibr">99</a></sup> Assessment for orthostatic hypotension should be timed to occur at 1 and/or 3 min after standing. Because seated to standing assessment can lead to under-detection of orthostatic hypotension, it is preferable, where possible, to test for orthostatic hypotension using a supine (lying) to standing assessment (see _Section [5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4)_).<sup><a href="javascript:;" reveal-id="ehae178-B56" data-open="ehae178-B56" class="link link-ref link-reveal xref-bibr">56</a>,<a href="javascript:;" reveal-id="ehae178-B98" data-open="ehae178-B98" class="link link-ref link-reveal xref-bibr">98</a>,<a href="javascript:;" reveal-id="ehae178-B726" data-open="ehae178-B726" class="link link-ref link-reveal xref-bibr">726</a></sup>

Assessing for orthostatic hypotension is important in managing adults with elevated BP or hypertension for several reasons. First, findings of trials linking more intensive BP control to improved outcomes may not generalize to patients with orthostatic hypotension, particularly when it is severe in magnitude (standing systolic BP < 110 mmHg<sup><a href="javascript:;" reveal-id="ehae178-B97" data-open="ehae178-B97" class="link link-ref link-reveal xref-bibr">97</a></sup>) and/or symptomatic. Second, orthostatic hypotension may be associated with symptoms that may limit the patient’s tolerability of more intensive BP-lowering approaches. Third, orthostatic hypotension may be associated with an increased risk of adverse effects commonly co-attributed to pharmacological BP lowering (such as hospitalizations for hypotension).<sup><a href="javascript:;" reveal-id="ehae178-B727" data-open="ehae178-B727" class="link link-ref link-reveal xref-bibr">727</a></sup> Fourth, orthostatic hypotension is associated with increased risk for CVD.<sup><a href="javascript:;" reveal-id="ehae178-B728" data-open="ehae178-B728" class="link link-ref link-reveal xref-bibr">728</a></sup>

However, the frequency of orthostatic hypotension is not increased in the more intensive BP-lowering arms of randomized trials compared with the less intensive BP-lowering arms.<sup><a href="javascript:;" reveal-id="ehae178-B726" data-open="ehae178-B726" class="link link-ref link-reveal xref-bibr">726</a>,<a href="javascript:;" reveal-id="ehae178-B727" data-open="ehae178-B727" class="link link-ref link-reveal xref-bibr">727</a>,<a href="javascript:;" reveal-id="ehae178-B729" data-open="ehae178-B729" class="link link-ref link-reveal xref-bibr">729</a>,<a href="javascript:;" reveal-id="ehae178-B730" data-open="ehae178-B730" class="link link-ref link-reveal xref-bibr">730</a></sup> As such, and in contrast to common belief, it does not appear that more intensive treatment of BP (which almost always requires more BP-lowering medication) worsens orthostatic hypotension. In contrast, there is some evidence that more intensive treatment of hypertension may actually reduce the risk of orthostatic hypotension.<sup><a href="javascript:;" reveal-id="ehae178-B730" data-open="ehae178-B730" class="link link-ref link-reveal xref-bibr">730</a>,<a href="javascript:;" reveal-id="ehae178-B731" data-open="ehae178-B731" class="link link-ref link-reveal xref-bibr">731</a></sup>

The aetiology of orthostatic hypotension may be considered as neurogenic or non-neurogenic, with the latter being far more common.<sup><a href="javascript:;" reveal-id="ehae178-B99" data-open="ehae178-B99" class="link link-ref link-reveal xref-bibr">99</a></sup> Patients with orthostatic hypotension may have underlying neurodegenerative diseases, diabetes, B12 deficiency,<sup><a href="javascript:;" reveal-id="ehae178-B732" data-open="ehae178-B732" class="link link-ref link-reveal xref-bibr">732</a></sup> renal failure, dehydration, prolonged recumbency, deconditioning, and triggering medications (like alpha-blockers, beta-blockers, diuretics, nitrates, antidepressants, and antipsychotics). Of note, ACE inhibitors, ARBs, and dihydropyridine CCBs are examples of BP-lowering medications that appear to have less impact on orthostatic hypotension, and their adverse impact, if any, on orthostatic hypotension typically occurs in the first 2 weeks or so after starting or intensifying treatment.<sup><a href="javascript:;" reveal-id="ehae178-B733" data-open="ehae178-B733" class="link link-ref link-reveal xref-bibr">733</a></sup>

Managing patients with supine hypertension and orthostatic hypotension is a common clinical conundrum. More detailed reviews on this topic are available elsewhere.<sup><a href="javascript:;" reveal-id="ehae178-B98" data-open="ehae178-B98" class="link link-ref link-reveal xref-bibr">98</a>,<a href="javascript:;" reveal-id="ehae178-B99" data-open="ehae178-B99" class="link link-ref link-reveal xref-bibr">99</a></sup> The approach to managing orthostatic hypotension should be non-pharmacological at first. Patients with orthostatic hypotension should be asked to change position slowly, maintain adequate hydration, and avoid alcohol and large meals. Compression stockings, crossing legs while standing, and abdominal binders may also help and should be trialled.<sup><a href="javascript:;" reveal-id="ehae178-B734" data-open="ehae178-B734" class="link link-ref link-reveal xref-bibr">734</a>,<a href="javascript:;" reveal-id="ehae178-B735" data-open="ehae178-B735" class="link link-ref link-reveal xref-bibr">735</a></sup> Abdominal heating pads and a head-up bed position can reduce supine (typically nocturnal) hypertension, which may reduce nocturnal diuresis and daytime orthostatic hypotension.<sup><a href="javascript:;" reveal-id="ehae178-B736" data-open="ehae178-B736" class="link link-ref link-reveal xref-bibr">736</a></sup>

The treatment of orthostatic hypotension among those with supine hypertension is not to automatically down-titrate BP-lowering medications. Rather, reversible causes should be sought and treated (including discontinuation of offending medications), and patients requiring BP-lowering medication should be switched to BP-lowering medications that are less likely to cause orthostatic hypotension. When symptoms are disabling and the above interventions do not help, particularly in neurogenic orthostatic hypotension, the best evidence exists for midodrine to reverse orthostatic hypotension, and this may be given in conjunction with ongoing BP-lowering medications when supine hypertension exists.<sup><a href="javascript:;" reveal-id="ehae178-B99" data-open="ehae178-B99" class="link link-ref link-reveal xref-bibr">99</a></sup> An alternative option to midodrine is droxidopa, though this is less readily available. Specialist referral is prudent when persons with supine hypertension are prescribed these orthostatic hypotension treatments, as these agents can increase supine BP more than standing BP.

Recommendation Table 24

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376143)

Recommendations for managing hypertension in patients with orthostatic hypotension

![Recommendations for managing hypertension in patients with orthostatic hypotension](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt24.jpeg?Expires=1728462845&Signature=FIUs0Z0N6EjwP4ZGKo5j4r6hkGKsJcYKN2JB1PlJ6GixQ~q-UtIwZy~14fXKjKd4RUb5tRNNnq2niOeSpDyQTG5b3sBtJsOjqSBTwF63x2A4ePJ3hfuGzNPATLMNPQW5hLMufUHfwqJHkfj7~lAYhWDImoJOzFzBacn2IbFucf0fZr5g4-JUa3ttmcFnm68kQKgPAWUbIg-mPBuHp-irL1KGyrqSECr~E34-nzFPlyR9CmWNUZ8IH9~dkgSCkKpftlwIMiyiU5KTGsOBZaMVdtPTZZJ-PM2WSMcP56XJusb5w613C~45x9fcBmK4uT9XnyX2FhroyBUi1oElUTfkHw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.6. Diabetes

#### 9.6.1. Diabetes and elevated blood pressure/hypertension

Patients with diabetes (both type 1 and type 2) often have elevated BP or hypertension, and are about twice as likely to suffer a major CVD event over the medium to long term compared with those without diabetes.<sup><a href="javascript:;" reveal-id="ehae178-B737" data-open="ehae178-B737" class="link link-ref link-reveal xref-bibr">737</a></sup> Diabetes is also a major cause of microvascular events, such as retinopathy and nephropathy.<sup><a href="javascript:;" reveal-id="ehae178-B738" data-open="ehae178-B738" class="link link-ref link-reveal xref-bibr">738</a>,<a href="javascript:;" reveal-id="ehae178-B739" data-open="ehae178-B739" class="link link-ref link-reveal xref-bibr">739</a></sup> Although the risk of CVD in patients with diabetes varies by screening and diagnostic methods,<sup><a href="javascript:;" reveal-id="ehae178-B740" data-open="ehae178-B740" class="link link-ref link-reveal xref-bibr">740</a>,<a href="javascript:;" reveal-id="ehae178-B741" data-open="ehae178-B741" class="link link-ref link-reveal xref-bibr">741</a></sup> as well as with the presence of other CVD risk factors,<sup><a href="javascript:;" reveal-id="ehae178-B740" data-open="ehae178-B740" class="link link-ref link-reveal xref-bibr">740</a>,<a href="javascript:;" reveal-id="ehae178-B742" data-open="ehae178-B742" class="link link-ref link-reveal xref-bibr">742</a></sup> on average, patients with diabetes are at ≥10% 10-year risk for CVD. However, formal risk estimation with the use of SCORE2-Diabetes among type 2 diabetes mellitus patients should be considered if they are aged <60 years (see _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_).<sup><a href="javascript:;" reveal-id="ehae178-B164" data-open="ehae178-B164" class="link link-ref link-reveal xref-bibr">164</a>,<a href="javascript:;" reveal-id="ehae178-B739" data-open="ehae178-B739" class="link link-ref link-reveal xref-bibr">739</a></sup>

#### 9.6.2. J-shaped curve of blood pressure and risk of cardiovascular disease in patients with diabetes

Evidence on the BP threshold and target for treatment in patients with diabetes has been subject to debate. Reports of a J-shaped association between BP and risk of CVD in diabetes,<sup><a href="javascript:;" reveal-id="ehae178-B743" data-open="ehae178-B743" class="link link-ref link-reveal xref-bibr">743</a></sup> and the lack of a clear benefit of treatment on cardiac outcomes at lower BP in some meta-analyses,<sup><a href="javascript:;" reveal-id="ehae178-B744 ehae178-B745 ehae178-B746" data-open="ehae178-B744 ehae178-B745 ehae178-B746" class="link link-ref link-reveal xref-bibr">744–746</a></sup> has led to some cautious recommendations for intensive treatment in this patient population.

An individual patient data meta-analysis by the Blood Pressure Lowering Treatment Trialists’ Collaboration tested treatment effects in 103 325 patients with diabetes and provided evidence against effect modification by categories of baseline BP down to a systolic BP of 120 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B445" data-open="ehae178-B445" class="link link-ref link-reveal xref-bibr">445</a></sup> BP reduction in patients with diabetes is expected to reduce the risk of diabetes-associated complications including retinopathy, vasculopathy, and nephropathy (albuminuria and end-stage renal disease), which adds weight to the importance of reducing BP in these patients (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B745 ehae178-B746 ehae178-B747" data-open="ehae178-B745 ehae178-B746 ehae178-B747" class="link link-ref link-reveal xref-bibr">745–747</a></sup> This task force also considered the fact that a proportion of patients with diabetes have orthostatic hypotension due to diabetic neuropathy,<sup><a href="javascript:;" reveal-id="ehae178-B748" data-open="ehae178-B748" class="link link-ref link-reveal xref-bibr">748</a></sup> which might affect the tolerability of BP lowering.

#### 9.6.3. Managing blood pressure in diabetes

We recommend that all patients with diabetes are offered pharmacological BP-lowering treatment with a BP target of 120–129/70–79 mmHg, if feasible and tolerated.<sup><a href="javascript:;" reveal-id="ehae178-B136" data-open="ehae178-B136" class="link link-ref link-reveal xref-bibr">136</a>,<a href="javascript:;" reveal-id="ehae178-B146" data-open="ehae178-B146" class="link link-ref link-reveal xref-bibr">146</a>,<a href="javascript:;" reveal-id="ehae178-B445" data-open="ehae178-B445" class="link link-ref link-reveal xref-bibr">445</a>,<a href="javascript:;" reveal-id="ehae178-B747" data-open="ehae178-B747" class="link link-ref link-reveal xref-bibr">747</a>,<a href="javascript:;" reveal-id="ehae178-B749 ehae178-B750 ehae178-B751 ehae178-B752" data-open="ehae178-B749 ehae178-B750 ehae178-B751 ehae178-B752" class="link link-ref link-reveal xref-bibr">749–752</a></sup> The task force further sees no strong evidence for a differential BP treatment targets in patients with diabetes and those without.<sup><a href="javascript:;" reveal-id="ehae178-B136" data-open="ehae178-B136" class="link link-ref link-reveal xref-bibr">136</a>,<a href="javascript:;" reveal-id="ehae178-B146" data-open="ehae178-B146" class="link link-ref link-reveal xref-bibr">146</a>,<a href="javascript:;" reveal-id="ehae178-B445" data-open="ehae178-B445" class="link link-ref link-reveal xref-bibr">445</a>,<a href="javascript:;" reveal-id="ehae178-B746" data-open="ehae178-B746" class="link link-ref link-reveal xref-bibr">746</a>,<a href="javascript:;" reveal-id="ehae178-B747" data-open="ehae178-B747" class="link link-ref link-reveal xref-bibr">747</a></sup> While the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial reported a null primary endpoint for more intensive BP targets in diabetes, stroke was marginally reduced.<sup><a href="javascript:;" reveal-id="ehae178-B137" data-open="ehae178-B137" class="link link-ref link-reveal xref-bibr">137</a></sup> Furthermore, extended follow-up of ACCORD,<sup><a href="javascript:;" reveal-id="ehae178-B750" data-open="ehae178-B750" class="link link-ref link-reveal xref-bibr">750</a></sup> as well as analyses of intensive BP reduction in those randomized to the standard glycaemic arm,<sup><a href="javascript:;" reveal-id="ehae178-B749" data-open="ehae178-B749" class="link link-ref link-reveal xref-bibr">749</a></sup> provide evidence suggesting benefit consistent with the SPRINT, STEP, and Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs (ESPRIT) trials.<sup><a href="javascript:;" reveal-id="ehae178-B136" data-open="ehae178-B136" class="link link-ref link-reveal xref-bibr">136</a>,<a href="javascript:;" reveal-id="ehae178-B146" data-open="ehae178-B146" class="link link-ref link-reveal xref-bibr">146</a>,<a href="javascript:;" reveal-id="ehae178-B545" data-open="ehae178-B545" class="link link-ref link-reveal xref-bibr">545</a></sup> Overall, all major BP-lowering medication classes are effective in preventing CVD in people with or without diabetes. Of note, however, albuminuria is more common in diabetes and, for this reason, ACE inhibitors and ARBs have potential advantages that may warrant consideration for BP-lowering in patients with diabetes (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S10](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><a href="javascript:;" reveal-id="ehae178-B753" data-open="ehae178-B753" class="link link-ref link-reveal xref-bibr">753</a></sup>

Evidence for modifying BP-lowering treatment in patients with pre-diabetes is somewhat limited. Furthermore, the relative effect of BP lowering is relatively consistent across different categories of BMI as a measure of obesity.<sup><a href="javascript:;" reveal-id="ehae178-B754" data-open="ehae178-B754" class="link link-ref link-reveal xref-bibr">754</a>,<a href="javascript:;" reveal-id="ehae178-B755" data-open="ehae178-B755" class="link link-ref link-reveal xref-bibr">755</a></sup> It is also noteworthy that elevated BP itself may increase the risk of diabetes,<sup><a href="javascript:;" reveal-id="ehae178-B755" data-open="ehae178-B755" class="link link-ref link-reveal xref-bibr">755</a></sup> emphasizing the potential role of BP lowering in preventing diabetes in addition to preventing CVD. Among the major classes of BP-lowering drugs, ACE inhibitors and ARBs are effective in preventing new-onset diabetes and can be considered in patients at risk of diabetes and who are indicated for BP-lowering therapy.<sup><a href="javascript:;" reveal-id="ehae178-B164" data-open="ehae178-B164" class="link link-ref link-reveal xref-bibr">164</a>,<a href="javascript:;" reveal-id="ehae178-B755" data-open="ehae178-B755" class="link link-ref link-reveal xref-bibr">755</a></sup>

Recommendation Table 25

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376153)

Recommendations for managing hypertension in patients with diabetes

![Recommendations for managing hypertension in patients with diabetes](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt25.jpeg?Expires=1728462845&Signature=TR37BPwlc8GOv6ewiHf5EtVXWRQX2OQq4yam3RxwriAu6ZCIt3TdHCYaCKUHWGaNuGXOUezBHGs7M~d16aywQw9mOHd5zRKDVpFWq4G8ML7Kbt2eUsU1R40juDO3QCyDADdfvtTp6A7SNiSParqbgy3XhiV1AX80y4sC1mHXy5ildeTvYmgrvEnOug6qGJizxnBVVsv0pk3QK~RlwBMs09T8wPUw6vOmvSh-RVAUug3xahtCM-rZQpKrrXOrk4L22eUulIpJgYGwJCHFe~zop1Gw2HMIvrdKV4s1p1XhNnfyHznzPYomEWrW~r7rN4TA-iPuGb2RH8ME8fsNN8WOEw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.7. Chronic kidney disease

#### 9.7.1. Relationship between hypertension and chronic kidney disease

Approximately 850 million people worldwide have CKD, with >80% of them hypertensive, and the prevalence is expected to rise to 1.56 billion by 2025.<sup><a href="javascript:;" reveal-id="ehae178-B756 ehae178-B757 ehae178-B758 ehae178-B759" data-open="ehae178-B756 ehae178-B757 ehae178-B758 ehae178-B759" class="link link-ref link-reveal xref-bibr">756–759</a></sup> The pathogeneses of hypertension and CKD are closely entwined.<sup><a href="javascript:;" reveal-id="ehae178-B760" data-open="ehae178-B760" class="link link-ref link-reveal xref-bibr">760</a></sup> Resistant hypertension, masked hypertension, HMOD, and higher night-time BP are common in patients with CKD.<sup><a href="javascript:;" reveal-id="ehae178-B761" data-open="ehae178-B761" class="link link-ref link-reveal xref-bibr">761</a></sup> CVD is one of the largest contributors to mortality in patients with CKD, with hypertension being a major risk factor.<sup><a href="javascript:;" reveal-id="ehae178-B760" data-open="ehae178-B760" class="link link-ref link-reveal xref-bibr">760</a>,<a href="javascript:;" reveal-id="ehae178-B762" data-open="ehae178-B762" class="link link-ref link-reveal xref-bibr">762</a></sup>

For the purposes of these guidelines, adults with moderate-to-severe CKD and elevated BP are at sufficiently high risk to be considered for BP-lowering drug therapy as outlined in _Section [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_ and the Central Illustration (_[Figure 19](javascript:;)_). We use Kidney Disease: Improving Global Outcomes (KDIGO) categories to define CKD-based risk, and our definition of moderate-to-severe CKD comprises persons with an eGFR of <60 mL/min/1.73 m<sup>2</sup> and/or albuminuria of ≥30 mg/g (≥3 mg/mmol).<sup><a href="javascript:;" reveal-id="ehae178-B19" data-open="ehae178-B19" class="link link-ref link-reveal xref-bibr">19</a></sup> For persons with mild CKD and elevated BP, a CVD risk assessment should be conducted before deciding on BP-lowering treatment.

#### 9.7.2. Blood pressure lowering in chronic kidney disease

BP lowering in patients with CKD is associated with beneficial effect on CVD events and mortality.<sup><a href="javascript:;" reveal-id="ehae178-B275" data-open="ehae178-B275" class="link link-ref link-reveal xref-bibr">275</a>,<a href="javascript:;" reveal-id="ehae178-B763 ehae178-B764 ehae178-B765 ehae178-B766" data-open="ehae178-B763 ehae178-B764 ehae178-B765 ehae178-B766" class="link link-ref link-reveal xref-bibr">763–766</a></sup> BP lowering reduces progression of CKD and the incidence of end-stage renal disease, but this tends to be only in those with significant proteinuria at baseline.<sup><a href="javascript:;" reveal-id="ehae178-B766" data-open="ehae178-B766" class="link link-ref link-reveal xref-bibr">766</a>,<a href="javascript:;" reveal-id="ehae178-B767" data-open="ehae178-B767" class="link link-ref link-reveal xref-bibr">767</a></sup>

#### 9.7.3. Managing blood pressure in chronic kidney disease

Patients with CKD should receive lifestyle advice, especially regarding reducing sodium intake. Dietary potassium supplementation recommendations are provided in _Section [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_, with caution required among persons with moderate-to-severe CKD. While exercise appears to have little effect on improving BP in patients with CKD<sup><a href="javascript:;" reveal-id="ehae178-B768" data-open="ehae178-B768" class="link link-ref link-reveal xref-bibr">768</a></sup> or patients on dialysis,<sup><a href="javascript:;" reveal-id="ehae178-B769" data-open="ehae178-B769" class="link link-ref link-reveal xref-bibr">769</a></sup> those with CKD on ACE inhibitor monotherapy have protection against adverse kidney outcomes, CVD events, cardiovascular death, and all-cause death.<sup><a href="javascript:;" reveal-id="ehae178-B770" data-open="ehae178-B770" class="link link-ref link-reveal xref-bibr">770</a>,<a href="javascript:;" reveal-id="ehae178-B771" data-open="ehae178-B771" class="link link-ref link-reveal xref-bibr">771</a></sup> Both ACE inhibitors and ARBs reduce the risk of CVD events and kidney failure compared with placebo; however, ACE inhibitors appear to do so with higher probability than ARBs.<sup><a href="javascript:;" reveal-id="ehae178-B772" data-open="ehae178-B772" class="link link-ref link-reveal xref-bibr">772</a>,<a href="javascript:;" reveal-id="ehae178-B773" data-open="ehae178-B773" class="link link-ref link-reveal xref-bibr">773</a></sup> Patients with CKD usually require combination therapy, and this should be initiated as a combination of a RAS inhibitor and a CCB or diuretic. In patients with eGFR < 30 mL/min/1.73 m<sup>2</sup>, an adequately up-titrated loop diuretic is necessary to define resistant hypertension. Chlorthalidone, typically added to a loop diuretic, also effectively lowers BP and reduces microalbuminuria in patients with resistant hypertension with stage 4 CKD (eGFR of 15–30 mL/min/1.73 m<sup>2</sup>).<sup><a href="javascript:;" reveal-id="ehae178-B774" data-open="ehae178-B774" class="link link-ref link-reveal xref-bibr">774</a></sup> The combination of an ACE inhibitor and an ARB is not recommended in CKD or any other BP-treatment scenario.

#### 9.7.4. Blood pressure targets in chronic kidney disease

Evidence regarding BP targets in patients with CKD is complex and controversial. The 2021 KDIGO Guideline suggested that adults with elevated BP and CKD be treated to a target systolic BP of <120 mmHg, when tolerated, using standardized office BP measurement (Class of Recommendation IIb).<sup><a href="javascript:;" reveal-id="ehae178-B19" data-open="ehae178-B19" class="link link-ref link-reveal xref-bibr">19</a></sup> This suggestion was based, in part, on the SPRINT trial.<sup><a href="javascript:;" reveal-id="ehae178-B545" data-open="ehae178-B545" class="link link-ref link-reveal xref-bibr">545</a></sup> It should be noted that patients with 24 h urine protein excretion ≥ 1 g/day or eGFR < 20 mL/min/1.73 m<sup>2</sup> were excluded from SPRINT. In patients with CKD, after a median follow-up of 3.3 years, the hazard ratio for the primary composite cardiovascular outcome was 0.81 (95% CI 0.63–1.05) and for all-cause death it was 0.72 (95% CI 0.53–0.99). Although intensive BP lowering in SPRINT resulted in greater early decline in eGFR, there was no evidence that this reduction in eGFR attenuated the beneficial effects of the SPRINT intervention on CVD events or death.<sup><a href="javascript:;" reveal-id="ehae178-B775" data-open="ehae178-B775" class="link link-ref link-reveal xref-bibr">775</a></sup>

Several systematic reviews have examined the benefit of intensive BP control in patients with CKD (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)). Some have shown no benefit of intensive BP control on renal outcomes,<sup><a href="javascript:;" reveal-id="ehae178-B764" data-open="ehae178-B764" class="link link-ref link-reveal xref-bibr">764</a>,<a href="javascript:;" reveal-id="ehae178-B767" data-open="ehae178-B767" class="link link-ref link-reveal xref-bibr">767</a></sup> while others showed lower mortality in intensively treated vs. non-intensively treated patients.<sup><a href="javascript:;" reveal-id="ehae178-B275" data-open="ehae178-B275" class="link link-ref link-reveal xref-bibr">275</a></sup> Highlighting the beneficial effects of SGLT2 inhibitors in persons with CKD<sup><a href="javascript:;" reveal-id="ehae178-B776" data-open="ehae178-B776" class="link link-ref link-reveal xref-bibr">776</a>,<a href="javascript:;" reveal-id="ehae178-B777" data-open="ehae178-B777" class="link link-ref link-reveal xref-bibr">777</a></sup> and finerenone in persons with CKD and diabetes<sup><a href="javascript:;" reveal-id="ehae178-B460 ehae178-B461 ehae178-B462" data-open="ehae178-B460 ehae178-B461 ehae178-B462" class="link link-ref link-reveal xref-bibr">460–462</a>,<a href="javascript:;" reveal-id="ehae178-B778" data-open="ehae178-B778" class="link link-ref link-reveal xref-bibr">778</a></sup> is relevant, though these drugs are not currently marketed for BP-lowering effects alone.

Recommendation Table 26

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376165)

Recommendations for managing hypertension in patients with chronic kidney disease

![Recommendations for managing hypertension in patients with chronic kidney disease](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt26.jpeg?Expires=1728462845&Signature=UkG1cXnSAloECwecmVKGguhQMdkXwvSzpIwWD4~FbZmLDB0C4yR7H0XecSW-gA96xLZctEx-uPLPpI-9pcKREoBOnZeKiBxWxLlk9wnyolv-UEUoZhl-nQz~xDGmHMUTDG5tpbbDfwXUwMWuRwSHncFTktJcCzdoWmCNKZOrIPRgv9ZVdSj~pYrygCHAWm8XSfZUGXooiqASb1tdq2WogXLOmGlPcGgymVu39mLiyYM42pn8Av-1D5BNai9Lq94t3jZDLEyH8xsH8aCRW9QjitKfWIwV6bOQx2yKL4lZEPUNjLl4MI10LUTmQnoOK5lgAdV64BmXIQr9UWZPnQUnfQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.8. Cardiac disease

#### 9.8.1. Blood pressure thresholds and targets in patients with cardiac disease

Recommended BP thresholds for initiating BP-lowering therapy and recommended BP targets in patients receiving therapy are provided in _Sections [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_ and _[8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_. All patients with a history of CVD (including coronary artery disease) are at increased risk of recurrent CVD. As such, these patients are recommended to be treated with BP-lowering therapy for confirmed baseline BP of ≥130/80 mmHg and the recommended treatment target BP of 120–129/70–79 mmHg, provided treatment is tolerated (see _Sections [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_ and _[8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_). As stated in _Section [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_, it should be remembered that a systolic BP of 120 mmHg (especially by out-of-office assessment) is likely the optimal point in the target range recommended in these guidelines. In addition to considering patients with known CVD at sufficiently high risk for more intensive BP treatment targets, the task force considers patients with both severe valvular heart disease and symptomatic heart failure to also be at sufficiently high risk. We also note that, whether used for angina control or BP control, a beta-blocker should not be combined with a non-dihydropyridine CCB.

#### 9.8.2. Coronary artery disease with particular reference to the blood pressure J-curve

Important considerations in patients with coronary artery disease are: (i) the BP J-curve (an observation suggesting that over-intensive BP lowering may increase CVD risk in some patients), and (ii) compelling indications for specific classes of BP-lowering medications.

The J-curve phenomenon describes increased risk for CVD observed among patients with the lowest and highest BP in the dataset, with the best CVD outcome rates typically observed among those with BP in the normal range (e.g. systolic BP of 100–120 mmHg and diastolic BP of 60–80 mmHg). For this reason, the J-curve is sometimes also called the U-curve, with both terms typically used interchangeably.<sup><a href="javascript:;" reveal-id="ehae178-B697" data-open="ehae178-B697" class="link link-ref link-reveal xref-bibr">697</a>,<a href="javascript:;" reveal-id="ehae178-B783" data-open="ehae178-B783" class="link link-ref link-reveal xref-bibr">783</a>,<a href="javascript:;" reveal-id="ehae178-B784" data-open="ehae178-B784" class="link link-ref link-reveal xref-bibr">784</a></sup>

However, observational data do not consistently demonstrate a BP J-curve with CVD risk.<sup><a href="javascript:;" reveal-id="ehae178-B697" data-open="ehae178-B697" class="link link-ref link-reveal xref-bibr">697</a></sup> It is more commonly observed among patients with established clinical CVD, such as those with coronary artery disease, or in secondary prevention cohorts.<sup><a href="javascript:;" reveal-id="ehae178-B785" data-open="ehae178-B785" class="link link-ref link-reveal xref-bibr">785</a>,<a href="javascript:;" reveal-id="ehae178-B786" data-open="ehae178-B786" class="link link-ref link-reveal xref-bibr">786</a></sup> Furthermore, the J-curve is more commonly observed when analysing diastolic BP values vs. systolic BP values, though it has been described for both.<sup><a href="javascript:;" reveal-id="ehae178-B114" data-open="ehae178-B114" class="link link-ref link-reveal xref-bibr">114</a>,<a href="javascript:;" reveal-id="ehae178-B697" data-open="ehae178-B697" class="link link-ref link-reveal xref-bibr">697</a></sup> This stronger relationship with diastolic BP has informed the hypothesis that the J-curve may be caused by reduced perfusion of major organs at low BP, which is particularly operative for diastolic BP in the coronary vasculature when considering ischaemic heart disease events (since coronary blood flow is largely confined to diastole).<sup><a href="javascript:;" reveal-id="ehae178-B786" data-open="ehae178-B786" class="link link-ref link-reveal xref-bibr">786</a>,<a href="javascript:;" reveal-id="ehae178-B787" data-open="ehae178-B787" class="link link-ref link-reveal xref-bibr">787</a></sup>

If excessive lowering of BP causes CVD events, this needs to be addressed in treatment recommendations provided by BP management guidelines. The 2018 ESC/ESH Guidelines on the management of arterial hypertension introduced, for the first time, lower bounds of BP-lowering treatment targets, implying that treatment be de-intensified for patients with on-treatment BP below these bounds (i.e. <120 mmHg systolic or <70 mmHg diastolic).<sup><a href="javascript:;" reveal-id="ehae178-B1" data-open="ehae178-B1" class="link link-ref link-reveal xref-bibr">1</a></sup> The 2023 ESH document also makes this argument.<sup><a href="javascript:;" reveal-id="ehae178-B788" data-open="ehae178-B788" class="link link-ref link-reveal xref-bibr">788</a></sup>

However, since 2018, compelling evidence has demonstrated that the BP J-curve evident in observational datasets is highly unlikely to reflect a causal process and can instead be attributed to residual confounding and/or reverse causation.<sup><a href="javascript:;" reveal-id="ehae178-B33" data-open="ehae178-B33" class="link link-ref link-reveal xref-bibr">33</a>,<a href="javascript:;" reveal-id="ehae178-B114" data-open="ehae178-B114" class="link link-ref link-reveal xref-bibr">114</a>,<a href="javascript:;" reveal-id="ehae178-B115" data-open="ehae178-B115" class="link link-ref link-reveal xref-bibr">115</a>,<a href="javascript:;" reveal-id="ehae178-B546" data-open="ehae178-B546" class="link link-ref link-reveal xref-bibr">546</a>,<a href="javascript:;" reveal-id="ehae178-B697" data-open="ehae178-B697" class="link link-ref link-reveal xref-bibr">697</a>,<a href="javascript:;" reveal-id="ehae178-B789 ehae178-B790 ehae178-B791 ehae178-B792 ehae178-B793" data-open="ehae178-B789 ehae178-B790 ehae178-B791 ehae178-B792 ehae178-B793" class="link link-ref link-reveal xref-bibr">789–793</a></sup>

Accordingly, while low BP can indicate a high-risk state, particularly among older adults and those with comorbidities, there is no evidence that this is a causal phenomenon. Indeed, if there is another indication for BP-lowering therapy (e.g. in a patient with wide pulse pressure and a baseline systolic BP of >140 mmHg but diastolic BP of <60 mmHg), the evidence suggests that such therapy should be provided if tolerated to reduce CVD risk.

There is a limit to how low BP can be treated without potentially tipping the scales in favour of CVD harm vs. CVD benefit. However, it is not clear what that limit is and how much it differs based on comorbidities. Currently, the data do not suggest that risk for CVD can be causally increased by treating any patient to the recommended intensive BP target outlined in these guidelines of as low as 120/70 mmHg. We also do not recommend stopping or de-intensifying BP-lowering medication among asymptomatic patients with on-treatment BP of <120/70 mmHg. It should be recognized, though, that there are no robust data demonstrating that an on-treatment systolic BP of <90 mmHg or an on-treatment diastolic BP of <50 mmHg is safe from a CVD perspective and there is clear potential for harm. Furthermore, it must be emphasized that the above discussion of the BP J-curve relates solely to CVD risk and does not consider the known non-CVD side effects of BP-lowering drugs, like, e.g. orthostatic hypotension, syncope, and renal injury. We do know that patients treated to a more intensive BP target of 120/70 mmHg are at increased risk for these side effects,<sup><a href="javascript:;" reveal-id="ehae178-B550" data-open="ehae178-B550" class="link link-ref link-reveal xref-bibr">550</a></sup> which is why these guidelines stress that this more intensive target should only be pursued among those in whom treatment is being tolerated (_Section [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_).

The second consideration in managing BP in patients with coronary artery disease is the recommended use of BP-lowering medications with compelling indications based on outcomes trials that demonstrated CVD outcomes benefits in the setting of coronary artery disease. These recommendations are provided in the recommendation table below.

#### 9.8.3. Valvular heart disease

Most patients with both severe heart valve disease and heart failure, defined by the 2021 ESC/European Association for Cardio-Thoracic Surgery (EACTS) Guidelines for the management of valvular heart disease,<sup><a href="javascript:;" reveal-id="ehae178-B794" data-open="ehae178-B794" class="link link-ref link-reveal xref-bibr">794</a></sup> can be considered at increased risk of CVD. Accordingly, it is recommended they are treated with BP-lowering therapy for confirmed baseline BP of >130/80 mmHg, and their recommended target of treatment is BP of 120–129/70–79 mmHg, provided treatment is tolerated. Persons with mild-to-moderate heart valve disease should have a CVD risk assessment prior to deciding their BP-lowering treatment threshold and target.

Vasodilating ARBs/ACE inhibitors are preferable over vasodilating dihydropyridine CCBs because of the link between valvular heart disease and subsequent heart failure and given the stronger efficacy evidence for ARBs/ACE inhibitors in the setting of heart failure once manifested.<sup><a href="javascript:;" reveal-id="ehae178-B795" data-open="ehae178-B795" class="link link-ref link-reveal xref-bibr">795</a></sup> In aortic valve stenosis, concomitant hypertension influences both the aortic root, the aortic valve, and the left ventricular structure and function.<sup><a href="javascript:;" reveal-id="ehae178-B796" data-open="ehae178-B796" class="link link-ref link-reveal xref-bibr">796</a></sup> In this subgroup, treatment preferably with ARBs/ACE inhibitors should be considered. A beta-blocker may be added if BP remains >140/90 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B796" data-open="ehae178-B796" class="link link-ref link-reveal xref-bibr">796</a>,<a href="javascript:;" reveal-id="ehae178-B797" data-open="ehae178-B797" class="link link-ref link-reveal xref-bibr">797</a></sup>

#### 9.8.4. Heart failure

Patients with symptomatic heart failure are at increased risk of CVD. Therefore, it is recommended that these patients are treated with BP-lowering therapy for confirmed baseline BP of >130/80 mmHg and their recommended treatment target is BP of 120–129/70–79 mmHg, provided treatment is tolerated and with out-of-office confirmation of on-treatment BP. Of note, many patients with systolic heart failure on maximal heart failure therapies have BP of <120/70 mmHg, and we do not recommend de-intensifying such treatment unless indicated by symptomatic side effects. Besides referencing the new evidence for ARNi and SGLT2 inhibitor therapies,<sup><a href="javascript:;" reveal-id="ehae178-B795" data-open="ehae178-B795" class="link link-ref link-reveal xref-bibr">795</a></sup> our 2024 recommendations for heart failure are largely unchanged from the 2018 ESC/ESH Guidelines on the management of arterial hypertension. Non-dihydropyridine CCBs should not be used in heart failure. Frailty and hypotension risk should be assessed in older heart failure patients being considered for ARNi and SGLT2 inhibitor therapies, and older patients should be closely followed to ensure they are tolerating such treatments. For more information on the management of heart failure, we direct readers to the latest ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.<sup><a href="javascript:;" reveal-id="ehae178-B798" data-open="ehae178-B798" class="link link-ref link-reveal xref-bibr">798</a></sup>

Recommendation Table 27

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376183)

Recommendations for managing hypertension in patients with cardiac disease

![Recommendations for managing hypertension in patients with cardiac disease](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt27.jpeg?Expires=1728462845&Signature=PXN488r7QdNycrDlLxqejc9WKBGaQxqLiqUCIImj~8ymfRfIHkH64RaUV9XmTQX7KPAEtJ534y9bdy~AM05NgrG8o~BST0B-aFus9yNJcm3hZS2lv~LWE4v62HZC5DgxCiFW2qWRle1Whjq7TGRtfzwU0cknYPhyp1EyhlWOF5p15IVfmneOUZqxs87q9FsqZIlqrRSnALJnELpfKXCzvNtWiDtJCY-9Lb-P6oRkiCzvKHGWOInU~Mr2Fg-VrMYtWwPYUBrfvI12BQXw4iCmoVaxhZam7a4Q6tZXzPPgWJgW7QR54z4CwFxBbauKL7P664eyz6aMIlljCdWucLB5kg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 9.8.5. Heart rhythm disease (including AF)

Not all patients with heart rhythm disease, including those with AF, are at increased risk for CVD and, as such, the management of BP among patients with heart rhythm disease should be the same as for the general adult population.<sup><a href="javascript:;" reveal-id="ehae178-B443" data-open="ehae178-B443" class="link link-ref link-reveal xref-bibr">443</a></sup> However, there is a close relationship between increased BP and AF risk, hence, ensuring good BP control is important.<sup><a href="javascript:;" reveal-id="ehae178-B801" data-open="ehae178-B801" class="link link-ref link-reveal xref-bibr">801</a>,<a href="javascript:;" reveal-id="ehae178-B802" data-open="ehae178-B802" class="link link-ref link-reveal xref-bibr">802</a></sup> Management of heart rhythm disorders should follow recommendations in guidelines specific to these conditions.<sup><a href="javascript:;" reveal-id="ehae178-B803" data-open="ehae178-B803" class="link link-ref link-reveal xref-bibr">803</a></sup>

### 9.9. Chronic cerebrovascular disease and/or cognitive impairment

#### 9.9.1. Role of hypertension in chronic cerebrovascular disease

Hypertension is a risk factor for chronic cerebrovascular disease through its direct effects on brain structure and microvasculature. This manifests as transient ischaemic attack (TIA) and stroke in the acute setting, but chronic hypertension can lead to covert stroke and white-matter ischaemic change over time, resulting in cognitive decline and progressive vascular dementia.<sup><a href="javascript:;" reveal-id="ehae178-B804 ehae178-B805 ehae178-B806 ehae178-B807 ehae178-B808" data-open="ehae178-B804 ehae178-B805 ehae178-B806 ehae178-B807 ehae178-B808" class="link link-ref link-reveal xref-bibr">804–808</a></sup> Hypertension is also associated with increased risk of Alzheimer’s disease,<sup><a href="javascript:;" reveal-id="ehae178-B809" data-open="ehae178-B809" class="link link-ref link-reveal xref-bibr">809</a></sup> and is a risk factor for developing AF, heart failure, and CKD, all of which are associated with increased risk of developing cognitive impairment and dementia.<sup><a href="javascript:;" reveal-id="ehae178-B810 ehae178-B811 ehae178-B812 ehae178-B813" data-open="ehae178-B810 ehae178-B811 ehae178-B812 ehae178-B813" class="link link-ref link-reveal xref-bibr">810–813</a></sup> For the purposes of these guidelines, adults with a history of stroke or TIA and elevated BP are considered at sufficiently high risk to be considered for BP-lowering drug therapy as outlined in _Section [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_ and the Central Illustration (_[Figure 19](javascript:;)_).

#### 9.9.2. Treatment in patients with history of prior stroke or transient ischaemic attack

In patients with a prior history of TIA and ischaemic stroke, BP-lowering treatment reduces the risk of any recurrent stroke by 20%.<sup><a href="javascript:;" reveal-id="ehae178-B814 ehae178-B815 ehae178-B816 ehae178-B817" data-open="ehae178-B814 ehae178-B815 ehae178-B816 ehae178-B817" class="link link-ref link-reveal xref-bibr">814–817</a></sup> The aetiology of stroke can affect the degree of risk reduction with pharmacological treatment, with greater reductions observed for intracerebral haemorrhage and lacunar ischaemic stroke syndromes.<sup><a href="javascript:;" reveal-id="ehae178-B818 ehae178-B819 ehae178-B820" data-open="ehae178-B818 ehae178-B819 ehae178-B820" class="link link-ref link-reveal xref-bibr">818–820</a></sup>

Most prior guidelines recommend an intensive BP target in patients with a prior history of stroke, typically using combination treatment (ACE inhibitor/ARB plus either a calcium channel antagonist or a thiazide/thiazide-like diuretic), with therapy commencing immediately after TIA and within a few days of ischaemic stroke (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) and see _Section [10.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s9.3)_ for acute BP management during hospitalization for stroke).<sup><a href="javascript:;" reveal-id="ehae178-B814" data-open="ehae178-B814" class="link link-ref link-reveal xref-bibr">814</a>,<a href="javascript:;" reveal-id="ehae178-B815" data-open="ehae178-B815" class="link link-ref link-reveal xref-bibr">815</a>,<a href="javascript:;" reveal-id="ehae178-B821 ehae178-B822 ehae178-B823 ehae178-B824" data-open="ehae178-B821 ehae178-B822 ehae178-B823 ehae178-B824" class="link link-ref link-reveal xref-bibr">821–824</a></sup>

Regimens containing an ACE inhibitor and thiazide/thiazide-like diuretic may be superior to beta-blockers in terms of stroke risk reduction.<sup><a href="javascript:;" reveal-id="ehae178-B825" data-open="ehae178-B825" class="link link-ref link-reveal xref-bibr">825</a>,<a href="javascript:;" reveal-id="ehae178-B826" data-open="ehae178-B826" class="link link-ref link-reveal xref-bibr">826</a></sup> Regarding intensive BP control after stroke, typically targeting a systolic BP of <130 mmHg, individual trials were somewhat inconclusive, but a meta-analysis showed a reduced risk of recurrent stroke of 22% in the intensive treatment group randomized to a target systolic BP as low as 120 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B543" data-open="ehae178-B543" class="link link-ref link-reveal xref-bibr">543</a>,<a href="javascript:;" reveal-id="ehae178-B824" data-open="ehae178-B824" class="link link-ref link-reveal xref-bibr">824</a>,<a href="javascript:;" reveal-id="ehae178-B827" data-open="ehae178-B827" class="link link-ref link-reveal xref-bibr">827</a>,<a href="javascript:;" reveal-id="ehae178-B828" data-open="ehae178-B828" class="link link-ref link-reveal xref-bibr">828</a></sup> Caveats to this recommendation would be for frail patients, who have a much higher rate of stroke and recurrent stroke than the general population, and who are more sensitive to adverse effects of BP-lowering agents (see _Section [9.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8.3)_).<sup><a href="javascript:;" reveal-id="ehae178-B596" data-open="ehae178-B596" class="link link-ref link-reveal xref-bibr">596</a>,<a href="javascript:;" reveal-id="ehae178-B606" data-open="ehae178-B606" class="link link-ref link-reveal xref-bibr">606</a>,<a href="javascript:;" reveal-id="ehae178-B607" data-open="ehae178-B607" class="link link-ref link-reveal xref-bibr">607</a>,<a href="javascript:;" reveal-id="ehae178-B829" data-open="ehae178-B829" class="link link-ref link-reveal xref-bibr">829</a></sup>

#### 9.9.3. Treatment in patients with chronic cerebrovascular disease and cognitive impairment

Treatment of hypertension represents a key mechanism for reducing the global burden of dementia at the population level.<sup><a href="javascript:;" reveal-id="ehae178-B830" data-open="ehae178-B830" class="link link-ref link-reveal xref-bibr">830</a></sup> Epidemiological studies have reported associations between mid-life hypertension and development of cognitive decline in later life, with, e.g. mid-life hypertension increasing relative risk of lifetime dementia by 20%–54%.<sup><a href="javascript:;" reveal-id="ehae178-B831 ehae178-B832 ehae178-B833 ehae178-B834 ehae178-B835 ehae178-B836 ehae178-B837" data-open="ehae178-B831 ehae178-B832 ehae178-B833 ehae178-B834 ehae178-B835 ehae178-B836 ehae178-B837" class="link link-ref link-reveal xref-bibr">831–837</a></sup> In one observational meta-analysis, an increased risk for dementia emerged with systolic BP of >130 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B831" data-open="ehae178-B831" class="link link-ref link-reveal xref-bibr">831</a></sup>

Evidence for lowering BP to reduce the risk of dementia is limited due to heterogeneity in populations studied, cognitive testing methods used, and the varied use of dementia or cognitive impairment or both as a primary outcome.<sup><a href="javascript:;" reveal-id="ehae178-B838" data-open="ehae178-B838" class="link link-ref link-reveal xref-bibr">838</a>,<a href="javascript:;" reveal-id="ehae178-B839" data-open="ehae178-B839" class="link link-ref link-reveal xref-bibr">839</a></sup> Findings from individual studies have mixed results (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B264" data-open="ehae178-B264" class="link link-ref link-reveal xref-bibr">264</a>,<a href="javascript:;" reveal-id="ehae178-B839 ehae178-B840 ehae178-B841 ehae178-B842 ehae178-B843" data-open="ehae178-B839 ehae178-B840 ehae178-B841 ehae178-B842 ehae178-B843" class="link link-ref link-reveal xref-bibr">839–843</a></sup> Studies on effects of BP-lowering treatment on white-matter intensities concluded that patients in the intensive-control arm had less white-matter intensity accumulation than in the standard-treatment arm.<sup><a href="javascript:;" reveal-id="ehae178-B841" data-open="ehae178-B841" class="link link-ref link-reveal xref-bibr">841</a>,<a href="javascript:;" reveal-id="ehae178-B844" data-open="ehae178-B844" class="link link-ref link-reveal xref-bibr">844</a></sup> Studies in which people with stroke and TIA were included reported a reduced risk of dementia and cognitive decline for the active-treatment group, but a mixed signal for dementia alone.<sup><a href="javascript:;" reveal-id="ehae178-B841" data-open="ehae178-B841" class="link link-ref link-reveal xref-bibr">841</a>,<a href="javascript:;" reveal-id="ehae178-B845" data-open="ehae178-B845" class="link link-ref link-reveal xref-bibr">845</a></sup> However, individual studies may have been under-powered and more recent meta-analyses do convincingly support efficacy in reducing dementia with BP-lowering treatment.<sup><a href="javascript:;" reveal-id="ehae178-B610" data-open="ehae178-B610" class="link link-ref link-reveal xref-bibr">610</a>,<a href="javascript:;" reveal-id="ehae178-B611" data-open="ehae178-B611" class="link link-ref link-reveal xref-bibr">611</a></sup> Indeed, these meta-analyses reported a reduced risk of incident dementia or cognitive impairment with BP lowering of 7%–13%.<sup><a href="javascript:;" reveal-id="ehae178-B610" data-open="ehae178-B610" class="link link-ref link-reveal xref-bibr">610</a>,<a href="javascript:;" reveal-id="ehae178-B611" data-open="ehae178-B611" class="link link-ref link-reveal xref-bibr">611</a></sup> While one trial suggested superiority of long-acting CCBs,<sup><a href="javascript:;" reveal-id="ehae178-B264" data-open="ehae178-B264" class="link link-ref link-reveal xref-bibr">264</a></sup> it is unclear if any first-line BP-lowering agent is preferable for preventing dementia and cognitive impairment.<sup><a href="javascript:;" reveal-id="ehae178-B846" data-open="ehae178-B846" class="link link-ref link-reveal xref-bibr">846</a>,<a href="javascript:;" reveal-id="ehae178-B847" data-open="ehae178-B847" class="link link-ref link-reveal xref-bibr">847</a></sup>

The role of competing risk mechanisms including orthostatic hypotension<sup><a href="javascript:;" reveal-id="ehae178-B848" data-open="ehae178-B848" class="link link-ref link-reveal xref-bibr">848</a></sup> and BP variability<sup><a href="javascript:;" reveal-id="ehae178-B849" data-open="ehae178-B849" class="link link-ref link-reveal xref-bibr">849</a></sup> may be important factors in treatment decisions for people with frailty, multimorbidity, and/or chronic cerebrovascular disease.

Recommendation Table 28

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376197)

Recommendations for managing hypertension in patients with chronic cerebrovascular disease and cognitive impairment

![Recommendations for managing hypertension in patients with chronic cerebrovascular disease and cognitive impairment](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt28.jpeg?Expires=1728462845&Signature=DeD2m2mfYbkBRkIZDg4ZxItUdfhPe1a1Y5zGYkp3LVLZn9Qr5O7Ox~MSnRy1D9z2VL6KRB9JLHmJJ8WqPU~kwKcJ1lKiQeEw2PlwqQ7SsDKyeM6f0aO4IVf3K4tfu6Gf5PdhDB0lYxBs6khLrCL1Pof04x4sNEjClOYPv9zUgQCqgOPnHGHZQUarmDcbfDpmOrgcKSqY-C8lej-zpR9pcipaMlBAUAQC1WT4SxGLZULivnKHGfRiGMaDQNQFCy~N5EJkNqPYgI5daVFcHqyUoyBWppLyorlB4dUjUthSRYVt0iOBye-vMY~TG5QTwwYP5wrGW6IyoQieoNnHmSGkww__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.10. Aortopathy

#### 9.10.1. Coarctation of the aorta

Aortic coarctation is associated with CVD in the long term, even following early surgical or percutaneous treatment. The most common complications are associated with hypertension, which is common in aortic coarctation. When aortic coarctation is not treated, patients often develop severe hypertension and HMOD (especially LVH and left ventricular dysfunction, aortopathy, and cerebrovascular complications).<sup><a href="javascript:;" reveal-id="ehae178-B850 ehae178-B851 ehae178-B852" data-open="ehae178-B850 ehae178-B851 ehae178-B852" class="link link-ref link-reveal xref-bibr">850–852</a></sup> No formal RCTs to define optimal medical treatment of hypertension in aortic coarctation have been conducted, therefore, patients not suitable for, or having undergone, intervention should be treated for hypertension following the core algorithm for the general population.

#### 9.10.2. Bicuspid aortic valve-related aortopathy

Bicuspid aortic valve is the most common congenital heart disease and is sometimes associated with aortopathy or aortic coarctation. Bicuspid aortic valve disease is associated with an increased risk of valve malfunction and adverse aortic events.<sup><a href="javascript:;" reveal-id="ehae178-B853" data-open="ehae178-B853" class="link link-ref link-reveal xref-bibr">853</a>,<a href="javascript:;" reveal-id="ehae178-B854" data-open="ehae178-B854" class="link link-ref link-reveal xref-bibr">854</a></sup> This risk is exacerbated by hypertension.

Beyond aortic dilation and aneurysm formation, bicuspid aortic valve disease is also a risk factor for aortic dissection and rupture.<sup><a href="javascript:;" reveal-id="ehae178-B855" data-open="ehae178-B855" class="link link-ref link-reveal xref-bibr">855</a></sup> Blood pressure should be carefully monitored and controlled.<sup><a href="javascript:;" reveal-id="ehae178-B856" data-open="ehae178-B856" class="link link-ref link-reveal xref-bibr">856</a></sup>

#### 9.10.3. Preventing aortic dilation and dissection in high-risk patients

A modest dilatation of the ascending aorta or aortic root is often associated with chronic hypertension and HMOD. An additional cause of aortopathy (bicuspid valve, coarctation, Marfan or other syndromes) should be considered in more severe cases.<sup><a href="javascript:;" reveal-id="ehae178-B857" data-open="ehae178-B857" class="link link-ref link-reveal xref-bibr">857</a></sup> Patients with aortic dilatation should have their BP optimally controlled following the core algorithm for the general hypertension population.

In patients with Marfan syndrome, prophylactic use of ARBs, ACE inhibitors, or beta-blockers may reduce complications or progression of aortic dilation.<sup><a href="javascript:;" reveal-id="ehae178-B857 ehae178-B858 ehae178-B859 ehae178-B860" data-open="ehae178-B857 ehae178-B858 ehae178-B859 ehae178-B860" class="link link-ref link-reveal xref-bibr">857–860</a></sup> More information is available in the 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases.<sup><a href="javascript:;" reveal-id="ehae178-B861" data-open="ehae178-B861" class="link link-ref link-reveal xref-bibr">861</a></sup>

### 9.11. Different ethnic groups

Influx and settlement of migrant populations in Europe have contributed to regional population growth and changes in its composition.<sup><a href="javascript:;" reveal-id="ehae178-B862" data-open="ehae178-B862" class="link link-ref link-reveal xref-bibr">862</a></sup> Ethnic minority populations are disproportionally affected by hypertension and hypertension-mediated complications, compared with historically native Europeans, with data suggesting migrant women are particularly vulnerable.<sup><a href="javascript:;" reveal-id="ehae178-B536" data-open="ehae178-B536" class="link link-ref link-reveal xref-bibr">536</a>,<a href="javascript:;" reveal-id="ehae178-B863" data-open="ehae178-B863" class="link link-ref link-reveal xref-bibr">863</a></sup> In particular, hypertension is more prevalent in those of African descent.<sup><a href="javascript:;" reveal-id="ehae178-B863" data-open="ehae178-B863" class="link link-ref link-reveal xref-bibr">863</a>,<a href="javascript:;" reveal-id="ehae178-B864" data-open="ehae178-B864" class="link link-ref link-reveal xref-bibr">864</a></sup> The predominant group of European black ethnicity originates from sub-Saharan Africa,<sup><a href="javascript:;" reveal-id="ehae178-B863" data-open="ehae178-B863" class="link link-ref link-reveal xref-bibr">863</a></sup> but specific studies on the management and control of hypertension in this population are lacking, and data are often extrapolated from studies in the African American population.<sup><a href="javascript:;" reveal-id="ehae178-B864" data-open="ehae178-B864" class="link link-ref link-reveal xref-bibr">864</a></sup> This assumption requires caution, as differences likely exist between these populations in terms of CVD risk, economic, and sociological status,<sup><a href="javascript:;" reveal-id="ehae178-B865" data-open="ehae178-B865" class="link link-ref link-reveal xref-bibr">865</a>,<a href="javascript:;" reveal-id="ehae178-B866" data-open="ehae178-B866" class="link link-ref link-reveal xref-bibr">866</a></sup> as well as responses to BP-lowering drugs.<sup><a href="javascript:;" reveal-id="ehae178-B867" data-open="ehae178-B867" class="link link-ref link-reveal xref-bibr">867</a></sup>

Black patients have a greater prevalence of low-renin, salt-sensitive hypertension and may be more predisposed to HMOD than white patients, possibly in part due to increased vascular stiffness.<sup><a href="javascript:;" reveal-id="ehae178-B864" data-open="ehae178-B864" class="link link-ref link-reveal xref-bibr">864</a>,<a href="javascript:;" reveal-id="ehae178-B868" data-open="ehae178-B868" class="link link-ref link-reveal xref-bibr">868</a>,<a href="javascript:;" reveal-id="ehae178-B869" data-open="ehae178-B869" class="link link-ref link-reveal xref-bibr">869</a></sup> Salt restriction, thiazide or thiazide-like diuretics, and CCBs appear particularly useful in black patients with hypertension, whereas RAS blocker monotherapy may be less effective.<sup><a href="javascript:;" reveal-id="ehae178-B870 ehae178-B871 ehae178-B872 ehae178-B873" data-open="ehae178-B870 ehae178-B871 ehae178-B872 ehae178-B873" class="link link-ref link-reveal xref-bibr">870–873</a></sup> If combination therapy is needed, in a recent RCT conducted in sub-Saharan African countries, amlodipine plus either hydrochlorothiazide or perindopril proved to be equally effective and superior, respectively, to hydrochlorothiazide plus perindopril.<sup><a href="javascript:;" reveal-id="ehae178-B874" data-open="ehae178-B874" class="link link-ref link-reveal xref-bibr">874</a></sup> When RAS blockers are used in combination therapy, ARBs may be preferable to ACE inhibitors, as angioedema appears more common with ACE inhibitors in black patients.

Despite some recent progress,<sup><a href="javascript:;" reveal-id="ehae178-B875" data-open="ehae178-B875" class="link link-ref link-reveal xref-bibr">875</a></sup> data on hypertension epidemiology and management in European immigrant patients are still lacking.<sup><a href="javascript:;" reveal-id="ehae178-B863" data-open="ehae178-B863" class="link link-ref link-reveal xref-bibr">863</a>,<a href="javascript:;" reveal-id="ehae178-B875 ehae178-B876 ehae178-B877" data-open="ehae178-B875 ehae178-B876 ehae178-B877" class="link link-ref link-reveal xref-bibr">875–877</a></sup>

Recommendation Table 29

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376211)

Recommendations for managing hypertension in different ethnic groups

![Recommendations for managing hypertension in different ethnic groups](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt29.jpeg?Expires=1728462845&Signature=o6G~JjEmKWjI5lgD0SJh6blI6oYFQcASr7vLKJzu47rgkmAbV6oxALu-O88lieu~6pjyClCLTzAGTkpFNRDnlLo6S~RUgzY8g99ZIPMkUbKiAPy3EVMV2KCBLGu9xTuaORAz5mtq-8CXEaqB~Isco7giMcTXpseHD64M0~7WerwOfrfkyjGz3u0Z5W8UDwWNvvdITJKUG3hkTMlEhLmVMjdBm2eU0AKhAA3ZFbQ85e9wtd9e~XN-rTDyQ737cJNugJn2oD5mXg3GZ1oG3F46YJ1jxleujYtyHMtHA7I~YTyI~-CROECg-sZwkwqhemdOm4OCxamfZoNYv~2TYo0exw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.12. Nocturnal hypertension

#### 9.12.1. Definition

Nocturnal hypertension is defined as night-time BP of >120 mmHg systolic and/or >70 mmHg diastolic by 24 h ABPM. Nocturnal hypertension can occur as day–night sustained hypertension or isolated nocturnal hypertension (daytime BP < 135/85 mmHg on 24 h ABPM). Physiologically, BP is expected to decrease during sleep by 10%–20% relative to daytime BP.<sup><a href="javascript:;" reveal-id="ehae178-B878" data-open="ehae178-B878" class="link link-ref link-reveal xref-bibr">878</a></sup> Night-time dipping patterns are classified into four groups:<sup><a href="javascript:;" reveal-id="ehae178-B879" data-open="ehae178-B879" class="link link-ref link-reveal xref-bibr">879</a>,<a href="javascript:;" reveal-id="ehae178-B880" data-open="ehae178-B880" class="link link-ref link-reveal xref-bibr">880</a></sup>

-   **Inverse dipping (riser):** nocturnal increase in BP (night-to-day ratio of >1.0).
    
-   **Non-dipper:** reduced night-time BP dip of <10% (or night-to-day ratio of >0.9 and ≤1.0).
    
-   **Normal dipping:** fall in night-time BP of >10% and <20% (or night-to-day ratio of 0.8 to 0.9).
    
-   **Extreme dipping:** marked fall in night-time BP of >20% (or night-to-day ratio of <0.8).
    

Patients with nocturnal hypertension may be dippers or non-dippers. Of note, the long-term reproducibility of dipping patterns appears to be low.<sup><a href="javascript:;" reveal-id="ehae178-B881" data-open="ehae178-B881" class="link link-ref link-reveal xref-bibr">881</a>,<a href="javascript:;" reveal-id="ehae178-B882" data-open="ehae178-B882" class="link link-ref link-reveal xref-bibr">882</a></sup>

#### 9.12.2. Epidemiology

Nocturnal hypertension has been observed in up to half of patients with hypertension,<sup><a href="javascript:;" reveal-id="ehae178-B883 ehae178-B884 ehae178-B885 ehae178-B886" data-open="ehae178-B883 ehae178-B884 ehae178-B885 ehae178-B886" class="link link-ref link-reveal xref-bibr">883–886</a></sup> and is associated with increased HMOD,<sup><a href="javascript:;" reveal-id="ehae178-B883" data-open="ehae178-B883" class="link link-ref link-reveal xref-bibr">883</a></sup> impaired renal function, and diabetes mellitus.<sup><a href="javascript:;" reveal-id="ehae178-B887" data-open="ehae178-B887" class="link link-ref link-reveal xref-bibr">887</a></sup> Nocturnal hypertension appears to be more prevalent in black<sup><a href="javascript:;" reveal-id="ehae178-B888 ehae178-B889 ehae178-B890" data-open="ehae178-B888 ehae178-B889 ehae178-B890" class="link link-ref link-reveal xref-bibr">888–890</a></sup> and Asian<sup><a href="javascript:;" reveal-id="ehae178-B891" data-open="ehae178-B891" class="link link-ref link-reveal xref-bibr">891</a>,<a href="javascript:;" reveal-id="ehae178-B892" data-open="ehae178-B892" class="link link-ref link-reveal xref-bibr">892</a></sup> populations. Masked uncontrolled hypertension, which occurs in 30% of patients treated for hypertension, is more often due to poorly controlled nocturnal BP than daytime BP on ABPM.<sup><a href="javascript:;" reveal-id="ehae178-B893" data-open="ehae178-B893" class="link link-ref link-reveal xref-bibr">893</a></sup>

Environmental factors, including sleep duration and higher humidity,<sup><a href="javascript:;" reveal-id="ehae178-B894" data-open="ehae178-B894" class="link link-ref link-reveal xref-bibr">894</a></sup> nocturia,<sup><a href="javascript:;" reveal-id="ehae178-B895" data-open="ehae178-B895" class="link link-ref link-reveal xref-bibr">895</a></sup> OSAS,<sup><a href="javascript:;" reveal-id="ehae178-B896" data-open="ehae178-B896" class="link link-ref link-reveal xref-bibr">896</a></sup> obesity, high salt intake in salt-sensitive patients,<sup><a href="javascript:;" reveal-id="ehae178-B897" data-open="ehae178-B897" class="link link-ref link-reveal xref-bibr">897</a></sup> orthostatic hypotension, autonomic dysfunction, CKD,<sup><a href="javascript:;" reveal-id="ehae178-B898 ehae178-B899 ehae178-B900" data-open="ehae178-B898 ehae178-B899 ehae178-B900" class="link link-ref link-reveal xref-bibr">898–900</a></sup> diabetic neuropathy/diabetes,<sup><a href="javascript:;" reveal-id="ehae178-B901" data-open="ehae178-B901" class="link link-ref link-reveal xref-bibr">901</a></sup> and old age<sup><a href="javascript:;" reveal-id="ehae178-B62" data-open="ehae178-B62" class="link link-ref link-reveal xref-bibr">62</a></sup> are associated with non-dipping. Moreover, nocturnal hypertension and absent night-time dipping pattern are more common in secondary hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B902" data-open="ehae178-B902" class="link link-ref link-reveal xref-bibr">902</a>,<a href="javascript:;" reveal-id="ehae178-B903" data-open="ehae178-B903" class="link link-ref link-reveal xref-bibr">903</a></sup>

#### 9.12.3. Night-time blood pressure as a cardiovascular disease risk factor

Nocturnal hypertension is a risk factor for adverse CVD events,<sup><a href="javascript:;" reveal-id="ehae178-B904" data-open="ehae178-B904" class="link link-ref link-reveal xref-bibr">904</a></sup> cerebrovascular disease, including stroke,<sup><a href="javascript:;" reveal-id="ehae178-B905" data-open="ehae178-B905" class="link link-ref link-reveal xref-bibr">905</a></sup> and cardiovascular mortality.<sup><a href="javascript:;" reveal-id="ehae178-B891" data-open="ehae178-B891" class="link link-ref link-reveal xref-bibr">891</a>,<a href="javascript:;" reveal-id="ehae178-B906" data-open="ehae178-B906" class="link link-ref link-reveal xref-bibr">906</a>,<a href="javascript:;" reveal-id="ehae178-B907" data-open="ehae178-B907" class="link link-ref link-reveal xref-bibr">907</a></sup> Night-time BP may provide more prognostic information than daytime BP, perhaps as it is less dependent on physical activities. Non-dipping<sup><a href="javascript:;" reveal-id="ehae178-B908 ehae178-B909 ehae178-B910" data-open="ehae178-B908 ehae178-B909 ehae178-B910" class="link link-ref link-reveal xref-bibr">908–910</a></sup> and reverse dipping (nocturnal rise in BP) may also be associated with increased CVD risk.<sup><a href="javascript:;" reveal-id="ehae178-B62" data-open="ehae178-B62" class="link link-ref link-reveal xref-bibr">62</a>,<a href="javascript:;" reveal-id="ehae178-B910 ehae178-B911 ehae178-B912 ehae178-B913" data-open="ehae178-B910 ehae178-B911 ehae178-B912 ehae178-B913" class="link link-ref link-reveal xref-bibr">910–913</a></sup> A nocturnal rise in BP is associated with an increased risk of dementia and Alzheimer’s disease in older men.<sup><a href="javascript:;" reveal-id="ehae178-B914" data-open="ehae178-B914" class="link link-ref link-reveal xref-bibr">914</a></sup> There is also some evidence that extreme dipping, particularly in untreated patients, is associated with an increased risk for CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B35" data-open="ehae178-B35" class="link link-ref link-reveal xref-bibr">35</a>,<a href="javascript:;" reveal-id="ehae178-B886" data-open="ehae178-B886" class="link link-ref link-reveal xref-bibr">886</a></sup>

#### 9.12.4. Treatment of nocturnal hypertension

There is no reliable evidence that BP-lowering medication should be routinely dosed at bedtime. The diurnal timing of drug administration is discussed in _Section [8.3.4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7.3.4)._ In patients with secondary hypertension, the underlying cause (OSAS, primary aldosteronism) should be treated as discussed in _Section [9.14](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8.14)_.

### 9.13. Resistant hypertension

#### 9.13.1. Definition of resistant hypertension

Resistant hypertension is defined as BP remaining above goal despite three or more BP-lowering drugs of different classes at maximally tolerated doses, of which one is a diuretic (_[Table 11](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae178-B915" data-open="ehae178-B915" class="link link-ref link-reveal xref-bibr">915</a></sup> Resistant hypertension should be managed at specialized centres with the expertise and resources to exclude pseudo-resistant hypertension (adherence testing) and causes of secondary hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B916" data-open="ehae178-B916" class="link link-ref link-reveal xref-bibr">916</a></sup>

#### 9.13.2. Non-pharmacological interventions

The Treating Resistant Hypertension Using Lifestyle Modification to Promote Health (TRIUMPH) trial demonstrated significant clinic and ambulatory BP reductions in patients with resistant hypertension participating in a 4-month lifestyle intervention comprising diet and exercise interventions delivered within a cardiac rehabilitation programme.<sup><a href="javascript:;" reveal-id="ehae178-B917" data-open="ehae178-B917" class="link link-ref link-reveal xref-bibr">917</a></sup>

#### 9.13.3. Pharmacological interventions

BP-lowering treatment of resistant hypertension with single-pill combinations is recommended to reduce the pill burden, thereby increasing drug adherence and persistence.<sup><a href="javascript:;" reveal-id="ehae178-B492" data-open="ehae178-B492" class="link link-ref link-reveal xref-bibr">492</a></sup>

As resistant hypertension often, and especially in CKD,<sup><a href="javascript:;" reveal-id="ehae178-B918" data-open="ehae178-B918" class="link link-ref link-reveal xref-bibr">918</a></sup> represents a state of salt retention and volume expansion secondary to relative aldosterone excess,<sup><a href="javascript:;" reveal-id="ehae178-B516" data-open="ehae178-B516" class="link link-ref link-reveal xref-bibr">516</a>,<a href="javascript:;" reveal-id="ehae178-B919" data-open="ehae178-B919" class="link link-ref link-reveal xref-bibr">919</a>,<a href="javascript:;" reveal-id="ehae178-B920" data-open="ehae178-B920" class="link link-ref link-reveal xref-bibr">920</a></sup> BP control may be improved by switching hydrochlorothiazide to long-acting thiazide-like diuretics, such as chlorthalidone.<sup><a href="javascript:;" reveal-id="ehae178-B921" data-open="ehae178-B921" class="link link-ref link-reveal xref-bibr">921</a>,<a href="javascript:;" reveal-id="ehae178-B922" data-open="ehae178-B922" class="link link-ref link-reveal xref-bibr">922</a></sup> However, a recent trial of chlorthalidone vs. hydrochlorothiazide—which probably included a sizeable proportion of adults with resistant hypertension—did not demonstrate any difference in systolic BP or CVD outcomes between the two medications. In the subgroup of patients with prior CVD, there was a strong trend of benefit with chlorthalidone on CVD outcomes.<sup><a href="javascript:;" reveal-id="ehae178-B447" data-open="ehae178-B447" class="link link-ref link-reveal xref-bibr">447</a></sup> Of note, the risk of hypokalaemia was higher in the chlorthalidone group than in the hydrochlorothiazide group.<sup><a href="javascript:;" reveal-id="ehae178-B447" data-open="ehae178-B447" class="link link-ref link-reveal xref-bibr">447</a></sup> In patients with eGFR < 30 mL/min/1.73 m<sup>2</sup>, an adequately up-titrated loop diuretic is necessary to define resistant hypertension.

Most patients with resistant hypertension require the addition of non-first-line BP-lowering drugs (_[Figure 22](javascript:;)_). Of these, low-dose spironolactone (25–50 mg daily) should be considered first.<sup><a href="javascript:;" reveal-id="ehae178-B459" data-open="ehae178-B459" class="link link-ref link-reveal xref-bibr">459</a>,<a href="javascript:;" reveal-id="ehae178-B515" data-open="ehae178-B515" class="link link-ref link-reveal xref-bibr">515</a>,<a href="javascript:;" reveal-id="ehae178-B923 ehae178-B924 ehae178-B925" data-open="ehae178-B923 ehae178-B924 ehae178-B925" class="link link-ref link-reveal xref-bibr">923–925</a></sup> In patients with resistant hypertension and type 2 diabetes, spironolactone (25–50 mg daily) reduced BP and albuminuria.<sup><a href="javascript:;" reveal-id="ehae178-B926" data-open="ehae178-B926" class="link link-ref link-reveal xref-bibr">926</a></sup> The use of spironolactone can be precluded by limited tolerability due to anti-androgenic side effects resulting in breast tenderness or gynaecomastia (in about 6%), impotence in men, and menstrual irregularities in women.<sup><a href="javascript:;" reveal-id="ehae178-B927" data-open="ehae178-B927" class="link link-ref link-reveal xref-bibr">927</a></sup> The efficacy and safety of spironolactone for treating resistant hypertension have not yet been established in patients with significant renal impairment. Moreover, spironolactone, especially in addition to RAS inhibitors, increases the risk of hyperkalaemia.<sup><a href="javascript:;" reveal-id="ehae178-B927" data-open="ehae178-B927" class="link link-ref link-reveal xref-bibr">927</a>,<a href="javascript:;" reveal-id="ehae178-B928" data-open="ehae178-B928" class="link link-ref link-reveal xref-bibr">928</a></sup> Therefore, spironolactone should be restricted to patients with an eGFR of ≥30 mL/min/1.73 m<sup>2</sup> and a plasma potassium concentration of ≤4.5 mmol/L.<sup><a href="javascript:;" reveal-id="ehae178-B459" data-open="ehae178-B459" class="link link-ref link-reveal xref-bibr">459</a></sup> Steroidal MRAs are contraindicated in patients with an eGFR of <30 mL/min/1.73 m<sup>2</sup>. Serum electrolytes and kidney function should be monitored soon after initiation and frequently thereafter. In patients with resistant hypertension and CKD (eGFR of 25–45 mL/min/1.73 m<sup>2</sup>), the oral potassium binder patiromer enabled more patients to continue treatment with spironolactone.<sup><a href="javascript:;" reveal-id="ehae178-B929" data-open="ehae178-B929" class="link link-ref link-reveal xref-bibr">929</a></sup>

![Management of resistant hypertension.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f22.jpeg?Expires=1728462845&Signature=5D-GhDgSTuORpFbi~ZKmoKv8Dzhyc0xqTvfLJuRU~DxgUVw9mx-9KyCASuhnE~Eat6EgMbZxCcIh0WCFnnt5n2LMAsWhPFYeufKgrXyUQkLqFqbfzl3x9Q~JL85jUg~rQSlhOF7EusmlTO4MEBwhHjjrWx4Nub6iun-7Ex-ndkU5x6ZVvq0MY7ft-CIn7CfGgvWDPRjM2P7lQIv3dPptd3yqfbaPa1oMF3NjFztg3yQCuiK5o1SjIycsb8k3kvP5fBjERSrbIkS-Y55yXwYIi2MNp7mmxKFKG-53nHQ2uN6RI4NIIdDbSD5YUQrwTnfv4vDc53IBAUel-GvjLJdmlQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 22

Management of resistant hypertension.

BP, blood pressure; K<sup>+</sup>, potassium; SPC, single-pill combination.

[Open in new tab](https://academic.oup.com/view-large/figure/479376233/ehae178f22.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f22.jpeg?Expires=1728462845&Signature=wTNZPJhAW4qMYwNroNzc8bPLWQQDdNcJJ1qoUkiJkFkn9lk28iPnF5LCjDDk2QVRuha71PgvgEdsI3QkK~14Ln8s46cjnyRi6zoY-vCYDpcv47yQHVyNhbf-Uu~4zoLnJ1Wl3HnnD8tIORiUswEwcjmvWJuBp~w9m~wMOvRHaj~OresKbekdAOIFvl5aqjdLuVUI-Samu--P1NXwctfK3Ccd9TR5HgW57zhAGDnIzAPd4Jr8w-f3~AFsD966VVpt7RLEn5M9-A8ju-uG86xyMNMRslgZzvFWSgFURODBX0ZZlVaTNbywbXj3jw3wdL4rHcoO55gMpbGhsMPzse~OIg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479376233&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

If spironolactone is not tolerated due to anti-androgen side effects, eplerenone may be used. If eplerenone is used, higher doses (i.e. 50–200 mg daily) and twice-daily dosing may be necessary to achieve a BP-lowering effect.<sup><a href="javascript:;" reveal-id="ehae178-B503" data-open="ehae178-B503" class="link link-ref link-reveal xref-bibr">503</a></sup> Of note, eplerenone is not licensed for hypertension treatment in many countries.

When not already prescribed for a compelling indication, beta-blockers should be considered in the treatment of resistant hypertension, though their BP-lowering effects appear to be less potent than spironolactone in the setting of resistant hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B459" data-open="ehae178-B459" class="link link-ref link-reveal xref-bibr">459</a></sup>

Amiloride and clonidine have data suggesting they are as effective as spironolactone for BP lowering, though they lack outcomes data. A non-exhaustive list of additional medications sometimes used for BP-lowering purposes includes other centrally acting BP-lowering medications (e.g. methyldopa), hydralazine, aliskiren, minoxidil, triamterene, and loop diuretics (_[Figure 22](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae178-B515" data-open="ehae178-B515" class="link link-ref link-reveal xref-bibr">515</a>,<a href="javascript:;" reveal-id="ehae178-B516" data-open="ehae178-B516" class="link link-ref link-reveal xref-bibr">516</a></sup> As noted earlier, minoxidil use is often limited by side effects.

#### 9.13.4. Devices for blood pressure lowering

Several devices have been investigated for treating resistant hypertension. Of these, the most evidence is available for catheter-based renal denervation. As discussed in _Section [8.6.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7.6.1)_, several randomized, sham-controlled trials have been published, demonstrating a BP-lowering efficacy over 24 h for radiofrequency and ultrasound renal denervation in a broad spectrum of hypertension, including resistant hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B568" data-open="ehae178-B568" class="link link-ref link-reveal xref-bibr">568</a>,<a href="javascript:;" reveal-id="ehae178-B585" data-open="ehae178-B585" class="link link-ref link-reveal xref-bibr">585</a></sup> Other devices are still under investigation and are not recommended for routine use in clinical practice (_Section [8.6.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7.6.2)_).

Recommendation Table 30

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376239)

Recommendations for treating resistant hypertension (see Evidence Tables 42 and 43)

![Recommendations for treating resistant hypertension (see Evidence Tables 42 and 43)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt30.jpeg?Expires=1728462845&Signature=087TCPVSKopMosPmKu35MLTJkEDUC-d3P2vKX8T6ULDWIRoC~mbHlZoGqR5u4PxYJ65eQv2wYJL9NlnCGEJBq8a4LpQaqz0iU9sFZHGjS~YAvshZAYgxyZg9ytvjSH7lSfMo3B8udgvYGk-RfrD5Sh6TFoyKiHDJb4n3i611-9VlXhRyfw3EUzvQsG3xHs1J7hADfqorkYyvX7DA2XUrNfwZof-y8j~hqdORkf0dGeAlrHQuUpSiEAovkzpG3frllbcgP-YerDnMyn0votXUaTBfN9y6jx27LNRy5fvnFFnLEf2ZNJ46ITizvxmGB~g8zeyj7GCCQqgJ64CXVWhLbg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.14. Management of specific causes of secondary hypertension

#### 9.14.1. General considerations

These guidelines will describe only the general principles of managing the most common forms of secondary hypertension. For the rarer forms of secondary hypertension, patients should be referred to specialized hypertension centres.

By definition, secondary hypertension should be, for the most part, cured when the underlying cause has been unambiguously identified and removed. However, in clinical practice, this is not always the case. Vascular remodelling, a common feature of a delayed diagnosis of secondary hypertension, affects renal function and can account for residual high BP in some patients with secondary hypertension. The rate of cure is higher when the diagnosis is made early in the course of the disease. Most common forms of secondary hypertension are listed in _[Table 13](javascript:;)_.

#### 9.14.2. Primary aldosteronism

Primary aldosteronism (Conn syndrome) is the most common form of secondary hypertension. The management of primary aldosteronism depends on its subtype, particularly on adrenal lesions being unilateral or bilateral, because the unilateral forms are amenable to surgical treatment while the latter require lifelong medical treatment. In sporadic forms, unilateral primary aldosteronism is distinguished from bilateral primary aldosteronism by adrenal vein sampling or functional imaging with radiolabelled tracers.<sup><a href="javascript:;" reveal-id="ehae178-B930 ehae178-B931 ehae178-B932" data-open="ehae178-B930 ehae178-B931 ehae178-B932" class="link link-ref link-reveal xref-bibr">930–932</a></sup> In the much less common familial forms (necessitating a family history be taken), genetic testing for germline mutations is necessary.<sup><a href="javascript:;" reveal-id="ehae178-B933" data-open="ehae178-B933" class="link link-ref link-reveal xref-bibr">933</a></sup>

For unilateral primary aldosteronism, surgical removal of the offending adrenal gland is typically considered, unless the patient is older or has comorbidities of concern. Surgery is not an option for bilateral primary aldosteronism. Medical treatment is currently based on MRAs. Among MRAs, spironolactone is the most widely available. The effective dose, usually 50–100 mg once daily, can be titrated up to 300–400 mg once daily, if necessary. Eplerenone is also used and, despite being less potent than spironolactone and requiring twice-daily administration, it has the advantage of causing less gynaecomastia and erectile dysfunction in men.<sup><a href="javascript:;" reveal-id="ehae178-B934" data-open="ehae178-B934" class="link link-ref link-reveal xref-bibr">934</a></sup> Newer agents, such as the non-steroidal MRAs finerenone and exarenone, and the aldosterone synthase inhibitor baxdrostat, which lower BP in resistant hypertension,<sup><a href="javascript:;" reveal-id="ehae178-B326" data-open="ehae178-B326" class="link link-ref link-reveal xref-bibr">326</a>,<a href="javascript:;" reveal-id="ehae178-B474" data-open="ehae178-B474" class="link link-ref link-reveal xref-bibr">474</a></sup> are also being tested for treating primary aldosteronism. Of the familial forms, only glucocorticoid-remediable primary aldosteronism, now reclassified as familial hyperaldosteronism type 1, can be corrected with dexamethasone,<sup><a href="javascript:;" reveal-id="ehae178-B935" data-open="ehae178-B935" class="link link-ref link-reveal xref-bibr">935</a></sup> usually with low doses that are free of glucocorticoid effects and can be safely used during pregnancy.<sup><a href="javascript:;" reveal-id="ehae178-B936" data-open="ehae178-B936" class="link link-ref link-reveal xref-bibr">936</a></sup> For detailed information, readers are referred to the latest primary aldosteronism guidelines.<sup><a href="javascript:;" reveal-id="ehae178-B328" data-open="ehae178-B328" class="link link-ref link-reveal xref-bibr">328</a>,<a href="javascript:;" reveal-id="ehae178-B329" data-open="ehae178-B329" class="link link-ref link-reveal xref-bibr">329</a></sup>

#### 9.14.3. Renovascular hypertension

Patients with RVH should receive medical therapy to reduce BP in the first instance. Percutaneous transluminal renal angioplasty (PTRA) without stenting is the treatment of choice for fibromuscular dysplasia, and can restore renal perfusion pressure and lower BP.<sup><a href="javascript:;" reveal-id="ehae178-B937" data-open="ehae178-B937" class="link link-ref link-reveal xref-bibr">937</a></sup> When this is not feasible, RAS blockers are the drugs of choice for treatment, but they require careful monitoring of renal function over time, as they can cause acute renal failure in those with tight bilateral stenoses or a stenosed solitary functioning kidney. Possible involvement of the carotid, coronary, and other major arteries, possibly leading to dissection if BP is not controlled, should also be considered, as fibromuscular dysplasia is now recognized as a systemic disease affecting multiple vascular beds.

Patients with significant atherosclerotic renal artery stenosis are at very high risk of CVD and renal events. It is recommended that PTRA and stenting are performed in experienced centres due to the high risk of restenosis. Unfortunately, though these studies did not solely recruit patients with true significant atherosclerotic RVH, publication of some null trials<sup><a href="javascript:;" reveal-id="ehae178-B938" data-open="ehae178-B938" class="link link-ref link-reveal xref-bibr">938</a>,<a href="javascript:;" reveal-id="ehae178-B939" data-open="ehae178-B939" class="link link-ref link-reveal xref-bibr">939</a></sup> have decreased the enthusiasm for investigating atherosclerotic renal artery stenosis. This could result in more uncontrolled hypertension, recurrent flash pulmonary oedema (Pickering syndrome), and worsening renal function ultimately leading to end-stage renal disease.<sup><a href="javascript:;" reveal-id="ehae178-B940" data-open="ehae178-B940" class="link link-ref link-reveal xref-bibr">940</a></sup>

Recommendation Table 31

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376250)

Recommendations for managing hypertension in patients with renovascular hypertension (see Evidence Tables 44 and 45)

![Recommendations for managing hypertension in patients with renovascular hypertension (see Evidence Tables 44 and 45)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt31.jpeg?Expires=1728462845&Signature=lrYGgtVc~D4zTE9SDPzBJHTsPqBw0SBjpJiTS3VHzEByvMiGeAIhf6lKtBZVEPLtxrOxTW9p5uBQJJqrEjC0C6DrpBgRaQNLueb4mw~YRFoLGZOPSuSTR-1WUVR-vEzMnNOQxsqskaTqP5sgGDI2lS2t3pVQZtZ8icjza5rJNk8wRG4YHksnEDsX6Rt~yHu09x75Yi~1NkmcX-lNp~~4tKtUmZUOpKbbP1lU5-0SmRubLodKFFPpfYiORp3WYizp37PzO9pGqwJA0ZVvaSuUCv3YFqM7LURwZsvOg~2nOVd9XaXKNeP8oADuAO8SeyHf3Qv3EzwzI2EgEyvTC8Tgnw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 9.14.4. Phaeochromocytoma/paraganglioma

Phaeochromocytomas are rare adrenal tumours that secrete catecholamines and are present in <0.2% of patients with hypertension. A small percentage (<10%) of catecholamine-producing tumours are extra-adrenal and are derived from sympathetic and non-sympathetic nerves. More than 35% of the non-syndromic PPGLs are due to germline mutations.<sup><a href="javascript:;" reveal-id="ehae178-B338" data-open="ehae178-B338" class="link link-ref link-reveal xref-bibr">338</a></sup> These mutations should be screened for because, when found, they can drive management of the proband and the family and also inform the choice of functional imaging. Moreover, some germline mutations, such as those involving succinate dehydrogenase B, carry a risk of malignant adrenal tumours.<sup><a href="javascript:;" reveal-id="ehae178-B301" data-open="ehae178-B301" class="link link-ref link-reveal xref-bibr">301</a>,<a href="javascript:;" reveal-id="ehae178-B336" data-open="ehae178-B336" class="link link-ref link-reveal xref-bibr">336</a></sup>

Sympathetic PPGLs are usually secreting and present with chronic, episodic, or labile hypertension. Adrenergic crises cause hypertensive emergencies and should be treated with an intravenous (i.v.) alpha-1-blocker, such as phentolamine, doxazosin or terazosin, or labetalol. When given i.v. (1–2 mg/kg) twice weekly as a bolus over 1 min followed by a continuous infusion, labetalol also has alpha-blocker properties and has the advantage of allowing titration of the infusion based on the BP response, and avoids tachycardia via beta-blockade.

Identifying a single tumour mandates surgical excision after adequate pharmacological preparation, because secreting PPGLs can cause fatal events with no warning. Administering doxazosin or terazosin, followed by a beta-blocker, usually controls BP and adrenergic crises. As PPGLs are associated with a redistribution of volume from the periphery to the cardiopulmonary system,<sup><a href="javascript:;" reveal-id="ehae178-B944" data-open="ehae178-B944" class="link link-ref link-reveal xref-bibr">944</a></sup> patients with PPGLs have peripheral hypovolaemia that exposes them to the risk of profound hypotension, particularly right after tumour excision. Therefore, adequate fluid administration should be carefully managed.

#### 9.14.5. Obstructive sleep apnoea syndrome

The management of this prevalent condition should be driven by the result of a polysomnography study, which should provide the value of the AHI (the average number of episodes per hour) and the sleep position in which apnoeic–hypopnoeic episodes occur. For mild OSAS (AHI < 15), weight loss and advice on sleep hygiene are usually sufficient. For moderate (AHI of 15–30) and severe (AHI > 30) OSAS, continuous positive airway pressure (CPAP) is indicated and usually improves BP control and helps to resolve resistant hypertension. If CPAP is not tolerated, the site of upper airway obstruction should be determined by an Ear, Nose, and Throat evaluation with drug-induced sleep endoscopy as a potential step to corrective surgery.

#### 9.14.6. Drug-induced hypertension

Over-the-counter medications, prescribed drugs, and drug abuse (recreational substances and misuse of drugs) can cause hypertension ([Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S4](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

##### 9.14.6.1. Anticancer drug-induced hypertension

Growing evidence indicates that, while contemporary anticancer and anti-angiogenic drugs improve cancer survival, they can also cause hypertension ([Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S4](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). This is especially evident in patients treated with vascular endothelial growth factor inhibitors, in whom BP increases in 80%–90%.<sup><a href="javascript:;" reveal-id="ehae178-B945" data-open="ehae178-B945" class="link link-ref link-reveal xref-bibr">945</a></sup> Tyrosine kinase inhibitors and proteasome inhibitors also increase BP, as do adjuvant therapies (corticosteroids, calcineurin inhibitors, non-steroidal anti-inflammatory drugs, and anti-androgen hormone therapy). Hypertension caused by anticancer drugs is often dose limiting and may be reversible after therapy interruption or discontinuation. Evidence-based clinical trials specifically addressing patients who develop hypertension due to cancer therapy are lacking. It is recommended that management of hypertension in these patients follows that for the general population.<sup><a href="javascript:;" reveal-id="ehae178-B945" data-open="ehae178-B945" class="link link-ref link-reveal xref-bibr">945</a>,<a href="javascript:;" reveal-id="ehae178-B946" data-open="ehae178-B946" class="link link-ref link-reveal xref-bibr">946</a></sup> Managing these complex patients requires multidisciplinary healthcare involving oncologists, hypertension specialists, cardiologists, and nephrologists,<sup><a href="javascript:;" reveal-id="ehae178-B945" data-open="ehae178-B945" class="link link-ref link-reveal xref-bibr">945</a>,<a href="javascript:;" reveal-id="ehae178-B946" data-open="ehae178-B946" class="link link-ref link-reveal xref-bibr">946</a></sup> as highlighted in the 2022 ESC Guidelines on cardio-oncology.<sup><a href="javascript:;" reveal-id="ehae178-B946" data-open="ehae178-B946" class="link link-ref link-reveal xref-bibr">946</a></sup>

#### 9.14.7. Other forms of secondary hypertension

Other forms of secondary hypertension, such as genetic causes of hypertension (Liddle’s syndrome, glucocorticoid-remediable aldosteronism), excess liquorice, Cushing’s syndrome, thyroid disease, hyperparathyroidism, aortic coarctation, and acromegaly are rare. Affected patients should be referred to specialized centres for treatment.

## 10\. Acute and short-term lowering of blood pressure

### 10.1. Acute blood pressure management in hypertensive emergencies

#### 10.1.1. Definition and characteristics of hypertensive emergencies

Hypertensive emergency is defined as BP of ≥180/110 mmHg (see _[Figure 10](javascript:;)_) associated with acute HMOD, often in the presence of symptoms. Hypertensive emergencies are potentially life-threatening and require immediate and careful intervention to reduce BP, often with i.v. therapy.

Symptoms of hypertensive emergency depend on the organs affected but may include headache, visual disturbances, chest pain, shortness of breath, dizziness, and other neurological deficits. In patients with hypertensive encephalopathy, somnolence, lethargy, tonic–clonic seizures, and cortical blindness may precede a loss of consciousness; however, focal neurological lesions are rare and should raise the suspicion of stroke.

As outlined in _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6)_, we define HMOD among patients with chronically elevated BP or hypertension as the presence of specific cardiac, vascular, and renal alterations.<sup><a href="javascript:;" reveal-id="ehae178-B31" data-open="ehae178-B31" class="link link-ref link-reveal xref-bibr">31</a>,<a href="javascript:;" reveal-id="ehae178-B159" data-open="ehae178-B159" class="link link-ref link-reveal xref-bibr">159</a></sup> However, in the setting of hypertensive emergency, more acute manifestations of organ damage are relevant for management.

Acute manifestations of organ damage include:

-   Patients with severe acute hypertension associated with other clinical conditions likely to require urgent reduction in BP, e.g. acute onset of aortic dissection, myocardial ischaemia, eclampsia, or heart failure.
    
-   Malignant hypertension, defined as extreme BP elevations and acute microvascular damage (microangiopathy) affecting various organs.<sup><a href="javascript:;" reveal-id="ehae178-B947" data-open="ehae178-B947" class="link link-ref link-reveal xref-bibr">947</a></sup> The hallmark of this condition is small-artery fibrinoid necrosis in the kidneys, retina, and brain. The acute microangiopathy is typically characterized clinically by retinopathy (flame haemorrhages, cotton wool spots, and/or papilloedema). Other manifestations of microangiopathy include disseminated intravascular coagulation, encephalopathy (in about 15% of cases), acute heart failure, and acute deterioration in renal function.
    
-   Patients with sudden severe hypertension due to phaeochromocytoma, which can result in severe acute organ damage.
    

The term ‘hypertension urgency’ describes severe hypertension in patients without clinical evidence of acute organ damage. While these patients require BP reduction, they do not usually require admission to hospital, and BP reduction is best achieved with oral medication according to the drug treatment algorithm presented in _Section [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_. However, these patients may require more urgent outpatient review to ensure that their BP is controlled.

Acute and severe increases in BP can sometimes be precipitated by sympathomimetics such as methamphetamine or cocaine, when caution around beta-blocker use is also needed. Many patients in an emergency department with acute pain or distress may have acutely elevated BP that will normalize when the pain and distress are relieved, rather than requiring any specific intervention to lower BP.

A diagnostic work-up is necessary for patients with a suspected hypertensive emergency (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S12](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

#### 10.1.2. Acute management of hypertensive emergencies

Key considerations in defining treatment are:

1.  Establishing the affected target organ(s) and whether they require any specific interventions other than BP lowering.
    
2.  Determining whether there is a precipitating cause for the acute rise in BP and/or another concomitant health condition present that might affect the treatment plan (e.g. pregnancy).
    
3.  The recommended timing and magnitude of BP lowering required for safe BP reduction.
    

These considerations will inform the type of BP-lowering treatment required. Regarding BP-lowering drugs, i.v. treatment using a short half-life drug is typically ideal to allow careful titration of the BP response to treatment. This requires a higher dependency clinical area with facilities for continuous or near-continuous haemodynamic monitoring. Recommended drug treatments for specific hypertensive emergencies are provided in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S13](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_.

Rapid and uncontrolled or excessive BP lowering is not recommended in hypertensive emergency as this can lead to further complications. Although i.v. drug administration is recommended for most hypertensive emergencies, oral therapy with ACE inhibitors, ARBs, or beta-blockers (shorter-acting formulations like captopril or metoprolol) can also be effective. However, low initial doses should be used because these patients can be very sensitive to these agents, and treatment should take place in hospital. Further comprehensive details on the clinical management of hypertensive emergencies are available elsewhere.<sup><a href="javascript:;" reveal-id="ehae178-B242" data-open="ehae178-B242" class="link link-ref link-reveal xref-bibr">242</a></sup>

#### 10.1.3. Prognosis and follow-up

The survival of patients with hypertensive emergencies has improved over the past few decades, but these patients remain at high risk and should be screened for secondary hypertension.

### 10.2. Acute blood pressure management in acute intracerebral haemorrhage

In acute intracerebral haemorrhage, an increased BP is common and is associated with a greater risk of haematoma expansion and death, and a worse prognosis for neurological recovery. In trials testing immediate BP lowering (within <6 h) to a systolic target of <140 mmHg, the achieved systolic BP in the intervention group was typically 140–160 mmHg and was reported to reduce the risk of haematoma expansion.<sup><a href="javascript:;" reveal-id="ehae178-B948" data-open="ehae178-B948" class="link link-ref link-reveal xref-bibr">948</a>,<a href="javascript:;" reveal-id="ehae178-B949" data-open="ehae178-B949" class="link link-ref link-reveal xref-bibr">949</a></sup> Excessive acute drops in systolic BP (>70 mmHg) may be associated with acute renal injury and early neurological deterioration and should be avoided.<sup><a href="javascript:;" reveal-id="ehae178-B950" data-open="ehae178-B950" class="link link-ref link-reveal xref-bibr">950</a>,<a href="javascript:;" reveal-id="ehae178-B951" data-open="ehae178-B951" class="link link-ref link-reveal xref-bibr">951</a></sup>

### 10.3. Acute blood pressure management in acute ischaemic stroke

The beneficial effects of BP reduction in acute ischaemic stroke remain unclear. In patients not receiving i.v. thrombolysis or mechanical thrombectomy, there is no evidence for actively lowering BP unless it is extremely high (e.g. >220/120 mmHg). If BP is extremely high, an initial moderate relative reduction of 10%–15% over a period of hours may be considered.<sup><a href="javascript:;" reveal-id="ehae178-B952" data-open="ehae178-B952" class="link link-ref link-reveal xref-bibr">952</a></sup> The reason for a more conservative approach to acute BP management is that cerebral autoregulation may be impaired in acute stroke, and maintaining cerebral perfusion relies on systemic BP.

In contrast, patients who are treated with i.v. thrombolysis or mechanical thrombectomy (or both) should have more proactive management of severe hypertension, because they have an increased risk of reperfusion injury and intracranial haemorrhage. In patients undergoing treatment with i.v. thrombolysis, BP should be lowered to <185/110 mmHg prior to thrombolysis and then maintained at <180/105 mmHg over the following 24 h.<sup><a href="javascript:;" reveal-id="ehae178-B953" data-open="ehae178-B953" class="link link-ref link-reveal xref-bibr">953</a></sup> In patients undergoing treatment with mechanical thrombectomy (with or without i.v. thrombolysis) there is limited evidence from clinical trials, but BP should also be lowered to <180/105 mmHg prior to thrombectomy and maintained over the next 24 h.<sup><a href="javascript:;" reveal-id="ehae178-B953" data-open="ehae178-B953" class="link link-ref link-reveal xref-bibr">953</a>,<a href="javascript:;" reveal-id="ehae178-B954" data-open="ehae178-B954" class="link link-ref link-reveal xref-bibr">954</a></sup> Therefore, patients with acute ischaemic stroke and a BP of <180/105 mmHg in the first 72 h after stroke do not seem to benefit from the introduction or reintroduction of BP-lowering medication.<sup><a href="javascript:;" reveal-id="ehae178-B955" data-open="ehae178-B955" class="link link-ref link-reveal xref-bibr">955</a></sup> For stable patients who remain hypertensive (≥140/90 mmHg) ≥3 days after an acute ischaemic stroke, initiation or reintroduction of BP-lowering medication is recommended.

Recommendation Table 32

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376286)

Recommendations for acutely managing blood pressure in patients with intracerebral haemorrhage or acute ischaemic stroke

![Recommendations for acutely managing blood pressure in patients with intracerebral haemorrhage or acute ischaemic stroke](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt32.jpeg?Expires=1728462845&Signature=qxUJKSkIxrAdZQ~2RuYFr6qPWPDIOqE2psxRHeMvc5a7ZfD7O51IMcjpo~88mXyCs0qMW5Na2HuLYx4UlcBW8gYYqjq2~-JyXsLJ3ZTWs5GPj0fDvbtxq8RJU73OGIV6Vriiw05ANAAnEmIReEL9Pe2eqSM7ZMV2Z0q89gYpezrRAxpH8AASlknTQ4qOzRmjWt2txRFnG6iSWrd3LkIfmtYBSt0RvENwCXT-2cqryae7R4Cx87upuqbxH7B4dSMdGjgqc6ev9RG-TxMWN0nP9jzaaLEEHwNRsNI3xagL15hPynRnzT-KPPYLEkb8fAlkeCY~U4mS5~fm6v9aiwyfNA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 10.4. Acute blood pressure management in pre-eclampsia and severe hypertension in pregnancy

#### 10.4.1. Pre-eclampsia

Pre-eclampsia is discussed in _Section [9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_. Here we focus on its management in the acute setting. Pre-eclampsia is cured by delivery. Most international societies, including the ESC, recommend an intensive approach to BP lowering in pre-eclampsia.<sup><a href="javascript:;" reveal-id="ehae178-B89" data-open="ehae178-B89" class="link link-ref link-reveal xref-bibr">89</a>,<a href="javascript:;" reveal-id="ehae178-B964" data-open="ehae178-B964" class="link link-ref link-reveal xref-bibr">964</a>,<a href="javascript:;" reveal-id="ehae178-B965" data-open="ehae178-B965" class="link link-ref link-reveal xref-bibr">965</a></sup> In women with pre-eclampsia and severe hypertension, immediately reducing systolic BP to <160 mmHg and diastolic BP to <105 mmHg using i.v. labetalol or nicardipine (with administration of magnesium sulfate if appropriate and consideration of delivery if appropriate) was recommended in the 2018 ESC/ESH Guidelines on the management of arterial hypertension and the 2022 ESC Guidelines for management of cardiovascular disease in pregnancy.<sup><a href="javascript:;" reveal-id="ehae178-B1" data-open="ehae178-B1" class="link link-ref link-reveal xref-bibr">1</a>,<a href="javascript:;" reveal-id="ehae178-B89" data-open="ehae178-B89" class="link link-ref link-reveal xref-bibr">89</a></sup> The objective of treatment is to lower BP within 150–180 min.

Magnesium sulfate \[4 g i.v. over 5 min, then 1 g/h i.v.; or 5 g intramuscularly (i.m.) into each buttock, then 5 g i.m. every 4 h\] is recommended for eclampsia treatment but also for women with pre-eclampsia who have severe hypertension and proteinuria or hypertension and neurological symptoms or signs.<sup><a href="javascript:;" reveal-id="ehae178-B966" data-open="ehae178-B966" class="link link-ref link-reveal xref-bibr">966</a></sup> There is a risk of hypotension when magnesium is given concomitantly with nifedipine.<sup><a href="javascript:;" reveal-id="ehae178-B967" data-open="ehae178-B967" class="link link-ref link-reveal xref-bibr">967</a></sup> If BP control is not achieved by 360 min despite two medications, consulting critical care is recommended for intensive care unit admission, stabilization, and delivery (if appropriate).<sup><a href="javascript:;" reveal-id="ehae178-B966" data-open="ehae178-B966" class="link link-ref link-reveal xref-bibr">966</a></sup> Since plasma volume is reduced in pre-eclampsia, diuretic therapy should be avoided.

#### 10.4.2. Severe acute hypertension in pregnancy

Severe hypertension in pregnancy (without pre-eclampsia) may necessitate acute BP-lowering therapies. Severe hypertension in pregnancy is defined in general as systolic BP of >160 mmHg and diastolic BP of >110 mmHg and is associated with adverse maternal and peri-natal outcomes independent of pre-eclampsia and potentially of the same magnitude as eclampsia itself.<sup><a href="javascript:;" reveal-id="ehae178-B89" data-open="ehae178-B89" class="link link-ref link-reveal xref-bibr">89</a>,<a href="javascript:;" reveal-id="ehae178-B968" data-open="ehae178-B968" class="link link-ref link-reveal xref-bibr">968</a></sup>

There are differences in rate of BP control between i.v. labetalol and i.v. hydralazine in severe hypertension in pregnancy.<sup><a href="javascript:;" reveal-id="ehae178-B969" data-open="ehae178-B969" class="link link-ref link-reveal xref-bibr">969</a></sup> While evidence is conflicting,<sup><a href="javascript:;" reveal-id="ehae178-B667" data-open="ehae178-B667" class="link link-ref link-reveal xref-bibr">667</a>,<a href="javascript:;" reveal-id="ehae178-B668" data-open="ehae178-B668" class="link link-ref link-reveal xref-bibr">668</a></sup> hydralazine may be associated with more peri-natal adverse events than other drugs.<sup><a href="javascript:;" reveal-id="ehae178-B970" data-open="ehae178-B970" class="link link-ref link-reveal xref-bibr">970</a></sup> Nifedipine seems to provide lower BP with lower rates of neonatal complications than labetalol.<sup><a href="javascript:;" reveal-id="ehae178-B971" data-open="ehae178-B971" class="link link-ref link-reveal xref-bibr">971</a></sup>

Recommendation Table 33

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376294)

Recommendations for acutely managing blood pressure in patients with severe hypertension in pregnancy and pre-eclampsia (see Evidence Table 46)

![Recommendations for acutely managing blood pressure in patients with severe hypertension in pregnancy and pre-eclampsia (see Evidence Table 46)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt33.jpeg?Expires=1728462845&Signature=ctKbHxZ16lwmyeQJVoyZRDzTBPfzRHRdaoQ4tQOQw-wdsTA4i8Xg1eKsbdOgwnLjUFw7-ruZJ55MooUWMJf-Uy5BPYV9jDjzjNsNTuk5XkaHJmle2rh8VjrEYeUlyp8jXSBgVB6R5Z9xFa8-Qqo7Q6ZubrwX9x-fr2TkUQFfDTnZflNt9en5JaVIBd~43dYK3br6DKdVMn3lXt25VOPk74HUC-uZaUlc3-rGp92MjEoBF4WSvShtnavBneSBcIx5K18~6qs5YGqySaI6b5eoXJtRJdRbS8JcDTm4GYpMTn92CtVjDbDRQ5eRB5d1-238QljQ92q1LhUef3kOPiETNQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 10.5. Peri-operative acute management of elevated blood pressure

Details are provided in the ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery.<sup><a href="javascript:;" reveal-id="ehae178-B972" data-open="ehae178-B972" class="link link-ref link-reveal xref-bibr">972</a></sup> Peri-operative hypertension, hypotension, and BP variability are associated with haemodynamic instability and poor clinical outcomes for patients undergoing surgery.<sup><a href="javascript:;" reveal-id="ehae178-B973" data-open="ehae178-B973" class="link link-ref link-reveal xref-bibr">973</a></sup> Pre-operative risk assessment for BP management, therefore, should involve assessing for underlying end-organ damage and comorbidities.<sup><a href="javascript:;" reveal-id="ehae178-B974" data-open="ehae178-B974" class="link link-ref link-reveal xref-bibr">974</a></sup> Postponing necessary non-cardiac surgery is not usually warranted for patients with minor or moderate elevations in BP, as they are not at higher CVD risk.<sup><a href="javascript:;" reveal-id="ehae178-B130" data-open="ehae178-B130" class="link link-ref link-reveal xref-bibr">130</a>,<a href="javascript:;" reveal-id="ehae178-B975" data-open="ehae178-B975" class="link link-ref link-reveal xref-bibr">975</a></sup>

Avoiding large fluctuations in BP in the peri-operative course is important, and planning a strategy for a patient should account for the baseline office BP.<sup><a href="javascript:;" reveal-id="ehae178-B974 ehae178-B975 ehae178-B976 ehae178-B977" data-open="ehae178-B974 ehae178-B975 ehae178-B976 ehae178-B977" class="link link-ref link-reveal xref-bibr">974–977</a></sup>

There is insufficient evidence for reduced or increased peri-operative BP targets compared to usual care BP targets to lower peri-operative events.<sup><a href="javascript:;" reveal-id="ehae178-B978" data-open="ehae178-B978" class="link link-ref link-reveal xref-bibr">978</a></sup> No specific measure of BP appears better than any other for predicting risk of peri-operative events.<sup><a href="javascript:;" reveal-id="ehae178-B975" data-open="ehae178-B975" class="link link-ref link-reveal xref-bibr">975</a></sup>

#### 10.5.1. Blood pressure-lowering drugs in the peri-operative phase

Routine initiation of a beta-blocker peri-operatively is not necessary.<sup><a href="javascript:;" reveal-id="ehae178-B979" data-open="ehae178-B979" class="link link-ref link-reveal xref-bibr">979</a></sup>

Pre-operative initiation of beta-blockers in advance of high-risk, non-cardiac surgery may be considered in patients who have known coronary artery disease or myocardial ischaemia<sup><a href="javascript:;" reveal-id="ehae178-B980" data-open="ehae178-B980" class="link link-ref link-reveal xref-bibr">980</a></sup> or two or more significantly elevated clinical risk factors in order to reduce the incidence of peri-operative myocardial infarction.<sup><a href="javascript:;" reveal-id="ehae178-B979" data-open="ehae178-B979" class="link link-ref link-reveal xref-bibr">979</a></sup> Peri-operative continuation of beta-blockers is recommended for patients currently taking beta-blockers.<sup><a href="javascript:;" reveal-id="ehae178-B981" data-open="ehae178-B981" class="link link-ref link-reveal xref-bibr">981</a></sup>

Some studies suggest that continued use of ACE inhibitors is associated with a higher risk of peri-operative hypotension and subsequent end-organ damage including kidney injury, myocardial infarction, and stroke.<sup><a href="javascript:;" reveal-id="ehae178-B982" data-open="ehae178-B982" class="link link-ref link-reveal xref-bibr">982</a></sup> In the Prospective Randomized Evaluation of Preoperative Angiotensin-Converting Enzyme Inhibition (PREOP-ACEI) trial, transient pre-operative interruption of ACE inhibitor therapy was associated with a decreased risk of intra-operative hypotension.<sup><a href="javascript:;" reveal-id="ehae178-B983" data-open="ehae178-B983" class="link link-ref link-reveal xref-bibr">983</a></sup> A subsequent systematic review also showed a decreased risk of intra-operative hypotension with withholding ACE inhibitors/ARBs before surgery, but no association with decreased mortality or CVD outcomes.<sup><a href="javascript:;" reveal-id="ehae178-B984" data-open="ehae178-B984" class="link link-ref link-reveal xref-bibr">984</a></sup> On the other hand, vigilance is needed because withholding ACE inhibitors has also been shown to increase post-operative hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B985" data-open="ehae178-B985" class="link link-ref link-reveal xref-bibr">985</a></sup> In patients with heart failure, loop diuretics can be continued in patients prone to volume overload.<sup><a href="javascript:;" reveal-id="ehae178-B986" data-open="ehae178-B986" class="link link-ref link-reveal xref-bibr">986</a></sup> CCBs are generally considered safe pre-operatively.

## 11\. Patient-centred care in hypertension

### 11.1. Definition

Patient-centred care is defined as an attitude of the healthcare professional that closely aligns with the patient’s preferences and needs.<sup><a href="javascript:;" reveal-id="ehae178-B987" data-open="ehae178-B987" class="link link-ref link-reveal xref-bibr">987</a></sup> In the patient-centred approach (_[Figure 23](javascript:;)_), patients are viewed as active participants in health services, who work as partners alongside healthcare professionals. A patient-centred approach is associated with higher satisfaction rates, better adherence to recommendations and prescriptions, and better treatment, particularly in the management of chronic illness, such as hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B988" data-open="ehae178-B988" class="link link-ref link-reveal xref-bibr">988</a></sup> While there is limited evidence for the efficacy and effectiveness of specific shared decision-making intervention strategies in hypertension care,<sup><a href="javascript:;" reveal-id="ehae178-B989" data-open="ehae178-B989" class="link link-ref link-reveal xref-bibr">989</a></sup> it is viewed as an ethical imperative in healthcare practice and health policy, and in clinical guidelines.<sup><a href="javascript:;" reveal-id="ehae178-B130" data-open="ehae178-B130" class="link link-ref link-reveal xref-bibr">130</a></sup>

![Patient-centred care.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f23.jpeg?Expires=1728462845&Signature=EZmvrP45p6HG7YGYrAB6dJKrvueypQWi16k~t6z1To5nwlcgVXUT7DU1DfZr7t898YDLhv8GoCFhRvbPCKu4Dmkaei320h9N-ouwor~Eej1nGpeFn5OAnWo2-~CU~ecwGI6yqClyA9bFzYtouwVx0C9ZYTFoEGKCaNiu~xY2aSEJP1BceFLovx9Ge9sXfV3-XMJj2lPd2P~PSUtCco89X5EzJD7YB9UEZPBpc8Fr8f6MHwqI-WV2Oh2IKlXEIBEn-7j89FwHX0ZkLN8Q-SmeOfSqsvCTGch3Q27iyOBBxFvSWM-~n9FRmpBAcVqu2eThAmK7PRRrZaAAhYtdnBBrlQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 23

Patient-centred care.

[Open in new tab](https://academic.oup.com/view-large/figure/479376306/ehae178f23.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f23.jpeg?Expires=1728462845&Signature=oSy2SEpfjDeOFgC8w0m9HqS1fZ3gfTowv9eBQaQcakD-PBtF9FN1I~ZuhXNGr2GZpNjT3NjA6wzSgczv~3bw8hK7ukTBzDQwBwf3WwAFOoqE5mI6GWUzT5nCje4z7hp3FTr6s4vp7qnUDuSEcNYZmNu3N8qXfHu1PvFAIsNbzIz8eeI67hr6ZtCKgynFJ0KkOS6JVJixz2Y9Bqn2Jy6q4lTaXy-pXZJm0OrjKu-RcGiURea9QvU17MZ4UBJ25-pXJOSazi7gn9RQiFmRGjCeXa~I37O94eZ-05cNX6CGCKZ0DuYiVn2wryxjT--bIMIK3uipvRddEZB~mIhfyIHQyw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479376306&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

### 11.2. Communicating consequences of treatment

In line with patient-centred care, it is important to assess whether patients understand their hypertension-related risk, the rationale for any hypertension treatment, the benefits and harms of hypertension treatment, and that the treatment plan is also centrally guided by what matters most to the patient. Risk communication is challenging, and providers need to be led by the individual’s preferences when presenting more detailed numeric and visual representations of risk and the likely benefits and harms of hypertension treatment. Socio-demographic differences in healthcare need to be considered in patient–provider communication.<sup><a href="javascript:;" reveal-id="ehae178-B990" data-open="ehae178-B990" class="link link-ref link-reveal xref-bibr">990</a>,<a href="javascript:;" reveal-id="ehae178-B991" data-open="ehae178-B991" class="link link-ref link-reveal xref-bibr">991</a></sup>

Standard approaches to communicate consequences of treatment can involve 10-year risk of a CVD event with SCORE2 or SCORE2-OP. Alternatively, individual risk and risk reduction can be communicated in terms of ‘risk age’ or ‘heart age’ (_Section [7.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6.3)_).

Recommendation Table 34

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376310)

Recommendations for communicating consequences of treatment (see Evidence Table 47)

![Recommendations for communicating consequences of treatment (see Evidence Table 47)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt34.jpeg?Expires=1728462845&Signature=qrKHz6qNnRe9qAepGdaagbr5s6Zh0ioqmcevQf9qZUXAQENOL3l-UfNRkewvDNGdbL1qxAE5dLl-5mqRh6DRSt~GEnEbPoA9F6Vh~KCAi7CJmUGVmPtxXhFAH0Y5P5xWVTl7G7tIC51FF6-Bc4tmZ8cnk0T~Fg8e9zHfD68o0Usz-JllP5HN6ReRlypmXsGaZhdnOcatuAuCfT6eMYdruDSo1uXZsP-0~0opFadfS9kthVcQF7xvSPW9hCr-pMNOz8TT-bJkBnMDQ9dtNFF0ceIwRlRKAz2rO6YUpiqKKxddHO8T9uqVqXZESkPjQS7q4vrGHD5vx6NYStCktUSZ4Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 11.3. Self-measuring and monitoring

Self-care refers to individual responsibility for healthy lifestyle behaviours, as well as the actions required to cope with health conditions.<sup><a href="javascript:;" reveal-id="ehae178-B996" data-open="ehae178-B996" class="link link-ref link-reveal xref-bibr">996</a>,<a href="javascript:;" reveal-id="ehae178-B997" data-open="ehae178-B997" class="link link-ref link-reveal xref-bibr">997</a></sup> In the context of hypertension, it also includes self-management and self-measurement of BP.

Self-management includes lifestyle behaviour (diet, exercise, smoking, alcohol), co-management of medical treatments, and support for adhering to prescribed medication.<sup><a href="javascript:;" reveal-id="ehae178-B998" data-open="ehae178-B998" class="link link-ref link-reveal xref-bibr">998</a></sup> Self-monitoring allows high BP to be detected early,<sup><a href="javascript:;" reveal-id="ehae178-B999" data-open="ehae178-B999" class="link link-ref link-reveal xref-bibr">999</a></sup> and enables patients to co-manage medications with their healthcare provider.<sup><a href="javascript:;" reveal-id="ehae178-B1000" data-open="ehae178-B1000" class="link link-ref link-reveal xref-bibr">1000</a>,<a href="javascript:;" reveal-id="ehae178-B1001" data-open="ehae178-B1001" class="link link-ref link-reveal xref-bibr">1001</a></sup> Suitably validated and correctly used digital devices have the potential to support co-management,<sup><a href="javascript:;" reveal-id="ehae178-B1002" data-open="ehae178-B1002" class="link link-ref link-reveal xref-bibr">1002</a>,<a href="javascript:;" reveal-id="ehae178-B1003" data-open="ehae178-B1003" class="link link-ref link-reveal xref-bibr">1003</a></sup> and facilitate remote monitoring of BP.<sup><a href="javascript:;" reveal-id="ehae178-B76" data-open="ehae178-B76" class="link link-ref link-reveal xref-bibr">76</a>,<a href="javascript:;" reveal-id="ehae178-B81" data-open="ehae178-B81" class="link link-ref link-reveal xref-bibr">81</a>,<a href="javascript:;" reveal-id="ehae178-B1004" data-open="ehae178-B1004" class="link link-ref link-reveal xref-bibr">1004</a></sup>

Recommendation Table 35

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376314)

Recommendations for self-measuring and monitoring blood pressure (see Evidence Table 48)

![Recommendations for self-measuring and monitoring blood pressure (see Evidence Table 48)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt35.jpeg?Expires=1728462845&Signature=yDXb7ivuBeH4fvFf206DEvS4jVzre1RRs1QEn3KltdFW~fikmD1nMXokphVHgAk42jSwQrynliQMSQUlqYb7Dc83qIhiRdIlKGpKUzR8eUqvrabcB0Mhpr8QrsHmWfvmxTgJq05Sb7~lmFjBh1rDD88hB9NXwpfESLz8HSSvY2FvY7xrZhUECdu0SYpK3JjqFK94jLJ~XiPVkDZjFRf~n~MuFoN6RVGzLCCxZg7FWU7XJDxQlIkuivnHSTsQaNiu1XnJa0AfFA8gfgFB5dD~2xteidpCvdugnifHgT0x4NlyBge~KzDnXfVDjzqBsOkNlNTsA6cwLuxvIBqipOjuBg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 11.4. Facilitating medication adherence and persistence

Adherence (_[Figure 24](javascript:;)_) to BP-lowering drug regimens in clinical practice is almost always lower than seen in clinical trials.<sup><a href="javascript:;" reveal-id="ehae178-B1007" data-open="ehae178-B1007" class="link link-ref link-reveal xref-bibr">1007</a></sup> Most apparent treatment-resistant hypertension is accounted for by non-adherence.<sup><a href="javascript:;" reveal-id="ehae178-B1008" data-open="ehae178-B1008" class="link link-ref link-reveal xref-bibr">1008</a></sup> Adherence should always be assessed with a no-blame approach. Various methods are available to assess adherence and, along with details on barriers to adherence, are described in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) and _[Table S14](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_.<sup><a href="javascript:;" reveal-id="ehae178-B1009" data-open="ehae178-B1009" class="link link-ref link-reveal xref-bibr">1009</a></sup>

![The five dimensions of adherence (WHO, 2003) applied to hypertension.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f24.jpeg?Expires=1728462845&Signature=vYLCBfntJuKwk~iU-GCYRiemEtXqUJyg34wynLkd8oQ1tnXvCsaKojwLUsENVArhC1~2cqDDd6W9qq27gMNSF3eQWxgI2CpcUCQQUfPRagZcwXQK8u6M2Xa0kISQbWDtuKNcrx5Abplf5mCdCs2Rq0pjq7qQsruebWlFidSjOsHi~lShN2dSFr3qum~DjxlhtUGui8YEd3Zaf9QSFmGez8jJ21keqAFN-6~-CiqOVlR6-7DYDSmZ5uW9U~spHoguEnuQWdCjZFOSssu1q6LRGAmNgtEdR39JQUY1FpKPsrGUpQYQO70LEtyDvO-JDv3QcRf93bjMoRYYQFyanXcgAA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 24

The five dimensions of adherence (WHO, 2003) applied to hypertension.

[Open in new tab](https://academic.oup.com/view-large/figure/479376317/ehae178f24.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f24.jpeg?Expires=1728462845&Signature=b6lUTmKGA1K~5lzKsSPQw1YE89edoDWvGi8ubUS3YFzfWcg-QB-EWh8LXMZiK4YAyUoTcsXACTes4NtOWnNdKFPRuzf4vXSCqYzyOGhzboq9EqsWIyv9nzwaLra1p3T5taxUyng0w0ujUAewsHPdel4AAvegwUo-g3nornm5Q0iX1pxomANzSPRH0Q85fDEM1ZPIVE3QEvQn26woXKcm6qqkZJv7KOZBJ1XON~rv4bCFJXhvAnpF8lXzEkvvDr1ZnbJk5QnhDVG-3N2sYkqECPu5VPTWlxq1EBma8RTvfkKVO4PvsTHV5ZdVaQ8rUusmiyYi4HYUET72oCBHfvluvw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479376317&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Adherence may also be facilitated by an optimal therapeutic regimen, which can be achieved by medication reviews carried out at appropriate intervals. Several factors should be considered: (i) identifying drug-related adverse events and appropriate dosing levels, (ii) using long-acting drugs that require once-daily dosing (preferably drugs that are long-acting due to pharmacokinetic properties rather than galenic formulation), (iii) avoiding complex dosing schedules, (iv) using single-pill combinations whenever feasible, (v) taking into account the financial capacity of the patient to pay for a given regimen in the longer term, if relevant, or other pertinent aspects of the local or national healthcare systems, and (vi) enlisting support of a family member or other social support to facilitate medication adherence and persistence (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S15](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><a href="javascript:;" reveal-id="ehae178-B1010" data-open="ehae178-B1010" class="link link-ref link-reveal xref-bibr">1010</a></sup>

While there have been advancements in digital tools to support self-management of chronic illness including hypertension, there is little efficacy evidence evaluating these interventions. Therefore, it is premature to make recommendations about specific digital tools.

### 11.5. Multidisciplinary management

A collaborative approach to managing hypertension, using team-based care among physicians, nurses, pharmacists, dietitians, and physiotherapists, offers significant benefits over physician-only care. Multidisciplinary care is intended to be collaborative and complementary to regular medical care<sup><a href="javascript:;" reveal-id="ehae178-B1011" data-open="ehae178-B1011" class="link link-ref link-reveal xref-bibr">1011</a></sup> and is associated with lower systolic and diastolic BP<sup><a href="javascript:;" reveal-id="ehae178-B227" data-open="ehae178-B227" class="link link-ref link-reveal xref-bibr">227</a>,<a href="javascript:;" reveal-id="ehae178-B229" data-open="ehae178-B229" class="link link-ref link-reveal xref-bibr">229</a>,<a href="javascript:;" reveal-id="ehae178-B1012" data-open="ehae178-B1012" class="link link-ref link-reveal xref-bibr">1012</a>,<a href="javascript:;" reveal-id="ehae178-B1013" data-open="ehae178-B1013" class="link link-ref link-reveal xref-bibr">1013</a></sup> and improved outcomes.<sup><a href="javascript:;" reveal-id="ehae178-B230" data-open="ehae178-B230" class="link link-ref link-reveal xref-bibr">230</a>,<a href="javascript:;" reveal-id="ehae178-B1014" data-open="ehae178-B1014" class="link link-ref link-reveal xref-bibr">1014</a></sup> Task-shifting away from physicians is necessary to meet the huge need for the management of elevated BP and hypertension in the population.<sup><a href="javascript:;" reveal-id="ehae178-B1015" data-open="ehae178-B1015" class="link link-ref link-reveal xref-bibr">1015</a></sup> Prescribing remains a physician duty, but prescribing can be conducted under collaborative practice agreements with the multidisciplinary team in many countries.

Further details on patient-centred care in hypertension is provided in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA).

Recommendation Table 36

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376323)

Recommendations for multi/interdisciplinary blood pressure management (see Evidence Table 49)

![Recommendations for multi/interdisciplinary blood pressure management (see Evidence Table 49)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt36.jpeg?Expires=1728462845&Signature=P~-R8x9DR-AeWMnnteTDD8rIuJ~0RnpKYSufxKuW1-XCmftA6xInPxM8yl0lseySh0PX2Jm~PJxWN5KZDhp3cVAgLJra1D6cfV-lAQTCTr0lQZ7yf9mHBbBhMx7VkCJFW0B1CFvEXPIUoDDZB~Cj0XYGvBej69uBuWF7oIj76RHhPQ-C1rCBIP1BA7oJxs0r1PJA0h65tJCRJyWudi2Wi6cBw~U82cGByWWTaGxhxBDUknCiBopRCgayXZ6ZbrH3quW3qx8XgIs6GhiaTk7OMffdhDwf2pAIdsjClO0-UOgEkcTvuaKc4qI-tUmV7uMoQ9oSpRNLfhOeSVkbEyyRkQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 12\. Key messages

1.  Given the demographic transition and the worldwide ageing of populations, the number of individuals with elevated BP or hypertension is increasing worldwide.
    
2.  The trajectory of BP control appears to be worsening in North America, in some (but not all) European countries, and elsewhere around the world.
    
3.  The risk for CVD attributable to BP is on a continuous log-linear exposure variable scale, not a binary scale of normotension vs. hypertension.
    
4.  BP-lowering drugs can reduce CVD risk even among individuals not traditionally classified as hypertensive. Accordingly, a new BP category called ‘elevated BP’ is introduced. Elevated BP is defined as an office systolic BP of 120–139 mmHg or diastolic BP of 70–89 mmHg. Hypertension remains defined as office BP of ≥140/90 mmHg.
    
5.  Hypertension in women is under-studied in basic, clinical, and population research.
    
6.  HMOD suggests long-standing or severe hypertension and is associated with increased CVD risk.
    
7.  Absolute CVD risk must be considered when assessing and managing elevated BP.
    
8.  Despite the growing number of hypertension guidelines, the rates of diagnosis, treatment, and control of hypertension (and elevated BP) remain suboptimal. A major factor underlying this is poor implementation of evidence-based guidelines in real-world clinical practice.
    
9.  One of the most important changes in the 2024 Guidelines is the focus on evidence related to CVD outcomes of BP-lowering interventions rather than BP lowering alone.
    
10.  Irrespective of the threshold BP above which BP-lowering treatment (lifestyle or pharmacological or other treatment) is recommended, the on-treatment BP target is 120–129/70–79 mmHg for all adults, provided this treatment is well tolerated. There are several important exceptions to these targets and individualized decision-making is always the most important priority.
    

## 13\. Gaps in the evidence

1.  Drivers of worsening trajectories of BP control in women and men.
    
2.  Need for sex-specific data on epidemiology, risk factors, and pathophysiology of hypertension. Need for more prospective studies to assess women’s and men’s specific CVD risk factors pertinent to adults with elevated BP and hypertension, due to biological and socio-cultural conditions. This includes sex-specific weighting of traditional risk factors, as well as inclusion of sex-dependent, non-traditional, vascular risk factors such as stress, socio-economic conditions, and others.<sup><a href="javascript:;" reveal-id="ehae178-B1017" data-open="ehae178-B1017" class="link link-ref link-reveal xref-bibr">1017</a>,<a href="javascript:;" reveal-id="ehae178-B1018" data-open="ehae178-B1018" class="link link-ref link-reveal xref-bibr">1018</a></sup> We are also lacking data on sex-specific hormonal and genetic mechanisms and pathophysiology in the human.<sup><a href="javascript:;" reveal-id="ehae178-B1019" data-open="ehae178-B1019" class="link link-ref link-reveal xref-bibr">1019</a></sup> Another important area in need of investigation is a better understanding of the role of gender in the management of elevated BP and hypertension (including gender-driven barriers in accessing medical care and adherence).
    
3.  More widespread validation of home BP measuring devices. Validation protocols for cuffless BP measurement devices have just recently been proposed and need to be tested.
    
4.  Clinical effectiveness of HMOD in directing intensity of care and personalized approaches in managing elevated BP and hypertension.
    
5.  Best practice to screen and manage primary aldosteronism.
    
6.  Clinical benefits of treating low CVD-risk individuals with elevated BP and further data strengthening the use of BP-lowering medication among high-risk persons with baseline systolic BP of 120–129 mmHg.
    
7.  Need for more data on the sex-specific optimal dosing, effects, and adverse effects of BP-lowering drugs,<sup><a href="javascript:;" reveal-id="ehae178-B1020" data-open="ehae178-B1020" class="link link-ref link-reveal xref-bibr">1020</a></sup> in particular from specifically planned prospective randomized trials.
    
8.  More consideration for overall CVD outcomes of BP-lowering interventions.
    
9.  More European data (RCTs, real life) about the beneficial effect of treating patients with elevated BP and hypertension with polypills (inclusive of non-BP lowering medications).
    
10.  CVD outcomes-based data on MRAs as add-on therapy solely for resistant hypertension.
    
11.  Trials on the BP-lowering effects of newer antidiabetic drugs (such as SGLT2 inhibitors and GLP-1 receptor agonists) or drugs that now have indications for other conditions, such as finerenone or sacubitril-valsartan.
    
12.  Beneficial BP and CVD effects of increasing dietary potassium intake and other lifestyle interventions. Studies to disentangle the effect of sodium reduction vs. the effect of potassium supplementation on BP control and CVD outcomes.
    
13.  RCTs comparing single-pill combination therapy with fixed doses vs. multiple monotherapies and their effects on CVD outcomes.
    
14.  Cardiovascular outcomes trials of renal denervation.
    
15.  BP-lowering treatment RCTs on different ethnic and migrant groups established in Europe.
    
16.  Pharmacological BP management in young adults (aged <40 years) and better data on the efficacy of a life-course approach for the drug management of BP.<sup><a href="javascript:;" reveal-id="ehae178-B1021" data-open="ehae178-B1021" class="link link-ref link-reveal xref-bibr">1021</a></sup>
    
17.  CVD outcomes in moderately to severely frail and/or very elderly persons where BP medications have been deprescribed, and the impact of competing risks.
    
18.  Management of renal artery disease with haemodynamically stable but severe stenosis (i.e. without high-risk features).
    
19.  Need for clinical trials on managing hypertension in patients treated with anticancer drugs or anti-rejection drugs in recipients of an allograft transplant.
    
20.  Hypertension management in the setting of climate changes, global warming, air and other forms of pollution, pandemics, war zones, and in the context of drug restrictions experienced in some low-to-middle-income countries.
    
21.  Need to improve implementation of guidelines by healthcare providers.
    
22.  How to develop sustainable hypertension care at the intersection of growing numbers of patients and limited resources.
    
23.  Treat-to-target trials specifically testing BP-lowering drugs among drug-naïve persons with baseline BP of 120–129 mmHg and increased CVD risk.
    

## 14\. ‘What to do’ and ‘what not to do’ messages from the guidelines

A selected sample of the main messages from these guidelines are provided in _[Table 15](javascript:;)_.

Table 15

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376330)

What to do and what not to do

![What to do and what not to do](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178t15.jpeg?Expires=1728462845&Signature=X5Z5w42Fcpl2D1m5W7Vei8KhvtCt~lUObpzltVjZzug4NTfGK5HGcNwLWMm3Zqg7a6GrTNPWynqOb7TRkkN7jHBzKkZC0Vyo7o4Z97Zt7HvCR5QmMTX7kh3dWWORDJZq4Esl~bT5DuTYbMMQsU3udrNef~DfaYhLK~Xk0ROTvsqIavifhiRiWupERcxDVEBUcC2NNbkhi076Wh~TqujHNsrBJwy7s4x~gENaGA07mmAQbBItKagW5U1OkTP57GnnIJpsju42yg3qBlsuUo8EgN7GG-502HCu8PARf3J9Tr9x52jDCkrLMICMfJTdKqUXIsJEP2njXpfVyNEjSmwVhQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 15\. Evidence tables

[Evidence tables](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/2024_hypertension_guidelines_evidence_tables.pdf?Expires=1728462845&Signature=ouEM5I5CibCYM3GqloI7s9~JI00H8MfD81BoIcnVDVsDGQivmOCeLZtur9zJTFeWYqCcClqeEMk6Pu0FKutcCpA3bCVfHIEHxBgecDL8vuHWpTPZVNGaxkfDYObx8AXhAa4H9qrnjxJWbz-oz-o97M3f-IAMk7bfizdl2eplf2-SW9UvRMVT1zsx7sRR0mqQlsBgWq6v9Jq5FRHMKEx5ze25J0xci6V8Z0qKuOBP7BOT0TWXLf6qonytosxqeN4Jx4lAYEpH6O2JNn94hfqMt0kU3e5tmelGvUXUu2Hz8zROsR8n-lHF9BVUo9oWq4O5G4iKmeQyJ~CWvk9ITlriNg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) are available at _European Heart Journal_ online.

## 16\. Data availability statement

No new data were generated or analysed in support of this research.

## 17\. Author information

**Author/task force Member Affiliations: Cian P. McCarthy**, Cardiovascular Division Massachusetts General Hospital and Harvard Medical School Boston, MA, United States of America; **Rosa Maria Bruno**, PARCC, Université Paris Cité, Inserm, Paris, France, and Pharmacology & Hypertension, AP-HP, Hôpital Européen Georges Pompidou, Paris, France; **Sofie Brouwers**, Cardiovascular Center Aalst, Department of Cardiology, OLV Clinic Aalst, Aalst, Belgium, and Department of Experimental Pharmacology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium; **Michelle D. Canavan**, School of Medicine, College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland, and Department of Geriatric Medicine, University Hospital Galway, Saolta Hospitals Group, Galway, Ireland; **Claudio Ceconi**, Motusmed Clinic, Brescia, Italy; **Ruxandra Maria Christodorescu**, Department V Internal Medicine, University of Medicine and Pharmacy V Babes, Timisoara, Romania, and Research Center, Institute of Cardiovascular Diseases, Timisoara, Romania; **Stella S. Daskalopoulou**, Medicine Research Institute of the McGill University Health Centre, McGill University, Montreal, Canada; **Charles J. Ferro**, Department of Renal Medicine, University Hospitals Birmingham, Birmingham, United Kingdom, and Institute of Cardiovascular Sciences University of Birmingham, Birmingham, United Kingdom; **Eva Gerdts**, Department of Clinical Science, University of Bergen, Bergen, Norway, and Department of Heart Disease, Haukeland University Hospital, Bergen, Norway; **Henner Hanssen**, Department Sport, Exercise and Health, Medical Faculty, University of Basel, Basel, Switzerland; **Julie Harris** (United Kingdom), ESC Patient Forum, Sophia Antipolis, France; **Lucas Lauder**, Department of cardiology, University hospital Basel, Basel, Switzerland, and Department of internal medicine III, Cardiology, Angiology, and Intensive Care Medicine, Saarland university medical center, Homburg, Germany; **Richard J. McManus**, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; **Gerard J. Molloy**, School of Psychology, University of Galway, Galway, Ireland; **Kazem Rahimi**, Deep Medicine, Nuffield Department of Women’s and Reproductive Health, University of Oxford, Oxford, United Kingdom; **Vera Regitz-Zagrosek**, Charite, University Medicine Berlin, Gender in Medicine, Berlin, Germany; **Gian Paolo Rossi**, Department of Medicine, DIMED, University of Padua, Padua, Italy; **Else Charlotte Sandset**, Department of Neurology, Oslo University Hospital, Oslo, Norway, The Norwegian Air Ambulance Foundation, Oslo, Norway, and Institute of Clinical Medicine University of Oslo, Oslo, Norway; **Bart Scheenaerts** (Belgium), ESC Patient Forum, Sophia Antipolis, France; **Jan A. Staessen**, Non-Profit Research Association Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium, and Biomedical Research Group, Faculty of Medicine, University of Leuven, Leuven, Belgium; **Izabella Uchmanowicz**, Department of Nursing and Obstetrics, Faculty of Health Sciences, Wroclaw Medical University, Wroclaw, Poland; and **Maurizio Volterrani**, Exercise Science and Medicine San Raffaele Open University, Rome, Italy, and Cardiopulmonary Department, IRCCS San Raffaele, Rome, Italy.

### 18\. Appendix

**ESC Scientific Document Group**

Includes Document Reviewers and ESC National Cardiac Societies.

**Document Reviewers:** Ana Abreu (CPG Review Co-ordinator) (Portugal), Michael Hecht Olsen (CPG Review Co-ordinator) (Denmark), Marco Ambrosetti (Italy), Emmanuel Androulakis (United Kingdom), Lia Evi Bang (Denmark), Jesper Nørgaard Bech (Denmark), Michael A. Borger (Germany), Pierre Boutouyrie (France), Luís Bronze (Portugal), Sergio Buccheri (Sweden), Regina Dalmau (Spain), Maria Carmen De Pablo Zarzosa (Spain), Christian Delles (United Kingdom), Maria Manuela Fiuza (Portugal), Rahima Gabulova (Azerbaijan), Bjørn Olav Haugen (Norway), Christian Heiss (United Kingdom), Borja Ibanez (Spain), Stefan James (Sweden), Vikas Kapil (United Kingdom), Meral Kayikçioglu (Turkey), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Emanuela Teresa Locati (Italy), Sharon MacDonald (United Kingdom), Anastasia S. Mihailidou (Australia), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom) Martin Bodtker Mortensen (Denmark), Sandor Nardai (Hungary), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Peter M. Nilsson (Sweden), Agnes A. Pasquet (Belgium), Mónica Mendes Pedro (Portugal), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Ernst Rietzschel (Belgium), Bianca Rocca (Italy), Xavier Rossello (Spain), Jean-Paul Schmid (Switzerland), Eduard Shantsila (United Kingdom), Isabella Sudano (Switzerland), Ana Teresa Timóteo (Portugal), Georgios Tsivgoulis (Greece), Andrea Ungar (Italy), Ilonca Vaartjes (Netherlands), Frank Visseren (Netherlands), Heinz Voeller (Germany), Christiaan Vrints (Belgium), Adam Witkowski (Poland), Maria-Christina Zennaro (France), and Katja Zeppenfeld (Netherlands).

**ESC National Cardiac Societies actively involved in the review process of the 2024 ESC Guidelines for the management of elevated blood pressure and hypertension:**

**Albania:** Albanian Society of Cardiology, Naltin Shuka; **Algeria:** Algerian Society of Cardiology, Nadia Laredj; **Austria:** Austrian Society of Cardiology, Noemi Pavo; **Azerbaijan:** Azerbaijan Society of Cardiology, Ulvi Mirzoyev; **Belgium:** Belgian Society of Cardiology, Philippe van de Borne; **Bosnia and Herzegovina:** Association of Cardiologists of Bosnia and Herzegovina, Šekib Sokolović; **Bulgaria:** Bulgarian Society of Cardiology, Arman Postadzhiyan; **Croatia:** Croatian Cardiac Society, Jure Samardzic; **Cyprus:** Cyprus Society of Cardiology, Petros Agathangelou; **Czechia:** Czech Society of Cardiology, Jiri Widimsky; **Denmark:** Danish Society of Cardiology, Michael Hecht Olsen; **Egypt:** Egyptian Society of Cardiology, Wael M. El-Kilany; **Estonia:** Estonian Society of Cardiology, Priit Pauklin; **Finland:** Finnish Cardiac Society, Jari A. Laukkanen; **France:** French Society of Cardiology, Romain Boulestreau; **Georgia:** Georgian Society of Cardiology, Bezhan Tsinamdzgvrishvili; **Germany:** German Cardiac Society, Ulrich Kintscher; **Greece:** Hellenic Society of Cardiology, Maria Marketou; **Hungary:** Hungarian Society of Cardiology, Dénes Páll; **Iceland:** Icelandic Society of Cardiology, Þórdís Jóna Hrafnkelsdóttir; **Ireland:** Irish Cardiac Society, Eamon Dolan; **Israel:** Israel Heart Society, Talya Wolak; **Italy:** Italian Federation of Cardiology, Grzegorz Bilo; **Kazakhstan:** Association of Cardiologists of Kazakhstan, Meiramgul Kapsimetovna Tundybayeva; **Kyrgyzstan:** Kyrgyz Society of Cardiology, Erkin Mirrakhimov, **Latvia:** Latvian Society of Cardiology, Karlis Trusinskis; **Lebanon:** Lebanese Society of Cardiology, Ghassan Kiwan; **Libya:** Libyan Cardiac Society, Omar Msalem; **Lithuania:** Lithuanian Society of Cardiology, Jolita Badarienė; **Luxembourg:** Luxembourg Society of Cardiology, Cristiana-Astra Banu; **Malta:** Maltese Cardiac Society, Matthew Mercieca Balbi; **Moldova (Republic of):** Moldavian Society of Cardiology, Alexandru Caraus; **Montenegro:** Montenegro Society of Cardiology, Aneta Boskovic; **Morocco:** Moroccan Society of Cardiology, Najat Mouine; **Netherlands:** Netherlands Society of Cardiology, Tom Vromen; **North Macedonia:** National Society of Cardiology of North Macedonia, Marijan Bosevski; **Norway:** Norwegian Society of Cardiology, Helga B. Midtbø; **Poland:** Polish Cardiac Society, Adrian Doroszko; **Portugal:** Portuguese Society of Cardiology, Hélder Dores; **Romania:** Romanian Society of Cardiology, Elisabeta Badila; **San Marino:** San Marino Society of Cardiology, Roberto Bini; **Serbia:** Cardiology Society of Serbia, Dragan Vojislav Simić; **Slovenia:** Slovenian Society of Cardiology, Zlatko Fras; **Spain:** Spanish Society of Cardiology, Pilar Mazón; **Sweden:** Swedish Society of Cardiology, Jonas Spaak; **Switzerland:** Swiss Society of Cardiology, Thilo Burkard; **Syrian Arab Republic:** Syrian Cardiovascular Association, Elias Barakat; **Tunisia:** Tunisian Society of Cardiology and Cardiovascular Surgery, Salem Abdessalem; **Türkiye:** Turkish Society of Cardiology, Yilmaz Gunes; **Ukraine:** Ukrainian Association of Cardiology, Yurij M. Sirenko; **United Kingdom of Great Britain and Northern Ireland:** British Cardiovascular Society, Adrian J. B. Brady; and **Uzbekistan:** Association of Cardiologists of Uzbekistan, Gulnoz Abdusattarovna Khamidullaeva.

**ESC Clinical Practice Guidelines (CPG) Committee:** Eva Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) (Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja Zeppenfeld (Netherlands).


## Author notes

John William McEvoy and Rhian M Touyz Chairpersons contributed equally to the document and are joint corresponding authors.

Cian P McCarthy and Rosa Maria Bruno Task Force Co-ordinators contributed equally to the document.

**Author/Task Force Member affiliations are listed in author information.**

<sup>1</sup>Representing the European Renal Association (ERA), <sup>2</sup>Representing the European Society of Endocrinology (ESE), <sup>3</sup>Representing the European Stroke Organisation (ESO), <sup>4</sup>Representing the European Geriatric Medicine Society (EuGMS).

**ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.**

**ESC subspecialty communities having participated in the development of this document:**

**Associations:** Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), Heart Failure Association (HFA).

**Councils:** Council for Cardiology Practice, Council on Hypertension, Council on Stroke.

**Working Groups:** Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, E-Cardiology.

**Patient Forum**

**Disclaimer.** The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.

**Permissions.** The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher of the _European Heart Journal_ and the party authorized to handle such permissions on behalf of the ESC ([journals.permissions@oup.com](mailto:journals.permissions@oup.com)).

 ![graphic](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178il3.jpeg?Expires=1728462844&Signature=K7wnmHXf5cZujSGBklwEG9yUEZa661k4aJHJ6mbsRM-dLpGrNc03w2qgjWbwNHB71B5wgOJf2-BsL~rQsLElkYfi~hLbhfXjswDu7QWL9V5bH90h0z8FsfRgnnhec1R7DzFb9~L8A1f-9IC1XxyO4OaS0oT9dAXIQVDzpKyXZmE-AJVSJBAwHIhpZMPRvdcgwrS4PU4sWtJ-CP49LKSQ0iIyej5MfOTuMmsQbvlU~MVZ-IJq6sWRzLz3VAvL6umIG~kLP9dRoe6pqDKHrs0LDa2AcbQfBKW~mMbJxGcKT8qH3l-hFBCd1XJgZvC--BssbXFc4y3ga2zFLCzWvQnjwg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) All experts involved in the development of these guidelines have submitted declarations of interest, which are reported in a supplementary document to the guidelines. See the _European Heart Journal_ online or [www.escardio.org/Guidelines](https://www.escardio.org/Guidelines) for supplementary documents, as well as evidence tables.

  ![graphic](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178il4.jpeg?Expires=1728462844&Signature=Uok7hDvPxFT3d~1RJy9LSmybAUAgvvgord~KlDRiQKZ88AMXHz9o4X15d1PsK2yVQ0VxGXPeoUCFNqKQ-Qb-n4RpImN5fVooV5060kD6jtBqmFJVY-ZDEuVR6uBgYDYlVoGTJnsEU7EdNFNAyjztFXZlbYXKO3vocogQ4UXRI51gv1ouSmwujlS63F0twr0MqIFkn8F~yiZUrnwpvtXC0~bCDuwdmFDsFcQyOv4IGiZ71BkKWNrchFwE~-B64ue1J3mdlmyYUT09Glfb38ZNvBbcOTYpW24ld6q4AMjc4dM-k4oD~pIXGwjwnY0S7EXzaeVTMcr1HH5AbgsJE-hVSQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)  [Click here](https://doi.org/10.1093/med/9780198784906.001.0001) to access the corresponding ESC CardioMed chapters.

© The European Society of Cardiology 2024. All rights reserved. For permissions, please email: journals.permissions@oup.com

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ([https://academic.oup.com/pages/standard-publication-reuse-rights](https://academic.oup.com/pages/standard-publication-reuse-rights))

## Supplementary data

[ehae178\_Supplementary\_Data](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) - pdf file

[2024\_Hypertension\_Guidelines\_Evidence\_Tables](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/2024_hypertension_guidelines_evidence_tables.pdf?Expires=1728462845&Signature=ouEM5I5CibCYM3GqloI7s9~JI00H8MfD81BoIcnVDVsDGQivmOCeLZtur9zJTFeWYqCcClqeEMk6Pu0FKutcCpA3bCVfHIEHxBgecDL8vuHWpTPZVNGaxkfDYObx8AXhAa4H9qrnjxJWbz-oz-o97M3f-IAMk7bfizdl2eplf2-SW9UvRMVT1zsx7sRR0mqQlsBgWq6v9Jq5FRHMKEx5ze25J0xci6V8Z0qKuOBP7BOT0TWXLf6qonytosxqeN4Jx4lAYEpH6O2JNn94hfqMt0kU3e5tmelGvUXUu2Hz8zROsR8n-lHF9BVUo9oWq4O5G4iKmeQyJ~CWvk9ITlriNg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) - pdf file

[DOI\_Summary\_2024\_ESC\_Guidelines\_elevated\_BP\_and\_htn\_ehae178](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/doi_summary_2024_esc_guidelines_elevated_bp_and_htn_ehae178.pdf?Expires=1728462845&Signature=BsdfAFp6KSnR~otqXyYWVu~FuLBgct1F6AdpxFsnD7aRwF1x8xmTBFpfvx4IRTuumO5qeODW2RG6Xzfs6WMYYVl5k2U3GVusiq0wbZNJ8vbHAcuM8QLb7qsodTt3IceeLpgW~fWczWf74QtEF3aQQWR6Q6hw4p82aFcBQsNSWIt8zbSScSLaeso-t4T53cFJrJ2Ot4B1stClcu4EuWlWQER~ve19SfGE8M6AaGGuRr8Y8lmOTO-7j4QCxzsg-IYdkm220v4WJoO8O~gx~9JhwhcaNjDQYo2kSAAj93uAiOAruFeOtwOAFjinQIJrAKulMcOMJFXPj5GxQEUEVkEV6A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) - pdf file

